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Abstract
The growing knowledge of cell biology and evidence for the role of p-catenin
signalling network in homeostasis and carcinogenesis encourages further
investigation into the regulatory network of nuclear ~-catenin signalling
complex. While the role of canonical Wnt signalling in the development of
both normal tissue and malignant tumours is well documented, the molecular
basis of these functionally distinct nuclear transcriptional programs is poorly
understood. Many proteins are associated with cytoplasmic B-catenin for
regulation of Wnt/p-catenin pathway activities. However, in the nucleus, the
LEF/TCF family of transcription factors, which have DNA binding properties,
remains the sole focus as unambiguous partners of p-catenin.
In addition to LEF/TCFs interaction of p-catenin with several other,
transcriptional co-activators and/or co-repressors is required for gene
regulation. This regulation may also be influenced by alterations of p-catenin
protein such phosphorylation of p-catenin which dramatically alters its
trafficking and function. Delineation and functional description of nuclear
cofactors that interact with unphosphorylated (Le. nuclear) p-catenin will
further unravel the mechanisms of p-catenin-mediated nuclear transcription,
and may also identify whether distinct patterns of transcriptional cofactors are
engaged in normal development versus tumour progression.
Human FLYWCHI, a conserved member of the mammalian C2H2 zinc finger
proteins, was identified as one of the phosphorylation-independent Catenin-
Interacting-Proteins (CIPs) in a recent screening performed in Dr Nateri's
laboratory using a modified yeast-2-hybrid RRS. FLYWCHI is a previously
uncharacterized protein with no known function in mammals. Herein, we have
shown that; i) in human cells, FLYWCHI physically interacts with p-catenin
and represses its transcriptional activity, ii) it regulates the expression of some
if not all downstream target genes, iii) in the intestine, Flywch 1 marks the
crypt-based columnar-cells (CBCs), which function as stem cells, but does not
mark any of the differentiated cells in normal villi, ivYFLYWCHI expression is
11
strongly down-regulated in eRe cell lines but its expression is up-regulated
and restricted to a subpopulation of tumour cells in both human and ApcMinl+
mouse. Our data also showed that v) FLYWeHI controls eRe cell
morphology and inhibits cell migration through up-regulation of E-cadherin
which may not be related to ZEB2-mediated EMT.
Collectively, our data suggest that FLYWCI I I is a novel nuclear f)-catenin
interacting protein that inhibits cell motility by antagonizing the activity of
Wntl~-catenin signalling pathway. As changes in cell motility is a key step
toward invasion and metastasis, FLYWeH 1, therefore, may function as a
metastasis-suppressing factor which could potentially he of use in the
therapeutic field of colon cancer to control cancer spread.
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1.1 Background
1.1.1 Links between transcription and signalling in
development and diseases
In multicellular organisms, cells have ability to detect the status of the local
environment and respond appropriately during embryogenesis and
homeostasis. Multiple cytoplasmic signal transduction cascades (pathways)
triggered by different ligand/receptor interactions at the cell surface are the
mechanisms by which information about the extracellular environment is
communicated to the cell. These pathways control almost all cellular biological
activities and responses through tight regulation of the transcriptional
machinery of the cell (Serup, 2012, Heath, 2010).
Signalling pathways generally recruit specific DNA-binding transcription
factors to specified response elements within the promoter of their target genes,
thereby, controlling gene transcription. Maintaining a balanced relationship
between signalling pathways and the gene expression programme is the only
way to guarantee normal development and homeostasis. Accordingly, any
disturbance to this system leads to development of various disorders including
cancer (Clevers, 2006, Heath, 2010). For example, Wnt signalling through ~_
catenin maintains the progenitor and stem cell compartment of intestinal-crypts
(Miki et al., 2011, Nusse et al., 2008). Deregulation of Wnt signalling may
therefore lead to loss of normal intestinal homeostasis. Indeed, around 90% of
colorectal cancers (tumours of the large intestine) show deregulated Wntl~-
catenin signalling (Fevr et al., 2007).
Defects in highly conserved Wnt signalling pathway are well known to play
key roles in the development of many different types of cancer. This and the
above concepts are mechanistically explored in more detail within the
following sections throughout this chapter.
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1.1.2 The Wnt signalling pathway: outlined definition
The Wnt signalling pathway is an ancient and evolutionarily conserved
pathway in metazoan animals (Komiya and Habas, 2008). This pathway
involves a large number of signalling molecules including Wnt-ligands, Wnt-
receptors, and several cytoplasmic Wnt-signal transducing proteins (see below
for detail). Exposure of cells to the extracellular Wnt-ligands stimulates several
intra-cellular signal transduction cascades, represented by the canonical (p_
catenin dependent) and the non-canonical (f)-catenin-independent) pathways.
The Wnt-signal transduction cascades control a huge number of biological
phenomena throughout all stages of animal development and adulthood. On the
other hand, defective Wnt signalling has catastrophic consequences that
underline a wide range of human pathologies including different types of
cancer.
1.1.3 Wnt family of secreted proteins
Wnts comprise a highly conserved family of genes throughout the metazoan
kingdom. The human genome harbours 19 Wnt genes (WNTs) that encode for
19 Wnt proteins (Miller, 2002). Historically, WNTs are defined by common
conserved amino acid sequences in the original members, i.e. the integrated
(int-i) in mouse (Nusse and Varmus, 1982, van Ooyen and Nusse, 1984) and
the segment polarity gene wingless (wg) in Drosophila (Rijsewijk et aI., 1987).
Therefore, the term Wnt which is a combined name resulted from a fusion of,
the name of Drosophila wingless (wg) and mouse int-i, was assigned to the
members of this family. Proteins encoded by this family of genes are defined as
small secreted glycoproteins of about 40 kDa (Cadigan and Nusse, 1997) that
share high (27% to 83%) amino acid sequence identity, including a conserved
pattern of 23 or 24 cysteine residues (Miller, 2002), a signal sequence for
secretion, and many glycosylation sites (Mason et aI., 1992).
Wnts function as extracellular ligands for the Wnt signalling pathway,
however, their function is highly regulated both intra- and extra-cellularly. The
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intracellular modifications include post-translational refinements such as
glycosylation (i.e. the enzymatic process that links saccharides to produce
glycans, either free or attached to proteins and lipids) and palmitoylation (i.e.
the covalent attachment of fatty acids) (Smolich et aI., 1993, Willert et aI.,
2003). These fine adjustments are part of the natural maturation process of Wnt
molecules that play crucial roles in secretion, trafficking, spreading and
signalling activities ofWnt proteins (Harterink and Korswagen, 2012, Port and
Basler, 2010). The mechanisms of secretion of Wnt molecules were further
clarified by the discovery of a transmembrane protein called Wntless (Wls)
(Banziger et aI., 2006, Bartscherer et aI., 2006, Goodman et aI., 2006). This
protein is thought to bind to Wnt molecules and facilitates their export from the
Golgi to the plasma membrane for release (reviewed by Harterink and
Korswagen, 2012, Lorenowicz and Korswagen, 2009, Port and Basler, 2010).
Binding of extracellular signalling molecules to Wnt proteins is among the
more common extracellular modifications. In most cases (but not all), these
molecules function as antagonists to Wnt activities through interruption of Wnt
binding to cell surface receptors. Examples of secreted proteins that antagonize
Wnt function are Dickkopf (Dkk) proteins (Glinka et aI., 1998), Writ-inhibitor
protein (WIF) (Hsieh et aI., 1999), soluble Frizzled-related proteins (SFRP)
(Hoang et aI., 1998), Cerberus (Bouwmeester et aI., 1996), and the context
dependent Wnt inhibitor Wise (Itasaki et aI., 2003). These molecules prevent
Wnt interaction with either Frizzled (Fz) or the LRP5/6 (low-density
lipoprotein receptor-related proteins 5 and 6) which eventually leads to
inhibition ofWnt signalling pathway (see below).
On the other hand, there are other molecules that function as agonists to
promote Wnt signalling pathway such as Norrin (Xu et aI., 2004), and R-
Spondin2 (Han et aI., 2011, Koeneman, 2009, Kazanskaya et aI., 2004).
Moreover, the adult intestinal stem cell marker Lgr5 (Leucine-rich repeat-
containing G-protein coupled receptor 5) and its relative gene Lgr4 were
recently identified as mediators of Wnt signalling pathway through R-Spondin
receptors (Glinka et aI., 2011, de Lau et aI., 2011). Considering the importance
of Wnt molecules in development and various cellular processes, each of these
secreted proteins, therefore, must be tightly regulated during embryogenesis
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and cell-fate determination to ensure that a proper level of Wnt-signals is
delivered.
After secretion and intervention by intra/extracellular modifications, Wnt
molecules eventually function as extracellular ligands to initiate the Wnt
signalling pathway through binding to cell surface receptors composed of Fz
and LRP-5/6 (Bhanot et al., 1996, Tamai et al., 2000). The intracellular
transduction of Wnt-signals activates various signalling pathways that can be
categorized into canonical (p-catenin dependent) or non-canonical (p-catenin
independent) pathways. Through these signalling pathways, Wnt proteins play
fundamental roles in almost every step of embryonic development, starting
from mesoderm induction to anterior-posterior body axis formation including
embryonic induction (proliferation), generation of cell polarity (migration) and
specification of cell fate determination (differentiation) (reviewed by
Hendrickx and Leyns, 2008, Logan and Nusse, 2004). Furthermore, this
pathway is also implicated in cell biology and homeostasis through
maintenance of stem cell properties (Hendrickx and Leyns, 2008, Reya and
Clevers, 2005).
1.2 Canonical Wnt signalling pathway
With the discovery of Wnt proteins and their functions as signalling molecules
in the early 1980s, the p-catenin-dependent pathway received the most
attention and became the best characterized signalling pathway. This pathway
is commonly referred to as the canonical Wnt signalling or Wntlp-catenin
signalling pathway which simply means transduction ofWnt-signals through p_
catenin, a central signal transducer and a key regulator of this pathway (Figure
1-1). The ultimate function of this pathway is signal transduction from
extracellular matrix into the nucleus. This role is accomplished through a series
of intracellular events comprising accumulation of stabilized p-catenin in the
cytoplasm, followed by its nuclear translocation and subsequent activation of
Wnt-target genes. This pathway is represented by two states, the "on" and "off'
states, based on the presence or absence of Wnt stimuli (see section 1.2.1 &
Figure 1-1). The process of activation and nuclear translocation of p-catenin is
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tightly regulated through several cytoplasmic and nuclear regulatory molecules
which are explored in more detail in the following sections.
1.2.1 Cytoplasmic events
Regulation of ~-catenin in the context of canonical Wnt signalling pathway has
been intensively studied both in the presence or absence of Wnt molecules. In
the absence of Wnt stimulation, the unbound cytosolic 13-cateninis degraded by
a destruction complex composed of a scaffolding protein Axin, glycogen
synthase kinase-3 beta (GSK-3~), casein kinase-I alpha (CKla), and
adenomatous polyposis coli (APC) (Ikeda et al., 1998, Kikuchi, 1999, Kishida
et aI., 1998, Liu et aI., 2002). Within this complex 0-catenin is phosphorylated
by coordinated action of both CKIa and GSK-3~; CKIa serves as a priming
kinase that phosphorylates Serine 45 (Ser45) of ~-catenin and enhances the
phosphorylation at Ser33, Ser37, and Threonine 41 (Thr41) by GSK-3~ (Amit
et al., 2002, Liu et al., 2002). The phosphorylated ~-catenin is then
ubiquitinated and recognized by the E3-ubiquitin ligase SCF(~-TrCP)
containing SKP-l, Cullin and the F-box protein ~-TrCP (Jiang and Struhl,
1998, Marikawa and Elinson, 1998) and subsequently degraded by the 26S-
proteasome machinery (Kitagawa et al., 1999) (Figure 1-1, left panel). This
will keep the cytosolic ~-catenin at a low level and in such a situation ~-catenin
does not accumulate in the nucleus (i.e. the pathway is switched off).
Upon extracellular stimulation, Wnt-ligands interact with cell surface receptors
consisting of Fz and LRP5/6 to form a ternary complex which leads to
inhibition of ~-catenin phosphorylation by the Axin destruction complex
(consisting ofAxin, APC, GSK-3~, and CKlu), thereby stabilizing ~-catenin
(Figure 1-1, right panel). Although formation of the trimeric complex between
Wnt, Fz and LRP is widely accepted as a prerequisite to trigger Wnt signalling,
the precise model of interaction and mechanisms of the subsequent signal
transduction is still open to debate. It has long been believed that the
interaction between Wnt proteins and its receptors, results in generating a
signal which is transduced intracellularly through a cascade of events involving
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the Dishevelled (Dvl) protein in a not fully understood manner. These events
were thought to inhibit the GSK-3~-dependent phosphorylation of ~-catenin
and disrupt the AxinJGSK-3~/CKla/~-catenin complex, which in tum increases
the cytoplasmic level of ~-catenin (Hino et aI., 2003, Kishida et aI., 1999,
Yamamoto et aI., 1999).
This model of Wnt-signals transduction in the cytoplasm has recently been
revised (Fuerer et aI., 2008, Nusse, 2012). According to the current model, Dvl
forms a complex with Axin and GSK-3~ through its N-terminal domain which
is similar to the DIX domain in Axin. Wnt binding to Fz/LRP receptors
enhances binding of this complex (Dvl/AxinJGSK-3~) to Fz. On the other
hand, GSK-3~ phosphorylates the Axin binding site residues of LRP 6 which
then primes the subsequent phosphorylation of another motif of LRP 6 by
CKI y, enabling the scaffolding protein (Axin) to bind to the phosphorylated
site of LRP 6. This interaction leads to subsequent inactivation of the
destruction complex governed by Axin. Consequently, ~-catenin will not be
phosphorylated by the GSK-3~ (Fuerer et aI., 2008, Nusse, 2012) (Figure 1-1,
right panel).
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Canonical Wnt signalling pathway
ON-state
Proteasomal
degradation +
C~OPII~as:~m~.~.~~~~~~~~ __ ~~~~~~"~~~~~
Coactivators ~ Corepressors
Nucleus
Figure 1-1: Schematic representation of Wntlp-catenin signalling pathway. (Left
panel) represents inactive state of WnU~-cateninsignalling pathway (i.e. OFF-state) in
which in the absence of Wnt stimulation, ~-catenin levels in the cell are kept low
through a dedicated destruction complex that consists of adenomatous polyposis coli
(APC), casein kinase I (CKI), glycogen synthase kinase 3 (GSK3), and Axin. This
complex targets ~-catenin for proteasomal degradation through phosphorylation (P).
Conversely, ~-catenin stability may also be regulated/enhanced by protein
phosphatases (PPs) such as (PP2A) through dephosphorylation of ~-catenin (Right
panel) represents active state of WnU~-catenin signalling pathway (i.e. ON-state) in
which Wnt-ligands bind to Frizzled receptors and low-density lipoprotein receptor-
related protein (LRP) coreceptors. The cytoplasmic tail of LRP binds to Axin in a Wnt-
and phosphorylation-dependentmanner. Phosphorylationof the tail of LRP is regulated
by GSK-3~, CK1, and Dishevelled (Dvl). As a consequence, ~-catenin will not be
phosphorylatedand/or degraded anymore,which leads to increased cytosolic level of~-
catenin, resulting in its translocation into the nucleus. The stabilized nuclear ~-catenin
then replaces Groucho on TCF/LEF transcription factors (TCF) and recruits other
auxiliary cofactors (co-activators and/or co-repressors) to form an active transcriptional
complex that regulate the expression of Wnt-target genes. The diagram is adapted from
(Nusse, 2012, Saadeddinet al., 2009).
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In addition to the current model of Wnt signalling described above, more
recently, a newer model of cytosolic Wnt-signal transduction has also been
proposed (Clevers and Nusse, 2012, Li et aI., 2012). In this new model, the E3-
ubiquitin ligase SCF(P- TrCP) was suggested to be associated to the Axin
destruction complex. As a result both phosphorylation and ubiquination of p_
catenin occurred inside the Axin complex (Li et aI., 2012). Wnt stimulation
induces the association of the intact complex with phosphorylated LRP. This
recruitment blocks p-catenin ubiquitination that normally occurring within the
complex, while the destruction complex still captures and phosphorylates p_
catenin. Saturation of the Axin complex by the accumulated phospho-p-catenin
allows the newly synthesized f3-catenin to accumulate in the cytoplasm and
subsequently trans locate to the nucleus to activate Wnt-target genes (Clevers
and Nusse, 2012, Li et aI., 2012).
Although the cytosolic p-catenin is intensively regulated through the
phosphorylation process (see above), in some circumstances, p-catenin can
escape from phosphorylation and subsequent degradation even in the absence
of Wnt stimulation. For instance, in pathological conditions, when the N-
terminal Serine and Threonine residues are mutated (Korinek et aI., 1997) or
when components of the destruction complex are defective such as APC
(Morin et aI., 1997) or Axin (Liu et aI., 2000). In such conditions, nuclear
translocation and accumulation of p-catenin will occur even in the absence of
Wnt-signals.
In contrast to the negative role of several kinases such as CKIa, CKIy, and
GSK3p in Wnt signalling pathway (see above), protein phosphatases such as
PP 1, PP2A, and PP2C, have been shown to positively regulate this pathway
(Bajpai et aI., 2004, Luo et aI., 2007, Strovel et aI., 2000). Generally, protein
phosphatases are signal transducing enzymes that dephosphorylate various
intracellular phosphoproteins involved in different pathways including Wnt
signalling pathway. (Barford, 1995, Jia, 1997). For example, PP2A was shown
to augment Wnt signalling through dephosphorylation of p-catenin (Bajpai et
al., 2004, Zhang et aI., 2009). Moreover, PP2C and PP} were also shown to
dephosphorylate Axin and, thereby, positively regulate Wntlp-catenin
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signalling pathway (Luo et al., 2007, Strovel et al., 2000). Thus, phosphatases
may play crucial role in balancing the cytosolic level of p-catenin through
dephosphorylation of p-catenin and/or components of the destruction complex.
The ultimate output of the activated canonical Writ-pathway is the
phosphorylation blockade (stabilization) and cytosolic accumulation of p_
catenin. The stabilized p-catenin then enters the nucleus, where it binds to
members ofT-cell factor (TCF) and lymphoid enhancer factor (LEF) TCF/LEF
transcription factors resulting in changes in expression programme of various
target genes, including c-myc, c-jun, cyclin DJ, Fra-I , CDHJ, and Axin2
(Bienz and Clevers, 2000, Kikuchi, 2000, Lustig et aI., 2002, Seidensticker and
Behrens, 2000, Batlle et aI., 2002). A complete list of Writ-target genes can be
found within the Wnt homepage (http://www.stanford.edu/group/nusselab/cgi_
binlwnt/target genes).
1.2.2 Nuclear events
Whereas the proximal events of Wntlp-catenin signalling pathway are
relatively well documented, the distal events of this pathway are less
understood. It seems that going down deeper into the nucleus where the core
transcriptional machinery of the cell is located, the pathway becomes more
challenging. However, some basic concepts have already been established.
At an early stage after identification of TCF/LEF transcription factors
(hereafter TCFs), it has been found that these molecules have a contradictory
functions during embryogenesis and development; activating transcriptional
processes in one subset of cells, but at the same time repressing the same
functions in a different subset. However, identification of p-catenin as a
specific binding partner of TCFs not only enabled the scientists to successfully
answer the mystery of TCFs function, but it also clarified the mechanism by
which TCFs could regulate transcription (reviewed by Hurlstone and Clevers,
2002).
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TCFs form a relatively small family of transcription factors comprising four
members in vertebrates (TCFI, TCF3, TCF4, and LEFI) and one orthologous
form in flies, worms and lower organisms such as Hydra (dTCF/pangolin,
POP-I, and hyTCF, respectively) (reviewed by Arce et al., 2006, van Noort
and Clevers, 2002). Members of this family are the most studied DNA binding
downstream effectors of Wntl~-catenin signalling pathway. Each contains an
N-terminal binding domain for ~-catenin and a specific DNA-binding high
mobility group (HMO) box (Arce et al., 2006, van Noort and Clevers, 2002).
Moreover, through alternative splicing and promoter usage, Tcfs may produce
multiple isoforms harbouring diverse functional domains (Figure 1-2)
(Hurlstone and Clevers, 2002).
Scientists now appreciate that TCFs function as bipartite regulators of Wnt-
target genes. In the absence of stabilized ~-catenin, TCFs are bound to
members of the Groucho family of co-repressors to keep Wnt-targets silenced.
Nuclear accumulation of stabilized ~-catenin antagonizes this repression
through displacing the co-repressor Groucho (Daniels and Weis, 2005) and
recruiting additional co-activators, the process which transcriptionally regulates
Wnt-target genes (Kikuchi, 2000, Mosimann et al., 2009). Thus, TCFs can be
considered as transcriptional switch, turning on in the presence of stabilized ~_
catenin, and converting repression to activation (Figure 1-1).
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Figure 1-2: Schematic representation of lcf splice variants and their most
conserved domains. Short forms of Tcf1 and Lef1 lack the N-terminal domain, which
interacts with ~-catenin. The CAD domain in Lef1 is required for context-dependent
activation of the TCRa enhancer. The HMG box mediates sequence-specific DNA
binding. The most divergent region of the Tef family members is the C-terminus, which
in certain longer isoforms contains a conserved motif, CRARF, that serves as an
additional DNA-binding domain and a strong transactivator of the WNT pathway (Atcha
et al., 2003, Atcha et al., 2007) and two CtBP binding sites. Taken and modified from
(Hurlstoneand Clevers, 2002).
Historically, identification of p-catenin as a potential co-activator of TCFs
further highlighted the importance of p-catenin in the context of the Wnt
signalling pathway, especially because it was not clear how p-catenin
transduces the signal into the nucleus, as it has no DNA-binding properties. On
the other hand, members of TCFs lack transactivation domain but they can
bind to DNA through their high mobility group (HMO) box (van Noort and
Clevers, 2002). Therefore, interaction of p-catenin with TCFs was a perfect
model of coordination between these two proteins.
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1.2.3 Regulation of Wnt/p-catenin downstream target genes
The activated Wnt signalling pathway has been associated with several
biological processes through regulation of Wnt-downstream target genes
(Batlle et aI., 2002, Clevers and Batlle, 2006, van de Wetering et aI., 2002, Van
der Flier et al., 2007). Direct displacement of the co-repressor Groucho by
stabilized nuclear ~-catenin on TCF/LEF transcription factors (Daniels and
Weis, 2005) leads to recruitment of ~-cateninlTCF complex to specific TCF
binding. elements in the promoter of Wnt-downstream target genes allowing
this complex to control their expression (Behrens et aI., 1996, Clevers and van
de Wetering, 1997).
Numerous Wnt-target genes have been identified in the past decade; however
studies are more focussed on the genes that are positively regulated by this
pathway and involved in cancer. One critical example is c-Myc which has been
identified as a direct target gene of ~-cateninlTCF4 complex (He et aI., 1998).
It has been shown that ~-cateninJTCF4 complexes regulate c-Myc expression in
colon cancer cells through specific Wntl~-catenin responsive DNA-elements
present in the promoter of c-Myc (He et aI., 1998). Subsequent studies have
revealed that the expression of the proto-oncogene c-MYC is deregulated
(mainly activated) in a variety of human cancers and is often associated with
poor prognosis (Pelengaris and Khan, 2003, Pelengaris et aI., 2002, Vita and
Henriksson, 2006).
In addition to c-Myc, many other genes are also targeted and positively
regulated by the activated Wnt signalling pathway such as Cyclin DJ
(Shtutman et aI., 1999, Tetsu and McCormick, 1999), c-jun & Fra-l (Mann et
aI., 1999, Nateri et aI., 2005), EphB2/3 and many other genes (Batlle et aI.,
2002). A comprehensive list of Wnt target genes can be found on the Wnt
homage (http://www .stanford.edu/ group/nusselab/ cgi -binlwntJ). Moreover, the
positive regulation of certain Wnt target genes in response to activated Wnt
signalling pathway is very well understood and often used as indicators for the
activation status of this pathway. For example, Ito et al. (2008) have used the
promoter activity and the protein expression of cyclin D 1 and c-Myc to show
changes in the transactivational activity of p-cateninlTCF4 m response to
13
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RUNX3 (Ito et al., 2008). Increasing evidence about the link of nuclear
localization of ~-catenin and downstream target gene activation in various
types of cancers led to the general assumption that Wnt/Bvcatenin signalling is
an oncogenic pathway. However, the oncogenicity nature of this pathway has
been recently revised (reviewed by Lucero et al., 2010). More details will be
found in (section 1.4.4).
Despite the common thought of positive gene regulation by the activated
Wnt/Ii-catenin pathway, negative regulation of this pathway on certain genes
has also been reported. For instance, Jamora et al. (2003) found that the Wnt-3a
activated Left and stabilized ~-catenin together led to direct repression of E-
cadherin during epithelial bud formation of hair follicles. This repression was
accomplished through direct binding of the ~-cateniniLeft complex to specific
Lefl-binding sites within the E-cadherin promoter (Jamora et aI., 2003). E-
cadherin was also reported to be indirectly down-regulated in embryoid bodies
by high level of Wnt signalling that was induced by Wnt-3a and involved in the
process of EMT (ten Berge et al., 2008). In addition to E-cadherin, the gene
expression of a tumour suppressor gene, p161NK4a, was shown to be directly
repressed by the activated Wnt pathway through the evolutionary conserved
TCF/LEF binding site in the promoter of this gene (Delmas et al., 2007).
Furthermore, the transcriptional repression of Wnt signalling pathway on
several other genes such as KAIl and osteocalcin promoter is also reported
(Kahler and Westendorf, 2003, Kim et al., 2005, Spencer et al., 2006).
However, it is yet unclear whether the negative effects of Wnt pathway on the
later genes are promoter specific and also whether these genes are conventional
targets of Wnt signalling pathway.
Often up or down-regulation of Wnt-downstream target genes is cell-type
specific and the cellular context, rather than the signal, determines the nature of
the response in a not fully understood manner (reviewed by Logan and Nusse,
2004). Therefore, further studies are required to delineate the mechanisms
involved in the transcriptional switch of ~-cateninlTCF complex to either
promote or inhibit gene expression.
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1.2.4 Role of nuclear cofactors on canonical Wnt signalling
A large body of evidence indicate that the transcriptional activity of ~_
cateninlTCF complex is tightly regulated in the nucleus through various
additional auxiliary proteins (either specific or general transcription co-
activators or co-repressors) that are implicated in the transcriptional activity of
nuclear ~-catenin. These additional cofactors form a complex network of
signalling and feedback loops that are required for the tight and precise
regulation of ~-cateninlTCF complex. It has been established that the nuclear
~-catenin acts as a platform to recruit these cofactors (Figure 1-3), in addition
to TCFs, to the promoter of Wnt-target genes. In general, these factors can be
classified into two groups; a) co-activators and b) co-repressors as described in
the following sections.
Coactivators
Corepressors
NTD
TCF4
(-700aa)
Figure 1-3: Nuclear interacting proteins of p-catenin and TCF4. Schematic shows
(top panel) ~-catenin and (bottom panel) TCF4 molecules with examples of their
nuclear cofactors. In both panels, blue boxes represent the positive cofactors (co-
activators), whereas red boxes the negative cofactors (co-repressors).The position of
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boxes indicates the approximate binding sites of these factors to ~-catenin and TCF4.
NTD stands for the amino-terminal domain, while CTD for the carboxy-terminal domain
of ~-catenin. HMG denotes the High-Mobility Group domain of TCF4. Adapted from
(Mosimann et al., 2009) and the Wnt home page
(http://www.stanford.edu/group/nusselab/cgi-bin/wntlprotein interactions.
1.2.4.1 Activation of p-cateninITCF complex through co-activators
p-catenin itself is acting as a transcriptional co-activator to modulate the
transcription of Wnt-target genes after coupling with members of TCFs in the
nucleus. Nevertheless, many other proteins (co-activators) have been identified
to further augment the activity of the p-cateninlTCF complex. Examples of
these proteins are p300/CBP (Hecht et aI., 2000, Takemaru and Moon, 2000),
Brg-I (Barker et aI., 2001), pygopus (pygo) (Kramps et aI., 2002, Townsley et
aI., 2004), ParafibrominiHyrax (Mosimann et aI., 2006), and many others, see
(Table 1-1).
These cofactors are interacting with p-catenin in the nucleus and increase its
transcriptional activity toward Wnt-target genes through different mechanisms.
Some are enhancing the promoter binding and facilitate the chromatin
remodelling at the promoter site of Wnt-target genes such as p300/CBP and
Brg-I (Barker et aI., 2001, Hecht et aI., 2000), while others promoting nuclear
localization of p-catenin such as pygopus (Townsley et aI., 2004). Moreover, in
CRC cells, c-Jun, TCF4 and p-catenin cooperate to activate the c-Jun
expression in a phosphorylation-dependent manner which in tum regulates
intestinal tumourigenesis through integrating JNK and APC/p-catenin
pathways (Nateri et aI., 2005).
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Table t-t: Proteins that activate the p-cateninrrCF signalling. Adapted from
(MacDonald et al., 2009, Shitashige et al., 2008).
Proteins Interaction Referencespartner(s)
AP-1
(both c-Fos & c-Jun) ~-catenin (Toualbi et al., 2007)
Topo 110 ~-catenin (Huang et al., 2007)
ERa ~-catenin (Kouzmenko et al., 2004)
p300/CBP ~-catenin (Hecht et al., 2000, Takemaru and Moon,2000)
pygopus (pygo) ~-catenin (Kramps et al., 2002, Townsley et al., 2004)
BCL9/1egiess ~-catenin (de la Roche et al., 2008, Kramps et al.,2002, Townsl~ et al., 2004)
Parafibrominl (Mosimann et al., 2006)
~ax
~-catenin
Brg-1
~-catenin (Barker et al., 2001)
PARP-1 TCF4 (Idogawa et al., 2005)
TNIK TCF4 (Mahmoudi et al., 2009)
Smad3 LEF1 (Labbe et al., 2000)
c-Jun ~-catenin and (Gan et al., 2008, Toualbi et al., 2007, Nateri
TCF4 et al., 2005)
PITX2 ~-catenin and (Vadlamudi et al., 2005)LEF1
Sox4 ~-catenin and (Sinner et al., 2007)TCFs
Mllt101
~-catenin and (Mahmoudi et al., 2010)
Af10-Dot11 TCFs
AP-', Activator Protein 1; Topo Ita, Topoisomerase II alpha; PARP-', Poly(ADP-
Ribose) Polymerase-1; ERa, Estrogen Receptor alpha; CBP, CREB-Binding Protein;
PITX2, Paired-like homeodomain Transcription Factor 2; TNIK, Traf2- and NCK-
interacting kinase.
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1.2.4.2 Inhibition of p-cateninlTCF complex through co-repressors
Although Wnt signalling via the ~-cateninlTCF complex is well documented as
a prerequisite for activation of Wnt-target genes (Behrens et aI., 1996, van de
Wetering et aI., 1997, Clevers and van de Wetering, 1997, van de Wetering et
aI., 2002, Van der Flier et aI., 2007), this pathway cannot always lead to gene
activation. Accumulated evidence over the past decade identified a number of
proteins that interact with nuclear p-catenin and antagonize its transcriptional
activity leading to transcriptional repression of Wnt-target genes. Accordingly,
maintaining the balance between activation and repression of Wnt signalling
pathway is an essential task during normal development. In this vein and in
certain circumstances, Wnt-signals need to be quenched in order to allow
healthy organogenesis during embryonic development. For example, repression
of Wntlp-catenin signalling is found to be required for normal development of
the anterior forebrain in zebrafish and mouse embryos. This function can be
accomplished by HESX1, a conserved transcription factor and Wnt signalling
antagonist, that is required for forebrain development in vertebrates
(Andoniadou et aI., 2007, Andoniadou et aI., 2011).
In addition to normal development, these co-repressors also play pivotal roles
in the process of tumourigenesis and cancer development functioning as
tumour suppressors through antagonizing the activated Wntl~-catenin
signalling pathway. A comprehensive list of proteins that have been identified
as co-repressors for the activated Wnt signalling pathway is presented in (Table
1-2). These proteins are collectively known as Wnt signalling antagonists that
negatively regulate the activity of Wnt signalling pathway through different
mechanisms; (i) most of these factors interact with ~-catenin and/or TCF/LEF
and disturb the formation of p-cateninlTCF complex. For example, ICAT
(inhibitor of p-catenin and TCF4) and p15RS antagonize Wnt signalling
through inhibiting the interaction and formation of p-cateninlTCF4 complex
(Tago et aI., 2000, Wu et aI., 2010), whereas RUNX3, forms a ternary complex
with p-cateninITCF4 by which attenuates Wnt signalling activity (Ito et al.,
2008).
18
Chap 1:General Introduction
Table 1-2: A comprehensive list of proteins that repress the activity of ~_
cateninfTCF complex. Adapted from (Le et al., 2008, MacDonald et al., 2009,
Shitashige et al., 2008).
Proteins Interaction Referencespartner(s)
ICAT ~-catenin (Tago et al., 2000)
AR ~-catenin (Pawlowski et al., 2002)
E2F1 ~-catenin (Morris et al., 2008)
FUS/TLS ~-catenin (Sato et al., 2005)
Foxosa and
~-catenin (Essers et al., 2005, Hoogeboom et al., 2008)Foxo4
Groucho/TLE ~-catenin (Cavallo et al., 1998, Daniels and Weis, 2005)
Gli3
~-catenin (Ulloa et al., 2007)
GR
~-catenin (Takayama et al., 2006)
HIF1a
~-catenin (Kaidi et al., 2007)
Mitt
~-catenin (Schepsky et al., 2006)
RAR
~-catenin (Easwaran et al., 1999)
Chibby
~-catenin (Takemaru et al., 2003)
Sox6
~-catenin (Iguchi et al., 2007)
Sox9
~-catenin (Akiyama et al., 2004)
Xsox3
~-catenin (Zorn et al., 1999)
Reptin52
~-catenin (Bauer et al., 2000)
Glis2
~-catenin (Kim et al., 2007)
LXRs
~-catenin (Uno et al., 2009)
HBP1 TCF4 (Sampson et al., 2001)
CtBP1 TCF4 (Valenta et al., 2003)
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Ku70 TCF4 (Idogawa et al., 2007)
HIC1 TCF4 (Valenta et al., 2006)
Daxx Tcf4 (Tzeng et al., 2006)
Kaiso TCFs (Iioka et al., 2009, Ruzov et al., 2009, Park et
al.,20051
HESX1 Tcf3 (Andoniadou et al., 2011)
Osx Tcf1 (Zhang et al., 2008)
p15RS ~-catenin and (Wu et al., 2010)TCF4
Runx3 ~-catenin and (Ito et al., 2008)TCF4
Xsox17 ~-catenin and (Chew et al., 2011, Sinner et al., 2007, Sinner etTCFs al., 2004, Zorn et al., 1999)
SF1 ~-catenin and (Shitashige et al., 2007a, Shitashige et al.,TCF4 2007b)
KLF4 ~-catenin and (Evans et al., 2010, Zhang et al., 2006)TCF4
SMRT and NCoR ~-catenin and (Song and Gelmann, 2008)TCF4
NLK ~-catenin and (Ishitani et al., 1999)TCF3/4
SF1, Splicing Factor-1; AR, Androgen Receptor; FUSfTLS, Fusion (FUS)lTranslocated
in Liposarcoma (TLS); GR, Glucocorticoid Receptor; HIF-1a, Hypoxia Inducible Factor-
1alpha; KLF4, Kruppel-Like Factor 4; Mitt, Microphthalmia-associated Transcription
Factor; CtBP1, C-terminal Binding Protein 1; RAR, Retinoic Acid Receptor; NLK,
NEMO-like kinase; HBP1, HMG-box transcription Factor 1; HIC1, Hypermethylated In
Cancer 1; Osx, Osteoblast-Specific Transcription Factor (Osterix); SMRT, Silencing
Mediator for Retinoid and Thyroid hormone receptor; NCoR, the Nuclear Receptor Co-
repressor; HESX1, HESX homeobox 1; lXRs, Liver X Receptors; ICAT, inhibitor of ~-
catenin and TCF4.
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Similar to this mechanism, RAR, Chibby, Sox 9, and HIF-la compete with
members of Tcf/Lef for binding to p-catenin (Akiyama et al., 2004, Easwaran
et aI., 1999, Kaidi et aI., 2007, Takemaru et aI., 2003). (ii) Some of the co-
repressors regulate Wnt-pathway via more than one mechanism; for example
Sox9, in addition to its competition role with members of Tcf/Lef, it can also
stimulate phosphorylation and translocation of p-catenin from the nucleus
which is subsequently degraded by the ubiquitinationJ26S proteasome pathway
(Akiyama et aI., 2004). In addition, the dynamic intracellular localization of p-
catenin and the subsequent activation of Wntlp-catenin pathway were found to
be controlled by the nuclear antagonist Chibby through its efficient
nuclear/cytoplasmic shuttling (Li et aI., 201Ob). (iii) The third antagonist-
mediated inhibitory mechanism of Wnt-pathway involves disruption of TCF
binding ability to DNA. For instance, SMRT and NCoR repress p-catenin
signaling through indirect binding, via p-catenin and/or TCF4, to the TCF4-
binding sites on the promoter ofWnt-target genes including CCNDI (Song and
Gelmann, 2008). Moreover, the osteoblast-specific transcription factor Osterix
(Osx) was found to interact with Tcfl through its N-terminal transactivation
domain and disrupt Tcfl binding to DNA (Zhang et aI., 2008). (iv) Another
method of Wnt signal suppression is co-repressor-mediated inhibition of co-
activator recruitment by p-catenin. This mechanism is exemplified by KLF4,
whose interaction with the C-terminal domain of p-catenin inhibits recruitment
of the co-activator, p300/CBP by p-catenin leading to inhibition of p300/CBP-
mediated p-catenin acetylation as well as histone acetylation on Wnt-target
genes (Evans et al., 2010). The putative p-catenin interaction partners are
themselves regulated by several extracellular stimuli. Therefore, it is plausible
to expect that their subsequent effects on p-catenin activity are modulated in a
context-dependent manner. In this view, different cellular context, may lead to
various outcomes of activated Wnt signalling pathway (Lucero et aI., 2010).
Alteration of Wnt/ff-catenin signalling pathway through p-catenin co-repressors
is often involved in crucial biological processes ranging from normal
development to cancer. For instance, Sox9 regulates the progression of the
chondrocyte differentiation pathway during endochondral bone formation
through inhibition of p-catenin (Akiyama et al., 2004), whereas the Wnt
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signalling attenuator RUNX3 was proposed to function as a tumour suppressor
during intestinal tumourigenesis (Ito et al., 2008). Moreover, expression of
Chibby, a nuclear p-catenin associated antagonist of the WntlWingless
pathway, was also linked to embryonic development and cancer (Takemaru et
al.,2003).
Collectively, these findings indicate that p-catenin co-repressors function as
potential gate keepers for the activity of p-cateninlTCF complex, ensuring that
the proper threshold of p-catenin is achieved before its interaction with TCFs.
This tight regulation of Wnt signalling in the nucleus determines precise
downstream effects in both normal and cancer development based on the
overall outcome of the interaction between co-activators and co-repressors with
the p-cateninlTCF complex. Given the regulatory importance of nuclear
cofactors (both co-activators and co-repressors) on Wnt signalling pathway, it
is, therefore, predictable that any newly described protein-protein interaction
with the nuclear p-catenin could have crucial involvement in normal versus
tumour development.
A less understood aspect of Wntlp-catenin signalling is the discovery and
involvement of many DNA-binding transcription factors, other than TCF/LEF,
in this pathway. Notably, many of these factors including KLF4, Glis2 and 3,
HICI, and Osx belong to the Cys2-His2 (C2H2) family of zinc finger proteins
characterized by having multiple C2H2-type zinc finger DNA-binding domains
(Evans et al., 2010, Kim et al., 2007, Ulloa et al., 2007, Valenta et al., 2006,
Zhang et al., 2008, Zhang et al., 2006). These zinc finger-containing p-catenin
partners could significantly expand the gene expression programs controlled by
Wntlp-catenin signalling. Due to possessing potential DNA binding properties
in addition to their ability to interact with [I-catenin and/or rCFs (see above
and Table 1-2), zinc finger proteins could disrupt the formation of the p_
cateninlTCF complex and recruit nuclear p-catenin to the promoter of specific
target genes independently to rCFs. However, this model of nuclear p-catenin
recruitment just started to be explored and it needs to be further clarified.
As the current work demonstrates identification and characterization of a novel
p-catenin interacting protein called FLYWCH-type zinc finger protein 1
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(FLYWCH1), comprehensive information about FLYWCH1 and the family of
zinc finger proteins is given in (sections 1.5 & 1.6).
1.3 Non canonical Wnt signalling pathway
In addition to the canonical Wnt-pathway, Wnt-ligands can also trigger non-
canonical pathways which are often referred to as ~-catenin independent
pathways. The non-canonical pathways can be further divided into at least
three other distinct branches, the WntlCa2+, the WntlJNK and the Wntlplanar
cell polarity (PCP) pathways. Upstream, the non-canonical pathways also
involve WntlFz binding but in an LRP and ~-catenin-independent manner.
However, the mechanism of downstream signal transduction through these
pathways is less understood.
Traditionally, non-canonical pathways were implicated in the regulation of cell
movement, polarity, and orientation. However, evidence suggests the
involvement of these pathways in various aspects of normal development,
diseases and cancer (reviewed by De, 2011, Kikuchi and Yamamoto, 2008,
Kohn and Moon, 2005, Sugimura and Li, 2010, Veeman et al., 2003).
Moreover, in addition to the WntlFz pathways, other non-frizzled branches of
non-canonical Wnt-pathway have also been proposed such as Ryk (Lu et al.,
2004), Ror2 (Oishi et al., 2003), and R-Spondin (Kazanskaya et al., 2004)
pathways. The non-frizzled Wnt-pathways were also implicated in several
important cellular processes such as cell migration and convergent extension
(Angers and Moon, 2009, Clark et al., 2012, Semenov et al., 2007).
In general, Wnt signalling pathways (both canonical and non-canonical) are
among the most important pathways that have been widely implicated in
numerous aspects of development, cell biology and tumourigenesis. However,
as outlined above Wntl~-catenin signalling is of particularly relevance to the
normal biology and carcinogenesis of intestine and the following sections
explore this in more detail.
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1.4 Role of canonical Wnt signalling in intestinal
biology
Activated WntJ~-catenin pathway has important implications in all aspects of
intestinal biology ranging from normal development, to cellular homeostasis
and carcinogenesis depending on the context of activation and the surrounding
microenvironment. The various genetic programs controlled by this pathway
through regulation of Wnt-responsive genes are the most important aspect of
this pathway.
1.4.1 The normal architecture of intestine
The intestine represents a very attractive experimental model, in terms of both
normal intestinal development and cancer formation. Anatomically, it has been
divided into the small intestine and the large intestine (comprising the colon
and rectum). The small intestine can be further sub-divided into the duodenum,
the jejunum, and the ileum. Inmammals, the architecture of small intestine is
composed of villi and crypts, lined by a single epithelial layer that is renewed
continuously every few days (less than one week) (van der Flier and Clevers,
2008). This single layer of epithelium consists of stem cells, transit-amplifying
cells and the terminally differentiated subtypes of defensin-secreting Paneth
cells, hormone-secreting enteroendocrine cells, mucous-secreting goblet cells,
and absorbing enterocytes (Figure 1-4) (Brabletz et al., 2009). Moreover,
recently, a new type of secretory cells, known as "tuft" cells, has been added to
the list (Gerbe et al., 2011).
The modular organization of the colon epithelium is similar to that of the small
intestine, except for the absence of villi and Paneth cells (van der Flier and
Clevers, 2008). Many signalling pathways have been reported to play crucial
roles during intestinal morphogenesis, among them the Wnt/~-catenin
signalling has received the most attention. This pathway often coordinates with
other signalling pathways such as Hedgehog, Notch, JNK (c-Jun N-terminal
kinases) and BMP (bone morphogenic protein) to create and maintain the
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microenvironment required for intestinal development and homeostasis
including stem cell regulation, lineage specification and maturation (Miki et
aI., 2011, Nusse et aI., 2008, Saadeddin et aI., 2009). Therefore, any
disturbance to these pathways may negatively or positively affect the normal
structure and organization of the intestine resulting in different type of diseases
including cancer (Brabletz et aI., 2009, Scoville et aI., 2008, Clevers, 2006,
Clevers and Nusse, 2012).
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Figure 1-4: The architecture of the small intestinal mucosa. Terminally
differentiated intestinal epithelial cells (red) are found in the villi; only Paneth cells are
located in the crypt base. Green indicates location of putative intestinal stem cells (dark
green) and the transit-amplifying cells. Crypt base columnar cells (CBCs) selectively
express the Wnt-target gene Lgr5/GPR49. Gradients (or components) of Wnt-pathway
that induce stemness or proliferation is indicated in green. Taken from (Brabletz et al.,
2009).
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1.4.2 Intestinal stem cells and homeostasis
Intestinal stem cells (ISCs) are mulitpotent and self-renewing cells occupying
the bottom of the crypt. These cells are cycling slowly, but produce rapidly
proliferating progeny cells called transient amplifying cells which gradually
differentiate into the five terminally differentiated cell types as described above
in (section 1.4.1).
Homeostasis in the context of intestinal epithelium means keeping a balance
between cell proliferation and differentiation which is required to maintain the
tissue's long-term self renewal capability (regeneration) along the crypt-villus
axis. This process of regeneration of small intestine is supported by the adult
stem cells (Brabletz et al., 2009). In addition to self renewal and pluripotency,
stem cells are also characterized by quiescence and asymmetric cell division.
These cells undergo infrequent asymmetric division in which a single stem cell
generates one rapidly cycling cell which gives rise to the differentiated cells
and another that replaces the parent stem cell (reviwed by Barker and Clevers,
2010).
Recent advances in molecular biology revealed two markers that are expressed
by the adult stem cells in the crypt of the small intestine; the LgrS (Barker et
aI., 2007) and the Bmil (a Polycomb group protein) (Sangiorgi and Capecchi,
2008). Although both of these markers were commonly used to detect the ISCs,
a recent study suggests that Bmi1 and LgrS identify two functionally distinct
populations of stem cells (Yan et aI., 2012). Scientists have spent an enormous
amount of effort to understand how the ISCs behave and how they are
regulated (Brabletz et al., 2009, Lander et aI., 2012, van der Flier and Clevers,
2008). As a result, the concept of the "stem cell niche", a supporting
microenvironment in which stem cells are found, was proposed (van der Flier
and Clevers, 2008). The stem cell niche in the intestine is most likely formed
by the subepithelial myofibroblasts (Mills and Gordon, 2001) and is tightly
regulated through a long-term crosstalk between epithelial and underlying
mesenchymal cells. Although many intrinsic and extrinsic factors are involved,
this crosstalk is mainly mediated by conserved signalling pathways, such as
Wnt, Hedgehog, Notch, PI3K and BMP (reviewed by Brabletz et aI., 2009).
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These pathways are ultimately regulating the developmental lineages of stem
cells in a predictable and reproducible manner.
Wnt/Bvcatenin signalling pathway is considered as a dominant force in
controlling cell fate and proliferation (homeostasis) of normal intestinal
epithelium through stages of development and adulthood (reviewed by Pinto
and Clevers, 2005). Several lines of evidence show the accumulation of ~-
catenin at the bottom of the crypt (8atlle et al., 2002, Lustig et al., 2002) and
also show the in vivo affects of Wnt signalling on the cell lineage across the
crypt-villus axis (Korinek et aI., 1998, Pinto et al., 2003). Indeed, active Wnt
signalling was shown to be essential for the maintenance of crypt progenitor
compartments in the intestine as inhibition of this pathway resulted in
significant defects in the regulatory program of the crypt. For instance, in mice
lacking the Tcf4 transcription factor, the epithelial stem-cell compartments
became deleted (Korinek et al., 1998). Similarly, Fevr et al. (2007) found that
upon blocking of Wntl~-catenin signalling, the transiently amplifying cells
were rapidly lost and the intestinal stem cells were also induced to terminally
differentiated cells, resulting in a complete block of intestinal homeostasis and
fatal loss of intestinal function (Fevr et aI., 2007). Moreover, inhibition of Wnt
signalling by DKKI in adult mice reduced cell proliferation and disturbed the
normal architectural of small intestine and colon (Pinto et al., 2003, Kuhnert et
al.,2004).
Taken together, these observations indicate that Wntl~-catenin signalling has
fundamental roles in regulating homeostasis of the intestinal epithelium
through maintaining the crypt stem celVprogenitor compartments. However,
the maintenance of the intestinal crypt-villus axis also requires a precise
control of the progenitor cell migration during both homeostasis and cancer
development. Models that explain the mechanisms of intestinal cell migration
and positioning across the crypt-villus axis are outlined below (section 1.4.3).
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1.4.3 Cell migration and positioning in intestinal crypts
In normal conditions of small intestine, the transiently amplified progeny of the
stem cells undergo bidirectional migration. Paneth cells migrate to the bottom
of the crypt, while the other three differentiated cell types (enteroendocrine
cells, goblet cells and enterocytes) migrate upward to the apex of the villus
(Potten and Loeffler, 1990, Stappenbeck et al., 1998).
Before identification of the role of Wnt signalling pathway in cell movement
and positioning across the crypt-villus axis, several alternative mechanisms had
been proposed to explain the driving force behind this organised cell
movement. For example, Loeffler et al. (1986) proposed a hypothetical
mechanism involved a cell-cell interaction leading to a local age-dependent
displacement of old cells with newborn cells. In this model, it was assumed
that all cells have certain ability to sense the age of their direct neighbours and
preferentially divide to displace their oldest neighbours to higher cell positions
(Loeffler et al., 1986).
Other researchers suggested a passive mechanism for intestinal cell migration
which can be summarized in two steps. First, generation of cells in the crypts
transmits a pressure along the crypt-villus axis. Second, gaps left by the
expelled mature cells at the top of the villi are immediately reoccupied by new
cells. As a result, the attached epithelial cells are forced to migrate upward
(reviewed by Heath, 1996). Although the passive model for intestinal cell
migration was proposed long time ago, this view is still widely accepted.
However, involvement of additional mechanisms such as chemoattraction or
repulsion in the regulation of intestinal cell migration cannot be excluded
(Solanas and Batlle, 2011).
Essential involvement of the core component of Wnt signalling pathway (p-
cateninlTCF complex) in the migration of intestinal epithelium cells was first
introduced by Hans Clevers group. Batlle et al. (2002) found that p-
cateninlTCF signalling potentially determines cell positioning along the crypt
axis in the small intestine. This effect was mainly achieved through controlling
the expression of Wnt-targets EphB and ephrinB genes through p-cateninlTCF
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signalling (Batlle et al., 2002). Eph receptors comprise the largest known
subfamily of receptor tyrosine kinases characterized for binding to membrane-
bound ligands known as ephrins. These molecules play key roles in the process
of cell migration and adhesion during development (reviewed by Poliakov et
al.,2004).
Moreover, the interaction between EphB2/3 and ephrin-B1 was found to
compartmentalize the expansion of cancer cells both in vivo (in intestinal
adenomas) and in vitro (in CRC culture) (Cortina et al., 2007). In addition,
Ephrin-B2 ligand has been implicated in regulation of endothelial cell
morphology and motility independently of Eph-receptor binding (Bochenek et
al., 2010), indicating that the receptor/ligand interaction is not always required
for the function of these molecules.
The migration of progenitor cells In intestinal epithelium is harmonically
orchestrated through differential expression of Eph/ephrin molecules by Wnt
signalling pathway. It has been shown that p-cateninITCF signals promote the
expression of EphB2 and EphB3 receptors, whereas they repress the expression
of EphB ligands, namely ephrin-Bl and ephrin-B2 (Batlle et al., 2002). The
strength ofWnt signal as well as EphB2/3 expression is high in cells resident at
the bottom of the crypt, while as cells are migrating upward the Wnt
signals/components are reducing gradually permitting gradual increase in
expression of ephrin-Bl and ephrin-B2 ligands. The opposite expression of
EphB receptors and ephrin-B ligands in different cell compartments along the
crypt axis leads to differential adhesion capabilities of the epithelial cells which
eventually regulate cell positioning and migration along the crypt-villus axis
(Wong et al., 2010a).
Although, the biological effects of Eph/ephrin molecules are relatively well
understood, regulatory factors and/or pathways upstream to these molecules are
largely unknown. Moreover, the link between gradient concentration of Wnt
signalling pathway and the differential expression of Eph-B/ephrin-B proteins
along the crypt axis is not fully understood. Furthermore, in addition to
Eph/ephrin proteins, many other factors have been involved in regulation of
cell adhesion and migration in the intestinal epithelium such as E-cadherin,
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p120-catenin, and Small GTPases of the Rho family (reviewed by Solanas and
Batlle, 2011). Thus, identification of factors that could provide specificity to
the components of Wnt signalling pathway to differentially regulate
downstream target genes that involved in cell migration remains of particular
interest.
1.4.4 Intestinal tumourigenesis
Giving the critical roles of Wntlp-catenin signalling in normal development,
stem cells homeostasis, and cell positioning in the intestine (sections 1.4.1 to
1.4.3), it is not surprising that aberrant activation of this pathway is strongly
associated to intestinal/colon tumourigenesis. Indeed, it has been found that
deregulation of Wntlp-catenin signalling pathway, the central early event in
colorectal carcinogenesis, is implicated in over 90% of human colorectal
cancers (Fevr et al., 2007). Most of these cases are linked to mutational
inactivation of Wntlp-catenin pathway components including APC, AXINI or
CTNNBI genes. For instance, mutation of APC, the most common cause of
activated Wnt signalling, occurs in 85% of all sporadic and hereditary
colorectal tumours (Kinzler and Vogelstein, 1996). These mutations (both
germline and somatic) result in truncated proteins lacking important domains
such as AXIN and p-catenin binding sites (reviewed by Segditsas and
Tomlinson, 2006). In addition, mutations in AXINI and CTNNBI genes were
also broadly detected in colorectal cancer cell lines (Ilyas et al., 1997, Morin et
al., 1997, Shimizu et al., 2002, Webster et al., 2000).
Mutant APe and Axin proteins are unable to form a proper destruction
complex with GSK-3p which subsequently impairs the phosphorylation of p-
catenin. Similarly, amino acid substitutions in the phosphorylated residues of
p-catenin lead to phosphorylation blockade and stabilization of this protein.
Either type of disruption leads to accumulation and nuclear translocation of p-
catenin which ultimately causes aberrant activation of Wnt signalling pathway.
Moreover, alteration of p-catenin expression in colorectal cancer, adenoma,
and both dysplastic and nondysplastic aberrant crypt foci (ACF) was also
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reported (Mi et al., 2009). Given the importance and influence of Wnt
signalling components on the stability of cytosolic p-catenin, appropriate
regulation of these components in the context of Wnt-pathway is a crucial step
by which the accumulation of nuclear p-catenin can be regulated. In addition,
p-catenin is tightly regulated in the nucleus through several regulatory
cofactors. The basic concept behind this regulation of p-catenin in both
cytoplasmic and nuclear compartments is to transcriptionally modulate Wnt-
target genes, including those related to human colon cancer (Table 1-3), in a
spatial and temporal manner.
Table 1-3: Examples of Wntlp-catenin downstream target genes involved in
cancer. Taken from Wnt homepage hosted by Nusse
(http://www.stanford.edu/-rnusse/pathways/targets.html).
Genes Organism/system in Referenceswhich first identified
e-mye human colon cancer (He et aI., 1998)
Tef-7 human colon cancer (Roose et al., 1999)
LEF7 human colon cancer (Filali et al., 2002, Hovanes et
al.,2001)
ejun human colon cancer (Mann et aI., 1999)
fra-7 human colon cancer (Mann et al., 1999)
VEGF human colon cancer (Zhang et al; 2001)
EphB/ephrin-B human colon cancer (Batlle et al., 2002)
Cye/in 01 human colon cancer (Tetsu and McCormick, 1999)
Cdh7 (E-cadherin) Mouse hair follicle (Jamora et al., 2003)
It has been established that signalling through p-cateninlTCF complex
constitutes the principal driving force behind the biology of the crypt (Korinek
et aI., 1998). In the same context, Wnt/Bvcatenin signals resulting from aberrant
accumulation of nuclear p-catenin play essential roles in tumourigenesis of the
31
Chap 1: General Introduction
intestine. This view is strongly supported by the fact that the majority of Wnt-
target genes in human colorectal cancer cells are physiologically expressed in
intestinal crypts by either Paneth cells or transit-amplifying cells (van de
Wetering et aI., 2002, Van der Flier et aI., 2007). One of the well studied
examples of the direct Wnt-target genes expressed in the intestinal crypt are
EphB/ephrin-B genes. In addition to their critical implication in cell migration
and positioning in the intestinal crypt (section 1.4.3), these molecules were also
involved in carcinogenesis of intestine. It has been reported that dissociation of
EphB2 kinase-dependent and independent pathways play critical roles in
progenitor cell proliferation and tumour suppression (Genander et aI., 2009).
Moreover, recent data indicate that ephrin-B2 has been strongly involved in
tumour angiogenesis and lymphangiogenesis through regulating members of
VEGF (vascular endothelial growth factor) family of growth factors
(Sawamiphak et aI., 2010, Wang et aI., 2010). Similarly, deregulation of
ephrin-B2 disturbed the normal architecture, function, and vascularisation of
the mammary gland and promoted metastasis formation in transgenic mice
(Haldimann et aI., 2009). Thus, through direct regulation of the Wnt-target
genes transcriptional program, ~-catenin can potentially control normal
development as well as carcinogenesis of the intestine in the context of
canonical Wnt signalling pathway.
This classical model of B-catenin involvement in colon cancer became more
complicated as many potential p-catenin interacting partners other than TCFs
were already discovered and identification of novel partners is still ongoing.
On the other hand, the oncogenicity of this pathway has been recently
reconsidered in some types of cancer such as melanoma where the stabilized ~-
catenin was not enough to induce melanoma in mice (Delmas et aI., 2007).
Furthermore, TCF4, the main downstream effector of Wnt signalling pathway,
has been shown to function as a tumour suppressor in a Tcf4 conditional knock
out mouse (Angus-Hill et al., 2011). Moreover, activated Wntl~-catenin
signalling in patient tumours, indicated by increased levels of nuclear ~-
catenin, correlated with an improved rather than poorer prognosis (reviewed by
Lucero et aI., 2010). This controversial role of ~-cateninlTCF4 signalling in
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cancer may be further explained by the contribution of other regulatory
proteins involved in various roles mediated by ~-catenin.
1.4.5 Multistep carcinogenesis in colorectal cancers
Colorectal cancer (CRC) is the 2nd most common cause of cancer-associated
death in developed countries (Ricci-Vitiani et al., 2007). It occurs either
sporadically as a result environmental and dietary factors, or hereditary in the
context of a familial predisposition such as familial adenomatous polyposis
(FAP) (Cunningham et al., 2010, Fodde et al., 2001, Pinto and Clevers, 2005).
In both cases, CRCs arise from a series of well-defined histo-pathological
changes associated with specific genetic alterations in a number of oncogenes
and tumour-suppressor genes resulting in malignant tumour development in a
stepwise process known as multistep colorectal tumourigenesis (Yamada and
Mori, 2007, Fodde et al., 2001, Hughes and Huang, 2011).
The concept of multistep colorectal tumourigenesis was first introduced by
Fearon and Vogelstein at early 1990s. In their model they described a process
by which normal colonic cells could transform to tumour cells through a
number of genetic alterations/mutations in both proto-oncogenes and tumour-
suppressor genes (Fearon and Vogelstein, 1990). Since then the accumulated
evidence further supported this model and increased our understanding about
how solid tumour developed and led to today's knowledge of tumour
. .
carcmogenesis.
Although the precise order of alterations necessary for cancer development are
not fully understood, it is widely believed that mutation in APe (adenomatous
polyposis coli), a classic tumour-suppressor gene found on chromosome 5q, is
the earliest and essential genetic alteration in the sequential events of colon
tumour development (Figure 1-5) (Yamada and Mori, 2007, Huang et al., 1997,
Fearon and Vogelstein, 1990, Pinto and Clevers, 2005, Pino and Chung, 2010).
Germline mutations in APe cause the inherited familial adenomatous polyposis
(FAP) syndrome with tumours containing mutated/inactivated wild-type allele
of APe, most often by deletion (Goss and Groden, 2000, Kinzler and
Vogelstein, 1996). People with FAP develop hundreds to thousands of colonic
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adenomas at an early age. If not surgically removed, the risk of these polyps
developing into cancer rises dramatically with age and during the third to
fourth decade of life the lifetime risk of colon cancer approaches 100% (Fodde
et al., 2001, Markowitz et al., 2002, Albuquerque et al., 2002). Accordingly,
appearance of aberrant crypt foci (ACF) is one of the earliest alterations seen in
the epithelium during the adenoma-carcinoma sequence of CRCs development
(Bird, 1995, Fodde et al., 2001). ACFs contain dysplastic cells that could
progress into benign adenomatous polyps and mutations in APC are closely
related to the development of dysplasia in these small lesions (Fodde et aI.,
2001). Subsequent mutations in other genes (see below) along with the
alterations in critical signalling pathways such as Wntl~-catenin pathway lead
to gradual progression of the benign adenomatous polyps into carcinoma
(Albuquerque et aI., 2002, Pinto and Clevers, 2005, Fodde et aI., 2001, Hughes
and Huang, 2011, Kinzler and Vogel stein, 1996).
One of the well documented roles of APC gene is regulation of Wnt/B-catenin
signalling pathway. It has been established that APC is an important
component of the destruction complex found in the cytoplasm (see section
1.2.1 & Figure 1-1) and responsible for the degradation of the p-catenin protein
that involved in the canonical Wnt signalling pathway. Through this
degradation, APC protein functions as a suppressor of this pathway, and
thereby inhibits the p-catenin mediated transcriptional activity (Aoki and
Taketo, 2007, Markowitz et aI., 2002). However, mutations in the APC gene
interfere with this function and lead to an increased cytoplasmic pool of p-
catenin which subsequently translocate into the nucleus and activates Wnt-
target genes including c-Myc, Cyclin DI, c-jun & Fra-I, resulting in increased
cell proliferation (He et aI., 1998, Shtutman et aI., 1999, Tetsu and
McCormick, 1999, Mann et aI., 1999). Much more detail about the canonical
Wnt signalling pathway is mentioned in (section 1.2).
In addition to increased cell proliferation by Wnt signalling pathway, other
genetic alterations (see below) activate additional pathways such as
transforming growth factor ~ (TGF-~) pathway that play crucial roles in
tumour development (Fodde et aI., 2001). These alterations cause gradual
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changes in tumour cell physiology which ultimately lead to aberrant biological
activities known as hallmarks of cancer such as uncontrolled cell proliferation,
resisting cell death, insensitivity to antigrowth signals, angiogenesis ... etc
(Hanahan and Weinberg, 2000, Hanahan and Weinberg, 2011).
Other genetic alterations including activation of the oncogene K-RAS (occurs in
35-50% of CRCs) and inactivation of the tumour suppressor TP53 (occurs in
more than 50% of CRCs), are thought to be later events that occur in the
multistep colorectal carcinogenesis (Figure 1-5) (Calistri et al., 2006, Judson et
al., 2006, Fodde et al., 2001, Hughes and Huang, 2011, Boland and Goel, 2010,
Pino and Chung, 2010).
APClp-catenin
!
KRASI, ~ TP53, PIK3CAloss of 18q!
Normal
mucosa
+
Aberrant
crypt focus
Early
adenoma
Late
adenoma
Invasive
cancer
t
EGFR,COX2
Figure 1-5: Multistep genetic model of colorectal carcinogenesis. The initial step in
colorectal tumorigenesis is the formation of aberrant crypt foci (ACF). Activation of the
Wnt signalling pathway can occur at this stage as a result of mutations in the APC
gene. Progression to larger adenomas and early carcinomas requires activating
mutations of the proto-oncogene KRAS, mutations in TPS3, and loss of heterozygosity
at chromosome 18q. Mutational activation of PIK3CA occurs late in the adenoma-
carcinoma sequence in a small proportion of colorectal cancers. Chromosomal
instability is observed in benign adenomas and increases in tandem with tumour
progression. Taken from (Pino and Chung, 2010).
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In addition to mutations in the above genes, alterations in several other genes
have also been identified along the multistage process of colon tumour
progression. These include activations of oncogenes such as B-RAF, PIK3CA,
and CTNNBI and inactivation of tumour-suppressor genes such as SMAD2 &
SMAD4, DCC, Cox-2, EGFR, and TGFp (reviewed by Markowitz et al., 2002,
Fodde et al., 2001, Pinto and Clevers, 2005, Boland and Goel, 2010).
Moreover, the sequential acquisition of cancer development is promoted by the
loss of the genomic stability including chromosomal instability (CIN),
microsatellite instability (MSn, and CpG-island methylator phenotype (CIMP)
(Dahlin et al., 2010, Boland and Goel, 2010, Pino and Chung, 2010). CIN
occurs in 65-70% of sporadic colorectal cancers and characterized by
widespread imbalances in chromosome number (aneuploidy) and structure due
to a variety of defects including abnormal chromosomal segregation, telomere
stability, DNA damage response, deletions, replications, insertions, base
substitutions, and chromosomal rearrangements (Gollin, 2005, Pino and
Chung, 2010). Certain genes described above are commonly associated to CIN
such as APC and p53 (Pino and Chung, 2010). MSI occurs in 12-17% of
colorectal cancers and associated to inactivation of DNA mismatch repair
genes during DNA replication (Boland and Goel, 2010). The germ-line MSI
pathway (occurs in about 3% ofCRCs) is associated to the Lynch syndrome or
HNPCC (hereditary nonpolyposis colorectal cancer) (Boland and Goel, 2010)
and see below. The third form of genomic instability, CpG-island methylator
phenotype (CIMP), is characterised by extensive hypermethylation of CpG-
rich promoters and associated with microsatellite instability (MSI) and BRAF
mutation in colorectal cancer (Issa, 2004, Dahlin et al., 2010, Ogino et al.,
2009). CIMP is attributed to 70-80% of sporadic MSI-positive and 15% of total
CRCs (lssa, 2004).
Lynch syndrome (HNPCC), is an autosomal dominant disorder and a common
cause of hereditary colorectal cancer (Lynch and Lynch, 2000). Patients with
this syndrome have an 80% lifetime risk of colon cancer (Markowitz et al.,
2002). The genetic basis of HNPCC contributes to microsatellite instability
caused by germline mutations in components of the DNA mismatch repair
(MMR) genes (Markowitz et al., 2002, Kinzler and Vogelstein, 1996). The
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products of these genes recognize and correct base pair mismatches and small
nucleotide mutations (insertion/deletion) that occur during DNA replication
and, thereby, preserve genomic integrity. Therefore, in cells with MMR defects
the mutation rate is much higher (100-1000 folds) than normal cells (Fishel and
Wilson, 1997, Narayan and Roy, 2003). In 90% of cases of HNPCC, mutations
are found in MSH2 or MLHl, which encode two required components of the
mismatch repair complex. In addition to MSH2 or MLHl, mutations in at least
two other MMR genes (MSH6, and PMS2) have also linked to HNPCC
(reviewed by Jensen et al., 2010, Markowitz et al., 2002).
1.5 The family of zinc finger proteins
The term zinc finger protein (ZFP) is applied to an important family of
eukaryotic proteins that have one or multiple zinc finger domains or motifs. A
zinc finger motif can be described as a small, functional, independently folded
domain that is organized strategically through coordination of one or more zinc
ions to stabilize its structure (Iuchi and Kuldell, 2005, Michalek et al., 2011).
The main feature of zinc finger motifs is the presence of cysteine and/or
histidine residues around a zinc ion forming a tetrahedral geometry (Figure
1-6) (Brayer and Segal, 2008). This domain will be folded to a functional unit
only in the presence of zinc; in the absence of zinc the domain will be unfolded
and hence unfunctional (reviewed by Michalek et al., 2011).
Historically, zinc finger motifs were first identified by a group of scientists in
1985 in the lab of Aaron Klug at the MRC laboratory of Molecular Biology in
Cambridge, where they were working on a Xenopus transcription factor,
TFIIIA (Miller et al., 1985). Thereafter, a large number of proteins (more than
24,000) with similar zinc finger domains have been discovered and annotated
as C2H2 (Cys--Hisi) or classical zinc finger proteins (CZFPs) (Iuchi and
Kuldell, 2005). Since its discovery, the family of zinc finger proteins has been
found to be widespread in nature and has been considered as one of the largest
families of regulatory proteins in mammals (Kubo et al., 1998, Iuchi, 2001).
Accordingly, recent findings indicate that approximately 3% of the whole
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human genome encodes zinc finger proteins (Klug, 2010), suggesting that these
motifs could have crucial biological implications.
Figure 1-6: The canonical C2H2 zinc finger structure. A ribbon diagram of the third
C2H2 domain from TFIIiA in Xenopus /aevis (POB accession number HF3) is showing
the canonical stabilization of the f3f3a fold by the coordination of a zinc ion (yellow) by
two cysteine (green) and two histadine (blue) residues. Taken from (Brayer and Segal,
2008).
Although zmc finger motifs were originally identified as DNA-binding
domains (Miller et al., 1985), a growing body of evidence has described these
motifs as interaction modules that can bind to various compounds such as
DNA, RNA, proteins, and small molecules (Brayer and Segal, 2008, Krishna et
al., 2003). Some of these fingers support both DNA and protein interactions
such as Spl, and Ying Yang 1 (YYl) (Rotheneder et al., 1999, Seto et al.,
1993, Zhou et al., 1995). Thus, it is not surprising that zinc finger-containing
proteins have been broadly involved in various biological processes of the cell
including gene expression, replication and repair, metabolism, signal
transduction, proliferation, differentiation and development (reviewed by Iuchi
and Kuldell, 2005, Krishna et aI., 2003, Matthews and Sunde, 2002). In
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addition, zinc finger-containing proteins, especially those contain the classical
C2H2 zinc fingers have been potentially implicated in tumour suppression
activities such as Wilms tumor suppressor protein (WT1) (Madden et al.,
1993), zinc-finger proteins; ZNF382 (Cheng et al., 2010) and lNF545 (Wang
et al., 2012).
Zinc fingers are structurally and functionally diverse and are present among a
vast variety of proteins. Therefore, scientists have tried to classify them based
on different criteria such as the number and type of amino acids involved in
zinc coordination (Leon and Roth, 2000) or based on the structural properties
and the overall shape of the protein backbone in the folded domain (Krishna et
al., 2003). The latter model is more comprehensive and systematic. According
to this model, zinc fingers have been classified into eight fold groups (Table
1-4), three of these fold groups (C2H2-like finger, treble clef finger, and the
zinc ribbon) comprise the majority of these fingers (Krishna et al., 2003).
As our understanding of zinc fingers has increased, more than 14 different
classes and subfamilies of these proteins have been identified such as C2C2,
CCHC, CCCH, LIM, RING, TAl, and FYVE with more focus on the C2H2
classical family of zinc finger proteins (reviewed by Brayer and Segal, 2008,
Iuchi and Kuldell, 2005, Michalek et al., 2011). However, up to now the
functional involvement of some of these proteins in the biological system of
the cell remains unknown.
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Table 1-4: Structural classification of zinc fingers. Taken from (Krishna et aI.,
2003), also available at (http://prodata.swmed.edu/zndb/zndb_view.php).
Fold groups Representative structure
Gag knuckle
Treble clef
Zinc ribbon
Zn2/Cys6
TAZ2 domain
like
Zinc binding
loops
Metallothionein
Brief description
Beta-hairpin followed by an alpha-helix. Two zinc
ligands are contributed by a zinc knuckle at the
end of the beta-hairpin and the other two ligands
are from the C-terminal end of the alpha-helix.
Two short beta-strands connected by a turn (zinc
knuckle) followed by a short helix or a loop. Two N-
terminal zinc ligands are donated by the zinc
knuckle and two others come from the loop or are
placed at both ends of a short helix.
Beta-hairpin at the N-terminus and an alpha-helix
at the C-terminus. First two ligands come from the
zinc knuckle and the second two ligands are
donated by the N-terminal turn of the helix.
Two beta-hairpins forming two structurally similar
zinc-binding sub-sites. The ligands are contributed
by two zinc-knuckles.
Zinc-binding domains in which two ligands are
from a helix and two more from a loop.
Zinc-binding domains where the ligands are
located at the termini of alpha-helices.
Zinc binding loops found in larger proteins
probably stabilized by zinc and may be viewed as
small but separate domains. Common structural
feature of these domains is that at least three zinc
ligands are very close to each other in sequence
and are not incorporated into regular secondary
structural elements.
Cysteine-rich loops, which bind a variety of metals.
No clearly defined regular secondary structural
elements can be detected and the protein chains
are wrapped around a metal cluster with multiple
cysteines liganding metals.
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1.6 FLYWCH-type zinc finger proteins
1.6.1 Origin and description
The FLYWCH motif is one of the less studied members of the classical C2H2
zinc finger domains. The name "FLYWCH" refers to the amino acid consensus
sequence of this motif which characterized by the presence of four
hydrophobic amino acid residues [F (phenylalanine), L (leucine), Y (tyrosine),
and W (tryptophan)] in conserved positions in addition to a preserved C2H2
motif. Buchner et al. (2000), first described this domain as an anonymous new
member of the classical C2H2 family of zinc finger motifs in the Drosophila
Modifier of mdg4 proteins Mod(mgd4) (Buchner et al., 2000). Three years
later, this domain was annotated as a FLYWCH domain based on the presence
of FLYWCH consensus sequence (FIY-Xn-L-Xn-FN-Xn-WXCX6-12CX17-
22HXH; where X indicates any amino acid) (Dom and Krauss, 2003).
Moreover, a later report revealed the presence of this motif in another
Drosophila protein namely "Drosophila GST-containing FLYWCH zinc finger
protein" (dGFZF) (Dai et al., 2004).
In addition to Drosophila, FLYWCH motifs were also identified in two
proteins of Caenorhabditis elegans (c. elegans); PEB-l (Beaster-Jones and
Okkema, 2004) and FLYWCH transcription factors; FLH-l, FLH-2, and FLH-
3 (Ow et al., 2008). Moreover, FLYWCH motifs have also found in a highly
conserved un characterized protein in mammals named as FLYWCHI (Gene
ID: 84256). More information about this protein is given below.
1.6.2 Function and importance
The Drosophila mod(mdg4) gene, in which the FLYWCH motif was first
identified, encodes a family of at least 26 protein isoforms. All these isoforms
share a common N-terminal region, but differ in their C-termini which, with a
few exceptions, contain a conserved FLYWCH zinc finger motif (Dom and
Krauss, 2003). The Drosophila Mod(mdg4) proteins were suggested to have a
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putative function as chromatin modulators involved in higher order chromatin
domains. Moreover, a general model of function of these isoforms in
Drosophila was also proposed (Figure 1-7) (Dorn and Krauss, 2003). In this
model, different Mod(mdg4) protein isoforms were considered as specific
chromatin modules that interact with identical partners through their common
BTBIPOZ (BTB) N-terminal region. Each isoform then selectively interacts
and recruits specific proteins to different chromatin sites through their variable
C-termini which contain FLYWCH motif.
This proposed function of FLYWCH motif was based on previous evidence
that proteins with FLYWCH domain were involved in protein-protein
interactions; for example, the Drosophila Mod(mdg4)-67.2 isoform interacts
with the DNA-binding protein Suppressor of Hairy-wing (Su(Hw)) via its C-
terminal region which contains a FLYWCH domain (Gause et al., 2001, Ghosh
et al., 2001). Moreover, the specific C-terminal region of another isoform,
Mod(mdg4)-56.3/DOOM, containing the conserved FLYWCH motif was
shown to be responsible for its interaction with the inhibitor of apoptosis
protein of Baculovirus OpIAP (Harvey et al., 1997).
The second Drosophila FLYWCH motif-containing protein, dGFZF, possesses
a tandem array of four FLYWCH motifs at the N-terminal domain and is
expressed through all stages of Drosophila embryonic development. Thus, it
has been postulated to have an important role in maintaining homeostasis
during Drosophila development (Dai et al., 2004). dGFZF which is also known
as Suppressor of Killer of prune Su(Kpn) (Provost and Shearn, 2006) lacks the
nuclear localization signal (NLS) motif and is localized into the cytoplasm in
Drosophila S2 cells. Therefore, it is not clear whether FLYWCH motifs of this
protein could bind DNA. However, its involvement in protein-protein
interactions was predicted (Dai et al., 2004, Provost and Shearn, 2006). Thus,
FLYWCH motifs within Drosophila proteins may playa crucial role in gene
regulation and development through interaction with other transcription factors
and/or binding to DNA.
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Figure 1.7 : Model representing Mod(mdg4) proteins as chromatin modules. A
Mod(mdg4) homodimer formed via interactions between Nterminal BTB domains and
other proteins is shown. Ahmad, Engel & Prive (1998) postulated such a putative
protein binding site formed by the BTB domain dimer (Ahmad et al., 1998). The Chip
protein was demonstrated to interact with the common N-terminal region present in all
Mod(mdg4) isoforms (Gause et al., 2001). The variable C-terminal regions of different
Mod(mdg4) protein isoforms, mostly containing the FLYWCH motif, are postulated to
interact with different proteins, and thereby mediating targeting of the proteins to
different chromatin sites. The DNA binding protein Su(Hw), which was found to interact
with Mod(mdg4)-67.2 (Gerasimova et al., 1995) is shown. The inhibitor of apoptosis
protein (lAP) represents another interacting protein, which interacts with the specific
domain of Mod(mdg4)-56.3 (Harvey et al., 1997). Taken from (Dorn and Krauss, 2003).
In C. elegans, FLYWCH-motif containing proteins have been involved in
specific DNA binding (Beaster-Jones and Okkema, 2004, Ow et aI., 2008). For
instance, PEB-l is one of four proteins in C. elegans which contains a single
copy of the conserved FLYWCH motif at the N-terminus domain. This protein
was identified as a site-specific DNA-binding protein and the FLYWCH motif
was found to be necessary for its DNA binding properties as well as in vivo
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function (Beaster-Jones and Okkema, 2004). Three other proteins in C. elegans
were recently identified as FLYWCH transcription factors; FLH-l, FLH-2, and
FLH-3. These factors also contain a single copy of the conserved FLYWCH
domain at their N-termini and they have been shown to bind the promoters of
several microRNA (miRNA) genes and repress their expression during
embryogenesis (Ow et al., 2008). Moreover, the yeast one-hybrid (YIH)
analysis showed that PEB-l could also binds to the promoter of several
miRNAs (Martinez et al., 2008). These data emphasize the importance of
FLYWCH-motif containing proteins in the regulatory network of miRNA in C.
elegans which perhaps could be expanded to other proteins that contain this
type of zinc finger domains in mammals.
Although the human FLYWCHI gene was identified a few years ago
(Brandenberger et al., 2004, Stelzl et al., 2005), the protein product of this gene
(FLYWCHI) remained uncharacterized. Therefore, information about this
protein in human and other mammals is currently very limited. In fact, there is
no published report, so far, about FLYWCHI in mammals. Thus, in the current
work, for the first time, human FLYWCHI was bioinformatically analyzed and
experimentally characterized. FLYWCHI contains a tandem array of five
FLYWCH-type DNA-binding zinc finger motifs. However, no evidence for the
presence of a transactivation domain within the coding region of this protein is
currently available. Importantly, the FLYWCH motifs are highly conserved
within all currently identified members of mammalian FLYWCHI family of
proteins including mouse, chimpanzee, dog, cow, and rat (see chapter 3 of the
present study).
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1.7 Rational and objectives of this study
1.7.1 Rational
While the role of canonical WntJ~-catenin-signalling in the development of
both normal and malignant tissues is well documented, the molecular basis of
these functionally distinct nuclear transcriptional programs is poorly
understood. It has long been believed that members of TCFs are sole partners
of nuclear ~-catenin by which the downstream nuclear events of activated
WntJ~-catenin signalling pathway is mediated (Batlle et al., 2002, Graham et
al., 2001, Seidensticker and Behrens, 2000). However, the paradox of ~-
cateninlTCF interaction was challenged by identification of new strategies for
~-catenin-dependent but TCF-independent gene regulation. It has been reported
that ~-catenin interacts with Propl, a specific homeodomain factor, rather than
members of TCFs to regulate the cell lineage determination during pituitary
gland development (Olson et al., 2006). In addition, ~-catenin was also found
to regulate the pluripotency of ESCs through interaction and enhancement of
Oct4 activity independently of TCFs factors (Kelly et al., 2011).
Furthermore, the role of TCF4 in tumour development is still a subject of
debate. The conventional Tcf4-knockout mouse, dies shortly after birth, shows
a loss of proliferating cells in the small intestine, and it is presumed to lack a
functional stem cell compartment (Korinek et aI., 1998). This finding let to a
general assumption that the formation of TCF4/~-catenin complex is cancer-
promoting. However, later studies have found that TCF4 is mutated in several
cancers such as colorectal and bladder cancer (Lee et aI., 2010, Fukushima et
aI., 2001, Duval et aI., 1999). Moreover, recently a gut conditional depletion of
mouse Tcf4 increased cell proliferation leading to colon tumourigenesis
(Angus-Hill et aI., 2011), giving the notion that Tcf4 may function as a tumour
suppressor. In addition, the activity of ~-cateninlTCF4 complex is tightly
regulated in the nucleus through several co-activators and/or co-repressors (see
section 1.2.4). Taken together, these findings changed the classical view of the
canonical Wnt signalling pathway and encouraged scientists to investigate the
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molecular mechanisms involved in regulation of ~-catenin signalling in more
detail.
In this view, Dr Nateri and his colleagues has previously hypothesised that the
diversity of ~-catenin interaction with TCF4 and/or other cofactors may be
influenced by ~-catenin phosphorylation and may also identify whether or not
distinct patterns of transcriptional coregulators are engaged in ~-catenin
signalling during normal vs. tumour development (Dr Nateri, personal
communication). To this end, Dr Nateri's laboratory have recently identified
several other transcriptional cofactors, in addition to TCFs, that are possibly
interacting with ~-catenin in a phosphorylation-dependent and independent
manner using a modified yeast-2-hybrid based Ras-Recruitment System (RRS)
(Figure 1-8, A & B) (Saadeddin A et al. unpublished data). These factors may
be required for regulation of the downstream Wnt-target genes by ~-
cateninlTCF4. Among other candidates, CIPI (~-Catenin Interacting ~rotein
#1) which corresponds to the human FLYWCHI gene drew our attention and
further characterized in this work.
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Figure 1-8: Identification of Fl YWCH1 as unphosphorylated ~-catenin interacting
protein in yeast. A) Schematic representation of the modified yeast two-hybrid Ras
Recruitment System (RRS) used to identify new proteins that bind to p-catenin in a
phosphorylation-dependent and/or independent manner using mouse embryonic cDNA
library (Stratagene). B) A Western blot of ceillysates with antibodies to GSK-3p, FLAG
and p-p-catenn is shown. Phospho-p-catenin is induced by withdrawal of methionine.
CIP1 (p-catenin Interacting Protein-1), encodes a potential transcription factor with five
FLYWCH Zn-finger DNA-binding domains, called "FLYWCH1 ". It was identified as an
interactor that specifically bound to unphosphorylated ~-catenin in yeast. Figures are
taken from (Saadeddin A et al. unpublished data and Dr Nateri, personal
communication).
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1.7.2 Objectives & Aims
In the light of the above discussion regarding the interaction of FLYWCHI
with ~-catenin in yeast cells and considering that FLYWCHI is an
uncharacterized protein with unknown function in mammals, lots of questions
regarding FLYWCHI expression pattern & cellular distribution, its interaction
with ~-catenin in mammalian cells, and the its biological function in cancer
cells need to be answered. Therefore, the present project was aimed to study
the role ofFLYWCHI in CRC cells through:
i) Gain-of-function experiments by cloning and expressing the full-length
human FLYWCHI cDNA in different human cell lines.
ii) Physical and functional interaction experiments, including mapping the
interaction domains that are required for FLYWCHI interaction with ~-
catenin and vice versa in human cell culture.
iii) Characterization of the biochemical and the cellular properties of
FLYWCHl, including gene expression pattern and sub-cellular
localization.
ivy Exploring the effect of FLYWCHI on the biological traits of CRC cells
and evaluating its possible contribution to cancer development using
various approaches including Wnt-target genes analyses, as illustrated in
(Figure 1-9).
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Identification of novel p-catenin interacting proteins
using "Yeast 2-hybrid Ras recruitment system"
Cloning of Human FL YWCH1 cDNA
)10 mammalianexpressionveeto\,
t-----------------------------------------------------.---------- -------------------------------------------------------------------i Biochemical Analysis i Functional Analysis
i>Cell culture expression & sub-cellular i>Luciferase, migration, and proliferation assays.
i localization pattern. i> Target gene expression using qRT-PCR.
1>Site directed mutagenesis. 1>Tissue expression pattern (mouse and human)
i>Westem blot, Co-lP, and IF assays. i using ISH and TMA.
--- - -- --- --- -- -- - - -- -- - - - -- -- - - - - -- ----- --- ------- ---- --- -- -- - _- __ I ~ - - ----- -- - - -- - - --- - - - - -- - --------- - - - -- ---- - - - -- -- --- -- - - --
Role of FLYWCH1in CRC cells
Figure 1-9: Outline summary of the experimental research plans applied in this
study. The interaction of FLYWCH1 with ~-catenin was originally discovered in Dr
Nateri's laboratory in a yeast-2-hybrid assay. In the current work, FL YWCH1 gene is
cloned into different mammalian expression vectors and both biochemically and
biologically analysed using various approaches as indicated.
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All procedures were carried out under aseptic condition where appropriate and
relevant safety regulations were followed. Standard protocols used throughout
the thesis were either developed or followed from previously established
templates. Where necessary, modifications were incorporated into the standard
protocols for specific use.
2.1 Materials
2.1.1 Cell lines
A transformed human cell line HEK293T (Human Embryonic Kidney), human
fibroblast cells (called TIGER cells), and four human CRC cell lines (HCTI16,
DLD-l, SW620, and SW480) were used throughout this study. HEK293T cell
line (Dr Nateri's laboratory) was originally derived from normal human
embryonic kidney cells transformed to immortalized cells by sheared DNA
from adenovirus type 5 (Graham et aI., 1977). These fast-growing cells are
relatively easy to transfect with high transfection efficiency and protein yield
(Parham et aI., 1998, Pham et aI., 2006, Soni and Lai, 2011). The human
fibroblast cell line (Dr Nateri's laboratory) was a kind gift from professor
Gordon Peters (Molecular Oncology Lab, CRUK- London Research Institute).
HCT116 adenocarcinoma cell line contains mutation in the ~-catenin gene
(CTNNB1) (Ilyas et aI., 1997), while DLD-l, SW480, and SW620
adenocarcinoma cell lines contain different truncated forms of the APC gene
(Korinek et aI., 1997, Morin et aI., 1997). SW620 is a metastatic cell line,
derived from lymph nodes whereas other cancer cell lines are isolated from
primary CRC tumours (Zhuo et aI., 2012, Duranton et al., 2003). These cell
lines were originally purchased from the American Type Culture Collection
(ATCC) (Dr Nateri's laboratory).
The morphology of the cell lines was checked on regular basis for mycoplasma
infection and to confirm the correct identity of the cell lines. Whenever
required, further investigations for the cell line identities were also performed.
All cell lines were maintained as described in (section 2.2.4.1) and used within
low passage number (up to 12).
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2.1.3 Oligonucleotides
The oligonucleotides used in this study (Table 2-2 to Table 2-6) were designed
either manually for standard polymerase chain reaction (Pf'R) (section 2.2.2.5)
or with the help of the primer3 web based primer design tool (Version 004.0,
available at http://frodo.wi.mit.edu/primer31) for quantitative real time
polymerase chain reaction (qRT-peR) (section 2.2.3.3). The specificity of the
primers was checked by blasting the primer sequences against the NeBI
human transcript database (http://www.ncbi.nlm.nih.gov/tools/primer-blastl)
and an example is given in the (Appendix 10). All primers were supplied by
Sigma and upon arrival they were spun down and resuspended in an
appropriate volume of Sigma distilled water to give a final concentration of
100micromolars (~M) as a stock and stored at -20oe until use.
Table 2-2: PCR primers used to amplify the full-length (wild-type) and deletion
mutants of MYC-tagged FlYWCH1. Restriction enzyme sites are underlined, MYC-
epitopes* within the forward primers are shown in italic, and the stop codons within the
reverse primers are shown in bold. The core primer sequences are highlighted in grey.
Clones Primer sequences 5' to 3' Restrictionsites
Forward:
I- GGCTAGCATG
~ GAGCAGAAACTCATCTCTGAAGAAGATCTG NhelI
T""
I: GAACAGAAGCTCATCTCTGAGGAAGATCTG(_)
~
ATGCCCCTGCCCGAGCCCA
....J
u,
I Reverse:(_)
>-
~ TGGATGGCGAGTCCCAGTGATAATAGGAATTC fcoRI
GT
...--
:::2:
I
I ...-- Forward: GCTAGC(_) :::c
>- (_) ATGGAGCAGAAACTCATCTCTGAAGAAGATCTG Nhel
~
~
~TCGGGGGCCGCCTCCTG
....J
._
U.
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Reverse:
feaR I
~GGATGGCGAGTCCCAGTGATAATAGGAATTCGT
Forward:
N GCTAGCATGGAGCAGAAACTCATCTCTGAAGAAGAT Nhel
:2! CTQcTGCAGGCTGGGCAGGACGG,
, T""
U ::r:
>- u
:2!
~
.....J
U. Reverse:
fcoRI
~TGGCGAGTCCCAGTGATAATAGGAATTCGT
Forward: GGCTAGCATG
GAGCAGAAACTCA TCTCTGAAGAAGA TCTG NhelCV) GAACAGAAGCTCATCTCTGAGGAAGATCTG
:2!,
~TGCCCCTGCCCGAGCCCA, ..-
u::r:
>-u
:2!~
.....J
U. Reverse:
feaR I
~TCCGGCCCCTGGAGTTCTGAGAATTC
Forward: GGCTAGCATG
~
GAGCAGAAACTCATCTCTGAAGAAGATCTG Nhel:2! GAACAGAAGCTCATCTCTGAGGAAGATCTG,
, T""
~TGCCCCTGCCCGAGCCCAu::r:
>-u
:2!~
.....J
U. Reverse:
fcoRI
~AAGTGGACACGCTGCTCTGAGAATTC
*: The forward primers of M1 and M2 contain one copy of MYC-epitope; however two
copies of MYC-epitope were added to the forward primers of the wild-type and deletion
mutants M3 and M4.
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Table 2-3: PCR primers used to generate the full-length (wild-type) and deletion
mutants of eGFP-FLYWCH1. Restriction enzyme sites within both forward and reverse
primers are underlined, while the stop codons within the reverse primers are shown in
bold. The core primer sequences are highlighted in grey. Nucleotides A and C (AC)
within the forward primers (shown in bold Italic), retains in-frame ORF within the N-
terminal eGFP tag.
Clones Primer sequences S'to 3' Restriction
sites
I-
Forward:
3: AGATCTACATGCCCCTGCCCGAGCCCA BgnlI ,
....-n, :cI.L
<.9 <.)
Q)
~
Reverse:
.....J feaR II.L TGGATGGCGAGTCCCAGTGATAATAG
GAATTCGT
I Forward:-e--'
:c Bgnl<.) GGC AGATCTA~TCGGGGGCCGCCTCCTG
~....-
.....J::::2:
LJ..
I Reverse:a...
I.L
~ATGGCGAGTCCCAGTGATAATAGGAATTCGT
fcoRI
<.9
Q)
I Forward:....-
:c Bgnl<.)
GGCAGATCTAOCTGCAGGCTGGGCAGGACGG
~N
Li::::2:
I Reverse:n,
I.L fcoRI(9
Q) GGATGGCGAGTCCCAGTGATAATAGGAATTCGT
I
...- Forward::c
<.) Bgnl
~M
AGATCTAQATGCCCCTGCCCGAGCCCA
Li::::2:
,
Reverse:c,
I.L fcoRI(9
~TCCGGCCCCTGGAGTTCTGAGAATTCQ)
,
...- Forward::c
<.) Bgnl
3: AGATCTA TGCCCCTGCCCGAGCCCA
>--.::t
Li::::2:
I Reverse:n,
I.L fcoRI(9 tAAGTGGACACGCTGCTCTGAGAATTCQ)
-
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Table 2-4: PCR primers used to generate the N-terminus, C-terminus, and the
middel deletion mutants of FLAG-p-catenin. Restriction sites are underlined, FLAG-
epitopes within the forward primers and the stop codons within the reverse primers are
shown in bold. The overhang complementary sequences of the internal forward primers
are shown in italic.The core primer sequences are highlighted in grey.
Clones Primer sequences 5' to 3' Restriction
sites
Forward:
Z AAAAGGAT CCAT GGAT TACAAGGATGACGACGATA BamHI<l, ,
AGGAACCATCACAGATGCTG~<.9 c
« c
.....J Cl)
U- ts
u Reverse:I Nona:l. ttGGTTTGATACTGACCTGTAAGCGGCCGTTTT
0 Forward:
<l AAAAGGATCCATGGATTACAAGGATGACGACGATA BamHI
I
,
<.9 .~ A~TGGCTACTCAAGCTGATTTG
« c
.....J .$
U- rn
« Reverse: Noda:l.
~CATTCCATTGTTTGTGCA TAAGCGGCCGCTTTT
Forward (internal) :
..-
0 GATGCTGCTCATCCCAC GTGGGCTGCAGAAAAT .....
I ::2
~
<.9
,
£
« c
.....J
.$U- rn Reverse (internal) :u,
a:l.
.....
~ATGCTGCTCATCCCACT
Forward (internal) :
N
0 TTACATCAAGAAGGAGC CAGTTCGCCTTCACTA .....
I ::2 [GGAl<.9
.~
« c
.....J
.$U- rn Reverse (internal) :u,
a:l.
CCTTTT~ATCAAGAAGGAGCT
.....
Forward (internal) :
CV)
0 GACCAGCCGACACCAACCTAGCTATCGTTCTTTTC .....
I ::E Mo IC
« 'c
.....J
.$U- rn Reverse (internal) :u,
co,
.....
CGTCATCTpACCAGCCGACACCAA
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Forward (external):
AAAAGGATCCATGGATTACAAGGATGACGACGATA
AGf.,TGGCTACTCAAGCTGATTTG
8amHI
Reverse (external):
Nod
~GGTTTGATACTGACC~~TAAGCGGCCGCTTTT
Table 2-5: PCR primers used to amplify mRNA of several p-catenin target genes
by qRT-PCR.
Target genes Primer sequences 5'- 3'
Forward: ACCCCAAGATCCTGAAACAG
e-Jun
Reverse: ATCAGGCGCTCCAGCTCG
Forward: AAAACCAGCAGCCTCCCGC
e-Mye
Reverse: GGCTGCAGCTCGCTCTGC
Forward: GCTGGAGGTCTGCGAGGA
eyelin Dl
Reverse: CATCTTAGAGGCCACGAACA
CDHl Forward: GTCTGTAGGAAGGCACAGCCTGTCG
(E-eadherin) Reverse: AGGACCAGGACTTTGACTTGAGC
EPHB2 Forward: AGGATTACCCTGTGGTGGTC
(EphB2)
Reverse: TACAACGCCACAGCCATAAA
EPHA4 Forward: CGACAAAGAGCGTTTCATCA
(EphA4) Reverse: GCTTCACCCAAGTGGACATT
ENFBl Forward: GGCAAGCATGAGACTGTGAA
(ephrin-Bl) Reverse: ACTCCAAGGTGGCATTGTTC
ENFB2 Forward: CTGCTGGATCAACCAGGAAT
(ephrin-B2) Reverse: TCTAGCACAGACGGCAACAG
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Table 2-6 : PCR primers used to amplify the entire sequence and fragments of the
exogenous genome-integrated FL YWCH1 from the genomic DNA extract of
HEK293T and HCT116 stable cell lines. Stop codons within the reverse primer that
used for cloning (Full-FLYWCH1-Rev-C) are shown in bold, while the restriction
enzyme site is underlined. The core primer sequence is highlighted in grey.
Primer use Primer sequence 5' to 3' Restriction
site
AIIPCR Forward (GFP-Fwd) : ------
amplifications CATGGTCCTGCTGGAGTTCGTG
N-terminal Reverse (FLYWCHl-
domain -------c Rev990) :CTGTGATGCGTGGGCACTGC2
co (1.0 Kb)~
en
ID
......c Full-length Reverse (Full-FLYWCHI-Rev) :"
------ID ..- (2.2 Kb)E::r:: TGGATGGCGAGTCCCAGTGAauc:s:
ID>-en_J Reverse (Full-FLYWCHI-Rev-IDu.. Full-length.L:: ,
-0..
C) :~GATGGCGAGTCCCAGTGATAATAG feaR I-u.. for cloning0(,9
§ ID (2.2 Kb) GAATTCGT:p
co
C,.)
~
a.
E N-terminal +«
part of the Reverse (FLYWCHI-Rev1446) :
C-terminal ------CGTGGTCACTGCCACCCGCCCGAC
domain
(1.4 Kb)
2.1.4 Antibodies
Different types of primary and secondary antibodies were used throughout this
study for both Western blotting and immunofluorescent analysis. Details about
the source of these antibodies and the dilution factors used are given in (Table
2-7).
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Table 2-7: List of primary and secondary antibodies used for Western blotting
and Immunofluorescent analysis. "NA" means not applicable.
Dilution used
Primary antibodies Source & catalogue number
WB IF
FLAG Monoclonal Mouse ANTI-FLAG® 1:1000 NAM2 antibody (Sigma, # F1804)
MYC (9E10) Polyclonal Mouse antibody 1:1000 NA(Sigma)
GFP Polyclonal Mouse antibody 1:1000 NA(Invitrogen)
FLYWCH1* Mouse polyclonal to FLYWCH 1 1:500 1:50(Abcam, # ab69284)
E-Cadherin Monoclonal Mouse IgG2a, K (BD 1:5000 1:100Biosciences, # 610181)
~-Catenin
Monoclonal Mouse IgG1
1:2000 1:100(BD Biosciences, # 610154)
ZEB2, [SIP1 (H-260)] Polyclonal Rabbit antibody (Santa 1:1000 1:50Cruz, # SC-48789)
Vimentin (RV202) Mouse monoclonal antibody 1:1000 1:100(Santa Cruz, # sc-32322)
~-actin Mouse monoclonal (AC-15) to 1:10,00 NAbeta Actin (Abcam, # ab6276) 0
Dilution used
Secondary antibodies Source & catalogue number
WB IF
Goat anti-mouse IgG-HRP (Santa Cruz, # sc-2005) 1:5000 NA
goat anti-rabbit IgG-HRP (Santa Cruz, # sc-2004) 1:5000 NA
Rabbit anti-Goat IgG-HRP (OakoCytomatio, # P 0160) 1:2000 NA
Alexa Fluor® 488
Rabbit Anti-Mouse IgG (H+L) (Invitrogen, #A11059) NA 1:400
Alexa Fluor® 594
Goat Anti-Mouse IgG (H+L) (Invitrogen, # A11005) NA 1:400
Alexa Fluor® 594
Goat Anti-Rabbit IgG (H+L) (Invitrogen, # A11037) NA 1:400
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*: FLYWCHI antibody was purchased from Abeam, however, this antibody
was not widely used in this project due to its low detection efficiency and none
economical usage (for more detail see the discussion part of chapter 3).
2.2 Methods
2.2.1 DNA preparation and manipulation
2.2.1.1 DNA transformation and amplification
Plasmid DNAs were transformed into Escherichia coli (E. coli); either
commercially available XLI-Blue (XLI-B) competent cells (Stratagene, #
200249) or chemically prepared competent cells from DH5a and XLI-Blue
bacterial cells (see section 2.2.1.2). In both cases, 50 to 500 ng DNA was
mixed with 50 J.l.Icompetent cells in 1.5 ml sterile eppendorf tubes and
incubated on ice for 30 minutes. The mixture was heat shocked at 42°C for 50
seconds then chilled on ice for 2-3 minutes. 500 J.l.Iof Luria Broth (LB)
medium (Table 2-1) was added to the tubes and incubated horizontally at 37°C
for 1 hour in a shaking incubator. A small amount (15-20 J.l.I)of this culture
was spread on plates of LB agar containing IX concentration of a suitable
antibiotic (Table 2-1). Plates were incubated overnight at 37°C in a bacterial
growth incubator. A single colony was selected and recultured in LB medium
containing 1X concentration of appropriate antibiotic. The broth culture was
incubated overnight at 37°C in a shaking incubator then used for DNA
isolation. Miniprep Kit (section 2.2.1.3) was used for isolation of small
amounts of DNA, whereas, Midiprep Kit was used for isolation of large
amounts of DNA (section 2.2.1.5).
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2.2.1.2 Chemical preparation of bacterial competent cells
Chemical competent cells were prepared from strains of E. coli either XLI Blue
or DH5u under a sterile condition as follow: A pre-culture of cells was
prepared by incubating 10 ul Xl.l Blue or DH5u in 5 ml LB medium at 37°C in
a shaking incubator. After an overnight incubation 2 m! of the pre-culture was
added to 500 ml LB medium and incubated at 37°C in a shaking incubator. The
cell density was determined by the optical density (OD) readings of the culture
using S2100 Diode Array Spectrophotometer (biochrom, UK) at 600 nm. Once
the OD reading reached 0.5-0.6, the culture was split into two sterile bottles
and incubated on ice for 30 minutes then centrifuged at 2500 rpm for 12
minutes. The pellet of each bottle was resuspended in 20 ml TSD bufferl
(Table 2-1). The whole suspension was then transferred into a 50 ml Falcon
tube and incubated on ice for 15 minutes followed by centrifugation at 2500
rpm for 9 minutes. The pellet was resuspended in 7 ml TSD buffer2 (Table
2-1). Immediately after resuspension, the competent cells were aliquoted into
eppendorftubes and stored at -80°C until use.
2.2.1.3 DNA isolation using Miniprep kit
Small amounts of DNA (up to 20 ug of total DNA) were prepared using
GenElute Plasmid Miniprep Kit (Sigma, # PLN350). An optimized
manufacture's protocol applied in this study is illustrated below (Figure 2-1).
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I Overnight bacterial culture I
transformed E. coli in 5 ml LB medium
Clear lysate preparation:
-Pelet the culture and resuspend in 200 ~I
Resuspension Solution
-Add 200 ~I Lysis Solution and incubate on
ice for 3 mins
-Add 350 ~I Neutralization Solution
Column preparation:
-Add 500 ~I Column Preparation
Solution to binding column
Loading:
-Transfer clear lysate into binding column
Washing:
-Add 750 ~IWash Solution to column
Elution:
-Transfer column to a new tube
-Add 50-100 ~I Elution Solution
and stand for 1 min
1
~ -Spin for 10 mins
-Keep supernatant
(clear lysate)
~ -Spin for 1 min
-Discard flow-through
~ -Spin for 30 s
-Discard flow-through
~ -Spin for 30 s
-Discard flow-through
"? -Spin for 1 min
- -Keep flow-through
Pure plasmid DNA
Store at -20oC
Figure 2-1: Isolation of plasmid DNA using commercial Miniprep kit. Steps of pure
plasmid DNA isolation using Sigma GenElute Plasmid Miniprep Kit. All centrifugations
were performedat 13,000 rpm using a micro-centrifugeat 4°C.
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2.2.1.4 DNA isolation using manual Miniprep protocol
Manual Miniprep protocol, a cost effective method developed in our lab, was
also used to isolate plasmid DNA from the transformed bacterial culture. This
method was mainly used when highly purified plasmid DNA was not required.
For example, in case of cloning a huge number of colonies (up to 20) need to
be examined for the presence of a desired recombinant plasmid DNA for each
clone. In such instance, the plasmid DNA was extracted manually and tested
with specific restriction enzyme digestion (section 2.2.2.1). Bacterial cultures
with correct recombinant plasmid DNA were then subjected to pure DNA
extraction using either Miniprep (section 2.2.1.3) or Midiprep (section 2.2.1.5)
Kits. The main steps of the manual Miniprep protocol for plasmid DNA
recovery are summarized below in (Figure 2-2). The detailed protocol and the
composition of Solutions I, II, and III can be found in (Appendix 2).
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Overnight bacterial culture
transformed E. coli in 5 ml LB medium
If------,~··Pellet the culture for 5 mins 1
~ . ·Discard supernatant ;
____ J
·Resuspend pellet in 100 ~I -l Resuspension I
resuspension buffer (Solution I) f------ ·Pipette up and down or
.J, vortex
·Add 200 ~I of freshly prepared
lysis buffer (Solution II)
·Add 150 ~I of ice cold H Neutralization Ineutralization buffer (Solution III)
• Transfer supernatant to fresh
.J, ,
eppendorf tubes H DNA Precipitation I
·Add 2 volumes of absolute ethanol 1 I·Stand for 2 mins at room temp
·Incubate on ice for 3-5 mins
·Centrifuge for1 0 mins
·Keep supernatant
·Centrifuge for 5 mins
·Discard supernatant
·Resuspend DNA pellets in
50-100 ~I Sigma water
H Washing
. ·Centrifuge for 2 mins
1 I .Air dry pellet at room temp
--
H Elution I
I·Add 1 rnl of 70% ethanol
Isolated plasmid DNA
Store at -20oC
Figure 2-2: Isolation of plasmid DNA using manual Miniprep protocol. Steps of
plasmid DNA recovery using a manual Miniprep protocol. All centrifugations were
performedat 13,000rpm using a micro-centrifugeat 4°C.
2.2.1.5 DNA isolation using Midiprep kit
Large amounts of DNA (up to 300 ug of total DNA) were isolated using
Genopure Plasmid Midi Kit (Roche, # 03143414001) following the
manufacture's instruction as illustrated below (Figure 2-3).
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Overnight bacterial culture
transformed E. coli in 100 ml LB medium
1
-Resuspend pellet in 4 ml H Resuspension IResuspension Buffer
~
I-Add 4 ml Lysis Buffer H Alkaline lysis
-Pelette the culture for1 0 mins
I at 6,000 rpm
: -Discard supernatant
: -Plpette up and down or vortex
-Add 4 ml chilled Neutralization
Buffer and mix well Neutralization
-lncubate 5 min on ice
t
-Add 2.5 ml Equilibration Buffer Column
to binding column equi Iibration r
~I--__ ---"-Shake gently, do not vortex
..j, -lncubate 2-3 mins at room temp.
-Centrifuge for 30 mins at 9,000 rpm
-Keep supernatant (clear lysate)
L _ _
~ __ ~I -Allow column to empty by gravity flow
-Discard flow-throughI '
l__ __ ___:::"____J
~ __ --' -Allow column to empty by gravity flow
. -Discard flow-through
; -Allow column to empty by gravity flow
~--~: -Repeat this step
-Discard flow-through
~ __ __J; -Collect flow-through in15 ml
Falcon tubes
-Add 3.6 ml isopropanol
to the eluted DNA solution H DNA precipitation I1----- -Centrifuge for1 0 mins at 8,000 rpm
~ -Dscard supernatant
I-Add 3 ml chilled 70% Ethanol H,-__ W_aS_h_i"-=g__
~I- ·Centrifugefor 10 mins at 8,000 rpm
..j, ·Discard supernatant
·Air-dry the DNA pellet for
10 mins at room temp. H Drying'-----=--=---
1
·Dissolve the purified plasmid H
DNA in 100-200 ~IdH20
Dissolving I
Pure plasmid DNA
Store at -20oC
Figure 2-3: Isolation of plasmid DNA using Miniprep kit. Steps of pure plasmid DNA
purification using Roche Genopure Plasmid Midi Kit. All centrifugations were performed
at 2-8DC using an ultra-centrifuge at speeds indicated.
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2.2.1.6 Genomic DNA isolation
A suitable number of trypsinized cells (approximately 2x106 cells) were
centrifuged at 1000 rpm for 5 minutes. The pellet was washed once with PBS
and resuspended in 245 J.lI of DirectPCR lysis reagent (Viagen Biotech, #
402E) containing 0.12 Jlg/JlI Proteinase K (Sigma, # P6556). The genomic
DNA was released from the cells by incubating the samples at 56°C overnight
on a shaking thermomixer (Fisher, BLD-455-010C). At the end, the samples
were incubated at 85°C for 45 minutes to in activate the lysis buffer. The
resulted genomic DNA was directly used for PCR reactions to amplify the
DNA element of interest or stored at -20°C for further use.
2.2.1.7 DNA quantification and storage
DNA measurement was performed using a NanoDrop machine (NanoDrop
ND-lOOOUV-Vis Spectrophotometer, LabTech International Ltd, Ringmer,
UK). Briefly, small amounts of samples (2 J.lI) were pipetted onto the end of
the fiber optic cable (the receiving fiber) of the NanoDrop and the absorbance
was measured. DNA sample absorbance was measured at 230 nm, 260 nm and
280 nm; the absorbance values, concentrations and ratios at 230/260 nm and
260/280 nm were calculated by the NanoDrop ND-1000 software and
displayed on an attached computer. The 260/280 ratio can be used to evaluate
the purity of both DNA and RNA. A ratio of -1.8 is generally accepted as
"pure" for DNA; a ratio of -2.0 is generally accepted as "pure" for RNA. The
values of 260/230 ratio which is a secondary measure of nucleic acid purity are
often higher than the respective 260/280 values and they are commonly in the
range of 1.8-2.2. If these ratios are appreciably lower in either case, it may
indicate the presence of co-purified contaminants. More detail can be found in
the user manual provided by the manufacture. All DNA samples were stored at
-20°C until use.
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2.2.2 Gene cloning techniques
2.2.2.1 Restriction enzyme digestion
Plasmid DNAs were digested using specific Restriction Endonuc1eases
purchased from NEW ENGLAND BioLabs (NEB) according to
manufacturer's guidelines. Generally, 1 III of a restriction enzyme was used to
digest 1 Ilg of a plasmid DNA within 2-3 hours in a 20 III reaction containing
IX NEB buffer. Suitable NEB buffer and incubation temperature were used for
each particular restriction enzyme according to the manufacturer's instruction.
The efficiency and the specificity of these enzymes were analyzed by running
digested DNA samples on 1% agarose gel.
2.2.2.2 Agarose gel electrophoresis
1% agarose gel, which was commonly used for DNA electrophoresis, was
prepared by adding 1 gm of agarose powder (Eurogentec, # EP-OO10-05) to
100 ml of IX Tris Acetate EDTA (TAE) buffer (Sigma, # T9650). The powder
was dissolved and homogenized by gentle shake and heat using a microwave
for 1-2 minutes. The melted gel was allowed to cool down at room temperature
to 45-50°C then a small amount of Ethidium bromide (EtBr) (10-15 Ill)
(Sigma, # E1385) was added and mixed well. The final concentration of the
EtBr in the gel should be 0.05 Ilg/Ill. Meanwhile, a gel apparatus with an
appropriate comb was prepared. The gel was poured into the apparatus and left
at room temperature to solidify.
DNA samples were prepared by adding a small amount of lOX loading buffer
(the final concentration of the loading buffer should be IX). Samples were
marked carefully and loaded into the gel in a desired order. DNA markers;
either "1 Kb DNA ladder" (Invitrogen, #15615-016) or "DNA LADDER,
DIRECTLOAD, lKB" (Sigma, # D 3937) were also loaded with each set of
DNA samples to determine the size of DNA molecules (Figure 2-4). Generally,
gels were run at 100 volts for 50 minutes using IX TAE solution as running
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buffer. Bands of digested plasmid DNAs or PCR products were visualized and
captured using an ultraviolet transilluminator unit (UVidoc).
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Figure 2-4: DNA markers used for agarose gel electrophoresis. A) Represents the
1 Kb DNA ladder from Invitrogen and B) Represents the 1KB DNA LADDER,
DIRECTLOAD from Sigma. Both markers were used to determine the size of DNA
molecules on agarose gel.
2.2.2.3 DNA extraction from agarose gel
Desired bands of DNA with expected molecular sizes were excised from the
gel under Ultra Violet (UV) light. The UV exposure time should be as short as
possible to avoid DNA damage. The agarose gel slices were transferred into
clean eppendorf tubes and the DNA molecules were purified using GFX™
PCR DNA and Gel Band Purification Kit (GE Healthcare, # 28-9034-70)
following the manufacturer's protocol which can be summarized as below
(Figure 2-5).
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Figure 2-5: DNA extraction from agarose gel. Steps of DNA extraction from agarose
gel using GE Healthcare GFXTMpeR DNA and Gel Band Purification Kit. All
centrifugations were performed at 16,000 rcf using a micro-centrifuge at room
temperature.
2.2.2.4 DNA extraction/rom restriction enzyme digestions
The same protocol described above in (section 2.2.2.3) is used for DNA
extraction from restriction enzyme digestions. According to the manufacturer's
instruction, the size of the DNA molecules that can be retained by the GFX™
Purification Kit is restricted between 50 bp and 10 kb. Thus, if the unwanted
digested DNA fragments were smaller than 50 bp, DNA samples were not run
on agarose gel in order to be separated from the undesired DNA fragments.
Alternatively, DNA molecules in an enzymatic reaction were directly purified
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by adding 500 ~l capture buffer to up to 100 ul of the reaction. The same steps
described in (Figure 2-5) were also applied here.
2.2.2.5 Standard polymerase chain reaction (peR)
All standard polymerase chain reactions (PCR) were carried out using a
Thermal Cycler machine (Applied Biosystem). A typical reaction mixture
consisted of: Sigma distilled water (to complete the volume of the reaction to
the required final volume), IX PCR Buffer (QIAGEN), 0.25 mM dNTPs
(QIAGEN, # 201913), 1.0 ~M from each of the forward and reverse primers,
0.1-0.5 ug DNA template, and 0.25-1.0 ul of DNA Taq-Polymerase enzyme (5
units/ul) (QIAGEN, # 201205). The cycling parameters for a typical PCR
reaction are shown in (Table 2-8). However, some of the amplification
parameters such as the elongation time and the annealing temperature were
changed according to the purpose of the reaction, melting temperature of the
primers and the size of the amplicon.
Table 2-8: Cycling parameters for the standard polymerase chain reaction.
Cycle Steps Temperature eC) Time Number of cycles
Initial Denaturation 95 5.0 minutes 1
Denaturation 95 20 seconds
Annealing 55 20 seconds 35
Extension 72 1.0 minute
Final Extension 72 7.0 minutes 1
Cooling 4 00
-
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2.2.2.6 Overlapping rcu
The overlapping PCR strategy was used in this study to generate specific
middle deletions within the sequence of the gene (cDNA) of interest such as~-
catenin and FLYWCHI. The overlapping PCR was performed in two steps;
step one was aiming to amplify specific nucleotide sequences of the gene of
interest in two fragments (A & B), whereas step two was aiming to fuse these
two fragments in-frame (without making any frame-shift mutations) leaving a
distinct sequence of nucleotides (fragment C) to be deleted as summarized in
(Figure 2-6).
The primers mentioned here are just examples to outline the overlapping PCR
strategy. More details about the gene of interest and the primer sequences used
can be found in this Chapter (section 2.1.3) and in Chapter 4 (section 4.2.4.2 &
Figure 4-10). In general, for each deletion made, specific external and internal
primers have been used. OLI-F (a forward external primer) together with OL4-
R (a reverse internal primer) were used to amplify the N-terminal fragment
(fragment A). Similarly, OL2-R (a reverse external primer) and OL3-F (a
forward internal primer) were used to amplify the C-terminal fragment
(fragment B). The internal primers (OL3-F and OL2-R) share complementary
sequences which help to modify (mutate/delete) the region of interest and
facilitate the recombination of the amplified fragments in one unit as illustrated
in (Figure 2-6). Suitable restriction sites were also engineered to the 5' and 3'-
ends of the external primers for cloning.
The PCR cycling parameters shown in (Table 2-8) were also applied here to
amplify the desired fragments. Minor changes have been made to the
elongation time and annealing temperature according to the size of the
amplicon and the annealing temperature of the primers.
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Figure 2-6: Overlapping peR strategy. A schematic presentation of overlapping peR
technique; in step 1, both N-terminal and e-terminal domains (fragments A and B,
respectively) were specifically amplified and used as a template for step 2 of the peR to
generate a recombinant gene (cDNA) lacking a distinct nucleotide sequence (fragment
e) as indicated.
The peR product of step one was electrophoresed on 1% agarose gel and the
predicted DNA bands were extracted from the agarose gel as outlined in
(section 2.2.2.3). Small amounts of the purified peR products (both fragment
A and B) were used as a template for the peR reaction in step two. Lastly, 2-3
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III of the final PCR product was run on 1% agarose gel to confirm the
amplification of the recombinant DNA. The rest of the PCR product was
digested with suitable restriction enzymes and extracted directly from the
enzymatic digestion as described in (section 2.2.2.4). The purified PCR product
of each construct was then inserted (cloned) into a mammalian expression
vector as to be described in (section 2.2.2.7).
2.2.2.7 Ligation and bacterial transformation
The commonly used ligation strategy throughout this study was cohesive ends
ligation, yet the blunt end ligation was not excluded. For a typical ligation
reaction; distinct amounts of pre-digested DNAs for both plasmid backbones
and inserts (typically 1 :7 ratio) were mixed together in a sterile 1.5 ml
eppendorf tube containing IX T4 DNA ligase buffer (NEW ENGLAND
BioLabs, # B0202S) and 2 III T4 DNA ligase enzyme (NEW ENGLAND
BioLabs, # M0202S). The final volume of the reaction was completed to 20 III
with Sigma distilled water and the tubes were incubated at 4°C overnight.
Half volume of the ligated product (10 Ill) was transformed into 100 III of
chemical competent cells as described earlier in (section 2.2.1.1). After
transformation the entire culture was poured and spread on LB agar plates
containing 1X concentration of a suitable antibiotic. Plates were closed with
their lids and left at room temperature for 5-10 minutes to absorb the liquid
culture then incubated at 37°C for 24 hours. Several individual colonies
(typically 10-12 colonies) were selected and re-grown in LB media. Finally,
the plasmid DNA was manually extracted from the bacterial cultures using a
manual plasmid DNA extraction protocol (section 2.2.1.4).
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2.2.2.8 Clone verification
The incorporation of a right insert into a backbone vector was initially verified
using enzymatic digestions. Some constructs were further verified through
automated DNA sequencing (Sequencing Facilities, Queen's Medical Centre,
Nottingham University). The protein expression of all plasmid clones were also
confirmed by Western blotting analysis. The details of specific enzymes and
antibodies used to verify each clone is mentioned in Chapter 4 of this thesis.
2.2.3 Ribonucleic acid (RNA) isolation and reverse
transcription
2.2.3.1 RNA isolation
The total RNA was extracted from an appropriate amount of cells usmg
RNeasy Mini Kit (QIAGEN, # 74104). Cells were washed once with PBS and
lysed (either directly in the plates or after trypsinization) following the
manufacturer's protocol as illustrated below (Figure 2-7).
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Figure 2-7: Total RNA isolation, Summary of total RNA isolation/purification
procedure using Qiagen RNeasy Mini Kit. All centrifugations were performed at 8,000
ref using a micro-centrifuge at room temperature.
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2.2.3.2 Reverse transcription and complementary Deoxyribonucleic
acid (cDNA) synthesis
A maximum of 4 ug total RNA was used to perform reverse transcription and
cDNA synthesis using a SuperScript™ III First-Strand synthesis system
(Invitrogen, #18080-051) following the manufacturer's protocol (Figure 2-8).
The resulted cDNA samples were diluted (1:10) in Sigma nuclease free water
(Sigma, # W4502) and directly used for qRT-PCR analysis or stored at _20DC
until use.
Denaturation
RNA+ Primer + dNTPs (10 ~I)
Incubate at 65 DC for 5 minutes
Placeon ice for 2-3 minutes
Oligo (dT) Random Hexamers
Add 10 IJI eDNA Synthesis Mix Add 10 IJI eDNA Synthesis Mix
Jlncubate at 50 DCfor 50 minutes cDNA Synthesis Mix:
..j, lOX RT Buffer 2
Jlncubate at 85 DCfor 5 minutes I 25mM MllCl2 4
0.1 M DTT 2
I RNA Removal [ Add 1 IJI of RNase HIncubate at 37 DCfor 20 minutes RNaseOUT
..j, SuperScript III RT
Storage [ Dilute (1 :10) in Sigma water Total 10~1Use 3 ~I for PCR or Store at -20 DC
Figure 2-8: Synthesis of eDNA. Summary of cDNA synthesis procedure from total
RNA using Invitrogen SuperScriptTMIII First-Strand synthesis Kit.
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2.2.3.3 Quantitative real time polymerase chain reaction (qRT-PCRJ
2.2.3.3.1 Primer design
The primer3 web based primer design tool (Version 0.4.0) available at
http://frodo.wi.mit.edu/primer3/ was used to design primers for qRT-PCR.
Generally, primers were designed so that a pair of primers for a specific gene
of interest was selected in two different exons and the size of the amplicon was
limited to 100-200 base pairs. Moreover, the specificity of the primers was
checked by blasting as outlined in (section 2.1.3).
2.2.3.3.2 Reaction preparation
All reactions were performed in triplicate using 96 well plates provided by
Roche (LightCycler® 480 Multiwell plate 96, Roche, #04729692001). Each
reaction consisted of 10 IIIof 2X LightCycler®480 SYBR Green I Master Mix
(Roche, # 04707516001), 2 III of each diluted primer (10 IlM), and 5 III of
diluted cDNA template (1/10). Reaction volumes were made up to 20 IIIwith
PCR graded water provided by Roche. For each set of reaction a house keeping
gene such as hypoxanthine-guanine phosphoribosyltransferase (HPRT) was
used as a loading control. Samples without cDNA templates were also used as
negative controls (NTC).
Plates were sealed with LightCyc1er®480 sealing foil (Roche, #04729757001)
and run using a LightCycler®480 IIRT-PCR machine (Roche) following the
standard protocol provided by the manufacture. The amplification parameters
are shown in (Table 2-9).
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Table 2-9: Amplification parameters used for the quantative real time polymerase
chain reaction (qRT-PCR).
Cycle Steps Temperature (OC) Time Number of cycles
Pre-incubation 95 5.0 minutes 1
95 10 seconds
Amplification 55 10 seconds 40
72 10 seconds
95 5.0 seconds
Melting curve 65 1.0 minutes 1
97
-
Cooling 40 30 seconds 1
2.2.3.3.3 Data analysis
The qRT-PCR data was analyzed using the comparative CT (TMCT) method as
described previously (Livak and Schmittgen, 2001). CT values for each
reaction were first read by the LightCycler® 480 software (Roche, release
1.5.0) then exported to a Microsoft Excel file for further calculation and
statistical analysis.
2.2.4 General tissue culture techniques
All tissue culture works were performed in a class II cabinet hood under
aseptic condition. Separate hood and incubator were used for primary cell
cultures.
2.2.4.1 Human cell culture
The human cell lines described in (section 2.1.1) were maintained in RPMI
medium (Roswell Park Memorial Institute medium, RPMI-1640, Sigma, #
R0883) supplemented with 10% Fetal Bovine Serum (FBS) (Sigma, # F7524),
79
Chap 2: Materials and Methods
I% Penicillin-Streptomycin (Pen Strep) mixture solution (Invitrogen, # 15140-
122) and 1% L-Glutamine (Invitrogen, # 25030-081). In some occasions
DMEM (Dulbecco Modified Eagle Medium) (Sigma, # D6677) supplemented
with the same components mentioned for RPM! was also used.
Cell lines were incubated at 37°C in T-75 flasks (Coming Incorporation, UK)
with 5% C02 in a tissue culture specific incubator. The growth medium was
changed every 2-3 days and cells were passaged before they become confluent.
Generally, when the culture reached 90% confluency, cells were rinsed once
with sterile phosphate buffered saline (PBS) (Sigma, D8537) then 2 ml of IX
TrypsinlEDT A solution (Sigma, # T3924) was added to the culture. Flasks
were incubated at 37°C for 3-5 minutes and gently shook to allow cell
disassociation and detachment. The action of TrypsinlEDTA was then stopped
by adding 10 ml fresh complete RPM! medium and the cells were further
disassociated by gentle pipetting for several times through 10 ml pipettes.
Small amount of the cell suspension (typically ratio of 1:4) was expanded and
maintained in complete RPM! medium using T-75 flasks. The sub-cultivation
ratio can be varied from 1:3 to 1:5 according to the growth rate of the cell line
of interest.
2.2.4.2 Transient transfection
The transient transfection of various plasmid DNAs into different human cell
lines was accomplished using either lipofectamine™ 2000 (Invitrogen, #
11668-019) or FuGENE® HD (Roche, # 04709713001) transfection reagents
following the manufacturer's guidelines. Briefly, one day before transfection,
sub-confluent growing cell lines were washed and trypsinized as outlined in
(section 2.2.4.1). The trypsinized cells were diluted to a desired concentration
(this depends on cell type and con fluency of the culture) in complete RPM!
medium and subcultured into sterile tissue culture plates. Depending on the
purpose of the experiment, various tissue culture treated plates such as 24-well
plates, 6-well plates, or cell culture dishes were used. The subcultured cells
were allowed to grow overnight or longer to reach 60-70% con fluency.
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The transfection mixture was prepared as follow: for a typical 6-well plate
transfection, 10 III of a transfection reagent (either lipofectamine™ 2000 or
FuGENE® HD) was diluted in 250 III of Opti-MEM@ I Reduced Serum
Medium (Invitrogen, # 31985-047) in a sterile eppendorf tube and left for 5
minutes at room temperature. In the mean time, 4 ug of a plasmid DNA was
diluted in 250 III of Opti-MEM in another sterile eppendorf tube. The diluted
plasmid DNA and transfection reagent were combined together and mixed well
by pipetting to produce the transfection mixture. This mixture was incubated
for 15 minutes at room temperature. Meanwhile, during the last 5 minutes of
the incubation, the cell culture to be transfected was washed once with Opti-
MEM or PBS and the whole transfection mixture was added gently to the well
by pipetting down slowly along the side of the well. Plates were rocked gently
to get equal distribution of the transfection mixture and incubated at 37°C in a
tissue culture incubator. Six hours later, the transfection mixture was replaced
with fresh RPMI medium and further incubated for 36 hours. Eventually, the
transfected cells were used for different experiments and analysis.
The above described protocol for transient transfection was chosen based on
manufacturer's recommendations from Invitrogen
(http://products.invitrogen.com/) and Roche (http://www.roche-applied-
science.com/proddatalgpip/3 5 3 18 1 9.html) and published data (O'Reilly
et al., 2003, Hawcroft et al., 2003, Fischer et al., 2005). Moreover, these
protocols were also very well established in Dr Nateri's laboratory and
successfully applied to transfect and overexpress many plasmid DNAs
(including (3-cateninwhich is frequently used in this study) in different human
cell lines including those used in the current work (see section 2.1.1) (Babaei-
Jadidi et al., 2011, Nateri et aI., 2004, Nateri et aI., 2005, Ibrahim et aI., 2012).
Based on the information provided by these references and my laboratory
advisor (Dr Anas Saadeddin), the ratio 2.5:1 of the transfection reagent to DNA
and 36-48 hours expression time was used for transient transfection as outlined
above. These conditions, however, resulted in a sufficient transfection
efficiency and protein expression. The transfection efficiency was validated
through a visual assessment of the GFP fluorescence of the EGFP-fusion
construct of FLYWCHI (section 3.2.3.3) using a fluorescent microscope and
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the protein expression was validated by Western blotting analysis (sections
3.2.4). Experiments with poor transfection efficiency (less than 50%) were
neglected. It should be mentioned that we did not observe noticeable changes
in the intensity of the GFP fluorescence during the post-transfection time,
especially between 36-48 hours, which is mainly used to harvest the cells.
Moreover, all the conditions used to overexpress FLYWCHl, f3-catenin,and
their deletion mutants in human cell culture including the promoter activity of
the backbone vectors, the culture conditions, and the cell lines used, have been
previously optimized and established in our lab and by others as detailed
above. Therefore, further optimization steps through varying the DNA and/or
lipofectamine concentrations or varying the post-transfection times before
harvesting the cells were not conducted in this study. However, as information
about the half-life of FLYWCHI protein is currently unavailable, further
investigations of FLYWCH 1 expression time and stability in different cell lines
may yield valuable information.
2.2.4.3 Stable transfection
In order to obtain stable gene expression, a Lentiviral-Based Gene Delivery
system was used to achieve a permanent or a long term integration of the gene
of interest into the genome of specific cell lines. This system comprises two
main steps; the Lentiviral production and the cell transduction as detailed
below.
2.2.4.3.1 Lentivirus production
The Lentiviral Expression plasmid backbone vector (PLVX-Puro) (Appendix 7)
and packaging plasmids (see below) were kindly provided by Dr. Dominique
Bonnet (Cancer Research UK- London Research Institute). An optimized
protocol for viral particles production, and the transduction time for the
Lentiviral particles has been produced in our lab by Mr. Mohammed
Abuzinadah and other colleagues (Dr. Nateri's lab) (Babaei-Jadidi et al., 2011,
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Ibrahim et al., 2012) and a similar strategy is applied in this study as detailed
below.
A) Transfection: The transfection was started with seeding HEK293T cells in
T-75 tissue culture flasks (in triplicate) in complete RPM! medium. Cells were
incubated overnight to reach 70-80% confluency. Just before the transfection
started, the RPMI medium of each cell culture was replaced with 9 ml Opti-
MEM and the flasks were returned back to the incubator. For each transfection,
distinct amounts of plasmids (9 Ilg of the Lentiviral Expression plasmid
encoding the gene of interest, 6 and 3 ug of the packaging plasmids; pCMV
delta R8.74 and pMDG2 respectively) were diluted in 250 III Opti-MEM in a
sterile 1.5 ml eppendorf tube. In the mean time, 43 IIIof FuGENE is diluted in
650 III of Opti-MEM in a separate sterile tube and incubated at room
temperature for 5 minutes. The diluted plasmid DNA and FuGENE were
combined together, mixed well, and incubated at room temperature for 15
minutes. After incubation, the transfection mixture was added to the cell
culture flasks containing 9 ml Opti-MEM. The flasks were swirled gently to
get equal distribution of the transfection mixture and incubated overnight at
37°C. In the following day, the transfection mixture was replaced with 11 ml
complete culture medium and returned to the incubator. From now on the
culture medium was considered as a viral soup.
B) Viral soup collection: The culture medium containing viral particles (Le.
the viral soup) was collected for three respective days. Each time the soup was
collected, the transfected cells were re-fed with 11 ml of fresh complete RPMI
medium and the cultures were returned to the incubator. The viral soup was
kept in the fridge until the last collection was made.
C) Viral soup concentration: After the 3rd collection of the viral particles, the
viral soup was concentrated as follow. The soup was centrifuged at 4000 rpm
for 10 minutes to remove large particles/contaminants (e.g. flushed out cells)
from the soup. The supernatant was transferred to new falcon tubes and passed
through 0.45 11mpore size filters to eliminate any possible non viral particle
substances.
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Using a pasture pipette, equal amounts of the viral soup (-9 ml) was gently
added to specific centrifuge tubes containing 1 ml of 20% filter sterilized
Sucrose solution using pasture pipettes. This should make two layers of
solutions, the bottom layer of Sucrose solution and the top layer of viral soup.
The Lentiviral particles were precipitated at 40,000 rpm for 2 hours using a
BECKMAN LS-60M Ultracentrifuge. Finally, the viral pellet in each tube was
resuspended in 40 III PBS and the tubes were incubated at room temperature
for 10 minutes, then at 4°C for 1 hour. The concentrated viral particles were
ali quoted into eppendorf tubes in small amounts (60 III per tube). At this stage,
the viral particles are ready to infect cells or they can be kept at -SO°C for up to
6 months without losing their efficiency.
The calculation procedure of the functional Lentivirus titre or the multiplicity
of infection (MOl) that produced by the above described protocol was also
optimized by Mr. Mohammed Abuzinadah (Dr. Nateri's lab). The amount of
viral particles or MOl required to transduce the cell line of interest were then
calculated according to the equation below:
Mal required for transduction * Number of cells to be infected
X == Calculated Lentivirus titer
Where:
X= stock volume of Lentivirus particles required for transduction.
2.2.4.3.2 Lentivirus transduction and stable cell line generation
Lentiviral particles encoding the gene of interest were used to tranduce various
human cell lines as follow: Cells were subcultured and allowed to grow in
DMEM medium to reach 60-70% confluency in 6-well plates. The culture
medium was replaced with fresh DMEM medium containing 8 ug/ml
polybrene (Hexadimethrine bromide) (Sigma, # H9268). Twenty microlitres of
the concentrated Lentiviral particles (-6 x 109 viral particles) were directly
added to the culture medium in each well. Plates were rocked gently to obtain
equal distribution of the viral particles in the cell culture and incubated at
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37°C. After an overnight incubation, the transduced cells were selected with
Puromycin by replacing the growth medium with new DMEM containing 15
ug/ml Puromycin (Sigma, # P8833). The selection was continued for two
weeks then the resistant cells were trypsinized, counted and seeded into 96-
well plates (one cell per well). Cells were allowed to grow in Puromycin
selection for several days. Finally, the resistant cells were further amplified and
the stable expression of the gene of interest was validated through Western
blotting and/or PCR analysis.
2.2.5 Protein lysate preparation and analysis
2.2.5.1 Protein extraction and quantification
The total cellular protein was extracted from different cell lines either
transfected or untransfected as summarized below. The culture medium was
removed and the cells were rinsed once with PBS. Appropriate amounts
(typically 250-350 ul per one well of 6-well plate) of freshly prepared RIPA
lysis buffer (Table 2-1) containing protease inhibitor (Sigma # P8340) were
directly added to the surface of the cell culture and the plates were gently
rocked at 4°C for 15 minutes. The highly adhesive cells such as SW480 were
mechanically detached from the plate with a scraper. The cell lysate was
transferred into 1.5 ml eppendorf tubes and further incubated on ice for 10-15
minutes then centrifuged at 13000 rpm for 10 minutes at 4°C. The supernatant
(total cell lysate) was transferred into new eppendorf tubes and labelled
properly.
The protein quantification was performed using a BioRad Protein Assay
reagent (BIO-RAD, # 500-0006) following the manufacture's guidelines. The
BioRad reagent was diluted 1:5 in distilled water (dH20) and series standard
dilutions of BSA (Bovine Serum Albumin) (Sigma, # A4503) (0.1, 0.3, 0.5,
and 0.7 ~g/~l) were also prepared in dH20. The blank was prepared by adding
20 ul of dH20 to the first well of a 96-well micro test plate (Scientific
laboratory supplies, # MIC9038). This followed by adding 20 ~l of each BSA
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standard dilutions into separate microplate wells. The protein samples were
diluted (1110) directly in the wells of the microplate by mixing 2 J11of the
protein lysate with 18 J11dH20. Finally, 200 J11of the diluted BioRad reagent
was added to the wells of the microplate and incubated at room temperature for
5 minutes.
The absorbance of the protein-dye mixture was measured at 595 nm by a
Benchmark Plus microplate Spectrophotometer (BIO-RAD) using the Endpoint
protocol. The protein concentration was automatically calculated by the
machine's software (Microplate Manager, version 5.2.1 Build 106) on attached
computer based on the BSA standard curve. The quantified protein samples
were directly used for Western blotting analysis or stored at -80°C until use.
2.2.5.2 Western blotting (WB) analysis
2.2.5.2.1 Sample preparation and SDS-PAGE electrophoresis
The protein samples were prepared by mixing small portions of the celllysates
(typically 30 ug) with appropriate amount of 5X loading buffer (Table 2-1).
The final concentration of the loading buffer in the sample should be IX.
Samples were boiled for 4 minutes at 95°C on a thennoblock heater and cooled
down on ice for 5 minutes. The SDS-PAGE (sodium dodecyl sulfate
polyacrylamide gel electrophoresis) gel is composed of two parts, the stacking
and the resolving gels. The stacking gel is less concentrated than the resolving
gel and they both contain the following chemicals (dH20, acrylamide mix,
Tris, SDS, ammonium persulfate, and TEMED) in distinct compositions as
detailed below in (Table 2-10) and (Table 2-11).
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Table 2-10: Solution for preparing Resolving Gels for Tris-glycine SOS-PAGE.
Component volumes (ml) per gel
Solution components mold volume of
sml 10ml 1sml 20ml 2sml
8%
H2O 2.3 4.6 6.9 9.3 11.5
30% acrylamide mix 1.3 2.7 4 5.3 6.7
Tris (1.5 M, pH 8.8) 1.3 2.5 3.8 5 6.3
SOS (10%) 0.05 0.1 0.15 0.2 0.25
10% ammonium persulfate 0.05 0.1 0.15 0.2 0.25
TEMEO 0.003 0.006 0.009 0.012 0.015
10%
H2O 1.9 4 5.9 7.9 9.9
30% acrylamide mix 1.7 3.3 5 6.7 8.3
Tris-CI (1.5 M, pH 8.8) 1.3 2.5 3.8 5 6.3
SOS (10%) 0.05 0.1 0.15 0.2 0.25
10% ammonium persulfate 0.05 0.1 0.15 0.2 0.25
TEMEO 0.002 0.004 0.006 0.008 0.01
Table 2-11: Solution for preparing 5% Stacking Gels for Tris-glycine 50S-PAGE.
Component volumes (m!) per gel
Solution components mold volume of
1 ml 2ml 3ml 4ml sml
H2O 0.68 1.4 2.1 2.7 3.4
30% acrvlarnide mix 0.17 0.33 0.5 0.67 0.83
Tris (1.0 M, pH 6.8) 0.13 0.25 0.38 0.5 0.63
10% SOS 0.01 0.02 0.03 0.04 0.05
10% ammonium persulfate 0.01 0.02 0.03 0.04 0.05
TEMEO 0.001 0.002 0.003 0.004 0.005
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Gels with desired concentrations and combs (e.g. 10% gels with 10-well
combs) were casted and the protein samples along with protein markers were
loaded into the wells of the gel. Generally, two types of protein markers; either
"pre-stained Full range Rain Bow marker" (GE Healthcare, # RPN800E) or
"ColorPlus Prestained Protein Ladder, Broad Range" (NEW ENGLAND
BioLabs, # P77l1 S) were used to determine the size of the protein bands
(Figure 2-9).
A) kDa B) kDa
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Figure 2·9: Protein markers used for for SDS·PAGEanalysis. A) Represents the
"ColorPlus Prestained Protein Ladder, Broad Range" marker from NEW ENGLAND
BioLabs and B) Represents the "pre-stained Full range Rain Bow" marker from GE
Healthcare. Both markers were used to determine the size of protein molecules during
Western blotting analysis.
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The upper and the lower compartment of electrophoretic unit (miniVE Vertical
Electrophoresis System, AmershamlBiosciences, # 80-6418-77) were filled
with IX TGS running buffer (Tris/Glycine/SDS buffer, BIO-RAD, # 161-
0772) and the gel was run at 120 V for 2 hours using a BIO-RAD PowePac
supply. Based on the molecular size of the protein of interest, less concentrated
SDS-PAGE (e.g. 8%) and longer running time (up to 3 hours) with higher
voltage (up to 180) was also used in some occasions. Upon a desired separation
of the protein molecules (indicated by the colour and distance between the pre-
stained bands of the protein marker), the protein samples were transferred to a
Hybond-P PVDF membrane (GE Healthcare, # RPN303F) using a semi-dry
transfer system (BIO-RAD, UK) at 14 V for 70 minutes. When two membranes
were transferred at the same time, 18 V for 75 minutes was used.
Upon completion of the transference, membranes were rinsed once in TBS- T
(Tris buffer saline- Tween-20) which was prepared by adding 0.1% Tween-20
(Sigma, # P1379) to the TBS buffer (Table 2-1) just before use and then
blocked for 1 hour at room temperature in 3% of ECL Advance™ blocking
agent (GE Healthcare, # CPKI075) dissolved in TBS-T.
2.2.5.2.2 Immunoblotting
Membranes were immunoblotted with specific primary antibodies to detect
bands of the proteins of interest. Various dilutions and incubation times were
used according to the initial concentration of the primary antibodies and the
strength of the protein signal. Details of different types of primary and
secondary antibodies and their dilution factors used throughout this study are
given in (Table 2-7).
Briefly, membranes were incubated with suitable amounts of specific primary
antibodies diluted either in blocking reagent or in TBS- T and rolled for a short
time (up to 3 hours) at room temperature or longer time (overnight) at 4°C
using a Roller mixer (Stuart SRT6, UK). Membranes were washed three times
with washing buffer (TBS- T), 5-10 minutes each. The membranes then
incubated with appropriate amounts of secondary antibodies diluted in TBS- T.
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After incubation for 1 hour at room temperature the membranes were washed
three times with TBS-T, 5-10 minutes each. Finally, the ECL Advance™
Western Blotting detection Kit (GE Healthcare, # RPN2135) was used to
visualize the protein bands using a FluorChem®FC2 Imaging System (Alfa
Innotech, UK) following the manufacture's guidelines.
2.2.5.3 Co-immunoprecipitation (Co-IP) assay
In the current work, three different approaches were employed to
immunoprecipitated the protein of interest in the lysate of transfected cells as
detailed below.
2.2.5.3.1 FLAG-conjugated agarose beads
ANTI-FLAG®M2 Affinity Gel (Sigma, # A2220) beads were used to pull
down FLAG-tagged proteins following the manufacturer's guidelines. Briefly,
the beads were mixed thoroughly before use and for a typical Co-IP
experiment, 60 JlI of the homogenized beads was transferred into 1.5 ml
Eppendorf tube. The beads were washed once with 1 ml RIPA lysis buffer by
centrifuging the tubes at 500 ref for 4 minutes at 4°C. The Co-IP samples were
prepared by mixing appropriate amounts of protein lysates (usually 0.5 mg)
with the FLAG conjugated beads. The volume of the protein/beads mixture
was completed to 500 JlI with RIPA lysis buffer. The Eppendorf tubes were
closed tightly and incubated with gentle rotation for 2-3 hours at 4°C.
After incubation, samples were spun down at 500 ref for 8 minutes at 4°C then
the pellet (beads plus bounded protein complex) was washed 3-4 times with 1
ml RIPA lysis buffer. For each wash, the tubes were rotated 2-3 minutes at 4°C
and centrifuged at 500 ref for 5 minutes. The pellet was resuspended in a
suitable amount of IX SDAS-PAGE loading buffer and boiled at 95°C for 4
minutes followed by incubation on ice for 5 minutes. Beads were pelleted with
a short and gentle centrifuge and the supernatants of the Co-IP samples were
loaded and run by SDS-PAGE as described in (section 2.2.5.2.1). For each Co-
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JP experiment a set of input samples (normal Western blotting samples used to
show the lP-efficiency) were also prepared and run on the SDS-PAGE page at
the same time.
2.2.5.3.2 Magnetic beads
Dynabeads®Protein G (Invitrogen, # 10003D) was used to pull down proteins
with other epitope tags such as MYC-FLYWCHI (section 3.2.3.2) and/or the
endogenous proteins as described previously (Nateri et al., 2005). Here, the
beads were manually conjugated to a desired antibody as detailed below. Beads
were mixed thoroughly then 60 J.lIof the homogenized beads were transferred
to an Eppendorf tube and placed on the magnet to separate the beads from the
solution. The supernatant was discarded and the beads were resuspended in 200
J.lI PBS/Tween-20 solution containing distinct concentration of a primary
antibody of interest (typically 6 ug). Tubes were incubated with rotation for 45
minutes at room temperature. The beads-Ab complex was washed twice in 200
J.lI PBSlTween-20 solution by gentle pipetting. The magnet was used to
separate the supernatant from the beads between each wash. The conjugated
beads then used to pull down the protein of interest as outlined above in
(section 2.2.5.3.1) with the exception of using the magnet and PBS to pellet
and wash the beads during the washing process.
2.2.5.3.3 Agarose beads
Protein AlG PLUS-Agarose Immunoprecipitation Reagent (Santa Cruz, # sc-
2003) was also used to pull down both epitope-tagged andlor endogenous
proteins (such as MYC-FLYWCHI and endogenous TCF4) as summarized
below. The protein lysate (0.5 mg) was first mixed with a specific amount of
the primary antibody of interest (6-8 ug) in 1 ml RIPA lysis buffer. After 1
hour incubation at 4°C, 60 J.lIof the resuspended Protein AlG PLUS-Agarose
beads was added to the mixture and incubated with rotation for 2-3 hours at
40C. The rest of the procedure was carried out as described above in (section
2.2.5.3.1).
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2.2.6 Functional analysis
2.2.6.1 Indirect transcriptional assay
To assess the transcriptional activity of ~-catenin in different cell lines, the
TOPIFOP-Flash Firefly-luciferase reporter system was employed using the
Dual-luciferase kit (Dual-Luciferase® Reporter Assay, Promega, # EI91O), as
described previously (Nateri et aI., 2005). The TOP-Flash construct contains
Firefly luciferase coding region under a promoter containing three intact TCF-
DNA binding elements (ATCAAAG) upstream to the luciferase gene, whereas
FOP-Flash contains three mutated TCF-DNA binding elements (GCCAAAG)
and used as a negative control. A constitutively active vector encoding Renilla
luciferase gene was also used as an internal control.
Experiments were set up by seeding cells of a desired cell line in 24-well plates
(3 X 105 cells/well). After overnight incubation, cells were transiently
transfected (as outlined above in section 2.2.4.2) with the reporter constructs
along with construct (s) of the genes of interest. For all plasmid DNAs used in
this experiment except Renilla, 0.2 ug DNA plus 2 JlI of the transfection
reagent (lipofectamine™ 2000 or FuGENE® HD) were used to transfect cells
of a single well of 24-well plates, whereas 0.05 pg DNA/well was used for the
Renilla construct. Transfections were performed in triplicate and the cells were
harvested after 36 hours oftransfection using IX passive lysis buffer provided
within the Dual-Luciferase kit.
Two types of FLYWCHI clones, the untagged and MYC-tagged FLYWCHI
(sections 3.2.3.1 & 3.2.3.2) were mainly used in the luciferase assays
performed in this work. Both of these clones contain an EGFP reporter gene
that is separated from the FLYWCHI nucleotide sequence by an IRES
(internal ribosome entry site) sequence, but both are expressed under the eMV
promoter (Figure 3-8 & Figure 3-10). The transfection efficiency of all
luciferase experiments conducted in this study was visually assessed through
monitoring the expression level of the EGFP reporter gene by a fluorescent
microscope. Experiments with poor transfection efficiency (less than 50%,
judged by the fluorescence level of the EGFP gene) were neglected. Cells were
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lysed after 36 hours of transfection based on information discussed in (sections
2.2.4.2).
The activities of the Firefly and Renilla luciferase reporters were measured
using reagents provided by Promega following the manufacturer's protocol. In
brief, small amounts of freshly prepared lysates (l Ojil/well) were transferred to
a Microplate FluoroNunc 96 well plate (Fisher, # MPA-560-040A) in triplicate.
The activity of the firefly luciferase reporter was measured first by adding 50
ul/well Luciferase Assay Reagent II (LAR II) to generate a stabilized
luminescent signal which can be detected and read by a Luminoskan Ascent
Microplate Luminometer (Thermo Scientific, UK). Immediately after
quantifying the firefly luminescence, this reaction was quenched and the
Renilla luciferase reaction was concomitantly initiated by adding 50 Ill/well
Stop & Glo® Reagent to the samples in the same plate. This allowed the
activities of both firefly and Renilla luciferases to be measured sequentially
from the same samples.
The measurements were exported to a Microsoft Excel file and analyzed as
follows. First, the values of the firefly reading (TOP & FOP-FLASH) of all
samples (controls and experimental samples) were normalized to the values of
Renilla according to the following equation, Firefly/ Renilla* 1000. Second, the
normalized values of the experimental samples were divided on the normalized
values of the control samples to produce folds of change in luciferase
expression (induction/repression) of the experimental samples (both TOP &
FOP-FLASH) in comparison to the control samples. Finally, the normalized
values of the control samples were arbitrarily set to number one and then all
final values were plotted on a histogram to show the relative changes in
luciferase activity. An example of such calculation is given in (Appendix 14)
by presenting the raw/real data of one of the luciferase experiments performed
in this study.
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2.2.6.2 In vitro scratch assay
The in vitro scratch assay was performed as described previously (Babaei-
Jadidi et al., 2011, Liang et al., 2007) with slight modifications. Briefly, cells
were subcultured and grown in 6-well plates in triplicate. Using a narrow tip
marker, the bottom side of the wells was marked with a horizontal line. Cell
cultures were transfected at -80% confluency with a plasmid that encodes the
gene of interest such as eGFP-FLYWCHI-WT construct (section 3.2.3.3) or an
empty vector such as pEGFP-C2 (Appendix 6) to be used as a negative control.
The transfection was done as described in (section 2.2.4.2) and the cells were
incubated at 37°C for 24 hours (cells should reach 100% con fluency during
this period to form a monolayer). Then the transfected cells were starved
overnight in a serum free RPMI medium to synchronize the cells at GO.
Using p200 pipette tips three parallel wounds were scratched through the cell
culture of each well moving perpendicular to the marker line drawn on the
bottom of the well. Cell cultures were washed twice with PBS then maintained
in complete RPMI medium. The wounds were examined and the first batch of
images (zero time) were acquired using the lOX lens of a phase-contrast
microscope (Nikon, Model ECLIPSE TE2000-S) supplemented with a digital
camera (HAMAMATSU, Model C8484-05G). Images were taken just above
and just below each marker line to help orient the captured area in a way to be
easily recognized after 24 and/or 48 hours of incubation. A specific name was
given to each image indicating the well number and the position of the photo
according to the horizontal marker line (above the line or under the line). The
imaging process was repeated after 24 hours and/or 48 hours.
The images acquired for each sample were further analyzed quantitatively by
using a software called ImageJ which maintained by (Rasband, W.S., ImageJ,
U. S. National Institutes of Health, Bethesda, Maryland, USA,
http://imagej.nih.gov/ij/, 1997-2011). The distances between one side of the
scratch and the other (for each image) were measured using the "Freehand
Selections" command of the Image J software at certain intervals (e.g. time 0
and time 24 hour). Finally, the percentage of cell movement during the desired
time frame was calculated through the equation below:
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m24
Percentage of cell movement = 100 - (-- * 100)
mO
Where:
mO=wound measurement at zero time
m24= wound measurement at 24 hours
The rate of cell migration for the transfected cells was determined by
comparing the average of the percentage of cell movement of at least six
readings for each transfection. A visual evaluation was also performed to
provide a secondary assessment of motility.
2.2.6.3 Trans-well cell migration assay
The trans-well cell migration assay was performed using Boyden trans-well
chamber containing polycarbonated filters with 8 urn pore size (Costar, UK)
following the manufacturer's guidelines. Briefly, colorectal cancer cells (CRC)
such as HCT116 were subcultured and transfected as described in (section
2.2.4.2). The transfected cells were trypsinized and counted after 24 hours of
incubation using a Neubauer haemocytometer (Appendix 3). Meanwhile, the
trans-well chambers were incubated in 600 III of plain RPM! medium at 37°C
for 1 hour in 24-well plates.
The chambers were displaced into new wells of the 24-well plate containing
600 III of complete RPMI medium supplemented with 20% FBS. Using a
narrow tip marker, the bottom side of the wells were marked with 3 horizontal
and 3 vertical lines to facilitate cell counting. The trypsinized cells were spun
down and resuspended in suitable amounts of complete RPM! medium
supplemented with 10% FBS to make a desired final concentration of the cells
in the suspension. A distinct amount of cells (typically 5.0 x 104 cells/chamber)
in a final volume of 100 IIIwere seeded onto the upper part of the trans-well
chambers in triplicate. The number of seeded cells depends on the motility and
the adhesiveness property of the cell line of interest. Cells were incubated at
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37°C for 24 hours then the total number of migrated cells at the bottom of the
plates was manually counted using lOX lens of a bright field microscope. The
effect of the gene of interest on the motility of cancer cells was observed by
comparing the average number of migrated cells of the experimental samples
with the control samples. The experiment was repeated at least on 3
independent occasions and in triplicate format.
2.2.6.4 Cell cycle analysis
The propidium iodide (PI) staining method was used to analyze the effect of
the gene of interest on the cell cycle of CRC cells as described previously
(Babaei-Jadidi et al., 2011, Nateri et al., 2004). Briefly, cells were transfected
with desired plasmid DNAs in triplicate and suitable amounts of the transfected
cells (-3 x 105 cells) were transferred into flow cytometry tubes and washed
twice with PBS. for each wash cells were resuspended in 1 ml PBS and spun
down for 5 minutes at 1000 rpm. Cells were fixed by adding 1 ml of 70% cold
ethanol dropwise while vortexing the sample then left at 4°C for at least 30
minutes.
The fixed cells were washed twice in 1ml PBS, for each wash samples were
spun down for 5 minutes at 1000 rpm. Cells were stained with 300 IIIof diluted
(50 ug/ml) propidium iodide (PI) solution (Sigma, # P4864) in PBS containing
0.1 1lg/1l1of RNase A. The number of stained cells in each step of the cell cycle
was determined by a Coulter fC 500 flow cytometer (BEKMAN COULTER,
UK). finally, the data was further analyzed by using Windows Multiple
Document Interface (WinMDI) and Cylchred-Cell Cycle Analysis software.
2.2.6.5 Growth curve analysis
HCT116 cells were transiently transfected with plasmid DNAs of interest. The
transfected cells were counted and re-seeded in 24-well plates in triplicate at an
initial density of 5 x 104 cells/ml. The total number of cells was counted every
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24 hours by TI0 Automated Cell Counter (BID-RAD, # 145-0001) following
the manufacturer's guidelines for four respective days. The total number of cell
counts was plotted on a time versus number graph and the differences between
the experimental and control samples were statistically analyzed.
2.2.6.6 Immunofluorescent (IF) analysis
The IF assay, was used to visualize different endogenous or overexpressed
proteins and to compare their relative expression levels in different cells.
Generally, human cell lines (transfected or untransfected) were grown
overnight on coverslips (Size 22x22 mm) in 6-well plates. An optimized IF
protocol was applied to stain the cells in three steps as previously described
(Ibrahim et aI., 2012) and outlined below:
A) Fixation and permeabilization: Cells were washed twice in PBS and fixed
with 4% PFA (Paraformaldehyde) for 30 minutes at room temperature. The
fixed cells were washed twice in PBS for 5 minutes at room temperature and
incubated with 800 III of permeabilization solution (0.1% Triton X-lOO in
PBS) for 30 minutes. After permeabilization, the cells were washed twice in
PBS for 5 minutes at room temperature.
B) Blocking and staining with primary antibody: The permeabilized cells
were blocked with 800 III blocking solution, composed of 3% Bovine Serum
Albumin (BSA) in PBS, for 1 hour and washed once in PBS for 5 minutes at
room temperature. The blocked cells were incubated overnight at 4°C with 250
III of the primary antibody of interest diluted in 3% BSA. For the dilution
factors of the different primary antibodies used in this work see (Table 2-7).
Negative controls were incubated with 3% BSA only.
C) Staining with secondary antibody: After staining with the pnmary
antibody for overnight, the cells were washed four times in washing solution
(1% BSA and 0.1% Tween-20 in PBS) for 10 minutes at room temperature.
The secondary antibody was diluted in 3% BSA and gently added on top of the
coverslips (350 III per well) including the negative controls. Immediately after
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adding the secondary antibody, the plates were wrapped with aluminum foil
and incubated in a dark place for 1 hour at room temperature. The stained cells
were washed five times in the washing solution for 10 minutes at room
temperature. At the end, the coverslips were removed from the wells of the 6-
well plates and gently mounted on clean slides in an upside down position with
small amount of DAPI. The coverslips were sealed on the slides using nail
varnish and stored at 4°C in the dark.
The stained cells were inspected for the fluorescent signal of the proteins of
interest using Leica DMI3000 B Inverted microscope (Leica Microsystems,
UK). The integrated camera of the Leica microscope was used for the imaging
and the software provided by the supplier was used for image analysis
following the manufacture's instruction.
2.2.6.7 Phalloidin staining
Phalloidin is a commonly used dye for the morphological analysis. It can bind
F-actin and display the shape of the cells. The initial step of phalloidin staining
is similar to the IF protocol in which the cells were grown on coverslips, fixed,
and permeabilized with O.l% Triton X-lOO (see section 2.2.6.6). After
permeabilization, cells were incubated with diluted (50 ug/ml, in PBS)
fluorescent phalloidin conjugate solution (Sigma, # 1951) for 40 minutes in
dark. The stained cells were washed 2-3 times in PBS for 5 minutes at room
temperature then the coverslips were removed, mounted and analyzed with the
Leica microscope as described above in (section 2.2.6.6).
2.2.6.8 In Situ Hybridization (ISH) assay
2.2.6.8.1 Probe preparation, specificity and verification
A short fragment of FLYWCHI cDNA (651 bp), conserved between mouse and
human, was excised from the eGFP-FLYWCHI-WT clone (Figure 3-12) by
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restriction enzyme digestion using single cutter enzymes BamHI (cutting
position 166/170) and XhoI (cutting position 8111815). The resultant DNA
fragment spans 3 exons of human FLYWCHI gene (exons 1-3). The specificity
of the probe was confirmed by blasting the nucleotide sequence of the probe to
the human and mouse genomic and transcript database using nucleotide
BLAST suite facility provided by NCBI
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The result of the blast is presented in
(Appendices 11 & 12) and the size of the DNA fragment was confirmed by
running the digested DNA on 1% agarose gel. Finally, the DNA probe was
cloned into the MCS of pcDNA3 vector (Appendix 8) downstream to the T7
promoter using the same enzymes mentioned above. This clone was also
verified by restriction enzyme digestion analysis using BamHIIXhoI restriction
enzymes.
2.2.6.8.2 In vitro transcription and hybridization protocol
The FLYWCHI cDNA probe described above along with tissue microarray
(TMA) of human colorectal cancer tissues (provided by prof. Ilyas, Division of
Pathology, Nottingham University) and ApcMinl+ mouse intestinal tissues
(prepared by Dr Roya Babaei-Jadidi, Dr Nateri's lab) were sent to our
collaborator Dr B Spencer-Dene, CRUK-LRI, Histopathology Lab to perform
the ISH assay as detailed below. The mouse intestinal tissues were prepared in
the form of Swiss rolls by flushing the intestinal segments with cold PBS,
threading through with stainless steel rods in a rod holder (Dr Nateri's lab),
slicing and opening them longitudinally using a scalpel to expose tissue
epithelia to a fixative buffer composed of (10% Neutral Buffered Formalin
containing of 100 ml of 37% formaldehyde, 4g of NaH2P04, 6.5g of
Na2HP04 in 900 ml of H2o), and then rolling them around a metal or wooden
stick. These tissues were then processed and embedded in paraffin blocks as
described previously (Babaei-Jadidi et aI., 2011, Ibrahim et aI., 2012, Nateri et
al.,2005).
The T7 RNA polymerase was used for in vitro transcription of this DNA
fragment to generate a human FLYWCHI RNA probe using the digoxigenin
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(DIG)-RNA labelling mIX (Roche; 11277073910). In brief, 4 %
parafonnaldehyde (PFA)-fixed intestinal Swiss roll preparations were
sectioned (8 um, and placed onto glass slides by floating sections in a water
bath at 42°C), dewaxed, rehydrated, digested with 10 ug/ml proteinase K
(37°C for 18 minutes), and then incubated in 0.2 M HCI and refixed. After
prehybridization for 1 hour, slides were hybridized overnight at 57°C in buffer
containing 50 % deionized fonnamide, 10 % dextran sulfate, IX Denhardt's
solution, 10 mM Tris-HCI pH 7.6, 600 mM NaCI, 0.25 % Na dodecyl sulfate, 1
mM EDTA, 2 mg/ml transfer 0.2 M, and 2 ug/ml denatured digoxigenin-
labelled cRNA probe. The slides were rinsed in 5X saline-sodium citrate (SSC)
buffer at 57°C for 10 min, washed once in 50 % fonnamide in 2X SSC at 57°C
for 30 min, and then once in 2X SSC at 57°C for 30 min and twice in 0.2X
SSC for 30 min each at 57°C. After blocking with 1 % blocking reagent
(Roche), slides were incubated with sheep antidigoxigenin fab antibody
(Roche, 11093274910; 1:1,000) for 2 hours at 37°C. Substrate was developed
using NBTIBCIP (nitro-blue tetrazolium chloride and 5-bromo-4-chloro-3-
indolyphosphate p-toluidine salt).
2.2.7 Statistical analysis
All statistical evaluations were accomplished by the independent-samples T-
test (2-tailed) using SPSS software (IBM SPSS Statistics, version 19) and P <
0.05 was considered to be statistically significant. The error bars shown for all
charts represent the standard deviation (STDEV) for the sample's mean, unless
otherwise stated. Experiments were performed in triplicates for each case and
repeated on at least 2-3 independent occasions.
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Identification and expression of the human
FLYWCHI gene in mammalian cells
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3.1 Introduction
Despite the fact that human FLYWCHI gene was previously identified
(Brandenberger et al., 2004, Stelzl et al., 2005) and its sequence was deposited
on the NCBI (National Centre for Biotechnology Information) database
(http://www.ncbi.nlm.nih.gov/gene/84256), the protein product of this gene
was not previously characterized. Therefore, in the current work and for the
first time, the FLYWCHI coding sequence was bioinformatically analyzed and
experimentally characterized.
Our bioinformatics analyses show that the FLYWCHI gene encodes a protein
called FLYWCHI with five FLYWCH-type Zinc finger motifs. This protein
including its FLYWCH motifs is evolutionarily conserved in human, mouse,
chimpanzee, dog, cow, and rat. The FLYWCH motifs of FLYWCHI protein
may function as DNA-binding domains (see the discussion). However, there is
no evidence for the presence of a transactivation-domain within the coding
region of this protein.
Overexpression of proteins is a powerful approach to study their biological and
biochemical functions. In this chapter, we, successfully, tagged the full-length
FLYWCHI eDNA with different epitope tags such as MYC & eGFP, and
cloned these sequences into different mammalian expression vectors. The
protein expression of these clones and the sub-cellular localization of
FLYWCHI protein were also validated through Western blotting analysis and
fluorescent microscopy. The analysis revealed that the expression of eGFP-
tagged FLYWCHI resulted in bright fluorescent spots in the nucleus which
was distinct from the expression pattern of eGFP reporter gene in HEK293T
and CRC cells, implying that sub-cellular localization may be require for
FLYWCHI function.
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3.2 Results
3.2.1 Sequence and domain analysis of FLYWCHI
Human FLYWCHI gene is currently recognized under the official name
[FLYWCH-type zinc finger 1 (FLYWCHl)] on the NCBI database (Gene ID:
84256, http://www.ncbi.nlm.nih.gov/gene/84256).This gene is composed of
2,151 nucleotides encoding 716 aa (aa) residues (Figure 3-1A). To define the
presence of conserved domains within the aa sequence of FLYWCH1, related
bioinformatic resources such as Domain Mapping of Disease Mutations
(DMDM, http://bioinf.umbc.edu/dmdml) (Peterson et al., 2010) and protein
family (Pfam, http://pfam.sanger.ac.ukL) (Finn et al., 2010) databases were
interrogated. The analyses showed that FLYWCHI contains a tandem array of
five FLYWCH-type zinc finger motifs distributed along the protein sequence
(Figure 3-1, A & B). The FLYWCH domain was originally described as a
Cys2His2 motif (Buchner et al., 2000) and then annotated as FLYWCH domain
in the Drosophila Mod(mdg4) protein based on the presence of the FLYWCH
consensus sequence (FN-Xn-L-Xn-FN-Xn-WXCX6-12CX17-22HXH;
where X indicates any amino acid) (Dom and Krauss, 2003).
To validate the presence of such conserved domains in human FLYWCHI
protein, the sequence alignment of FLYWCH motifs was performed. The
alignment data revealed that the FLYWCH consensus sequence (F, L, Y, W,
C, & II) was highly conserved between zinc finger motifs of this protein
(Figure 3-1C). The data also show that each motif is composed of 177
nucleotides encoding 59 aa (Figure 3-1A). Moreover, in addition to the
presence of the FLYWCH consensus sequence, most of the other aa residues
within the coding sequence of FLYWCH motifs are highly conserved (Figure
3-1C), suggesting that these motifs may have important structural and
biological involvement in the function ofFLYWCHl.
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A) MPLPEPSEQEGESVKAGQEPSPKPGTDVIPAAPRKPREFSKLVLLTASDQDEDGVGSKPQEVHCVLS
LEMAGPATLASTLQILPVEEQGGVVQPALEMPEQKCSKLDAAAPQSLEFLRTPFGGRLLVLESFLYK
QEKAVGDKVYWKCRQHAELGCRGRAITRGLRATVMRGHCHAPDEQGLEARRQREKLPSLALPEGLGE
PQGPEGPGGRVEEPLEGVGPWQCPEEPEPTPGLVLSKPALEEEEAPRALSLLSLPPKKRSILGLGQA
RPLEFLRTCYGGSFLVHESFLYKREKAVGDKVYWTCRDHALHGCRSRAITQGQRVTVMRGHCHQPDM
EGLEARRQQEKAVETLQAGQDGPGSQVDTLLRGVDSLLYRRGPGPLTLTRPRP~EDQELPTQ
PEAPDEHQDMDADPGGPEFLKTPLGGSFLVYESFLYRREKAAGEKVYWTCRDQARMGCRSRAITQGR
RVTVMRGHCHPPDLGGLEALRQREKRPNTAQRGSPGGPEFLKTPLGGSFLVYESFLYRREKAAGEKV
YWTCRDQARMGCRSRAITQGRRVMVMRRHCHPPDLGGLEALRQREHFPNLAQWDSPDPLRPLEFLRT
SLGGRFLVHESFLYRKEKAAGEKVYWMCRDQARLGCRSRAITQGHRIMVMRSHCHQPDLAGLGALRQ
RERLPTTAQQEDPEKIQVQLCFKTCSPESQQIYGDIKDVRLDGESQ-
B)
Cl {116 2LRTPFGGRLLVLESFLYKQEKAVGDKVYWKCRQHAELGCRGRAITRGLRATVMRGHCH 174
G ~ 273 PLRTCYGGSFLVHESFLYKREKAVGDKVYWTCRDHALHGCRSRAITQGQRVTVMRGHCH 331:s: rJ)
~ 15 421 PLKTPLGGSFLVYESFLYRREKAAGEKVYWTCRDQARMGCRSRAITQGRRVTVMRGHCH 479
~ E 509 ~LKTPLGGSFLVYESFLYRREKAAGEKVYWTCRDQARMGCRSRAITQGRRVMVMRRHCH 567
600 FLRTSLGGRFLVHESFLYRKEKAAGEKVYWMCRDQARLGCRSRAITQGHRIMVMRSHCH 658
**:*::**::**:*****::***:*:****:**::*::***:****:*:*::***:***
FLYWCH
consensus
Fly L Fly WXC X6-12 C X17-22 HXH
Figure 3-1: Schematic presentation of FLVWCH motifs within human FLVWCH1
protein. A) Shows the aa sequence of full-length human FLYWCH1. The deduced aa
sequence indicates a complete identity of the FLYWCH1 IMAGE clone nucleotide
sequence (see section 3.2.2) translated to protein by ExPASy translate tool
(http://expasy.org/). The aa composition of FLVWCH motifs are highlighted in red and
the predicted NLS motif is boxed. B) A diagram shows tandem repeats of five FLYWCH
encoding domains across human FLYWCH1 protein. C) Alignment of FLYWCH domain
sequences shows the core aa residues (F, L, V, W, C, and H) of FLYWCH consensus
sequence highlighted in yellow. The starting and ending residue numbers given for
each domain indicate the aa numbering within the FLYWCH1 protein sequence. All
identical residues are indicated by asterisks (*) at the bottom line and the non-identical
residues by colons (:).
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Next, by using established nuclear localization signal (NLS) databases such as
the PredictProtein (available at www.predictprotein.org), a putative NLS motif
(KRAK) within the aa sequence of FLYWCHI (starting at aa position 390)
was predicted (Figure 3-1A, boxed sequence). This sequence highly resembles
the classical NLS motif represented by the consensus sequences (K-RJK -X-
KIR) (Hodel et al., 2001, Robbins et al., 1991, Chelsky et al., 1989, Dingwall
and Laskey, 1991).
Furthermore, a comprehensive homology analysis of the FLYWCHI gene in
human vs. other mammals was also performed. Reliable alignment and
comparison tools such as ClustalW2-Multiple Sequence Alignment (Goujon et
al., 2010, Alessi et al., 2007) (http://www.ebi.ac.uklTools/msalclustalw2D and
the HomoloGene data base (http://www.ncbi.nlm.nih.gov!homologene) were
used to align and compare the full nucleotide as well as peptide sequence of
human FLYWCHI including the conserved FLYWCH motifs to other animals.
Interestingly, the data showed that both peptide and nucleotide sequences of
FLYWCH1 are highly conserved within many species of mammals (Table
3-1). As shown in the table, the aa sequence of human FLYWCHl, shows
about 99, 82, 78, 73, and 74% similarity with Pan troglodytes, Canis lupus
familiaris, Bas taurus, Mus musculus, and Rattus norvegicus respectively.
Table 3-1: Pairwise alignment scores of FLYWCH1 peptide and nucleotide
sequences in human versus other animals. The HomoloGene automated system
was used to perform the protein and nucleotide sequence comparisons, the level of
similarity (identity) is shown in percentage (%).
Gene Identity (%)
Species Symbol Protein DNA
Homo sapiens FLYWCH1
vs. Pan troglodytes FLYWCH1 98.5 98.8
vs. Canis lupus familiaris FL YWCH1 81.9 83.9
vs. Bas taurus FL YWCH1 78.6 83.7
vs. Mus musculus Flywch1 73.1 76.4
vs. Rattus norvegicus Flywchl 74.2 78.3
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The multiple aa sequence alignment of FLYWCHI in the above mentioned
animals (Table 3-1) also showed conservation of the five FLYWCH domains
in all species (Figure 3-2). Moreover, careful examination of FLYWCHI aa
sequence revealed that in addition to the FLYWCH domains, the putative NLS
motif (KRAK) which was predicted for human FLYWCHI (Figure 3-1) was
also conserved in all these members (with one exemption) of mammalian
FLYWCHI proteins (Figure 3-2).
B) '----------------------~
396 HUMAN
400 PANTR
617 BaVIN
396 CANFA
383 Mouse
361 Rat
Figure 3-2: Multiple sequence alignment of FLYWCH1 in different animals. A)
Multiple full-length aa sequence alignment of FLYWCH1 shows the presence of five
conserved FLYWCH motifs within several members of FLYWCH1 family of protein as
indicated. Dark boxes correspond to FLYWCH domains, while light blue boxes to NLS
motifs (KRAK). Lines correspond to non-domain regions; dark lines or boxes show
matched parts, while light ones gaps. Vertical dark blue lines indicate splicing
boundaries. This alignment was generated using the Tree families database (Tfam
accession number TF337169). B) Represents alignment of a short aa sequence of
FLYWCH1 in the indicated animals shows the predicted conserved NLS motif (KRAK)
higlighted in blue.
The full-length aa sequence alignment of FLYWCH1 in the indicated animals
in (Figure 3-2) is presented in (Appendix 1). However, the aa sequence
alignment of full-length FLYWCHI in human and mouse (H-FLYWCHI and
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M-Flywchl, respectively) IS shown III (Figure 3-3) as an example.
Interestingly, both proteins share five unique FLYWCH domains with highly
significant aa similarities.
H-FLYWCHI MPLPEPSEQEGESVKAGQEPSPKPGTDVIPAAPRKPREFSKLVLLTASDQDEDGVGSKPQ 60
M-Flywchl MPLPEPSEQDCESLRAGQEPS---------VGARKPQESSNLVPARDKER---- -PKP- 44
: * 1<-: * *
H-FLYWCHI EVHCVLSLEMAGPATLAS-TLQILPVEEQGGVVQPALEMPEQKCSKLDAAAPQSLEFL T 119
M-Flywchl --TDVASQETSSTATLPNNTLQVAPVKKQGRIIH-------RKRSRVDAVPPQPLEFL'T 95
***: .. **"" ***: **;:** ::: :~ *::-:1<;0; ** 70 *.*
H-FLYWCHI Pr LLVLESFLY QEvAVGDk"VYWi<CRQHAELGCPGRAITRGL .ATVM GHCHAPDEQ 179
M-Flywchl t Fe I:,VH'F~Y QE!<AVGD·VYWKC'QHSELSC;;GP.AIT:;GFl'VTEMRDHCHPPEKE155
****** :*********************:**.********~:*.* **.* ~.*:::
H-FLYWCHI GLEAR-RQREKLPSLALPEGLGEPQGPEGPGGRVEEPLEGVGPWQCPEEPEPTPGLVLSK 238
M-Flywchl GLDRKKRHRGRPPSSALPEG-----------AEVQE--DEVSLWLYPVEPEPTP--QPST 200
: : *:* : ** ***** ** *y; * *
H-FLYWCHI PALEEEEAPRALSLLSLPPKKRSILGLGQARPLEFL TCYGGSFLVHESFLYKREVAVGD 298
M-Flywchl ETPEEEQGYRSLALQSLPPKKRPTPGVVRYRPLEFL'TCYGGTFLVHQSFLYKFEKTVGS 260
: "'-*"':. *:*:* ***** ....*
H-FLYWCHI VYWTC DHAL~GC S ,AITQGQlVTVMKGHCHQPDMEGLEARRQQEKAVETLQAGQDGP 358
M-Flywchl VYWTC EHAVHGCS,AITQGQ~VTVMrSHCHSPDIEGLQARRQQEKTIKKIQARRIGA 320
*****.**.****************** **
. . .
. * '* . * . .. . '1< •..... .
H-FLYWCHI G------SQVDTLLRGVDSLLYRRGPGPLTLTRPRPRKRAKVEDQELP-----------T 401
M-Flywchl GDLEDCDDIEDSLLQGVDSLFYRRGQGTLTLSRSKSKSKSKSRSKSKSKSRSRSRKRAKK 380
* : * * : ]I * . * ~* * : * . : . : . : : ....
H-FLYWCHI QPEAPDEH--QDMDADPGGPEFL~TPLGGSFLVYESFLYP<EKAAGEKVYWTCPDQA ,MG 459
M- Flywchl QQESSQEPPEEDQDVDPRGPEFL,'TPLGGNFLVYES FLYP ,ErVAGEI'VYWTCPDQAf.MG 440
.* * ** * ******.********"'****.**************
H-FLYWCHI C SA:TQG·· FVTVMEGHCHPPDLGGLEALRQREKRPNTAQRGSPGGPEFLI'TPLGGSFL 519
M-Flywchl C S AITQGQVTVMRSHCHPPDLLGLETLRQREKRPGPSQWDGPEGPEFLtTPLGGSFL 500
*********:*****.******* ***: * ...
H-FLYWCHI VYESFLY E'AAGEYVYWTCRDQAcMGCl\SRAITQGKPVMVMP-HCHPPDLGGLEALRQ 579
M-Flywchl VYESFLyr. EATGDr'VYWTC- DQAP.MGCKS.AITQGQKVMVMP. HCHPPDMGGLEALRQ 560
~***********:*:********~*************:********* * :**k +
H-FLYWCHI REHFPNLAQWDSPDPLRPLEFLPTSLGGPFLVHESFLYFKEKAAGEKVYWMCDQA,LGC 639
M-Flywchl RENFPNLTHWEGPEPLQPLEFLRTSLGGRFLVYESFLY_YEKAAGEYVYWMCPDQA<LGC 620
:~***::*:.": :***************:~***~***y***~~**~*********~
H-FLYWCHI SrAITQGH IMVMPSHCHQPDLAGLGALRQRERLPTTAQQEDPEKIQVQLCFKTCSPES 699
M-Flywchl SKAITQGR1VMVMRSHCHPPDLAGLEALRQREKAPSAAKKK-----------KKKKKKK 669
*******:*:*****,,* 1<*** *** * * .. * ....
H-FLYWCHI QQIYGDIKDVRLDGESQ 716
M-Flywchl KGIH------------- 673
. *.
Figure 3-3: FLYWCH1 amino acid sequence alignment in human and mouse. The
alignment shows five conserved FLYWCH motifs highlighted in yellow. Asterisks (*)
indicate positions which have a single, fully conserved residue, colons (:) indicate
conservation between groups of strongly similar properties, and periods (.) indicate
conservation between groups of weakly similar properties.
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Previous reports have shown that DNA with high GC-content could be more
stable than DNA with low GC-content (Hurst and Merchant, 2001, Yakovchuk
et aI., 2006). To investigate the GC-content ratio of FLYWCHI cDNA, a GC
ratio calculator tool (available at http://www.genomicsplace.comlgc calc.html)
was used. The results showed that FLYWCHI cDNA contains high GC-
content ratio, with 1,456 G's and C's out of 2,151 nuc1eotideswhich is equal to
67.7%, indicating that the full-length FLYWCHI may normally have a stable
structure.
3.2.2 Characterization of human FLYWCHI IMAGE clone
The IMAGE clone of the human FLYWCHI cDNA was purchased from
Geneservice (IMAGE ID: 4839062/AK34 PI6). The full-length nucleotide
sequence of this clone was provided by the supplier and it is also available on
the NCBI database
(http://www.ncbi.nlm.nih.gov/nuccore/22382197?report=genbank) under the
name "Homo sapiens FLYWCH-type zinc finger 1, mRNA (cDNA clone
MGC: 26050 IMAGE: 4839062), complete CDS" with a GenBank accession
number: BC028572.1. This sequence was used as a reference for FLYWCHI
IMAGE clone cDNA validation and manipulation.
According to the sequence alignment data analysis, the FLYWCHI IMAGE
clone sequence was matched to the human FLYWCHl, a gene that belongs to
the mammalian FLYWCHI family. This gene comprises eight exons and maps
to chromosome 16p13.3. Further genomic information for FLYWCHI (Gene
ID: 84256) can be found on the NCBI data base at
(http://www.ncbi.nlm.nih.gov/gene/84256).
The FLYWCHI IMAGE clone was received in a slant agar bacterial culture.
Upon arrival, a small portion of the culture was re-grown in 5 ml Luria broth
(LB) with Ampicillin (Amp) then the plasmid DNA was extracted. According
to the information provided by the supplier (Geneservice), the IMAGE clone
plasmid DNA is composed of 8,004 base pairs (bp) including the full-length
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FLYWCH1 coding region (2,151 bp) fused to 5' and 3' untranslated regions
(UTRs) (365 and 2,490 bp, respectively). This DNA fragment has been cloned
into the pBluescriptR vector (2,998 bp) (Figure 3-4) by the supplier. It should
be mentioned that there is one aa difference between the IMAGE clone
provided sequence (Gene ID: BC028572.1) and the gene bank sequence (Gene
ID: 84256) ofFLYWCHl. However, this difference does not cause any out-of-
frame reading ofFLYWCH1 nucleotide sequences.
AspEl (2084)
F1 intergenic region
APr
pBluescriptR
2998 bp
Sac II (662)
~ __ Notl (668)
EcoRl (734)
'--..I~===-:::-Safl (740)
Xhol (745)
8amHI (754)
Apal (792)
Acc651 (794)
Kpnl (798)
3 promotor /94.1%
M13r(1000%)
pUC ori
Figure 3-4: pBluescriptR (KS+) plasmid (Stratagene). Non-PCR- generated human
full-length FL YWCH1 eDNA was inserted into the pBluescriptR vector by the
Geneservice Ltd to produce FLYWCH1 IMAGE clone.
In order to verify the presence of full-length FLYWCH1 cDNA in the IMAGE
clone, a restriction enzyme digestion analysis was carried out. As an initial
step, all single cutter restriction enzymes within FLYWCHI cDNA including
the 5' and 3' UTRs were mapped (Figure 3-5) using version 2.0 of NEBcutter
tool (Vincze et aI., 2003)
(http://tools.neb.comlNEBcutter2/index.php).
available at
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Based on the above analysis in (Figure 3-5), the precise cut position (s) of a
number of single cutter restriction enzymes in addition to the number and size
of the expected digested fragments were determined as shown in (Table 3-2).
Table 3-2: List of single cutter restriction enzymes used for FLYWCH1 IMAGE
clone verification. The cut position (s), number and size of fragments resulted from
each restriction enzyme digestion are indicated.
Enzymes Cut position (s) Fragments Size (bp)
668
NoN 1 8,004
within multiple cloning site
798 1
Kpnl
within multiple cloning site
8,004
95/99 1
San 8,004
within 5' UTR
1,175/1,179 1
Xhol 8,004
within FLYWCH1 coding region
San 95/99 within 5' UTR 4,907
+ and 2 +
Kpnl 798 within multiple cloning site 3,100
San 95/99 within 5' UTR 5,430
+ and 2 +
fcoRI 2,673/2,677 within 3' UTR 2,582
The IMAGE clone plasmid DNA was then digested with the above single
cutter restriction enzymes specified in (Table 3-2) either individually or in
combination (Figure 3-6). The size and number of the digested DNA fragments
was analyzed by running the DNA on 1% agarose gel. As shown in (Figure
3-6A), the IMAGE clone plasmid DNA was linearized by each of the enzymes
used (lanes 1-4 for Sali, NotI, XhoI, and KpnI respectively). When two single
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cutter enzymes were used together such as SalI/KpnI and SalIJEcoRI (Figure
3-6B), two expected FLYWCH1 DNA fragments; 3,100 and 2,582 bp (lanes 1
and 2 respectively) were released from the pBluscriptR vector. In support of
supplier's information, the results of the restriction enzyme digestion
confirmed the presence of full-length FLYWCH1 eDNA in the IMAGE clone.
A) M 1 2 3 4 5
10,000
8,000
IMAGE clone
plasmid DNA
(8,004 bp)
B)
6,000
5,000
3,000
2,500
IpBluscriptRbackbone vector
FLYWCH1 cDNA
Figure 3-6: Restriction enzyme digestion analysis of FLYWCH1 IMAGE clone
plasmid DNA. Agarose gel shows A) Linearized full-length plasmid DNA (8,004 bp) of
FLYWCH1 IMAGE clone digested with single cutter enzymes. Lanes 1-4 correspond to
San, Nart, Xhal, and Kpnl respectively, while lane 5 represents the un-cut DNA of the
IMAGE clone B) Digested DNA with combination of two single cutter enzymes; lane 1
corresponds to SanlKpnl and lane 2 to San/feaRI. Fragments of FL YWCH1 cDNA;
3,100 bp (lane 1) and 2,582 bp (lane 2), were released from the rest of the IMAGE
clone sequence (backbone vector + 5' and 3' UTRs) as indicated. Letter M, represents
a 1Kb DNA ladder in bp (Sigma).
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According to the information available on the NCBI data base, human
FLYWCHI has two transcript variants; transcript variant (1), this variant
represents the longer transcript and encodes the longer isoform (a)
(http://www.ncbi.nlm.nih.gov/proteinlNP 115672.2), whereas transcript
variant (2) differs in the 3' UTR and coding region compared to variant (1).
The resulting isoform (b) is shorter at the C-terminus compared to isoform (a)
(http://www.ncbi.nlm.nih.gov/proteinlNP 065963.1). The IMAGE clone used
in this study represents the longer transcript which encodes the longer isoform
(isoform a; CCDS ID: CCDS45390.1). Thus, the expression of full-length
human FLYWCHI protein could be obtained using this cDNA clone.
3.2.3 Cloning of human FLYWCHI eDNA into mammalian
expression vectors
3.2.3.1 Cloning of un tagged human FLYWCH1 eDNA (FLYWClI1-
WT)
In order to avoid possible PCR amplification errors, the full-length FLYWCHI
cDNA was initially cloned into mammalian expression vectors using a
restriction enzyme digestion strategy. The restriction digestion or "cut and
paste strategy" was employed to cut a fragment of DNA containing the full-
length FLYWCHI cDNA from the IMAGE clone plasmid vector
(pBluescriptR) with San and EcoRI restriction enzymes (Figure 3-7A). A
mammalian expression vector (pI-EGFP2) was also digested with the same
restriction enzymes to create compatible cohesive ends (Figure 3-7B). pI-
EGFP2 is a modified pKW2T vector which was reconstructed to express eGFP
(Enhanced Green Fluorescence Protein) (Nateri et al., 2004) (see Appendix 4).
As shown in (Figure 3-7A), the size of the DNA fragment (2,582 bp) obtained
by this digestion is bigger than the calculated size of the coding region of
FLYWCHI cDNA (2,151 bp) based on the nucleotide sequence of this gene.
This difference is due to the cutting positions of the restriction enzymes used.
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San cuts ~269 bp upstream to the FLYWCHI coding region (inside the 5' UTR)
and EcoRI cuts ~162 bp downstream to the FLYWCHI coding region (inside
the 3' UTR). Thus, 431 extra nucleotides are fused to the cDNA sequence of
FLYWCHI obtained by this enzymatic digestion.
A) M San/feaRI
6,000
5,000
3,000
2,500
pBluescriptR backbone
vector (5,422 bp)
FLYWCH1 cDNA
(2,582 bp)
B) M San/feaRI
10,000
8,000
6,000
pl-EGFP2 backbone
vector (6,100 bp)
Figure 3-7: Restriction enzyme digestion analysis of FLYWCH1 IMAGE clone and
pl-EGFP2 plasmid vector. San and EcaRI restriction enzymes were used to A)
remove a full-length FLYWCH1 containing DNA fragment (2,582 bp) from the rest of the
FLYWCH1 IMAGE clone (pSluescriptR vector plus 5' and 3' UTRs), and also to B)
linearize the pl-EGFP2 vector (6,100 bp) as indicated. Letter M, denotes a 1Kb DNA
ladder in bp (Sigma).
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The FLYWCH1 coding region was then inserted into the multiple cloning site
of the pI-EGFP2 backbone vector to form a wild-type clone of untagged
FLYWCHI (FLYWCHI-WT, 8682 bp). Therefore, by using this clone the
FLYWCHI cDNA could be expressed under the CMV-promoter in mammalian
cells and SP6-promoter for in vitro analysis as illustrated in (Figure 3-8).
Untagged-FLYWCH1 cDNA
ApaU
feoRI
Hincllil
Lac i
FLYWCH1-WT
8682 bp
GMV
AMP
SV40 poly A
py replication ori
LacZ
Sad M13G
ORl
Figure 3-8: The plasmid map of untagged human FLYWCH1 clone. A diagram
shows the map of human FLYWCH1-WT clone (8,682 bp) with an untagged-FL YWCH1
cDNA expressed under CMV-promoter.
To validate this clone, the plasmid DNA molecules were recovered from
several transformed bacterial colonies and examined by the restriction enzyme
digestion method using the same enzymes used for cloning (SalI/EcoRI). As
shown in (Figure 3-9), a single band of DNA (2,582 bp) containing the full-
length untagged-FL YWCHI cDNA was released from the backbone vector
(pI-EGFP2, 6,100 bp). These data confirm the successful cloning of FLYWCHI
cDNA in pI-EGFP2 mammalian expression vector.
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M San/feaRI
3,054
pl-EGFP2 backbone
vector (6,1 00 bp)
7,126
6,108
2,036
Full-length FLYWCH1
cDNA (2,582 bp)
Figure 3-9: Restriction enzyme digestion analysis of untagged FLYWCH1 clone.
Agarose gel shows digested DNA with San/feaRI; a single band of untagged-
FLYWCH1 cDNA (2,582 bp) was released from the backbone vector pl-EGFP2 (6,100
bp) as indicated. Letter M, denotes a 1Kb DNA ladder in bp (Invitrogen).
3.2.3.2 Cloning of MYC-tagged human FLYWCHl (MYC-
FLYWCH1-WT)
Adding an epitope tag (such as MYC or eGFP reporter gene) to the
exogenously expressed FLYWCHI not only provides sensitive and specific
detection of this protein, but it also simplifies characterization of FLYWCHI
throughout the biochemical and biological analyses. In the current work, the
MYC-epitope tag which is a 10 aa segment of the human proto-oncogene c-
MYC was fused to the 5'-end of FLYWCHI cDNA using PCR (Figure 3-10).
In order to amplify the full-length FLYWCHI cDNA fused to the MYC-epitope
tag in-frame, specific primers were designed and the FLYWCHI IMAGE
clone plasmid DNA was used as a DNA template for the PCR reaction. The
NheI restriction enzyme site and two copies of MYC-tag epitope sequence
were engineered into the 51-end of the forward primer, whereas the EcoRI
restriction enzyme site and two copies of stop codons were added to the 31-end
of the reverse primer (Table 2-2).
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The standard PCR technique (section 2.2.2.5) was used to amplify the full
DNA sequence of MYC-tagged FLYWCHI (2,221 bp) using the above
described primers. The PCR product of MYC-FLYWCHI was digested with
NheIlEcoRl restriction enzymes and inserted into the multiple cloning site of
pIRES2-EGFP mammalian expression vector (see Appendix 5). The final
composition of the plasmid clone contains the MYC-tagged-FLYWCHI cDNA
under the expression of CMV-promoter as shown in (Figure 3-10).
MYC-FlYWCH1 cDNA
Nhel
MYC-FLYWCH1-WT
7514 bp
Figure 3-10: The plasmid map of MYC-tagged FLYWCH1 clone. A diagram shows
the map of MYC-FLYWCH1 plasmid clone (7,514 bp) with MYC-tagged human
FL YWCH1 eDNA expressed under CMV-promoter.
This clone was validated by restriction enzyme digestion analysis using NheI
and EcoRl. As shown in (Figure 3-11), a single band of MYC-FLYWCHI
(2,221 bp) released from the backbone vector (5,300 bp), confirming that the
MYC-epitope-fused FLYWCHI cDNA was successfully cloned into the
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plasmid vector. The FLYWCHI cDNA correct orientation and in-frame
construction with the MYC-epitope tag was further verified by automated
DNA sequencing (Appendix 9). In addition, the protein expression of this clone
was also confirmed by Western blotting analysis (Figure 3-14B). This clone
therefore can be broadly applied to overexpress MYC-FLYWCHI protein in
mammalian cells that could be used for different biochemical and functional
analysis.
M Nhel/£coRI
2,036
pIRES2-EGFP
(5,300 bp)
6,108
5,090
MYC-FLYWCH1
(2,221 bp)
Figure 3-11: Restriction enzyme digestion analysis of MYC-tagged human
FLYWCH1 clone. Agarose gel shows digested DNA with Nhel/£coRI; a single band of
MYC-tagged human FL YWCH1 cDNA (2,221 bp) was released from the backbone
vector used (pIRES2-EGFP, 5,300 bp) as indicated. Letter M, denotes a 1Kb DNA
ladder in bp (Invitrogen).
3.2.3.3 Cloning oj eGFP-tagged human FLYWCHl (eGFP-
FLYWCH1-WTj
In order to dissect the cellular localization of FLYWCHI in mammalian cell
culture, cloning of human FLYWCHI eDNA fused to eGFP was carried out
using the PCR strategy. Specific primers (Table 2-3) were designed and used
to amplify the full-length FLYWCHI eDNA using the FLYWCHI IMAGE
clone eDNA as a template. Suitable restriction enzyme sites were engineered to
the primers to facilitate the cloning process as detailed below. The BglII
restriction site was added to the 5'-end of the forward primer and two extra
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nucleotides (A & C) were also added to keep in-frame ORF (Open reading
frame) through the nucleotide sequences of the multiple cloning site (MCS) of
the plasmid vector (pEGFP-C2) (see Table 2-3). pEGFP-C2, is a mammalian
expression vector and contains the enhanced green fluorescent protein (eGFP)
reporter gene just upstream to the MCS (see Appendix 6). The EcoRI
restriction site and two copies of stop codons were also added to the 3'-end of
the reverse primer used as shown in (Table 2-3).
The standard PCR technique (section 2.2.2.5) was used to amplify the full-
length FLYWCHI cDNA (2,151 bp) from the FLYWCHI IMAGE clone
plasmid DNA using the above described primers. The PCR product was then
cloned into the MCS of the pEGFP-C2 plasmid vector in-frame to the eGFP
reporter gene. Thus, the expression of the eGFP-FLYWCHI fusion protein in
this clone is controlled by the CMV-promoter as illustrated in (Figure 3-12).
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Figure 3-12: The plasmid map of the eGFP-fused FLYWCH1 clone. A diagram
shows the map of eGFP-FLYWCH1 clone (6,886 bp) with N-terminal eGFP-fused
FL YWCH1 eDNA expressed under CMV-promoter.
The successful construction of this clone was confirmed by restriction enzyme
digestion analysis using BgnVEcoRI. As shown in (Figure 3-13), a single band
of FLYWCHI cDNA (2,151 bp) was released from the backbone vector (4,700
bp). The in-frame recombination of FLYWCHI cDNA with the eGFP sequence
of the plasmid vector was further verified by Western blotting (Figure 3-14A)
and fluorescent microscopic analysis (Figure 3-15). This clone can be used to
identify and study the FLYWCHI gene expression patterns including the sub-
cellular localization of this protein.
2,036
pEGFP-C2
(4,700 bp)
5,090
4,072
FLYWCH1
(2,151 bp)
Figure 3-13: Restriction enzyme digestion analysis of eGFP-fused human
FLYWCH1 clone. Agarose gel shows digested recombinant eGFP-FLYWCH1-WT
plasmid DNA with BgnilEcoRI. A single band of full-length FLYWCH1 eDNA (2,151 bp)
was released from the backbone vector pEGFP-C2 (4,700 bp) as indicated.
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3.2.4 Exogenous expression of human FLYWCHI cDNA clones
in cell culture
To validate the protein expression of the above FLYWCHI N-tenninal fusion
tagged and untagged clones, Western blotting (WB) analysis was carried out.
The cDNA of untagged-FLYWCHI (FLYWCHI-WT), MYC-tagged
FLYWCHI (MYC-FLYWCHI-WT), and eGFP-fused FLYWCHI (eGFP-
FLYWCHI-WT) clones were overexpressed in HEK293T cell line and the
protein lysate was examined by Western blotting analysis (see section 2.2.5.2).
The lysate of untransfected cells was also used as a negative control. Three
types of antibodies; Anti-FLYWCHl, Anti-MYC (EI0), and Anti-GFP (Table
2-7) were used to detect untagged, MYC-tagged, and eGFP-tagged FLYWCHI
proteins respectively as detailed below.
As shown in (Figure 3-14), a single band of overexpressed untagged-
FLYWCHI (-80 kDa) was detected in the lysate of the transfected cells but
not in the control (non-transfected) cells (Figure 3-14C, lane I vs. lane 2) using
anti-FLYWCHI antibody. This finding indicates that the endogenous level of
FLYWCHI protein cannot be detected using this antibody which was the only
antibody available during the course of this study. Similarly, a single band of
eGFP-tagged FLYWCHI (-106 kDa) (Figure 3-14A, lane 2) and MYC-
tagged-FLYWCHI (-82 kDa) (Figure 3-14B, lane 2) were also detected using
anti-MYC and anti-GFP antibodies respectively. Actin was used as a loading
control for all samples (Figure 3-14, A-C, bottom panels).
These data not only confirm the protein expression of all FLYWCH 1 different
clones in human cell culture, but also verify that the in-frame construction of
FLYWCHI to the MYC-epitope tag and eGFP-fusion proteins was successful.
Therefore, these clones can be potentially used to study the biochemical
properties of FLYWCHI which leads to characterization of this protein. In
addition, they can also be used for the biological and functional analyses of this
gene. One problem we faced during the SDS-PAGE gel electrophoresis
throughout this study is related to the visibility of the molecular weight
markers at the same exposure time used for the protein bands. In most cases the
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protein bands needed less exposure time than the molecular weight markers.
Therefore, we could not always show the markers side-by-side with the protein
bands on most of the Western blot membranes. However, different technical
approches were practicaly used to overcome this problem and to precicely
evaluate the molecular wiegh of the protein bands. First, the coloured bands of
the molecular markers on the PVDF membrane were highlighted with a normal
pen. Then after exposing the membrane with the EeL reagent (section
2.2.5.2.2), different exposure times in addition to visual assesments of the
exposed protein bands and the molecular markers were used to carefully
determine the molecular weights of the protein of interest.
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3.2.5 Sub-cellular localization of eGFP-FL YWCHI protein
To further examine the protein expression pattern and the sub-cellular
localization of FLYWCH1, a fluorescent microscopic analysis of
overexpressed eGFP-fused FLYWCHI protein in different human cell cultures
was performed. HEK293T, HCT116, and SW480 cell lines were transiently
transfected with either pEGFP-C2 vector (control) or eGFP-FLYWCHI-WT
clone. The green fluorescent signal of the eGFP reporter gene was observed in
all cases examined using a Leica DMI3000 B Inverted microscope (Leica
Microsystems, UK).
As shown in (Figure 3-15A, top panels), the control eGFp+ve-cells show a
scattered pattern of green signal throughout the transfected cells, whereas the
green signal of the eGFP reporter gene fused to FLYWCHI (eGFP-
rtvwcru'<een» was restricted to the nucleus in all three cell lines
examined (Figure 3-15A, bottom panels). To further confirm the nuclear
localization of FLYWCHl, the transfected SW480 cells were stained with a
DNA-binding marker, DAPI (4',6-diamidino-2-phenylindole) and visualized
under a fluorescent microscope. As shown in (Figure 3-15B, middle & bottom
panels), the expression of eGFP-FLYWCHI (green) was co-localized with
DAPI (blue) continuing that FLYWCHI is expressed and localized to the
nucleus. Furthermore, within the nucleus the FLYWCHI protein appears in a
punctate manner. This may suggest a possible localization of FLYWCHI
protein to the nucleolus. Collectively, these data, strongly introduce
FLYWCHI as a nuclear protein judged by the nuclear expression of this
protein in three different human cell lines.
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A) HEK293T HCT116 SW480
B) GFP OAPI Merge
Figure 3-15: Nuclear localization of human FLYWCH1. A) Different cell lines
(HEK293T, HCT116, and SW480) were transiently transfected with either pEGFP-C2
vector (control) or eGFP-FLYWCH1-WT clone. The transfected cells were subjected to
fluorescent microscope analysis. Top panels show the scattered expression of eGFP
protein, while bottom panels show the nuclear expression of eGFP-FLYWCH1 protein
in the indicated cell lines. B) Transfected SW480 cells (green) were stained with DAPI
(blue). Top panels show the expression of eGFP protein, while middle panels show the
expression of eGFP-FLYWCH1 protein. Bottom panels are magnified views of the
indicated area of eGFP-FLYWCH1 expressing cells (white boxes), emphasizing the
punctuate nuclear expression of this protein.
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3.3 Discussion
Beside the substantial progress toward human proteome identification, not all
the annotated protein coding genes have been characterized. When the function
of their protein products is unknown, genes are often named after the intrinsic
domains they contain. The protein product of FLYWCHI gene contains five
conserved FLYWCH-type zinc finger domains (Figure 3-1). Thus, the gene
and its protein product have been named as (FLYWCH-type zinc finger 1,
shortly assigned as FLYWCH1) by the HUGO Gene Nomenclature
Committee.
In order to further determine the precise positions of FLYWCH motifs within
human FLYWCHI protein and align this sequence with other mammalian
FLYWCH1, in the current work, a variety of established databases such as
HomoloGene and protein family (Pfam) were employed (Figure 3-1).
Interestingly, the analysis revealed that within the sequence of the five
FLYWCH motifs of human FLYWCH1, the aa residues are highly conserved
(Figure 3-1C). Moreover, the alignment data showed the presence of five
conserved FLYWCH domains within the aa sequence ofFLYWCHI in several
animals including mouse, rat and chimpanzee (Figure 3-2 and Appendix 1).
These data suggest that the physiological function of FLYWCHI may also be
conserved in mammals.
Proteins with FLYWCH domains have also been identified in other organisms
such as Drosophila, in which this domain was initially identified (Buchner et
aI., 2000, Dom and Krauss, 2003) and C. elegans (Beaster-Jones and Okkema,
2004, Ow et aI., 2008). FLYWCH motifs within Drosophila proteins may play
crucial roles in gene regulation and development through interaction with other
transcription factors and/or binding to DNA (Dom and Krauss, 2003, Dai et aI.,
2004, Provost and Shearn, 2006). Moreover, FLYWCH-motif containing
proteins in C. elegans have shown to bind DNA and play crucial roles in the
regulatory network of miRNA (Beaster-Jones and Okkema, 2004, Ow et aI.,
2008, Martinez et aI., 2008). Similarly, presence of five FLYWCH domains in
human FLYWCH 1 and its conservativity in several animals (section 3.2.1)
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indicates that these motifs may have crucial contribution to the biological
function of mammalian FLYWCHI.
During the course of this study there was no commercially available
FLYWCHI antibody that works endogenously for immunohistochemistry
(IHC), immunocytochemistry, Western blotting or ChIP-assay. However, we
managed to obtain a mouse polyclonal FLYWCHI antibody from Abeam (see
Table 2-7) which was only detecting the overexpressed level of FLYWCH 1 as
claimed by the provider (http://www.abcam.comIFLYWCHI-antibody-
ab69284.html) and also tested in cell culture in this study (Figure 3-14C). In
addition, even for the overexpressed protein to be clearly detected, a large
amount of protein and a high concentration of antibody were required. Despite
these limitations, the FLYWCHI antibody was used for the initial confirmation
of FLYWCHI expression (Figure 3-14C) and also to confirm its interaction
with ~-catenin (Figure 4-1). However, this antibody was not used for further
analysis in the current study. Alternatively, both MYC and eGFP tagged clones
of FLYWCHI (section 3.2.3) which were effectively detected by MYC and
GFP antibodies were used.
As an initial step towards the characterization of human FLYWCHI protein,
both epitope-tagged (MYC and eGFP) and non epitope-tagged FLYWCHI
cDNA were cloned into different mammalian expression vectors (section 3.2.3)
for different objectives. The cloning process was facilitated by obtaining the
human FLYWCHI cDNA IMAGE clone. This clone provided the intact full-
length human FLYWCHI cDNA which was used for direct (using restriction
enzymes) or indirect (using PCR) cloning of FLYWCHI. After validation of the
protein expression of FLYWCHI clones in human cell culture (Figure 3-14),
these clones became valuable resources for the forthcoming analyses to
investigate the biochemical properties of FLYWCHI and also to explore the
biological impacts of this previously uncharacterized protein in human cell
biology.
In agreement with the sub-cellular localization studies performed in this work
(Figure 3-1A), the expression of FLYWCH 1was shown to be restricted to the
nucleus in different human cell lines (Figure 3-15). These data supports the
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presence of the predicted NLS motif in the aa sequence of FLYWCHI.
Moreover, as mentioned above, FLYWCH motifs have been reported as DNA-
binding domains in C. elegans (Beaster-Jones and Okkema, 2004, Ow et al.,
2008). Therefore, it is possible that human FLYWCHI might use its putative
NLS and/or FLYWCH motifs to localize into the nucleus and bind DNA which
could be required for its function. Moreover, the nuclear localization of
FLYWCHI protein may indicate the possibility that FLYWCHI functions as a
transcription factor. These observations encouraged us to further characterize
and investigate the biological function of FLYWCHI using different
biochemical and functional analyses as addressed in the next following
chapters.
To sum up, in the current chapter the protein product of the human FLYWCHI
gene (FLYWCHl) was bioinformatically analyzed and the full cDNA
sequence of this gene was successfully tagged and cloned into different
mammalian expression vectors. In addition, the expression and nuclear
localization of FLYWCHI protein in different human cell lines was also
observed.
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CHAPTER4
The Interaction of FLYWCHI
with p-catenin in Human Cells
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4.1 Introduction
The evolutionarily conserved FLYWCH domain defines several eukaryotic
proteins; starting from Drosophila (Buchner et aI., 2000, Dai et aI., 2004, Dom
and Krauss, 2003, Provost and Shearn, 2006, Krauss and Dom, 2004) to C.
elegans (Beaster-Jones and Okkema, 2004, Ow et aI., 2008, Thatcher et aI.,
2001), and ending with several uncharacterized proteins in mammals including
human FLYWCHI (see section 3.2.1). The FLYWCH domain in Drosophila
Mod(mdg4) proteins has a putative role in protein-protein interactions; for
example, Mod(mdg4)-67.2 interacts with the DNA-binding protein Su(Hw) via
its FLYWCH domain (Gause et aI., 2001, Ghosh et aI., 2001). However, very
little information is available in the literature about the function of proteins
with FLYWCH domain in mammals.
Given that FLYWCHI had been identified in our lab as a potential interacting
partner with ~-catenin in a yeast-2-hybrid assay (Figure 1-8), we now sought to
evaluate whether this interaction occurred in human cells and, if so, where the
binding domains are located. We used co-immunoprecipitation with specific
antibodies against FLYWCHI and ~-catenin proteins when expressed as fusion
proteins with FLAG, MYC or GFP epitopes in human HEK293T cells.
Mutants with deletions at the N and C termini of FLYWCHI and ~-catenin
showed that amino acids within the C-terminal region of FLYWCHI
(containing 3 FLYWCH motifs) and the N-terminal domain of ~-catenin
protein (consisting of GSK3-~-phosphorylation region) are required for their
physical interaction.
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4.2 Results
4.2.1 FLYWCH1 interacts with ~-catenin in HEK293T cells
To investigate the possible in vivo interaction between FLYWCHI and p-
catenin in the cellular context, a co-immunoprecipitation (Co-IP) assay was
performed. HEK293T cells were co-transfected with expression plasmids
encoding; a constitutively active mutant clone of FLAG-tagged p-catenin
(FLAG_p_catS33A) in which the phosphorylation site Serine33 (S33) is mutated
to Alanine (A) provided by Dr. Nateri (Nateri et aI., 2005) and the eGFP fused
FLYWCHI clone (eGFP-FLYWCHI-WT) (see section 3.2.4). The protein
lysate was extracted from the cells and subjected to Co-IP using anti-FLAG
antibody-conjugated agarose beads as outlined in (section 2.2.5.3.1). Briefly,
500 ug of the protein lysate was incubated with 60 JlIof the FLAG-conjugated
beads for 2-3 hours. Non-immunoprecipitated protein lysates were used as
controls for the protein expression of plasmid constructs (Input). The standard
Western blotting procedure was applied to perform the SDS-PAGE and the
immunoblotting as described in (section 2.2.5.2).
The resultant expressed protein of the eGFP-fusion construct of FLYWCHI
(section 3.2.3.3) used in this experiment is composed of full-length FLYWCHI
protein (~80 kDa) fused to EGFP protein (26 kDa) resulting in a fusion protein
(EGFP-FLYWCHl) of 106 kDa. This protein is weakly detected by
FLYWCHI antibody on both Input and Co-IP blots (Figure 4-1, Top panel,
lanes 2, 3, & 7). However, the detection of eGFP-FYWCHl protein is
enhanced and strongly detected through re-blotting the same membrane with
the GFP antibody (Figure 4-1, middle panel, lanes 2,3, & 7).
As mentioned above the protein lysate of this experiment was
immunoprecipitated with FLAG-conjugated beads to pull down FLAG-p-
catS33A and if FLYWCHI is interacting with p-catenin, we should see a band of
EGFP-FLYWCHI (106 kDa) in lane 7 of the Co-IP blot where both eGFP-
FLYWCHI and FLAG_p_catS33A are co-expressed. Interestingly, the Co-IP blot
shows that in addition to p-catenin, a clear band of pulled-down eGFP-
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FLYWCHI protein was also detected by both anti-Fl.YWCHI and anti-GFP
antibodies (Figure 4-1, lane 7, arrowheads), suggesting that FLYWCHI may
directly interact with the nuclear ~-catenin. Notably, this band was only
appeared when both FLAG_~_catS33Aand eGFP-FLYWCHI were co-expressed
together but not individually (Figure 4-1, lanes 5 & 6 vs. lane 7) which
confirms the specificity of the binding. Thus, consistent with the RRS yeast-2-
hybrid data (Saadeddin A et al. unpublished data), these results indicate that
FLYWCHI physically interacts with the unphosphorylated nuclear ~-catenin in
human cell culture.
In~ut Co-IP.FLAG
2 3 4 5 6 7
FLAG-~-catS33A + + M + +
eGFP-FLYWCH1-WT + + kDa + + IB:
11
FLYWCH1-WT- 102 ~:E
()
~
~-catS33A
FLYWCH1-WT
Figure 4-1: Interaction of FLYWCH1 with p-catenin in human cell culture.
HEK293T cells were co-transfected with FLAG-~-catS33Aand eGFP-FL YWCH1-WT as
indicated. The protein Iystae was co-immunoprecipitated using anti-FLAG-conjugated
agarose beads. Both the Input and the Co-IP samples were immunoblotted with anti-
GFP (top panel), anti-FL YWCH1 (middle panel) and anti-FLAG (bottom panel)
antibodies. Arrowheads indicate protein bands of eGFP-FLYWCH1 detected by both
anti-FL YWCH1 and anti-GFP antibodies. "M", denotes the full range Rain Bow marker
from GE Healthcare. Asteriks (*) indicate unspecific bands. The experiment was
repeated on several occasions.
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Following our observation that FLYWCHI directly interacts with the nuclear
~-catenin (see above), we next investigated the potential regions involved in
FLYWCHlI~-catenin interaction. Thus, the PCR site-directed mutagenesis
(Liu and Naismith, 2008, Wang and Malcolm, 2002) was carried out to
generate several deletion mutants of both FLYWCHI and ~-catenin proteins as
detailed in the following sections.
4.2.2 Site-directed mutagenesis of human FLYWCHI
To identify which region of FLYWCHI is involved in its interaction with ~-
catenin, several deletion mutants of FLYWCHI cDNA were generated by site-
directed mutagenesis using specific primers with manually inserted epitope
tags and restriction sites. As shown in (Figure 4-2), the coding regions of
FLYWCH motifs were sequentially deleted over two N-terminal and two C-
terminal deletions ofFLYWCHl as summarized below:
FLYWCHI-Ml (AN120): l20aa are deleted from the N-terminus domain of
FLYWCHI (None of the FLYWCH motifs are removed).
FLYWCHI-M2 (AN350): 350aa are deleted from the N-terminus domain of
FLYWCHI (FLYWCH motifs no. I and 2 are removed).
FLYWCHl-l\t3 (AC120): l20aa are deleted from the C-terminus domain of
FLYWCH1 (FLYWCH motif no.5 is removed).
FLYWCHl-l\14 (AC350): 350aa are deleted from the C-terminus domain of
FLYWCHI (FLYWCH motifs no.3, 4, and 5 are removed).
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A) M3&M4
Fwd M1 Fwd
FLYWCH1
716aa
B)
WT (1-716)
M1 (b.N120) •
M2 (b.N350)
M3 (b.C120)
M4 (b.C350)
M2 Fwd
C)
Figure 4-2: Schematic presentation of FLYWCH1 PCR-site directed mutagenesis.
A) Represents the full-length coding region of FLYWCH1-WT cDNA with sites-specific
primer (s) to generate FLYWCH1 deletion mutants (M1-4) by PCR (8). The PCR
product of each deletion mutant was digested with specific restriction enzymes and
cloned into the MCS of a mammalian expression vector (C).
The above deletion mutants were tagged with either MYC or eGFP-epitope and
cloned into suitable mammalian expression vectors as described below in
(sections 4.2.2.1 & 4.2.2.2). The molecular weights of the recombinant cDNAs
and proteins encoded by FLYWCHI deletions varied according to the size of
the deleted cDNA region(s) as shown in (Table 4-1).
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Table 4-1: Expected molecular weights of FLYWCH1-recombinant cDNAs and
protein molecules.
DNA size Protein size
(bp) (kDa)
cDNA constructs
MYC-tagged eGFP-tagged MYC-tagged eGFP-tagged
FLYWCH1-WT 2214 2868
82 106
(-2.2 Kb) (-2.8 Kb)
FLYWCH1-M1
1824 2508
(lIN120) 69 93
(-1.8 Kb) (-2.5 Kb)
FLYWCH1-M2 1134 1818
43 67
(lIN350) (-1.1 Kb) (-1.8 Kb)
FLYWCH1-M3 1854 2508
69 93
(lIC120) (-1.8 Kb) (-2.5 Kb)
FLYWCH1-M4 1164 1818
43 67
(lIC350) (-1.2 Kb) (-1.8 Kb)
4.2.2.1 MYC-tagged deletion mutants of FLYWCH1
To facilitate the immunoblotting detection of FLYWCHI proteins encoded by
the above clones, the MYC-epitope tag was fused to the 5'-end of the amplified
fragment of each deletion. Suitable restriction sites (NheI and EcoRI) were
added to the forward and reverse primers respectively as shown in (Table 2-2).
These primers were used to amplify the deletion mutants of FLYWCHI that
described in (Figure 4-2) by PCR. The PCR products were digested with
NheIlEcoRI restriction enzymes and subsequently cloned into the pIRES2-
EGFP vector (Appendix 5). Successful ligation of FLYWCHI cDNA fragments
was confirmed by restriction enzyme digestion analysis using the same
enzymes that were used for cloning (NheIlEcoRI).
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As shown in (Figure 4-3), the digested DNA fragments of all FLYWCHI
deletion mutants MI-4 with expected molecular weights (1.8, 1.1, 1.8, and 1.2
Kb respectively) were removed from the backbone vector (5.3 Kb) and
visualized on 1% agarose gel. The wild-type clone (MYC-FLYWCHI-WT. 2.2
Kb) was used as a control to compare the size of DNA fragments of mutant
clones. These data confirmed the successful cloning of all MYC-tagged
FLYWCHI cDNA mutants into the pIRES2-EGFP vector. Deletions were also
confirmed by additional sequencing analysis.
Nhel fcoRI
I CMV I MYC-FLYWCH1 I IRES I
M WT M1 M3 M2 M4
2,036
1,636
1,018
Backbone vector
(pIRES2-EGFP)
6,108
5,090
MYC-FLYWCH1
cDNA inserts
Figure 4-3: Restriction enzyme digestion analysis of MYC-FLYWCH1 deletion
mutant clones. Top panel) A diagram shows the cutting position of Nhel and fcoRI
restriction enzymes within the DNA constructs. Bottom panel) Agarose gel shows the
Nhell fcoRI digested DNA fragments (2.2, 1.1, 1.2, 1.8, and 1.8 Kb, left to right)
corresponding to the wild-type cDNA clone (WT) and all the deletion mutants of MYC-
tagged-FLYWCH1 ( M1, M3, M2, and M4) respectively. Letter M, denotes a 1Kb DNA
ladder (Invitrogen).
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Next, the protein expression of all MYC-tagged FLYWCHI clones (WT, MI,
M2, M3, and M4) was examined by Western blotting analysis. HEK293T cells
were transfected with the above clones and the cell lysate was immunoblotted
using anti-MYC antibody. As shown in (Figure 4-4), the results of the Western
blot show that all constructs with MYC-tagged FLYWCHI cDNAs express
relevant proteins, indicating the successful cloning and the in-frame tagging of
these clones with MYC epitope. However, it should be noted that the protein
products of the C-terrninal deletion mutants (M3 & M4) exhibited slower
migration on the SDS-PAGE than the N-terrninal deletions. Although further
examinations are required to experimentally delineate this, but the slow
electrophoretic mobility of the C-terrninal deletions could be related to their
physicochemical properties and/or post-translational modifications. More
detailed discussion about this is provided in (section 4.3).
1 2 3 4 5
MYC-FLYWCH1-WT +
MYC-FLYWCH1-M1 +
MYC-FLYWCH1-M2 +
MYC-FLYWCH1-M3 +
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Figure 4-4: Western blotting analysis of MYC-tagged FLYWCHl clones. HEK293T
cells were transfected with the wild-type (WT, lane 1) and the deletion mutants of MYC-
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tagged FLYWCH1 clones (lanes 2-5 for M1, M2, M3, and M4 respectively). The lysate
was immunoblotted with anti-MYC antibody and the protein expression of each clone is
shown as indicated. ~-actin (bottom panel) was used as a loading control. "M", denotes
the full range Rain Bow marker from GE Healthcare. The marker was loaded on the
same membrane but separated from the presented blot by other samples. Expression
of these clones were detected on several occasions.
4.2.2.2 EGFP-tagged deletion mutants of FLYWCHI
In order to fuse the above described deletions of FLYWCHI eDNA (Figure
4-2) to the eGFP reporter gene, the desired sequences of FLYWCHI eDNA
were amplified by PCR. The amplified PCR products were then inserted into
the multiple cloning site of pEGFP-C2 vector (Appendix 6) in such a way that
the 31-end of the eGFP reporter gene (located just upstream to the MCS) fused
to the 51-end of FLYWCHI eDNA in-frame. These clones therefore are broadly
applicable for fluorescent microscopic observations such as sub-cellular
localization and immunofluorescent studies in addition to the biochemical and
biological analysis.
Specific primers (Table 2-3) with BgflI and EcoRI restriction sites were
designed to amplify the DNA fragments of four FLYWCHI deletion mutants
as illustrated in (Figure 4-2). Two complementary nucleotides (A & C) were
also added to the forward primers (Table 2-3) to prevent frameshift mutations
through the nucleotide sequences of eGFP-FLYWCHI clone. The desired PCR
products were digested and cloned into the pEGFP-C2 vector using
BgflIlEcoRI restriction enzymes. The successful insertion of FLYWCHI
fragments into the vector was examined by restriction enzyme digestion
analysis using the same enzymes used for cloning and also by further
sequencing analysis.
As shown in (Figure 4-5), digested DNA fragments with expected molecular
weights (1.8, 1.1, 1.8, and 1.1 Kb) corresponding to FLYWCHI deletion
mutants (Ml-4 respectively), were removed from the backbone vector (4.7 Kb)
and visualized on 1% agarose gel. These data indicate successful insertion of
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all FLYWCHI deletion mutants into the MCS of pEGFP-C2 vector. However,
the in-frame recombination of the FLYWCHI deletions to the eGFP reporter
gene was further investigated through protein expression (Figure 4-6) and
sequencing analyses (see below and the discussion section of this chapter).
B~nl fcoRl
I CMV I eGFP FLYWCH1 cDNA I
5,090
4,072 Backbone vector
(pEGFP-C2)
2,036
1,636 FLYWCH1 cDNA
1,018 inserts
Figure 4-5: Restriction enzyme digestion analysis of eGFP-FLYWCH1 deletion
mutant clones. Top panel) A diagram shows the cutting position of Bgnl and feoRI
restriction enzymes within the plasmid constructs. Bottom panel) Agarose gel shows
digested DNA fragments (1.8, 1.1,1.8, and 1.1 Kb) of all deletion mutants of FLYWCH1
(M1, M2, M3, and M4 respectively) removed from the pEGFP-C2 backbone vector (V)
(4.7 Kb) using Bgnl/feoRI restriction enzymes as indicated.
Next, the protein expression of all eGFP-tagged mutant clones of FLYWCHI
was examined by Western blotting analysis. HEK293T cells were transfected
with these clones and the protein lysate was immunoblotted by anti-GFP
antibody. As shown in (Figure 4-6), the expression of all eGFP-tagged
FLYWCHI clones was detected. In addition to the sequencing results, these
data further confirmed the in-frame construction of FLYWCHI coding region
to the eGFP reporter gene. Similar to the MYC-tagged deletion mutant clones
of FLYWCHl, the C-terminal deletions (especially M4) tend to migrate more
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slowly on the SDS-PAGE than the N-tenninal deletions. These differences can
be explained by changes in the physicochemical properties of these clones
and/or post-translational modifications. However, further studies would still be
required to examine this possibility. More discussion about this is provided in
(section 4.3).
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eGFP-FL YWCH1-WT +
eGFP-FL YWCH1-M1 +
eGFP-FLYWCH1-M2 +
eGFP-FL YWCH1-M3 +
eGFP-FL YWCH1-M4 + M 18:
FLYWCH1-WT - 1Q9
FLYWCH1-M1 & M3 - 80
FLYWCH1-M4 -
FLYWCH1-M2 - GFP
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~-actin
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Figure 4-6: Western blotting analysis of eGFP·FLYWCH1 clones. HEK293T cells
were transfected with the wild·type (WT, lane 2) and the deletion mutants of eGFP-
tagged FLYWCH1 clones (lanes 3-6 for M1, M2, M3, and M4 respectively). The lysate
was immunoblotted with anti·GFP antibody and the protein expression of each clone
was detected as indicated. The lysate of untransfected cells (lane 1) was used as a
negative control and ~·actin (bottom panel) was used as a loading control. "M", denotes
the ColorPlus Protein marker (in kDa) from NEW ENGLAND BioLabs. Expression of
these clones were detected on several occasions.
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4.2.3 Mapping the interaction site of FLYWCHI with p-
catenin
The deletion mutants of MYC-tagged FLYWCHI were used to map the
interaction site of FLYWCHI with p-catenin using a Co-IP assay. HEK293T
cells were co-transfected with expression plasmids encoding a constitutively
active form of p-catenin (FLAG- p_catenins33A)and the deletion mutants of
MYC-tagged FLYWCHI (MI, M2, M3, and M4) in addition to the wild-type
clone. The protein lysate was co-immunoprecipitated with anti-FLAG
antibody-conjugated agarose beads and immunoblotted with anti-MYC
antibody.
The protein expressions of all clones were detected by Western blotting
analysis of the Input blot as shown in (Figure 4-7, bottom panel). It should be
mentioned that, due to low expression efficiency and/or poor antibody
detection of some mutant clones especially MI (Figure 4-7, red boxes in lane
3), both the Input and Co-IP blots were exposed for short and longer time to
visualize and confirm the protein expressions. The long exposure is presented
in (Appendix 15). The Co-IP data revealed that FLAG-p-catenin could pull
down each of the wild-type, deletions, MI, M2 and M3, but not M4 of
FLYWCH I (Figure 4-7, top panel) in which FLYWCH motifs number 3-5 are
deleted. These results suggest that the C-terminal region of FLYWCHI
containing the last three FLYWCH motifs may be required for its interaction
with p-catenin.
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Figure 4-7: Mapping the interaction site of FLYWCH1 with p-catenin using Co-IP
assay. HEK293T cells were co-transfected with the indicated constructs. The protein
Iysates were co-immunoprecipitated using anti-FLAG-conjugated agarose beads. Top
panel) Shows immunblotting for the Co-IP samples with anti-MYC antibody. Bottom
panel) Shows immunblotting for the input samples with anti-FLAG, anti-MYC, and anti-
~-actin antibodies as indicated. Red boxes indicate weak detection of M1-deletion
mutant protein on both Co-IP and Input blots. Explanation about the slow migratory
characteristics of deletion mutants M3 & M4 is provided in the text (sections 4.2.2.1 &
4.3). "M", denotes the full range Rain Bow marker from GE Healthcare. Asteriks (*)
indicate unspecific bands. The experiment represents 3 independent Co-IP
approaches.
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In order to support the Co- IP data, a fluorescent microscope observation for
FLYWCH 1 deletion mutants was also performed. All deletion mutants of
eGFP-tagged FLYWCHI (MI-M4) in addition to the wild-type (WT) and the
empty vector (pEGFP-C2) were transiently expressed in HCTl16 cell line. The
localization of FLYWCHI proteins was observed by a fluorescent microscope
taking advantage from the eGFP-tag fused to these mutant clones.
As shown in (Figure 4-8), the fluorescent analysis revealed that the expression
of the eGFP-fused wild-type FLYWCHI (eGFP-FLYWCHI-WT) and
deletions MI-M3 of FLYWCHI were restricted to the nucleus in a spotty
format. It is noteworthy to mention that the expression level of eGFP-fusion
FLYWCHI protein was not equal in all transfected cells. Some cells were
characterized by high level of GFP fluorescence, while the GFP fluorescence
level of majority of cells was low. This may due to the nature of the transient
transfection using plasmids. In such a system the number of trans gene copies
that are introduced into the cell vary (reviewed by Adamson et aI., 2011) and
subsequently, those cells with high copy number of transgene could display
strong GFP fluorescence and require less exposure time to be visualized by the
fluorescent microscope and vice versa. Indeed, it has been reported that the
intensity of GFP fluorescence is directly proportional to the GFP gene copy
number and the GFP mRNA abundance in the cells (Soboleski et al., 2005). As
a result of this variation, cells with high GFP fluorescence may not show
proper punctate nuclear expression at the same exposure time used for the cells
with low GFP fluorescence. Instead, false diffusion of the GFP fluorescence
outside the nucleus may be seen (Figure 4-8).
Moreover, the green signal of the C-terminal deletion mutant M4 had clearly
diffused into the cytoplasm and showed fewer or no spots in the nucleus
(Figure 4-8, bottom panel), somehow resembling the expression pattern of the
empty vector (Figure 4-8, top panel). These data support the results of the Co-
IP experiment and collectively indicate that the C-terminal domain of
FLYWCHI is important for both protein-protein interaction and nuclear
localization of this protein.
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Figure 4·8: A C·terminal deletion mutant of FLYWCH1 (FLYWCH1·M4)changed
the nuclear localisation of this protein. HCT116 cells were transiently transfected
with pEGFP·C2 vector (control), the eGFP-tagged Wild-type (WT) and all deletion
mutants of eGFP·fused FLYWCH1 (M1-M4). The transfected cells were fixed on
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coverslips and stained with OAPI (blue). The GFP expression (green) of these proteins
were visualized by a fluorescent microscope as indicated.
Next, in order to identify the interaction domain of p-catenin with FLYWeHl,
the site-directed mutagenesis (Liu and Naismith, 2008, Zheng et al., 2004) and
overlap extension peR (Heckman and Pease, 2007) techniques were employed
to generate several deletion mutants of p-catenin as described below.
4.2.4 Site-directed mutagenesis of p-catenin cDNA
The amino acid sequence of p-catenin has been divided into three regions; the
N-terminus, the Csterminus and the armadillo repeats (Figure 4-9A). In the
current work, we employed peR site-directed mutagenesis and overlap
extension Pf'R, in a similar strategy as outlined above, to generate five deletion
mutant clones for p-catenin cDNA as shown in (Figure 4-9). Each deletion
caused removal of a complete domain or specific part of a domain as
summarized below:
FLAG-IJ-catenin-AN (N-terminal deletion, AN126): Nucleotides encoding
the first 126 aa of the N-terminal domain of p-catenin are removed.
FLAG-p-catenin-MDI (Middle deletion number I, A121-276): NucIeotides
encoding aa number 121 to 276 corresponding to the armadillo repeats number
1 to 4 (RI-4) ofjl-catenin are removed.
FLAG-p-catenin-MD2 (Middle deletion number 2, A270-483): NucIeotides
encoding aa number 270 to 483 corresponding to the armadillo repeats number
5 to 9 (R5-9) of p-catenin are removed.
FLAG-p-catenin-MD3 (Middle deletion number 3, A477-713): NucIeotides
encoding aa number 477 to 713 corresponding to the armadillo repeats number
10 to 12 (RI0-12) of'B-catenin are removed.
FLAG-p-catenin-AC (C-terminal deletion, ACI80): NucIeotides encoding
the last 180 aa of the Cvtenninal domain of p-catenin are removed.
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Specific primers described in (Table 2-4) were used to amplify the above
mutations of ~-catenin cDNA. The peR amplicons were gel extracted, digested
and cloned into a mammalian expression vector, pcDNA3 (for a complete map
of pcDNA3 vector seeAppendix 8).
A)
B)
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FLAG-G-catenin: Size(kOa)
Holoaa1-781 • • • ========== • • •87
boN126(boN)--j", -==========:J • • 74
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M77-713 (M03) ..~ -- 62
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Figure 4-9: Schematic presentation of p-catenin site-directed mutagenesis. A
diagram shows A) the N-terminus (NTD, blue), e-terminus (eTD, blue), and the central
armadillo repeats domain (brown) of ~-catenin and B) the wild-type (halo) and specific
deletion mutants of ~-catenin amplified by peR. The peR product of each deletion was
C) digested with specific restriction enzymes (8amHIINod) and cloned into the multiple
cloning site of pcDNA3 vector. Black boxes represent FLAG-epitope tag.
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4.2.4.1 Cloning of p-catenin N-terminal and C-terminal deletions
In order to examine the involvement of the N- and/or Csterminal domains of ~-
catenin in the FLYWCHlI~-catenin interaction, the N-terminal (~-catenin-
~NI26) and C-terminal (~-catenin-~CI80) mutant clones of ~-catenin were
generated by peR. To facilitate the immunoblotting detection of these deletion
mutants, the cDNA of each clone was tagged with the FLAG-epitope sequence
at the 5'-end. This was performed by adding the FLAG nucleotide sequence to
the forward primers. Suitable restriction sites (BamHI and NotI) were also
added to both forward and reverse primers respectively for cloning (Table 2-4).
The PCR products were then digested with BamHIINotI and cloned into
pcDNA3 vector (Appendix 8).
4.2.4.2 Cloning of p-catenin middle deletion mutants
To investigate the involvement of ~-catenin-armadi11orepeat in its interaction
with FLYWCHl, the armadillo repeats were sequentially deleted over three
middle deletions; MDl, MD2, and MD3. These deletions are lacking the
armadillo repeats RI-4, R5-9, and RI0-12 respectively, while both of the N-
terminal and C-terminal domains remained intact (Figure 4-9B). To do this, the
overlap extension peR strategy was employed. For each middle deletion made,
a pair of specific internal primers with overhang complementary sequences and
a pair of flanking external primers with specific restriction sites (BamHIINotI)
were designed (Figure 4-10). To facilitate the immunoblotting of these clones,
the amplified fragments were tagged with FLAG-epitope. This epitope was
fused to the 5'-end of the forward flanking external primers as shown in (Table
2-4).
The overlap extension peR applied in this study was performed in two steps.
First, the desired fragments of ~-catenin (A and B) were amplified using the
FLAG-~-catenin-WT cDNA as a template (Figure 4-10A&B). The deletion of
interest (fragment e) was introduced by the specific internal primers described
in (Table 2-4). As shown in (Figure 4-10A), the forward internal primer
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(Internal Fwd) has a short 5'-overhang complementary strand to the reverse
internal primer (Internal Rev) indicated by red colour. The complementary
strands create overlapping nucleotide sequences within the intermediate
amplified DNA fragments (Figure 4-1OB).
Second, the flanking external primers were used to amplify an integrated strand
of ~-catenin contains the nucleotide sequence of fragments A and B, but not C
(Figure 4-10, C&D) using the purified DNA of fragments A and B as a
template. The final PCR product (AB) of each deletion was gel extracted,
digested with BamHVNotI restriction enzymes and cloned into pcDNA3 vector
(Figure 4-1OE).
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Figure 4-10: Generation of middle deletion mutant clones of p-catenin by
overlapping PCR. A) Specific fragments of ~-catenin cDNA were amplified in the first
step of the PCR reaction using both complementary internal and flanking external
primers as indicated. B) The intermediate peR products (fragments A and 8) with
overhanged strands were gel extracted and C) used as a template in the second step of
the peR reaction using the flanking external primers only. D) The final peR product
(AB) containing the deletion of interest was E) digested with 8amHII Nod restriction
enzymes and inserted into the multiple cloning site of pcDNA3 vector.
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4.2.4.3 Validation of FLAG-p-catenin (Fl.Ati-Bcat) clones
Initially, the successful ligation of ~-catenin cDNA molecules in pcDNA3
vector was examined through restriction enzyme digestion analysis. BamBI
and NotI were used to release the intact coding region ofFLAG-~-catenin from
the backbone vector. DNA fragments of the wild-type and the deletion mutants
of ~-catenin (.6.N,MDl, MD2, MD3, and .6.C)with expected molecular weights
(2.3, 2.0, 1.9, 1.7, 1.6, and 1.8 Kb respectively) were removed from the
backbone vector (5.4 Kb) and visualized on 1% agarose gel (Figure 4-11).
These data confirmed the successful insertion of all ~-catenin deletion mutants
into pcDNA3 vector.
BamHl Nod
I CMV I FLAG-@-cateninclones I
5,090 Backbone vector(pcDNA3)
3,054
2,036 ~-catenin eDNA
1,636 inserts
Figure 4-11: Restriction enzyme digestion analysis of FLAG-p-catenin clones.
Top panel) An illustration shows the position of BamHI and Nod restriction enzymes
within ~-catenin plasmid constructs. Bottom panel) Agarose gel shows BamHlfNoO
digested DNA fragments (2.3, 2.0, 1.9, 1.7, 1.6, and 1.8 Kb) for the wild-type (WT) and
the deletion mutants of FLAG-tagged a-catenin (~N, MD1, MD2, MD3, and !:Ie)
respectively. M: Marker, bp.
Next, Western blotting analysis was performed to examine the protein
expression of these clones in HEK293 cells. The anti-FLAG antibody was used
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to detect the protein product of FLAG-~-catenin clones in the lysate of
transfected cells. Both wild-type (FLAG-~-cat-WT) and activated form
(FLAG_~_catS33A)of FLAG-~-catenin clones were used as positive controls for
the expression of other clones in this experiment. The protein product of
FLAG-~-catenin constructs; ~_catS33A,WT, DoN, MD1, and MD2 with their
relevant molecular weights (87, 87, 74, 71, and 64 kDa respectively) were
detected by the FLAG antibody as shown in (Figure 4-12). However, the
expression level of the last middle deletion (MD3, 62 kDa) and the C-terminal
deletion (DoC, 68 kDa) were not detected on the blot (Figure 4-12, lanes 4 and 7
respectively). This might due to instability and degradation of these proteins by
the proteasome degradation system. To check this possibility, a proteasome
inhibitor (Sigma, # C2211) was used to prevent the protein degradation and
improve the immunodetection of these clones. To do this, in a seprate
experiment, HEK293T cells were transfected with these two clones and 12
hours before lysing the cells, a small amount (2 IlM/ml) of the proteasome
inhibitor was directly added to the culture medium of the transfected cells. As
shown in (Figure 4-12, lanes 8 and 9), the protein expression of these two
clones (DoC and MD3) were stabilized and detected by the anti-FLAG antibody,
yet the expression and/or detection efficency is still very low. Moreover, the N-
terminal deletion of ~-catenin (DoN) exhibited a slightly faster electrophoretic
mobility in comparision to its calculated molecular weight from the
corresponding nucleotide sequence. Although further studies would still be
needed to experimentally describe this, but the electrophoretic mobility shift of
a recombinant protein could be related to the physicochemical properties
and/or post-translational modifications. More detailed discussion about this is
provided in (section 4.3).
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Figure 4-12: Western blotting analysis of FlAG-p-catenin mutant clones.
HEK293T cells were transfected with FLAG-~-catS33A,FLAG-~-cat-WT, and the deletion
mutants of FLAG-tagged ~-catenin (bN, bC, MD1, MD2, and MD3) respectively. The
protein lysate was immunoblotted with anti-FLAG antibody and the protein expressions
of FLAG-tagged ~-catenin clones were detected on the blot as indicated. Lanes 8 & 9
were treated with proteasome inhibitor. "M", denotes the full range Rain Bow marker
from GE Healthcare. This pattern of expression was independently observed on several
occasions.
4.2.5 Mapping the interaction site of p-catenin with
FLYWCHI
To investigate which region of ~-catenin is involved in its interaction with
FLYWCHl, a Co-IP assay was carried out. HEK293T cells were co-
transfected with expression plasmids encoding; eGFP-FLYWCHl-WT and the
deletion mutants of FLAG-tagged p-catenin (~N, MDl, and MD2) in addition
to FLAG_p_catenins33A.The protein lysate was co-immunoprecipitated with
anti-FLAG-conjugated agarose beads and immunoblotted with both anti-GFP
and anti-FLAG antibodies.
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The protein expressions of all used clones were detected on the Input blot as
shown in (Figure 4-13, left panels), and the pulled down proteins of FLAG-~-
catenin are shown on the Co-JP blot (Figure 4-13, right, middle and bottom
panels). Interestingly, the Co-JP data show that the full-length p-catenin (~-
catenins33A,lane 2) and middle deletions MDl (lane 4) and MD2 (lane 5) but
not the N-terminal deletion (~N, lane 3) were able to pull down FLYWCHl
protein (Figure 4-13, right top panel), suggesting that the N-terminal domain of
p-catenin is required for its interaction with FLYWCHl. In addition
FLYWCHI protein was not pulled down by the FLAG beads in the absence of
FLAG-~-catenin (Figure 4-13, right top panel, lane 1), indicating that the Co-
JP results are specific. Collectively, these results suggest that the N-terminal
domain of p-catenin, but not the armadillo repeats (Rl-9) may be required for
its interaction with FLYWCHI.
Input Co-IP: FLAG
2 3 4 5 2 3 4 5
eGFP-FLYWCH1-WT + + + + + + + + + +
FLAG-~-cateninS33A - + +
FLAG-~-catenin-l\N - + +
FLAG-~-catenin-MD1 - + + -
FLAG-~-catenin-MD2 - + +
~-cats
FLYWCH1
Figure 4-13: Mapping the interaction site of p-catenin with FLYWCH1 using Co-IP
assay. HEK293T cells were co-transfected with the indicated expression plasmid
DNAs. The protein Iysates were co-immunoprecipitated using anti-FLAG-conjugated
agarose beads and immunoblotted with both anti-GFP and anti-FLAG antibodies. Left
panel) Shows Western blotting analysis for the input samples. Right panel) Shows
Western blotting for the Co-IP samples. liM", denotes the full range Rain Bow marker
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from GE Healthcare. Asterik (*) indicates unspecific bands. The experiment represents
2-3 independent Co-IP approaches.
4.3 Discussion
In the current work, the in vivo interaction between human FLYWCHI and ~-
catenin in the cell culture was examined using Co-IP assays. Consistent with
the RRS data (Saadeddin A et al. unpublished data), the Co-IP results
confirmed the association of FLYWCHI with the unphosphorylated ~-catenin
(~_catS33A)in the lysate of HEK293T cells (Figure 4-1). Similar to this finding,
many other proteins have been reported to interact with the nuclear ~-catenin
such as T cell factor/lymphoid enhancer factor (TCF/LEF) family of proteins
(TCFs) (Graham et al., 2000), CBP (Takemaru and Moon, 2000), ICAT (Tago
et al., 2000) and Chibby (Takemaru et al., 2003). Members of TCFs are among
the most studied interacting proteins to the nuclear ~-catenin. TCFs are nuclear
transcription factors with DNA-binding properties, but they are lacking the
transactivation domains. In contrast, ~-catenin has a transactivation domain
without DNA binding abilities. FLYWCHI was shown to be expressed in the
nucleus (see section 3.2.5) and it is physically interacts with unphosphorylated
~-catenin (Figure 4-1). This increases the possibility that FLYWCH 1may acts
as a nuclear transcription factor and thereby regulates the transcription of other
genes.
The FLYWCHI protein contains five conserved FLYWCH motifs (see section
3.2.1). In the current study, the role of these motifs in FLYWCHl/~-catenin
interaction was evaluated through mapping the interaction site of FLYWCHI
with ~-catenin. Interestingly, deletion M4, a C-terminal deletion lacking the
last three FLYWCH motifs, lost its interaction ability with ~-catenin (Figure
4-7). Furthermore, the same deletion lost the nuclear spotty expression pattern
of the wild-type clone and showed a scattered green signal throughout the cells
resembling the expression of the eGFP reporter gene alone (Figure 4-8). It
should be mentioned that deletion M4 also lacks the predicted NLS motif (see
section 3.2.1). Collectively, these results suggest that the C-terminal domain of
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human FLYWCHI containing the putative NLS sequence and the last three
FLYWCH motifs is not only required for the interaction ofFLYWCHI with f-
catenin but it also important for the sub-cellular localization and perhaps for
the biological function (s) of this protein.
In the current work we used site-directed mutagenesis to generate several
deletion mutant clones of both FLYWCHI and ~-catenin using PCR (Figure
4-9). The 5' end of the coding region of these clones were fused to specific
epitope tags and their protein expression was confirmed by Western blotting
analysis using SDS-PAGE (sections 4.2.2 & 4.2.4). Although SDS-PAGE is
widely used to determine the molecular weight of many proteins based on their
electrophoretic mobility, some exceptions always exist (Matagne et aI., 1991).
Different factors such as protein structure, post-translational modifications, and
amino acid composition could affect the nature of the protein including the
acidity, hydrophobicity, SDS-Ioading capacity...etc, and alter its
electrophoretic migration (Rath et aI., 2009, Garcia-Ortega et aI., 2005,
Matagne et aI., 1991).
Notably, both the C-terminal deletion mutants of MYC-tagged FLYWCHI
(M3 and M4) and the M4-deletion mutant of eGFP-tagged FLYWCHI run
slower on the SDS-PAGE than their N-terminal deletion counterparts (MI and
M2) (Figure 4-4, lanes; 2 & 3 vs. 4 & 5) and (Figure 4-6, lane 4 vs. lane 6)
respectively. Furthermore, the protein product of the N-terminal deletion of ~-
catenin (DoN)showed a smaller band, slightly below its calculated molecular
weight (74 kDa) on the SDS-PAGE gel (Figure 4-12, lane 3). Although we are
not certain about the exact cause of these vareation in molecular weight of the
deletion mutants, modifecations of the PCR amplified DNA fragments such as
frameshift mutations and aminoacid substitutions or post-translational
modifications such as phosphorylation and ubiquitination are possible
mechanisms that might have affected the nature of these deletion mutant
proteins and changed their electrophoretic migration on the SDS-PAGE. In this
study, we have used specific primers (Tables 2-2 to 2-4) to amplify specified
fragments of both FLYWCHI and ~-catenin clones by PCR. The presence of
desired DNA sequences of these clones were confirmed by restriction enzyme
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digestion analysis (Figures 4-3, 4-5, & 4.11). Moreover, the in-frame
construction of FLYWCHI and/or ~-catenin coding regions to their relevant
epitope tags was also confirmed by sequencing. The sequencing data analysis
confirmed that the open reading frame was maintained throughout the multiple
cloning sites of the plasmid vectors upstream to the coding region of the
inserts. An example of the sequencing data analysis is presented in (Appendix
13).
Although we have not analyzed the full-length nucleotide sequence of all
deletion mutant clones, the sequencing data covered substantial regions
upstream and/or downstream to the 5' end of the clones. We have aligned these
sequences with the gene bank sequence of the gene of interest and did not find
any modifications such as framshift mutations or amino acid substitutions.
Therefore, we assumed that the amino acid composition of these clones may
not be modified. Altematevly, its very much possible that the post-translation
modifications and/or changes in the physicochemical properties may be the
cause of the low electrophoretic mobility of FLYWCHI C-terminal deletions.
This possibility is further supported by the fact that the protein product of these
clones did not migrate to their calculated positions (i.e. migrated slower than
expected), giving the notion that these proteins may be subjected to post-
translation modifications such as phosphorylation, glycosylation, or
ubiquitination. Moreover, the fast electrophoretic mobility of the N-terminal
deletion of ~-catenin (~N) can also be explained in the same context as some
of the physicochemical properties of proteins such as hydrophobicity can cause
faster migration of the modified protein products (Shirai et al., 2008). Thus,
further observations in this regard may provide valuable insight toward furher
characterization of FLYWCHI and/or p-catenin proteins. Although these area
of study were not further investigated due to time limitations of the present
work, various methods such as 2D gel electrophoresis, mass spectrometry,
protein crystallography and structure-function predictions (reviewed by
Baumann and Meri, 2004) can be used to fully explore the variations of the
electrophoretic mobility shifts, exhabited by some deletion mutant clones of
FLYWCHI and ~-catenin.
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Despite the above considerations, these observations suggest that the amino
acid residues within the C-terminal domain of FLYWCH 1 and those within the
N-terminal domain of ~-catenin may have critical involvment in the protein
conformation structure and/or folding and thereby may be affecting the
function of these proteins. Moreover, despite having the desired recombinant
cDNA (lane 2 in Figure 4-3 & Figure 4-5) and equal loading of protein lysates,
the Ml-deletion mutant ofFL YWCHI (both MYC & eGFP tagged clones) was
less expressed in comparison to other deletion mutant clones of FLYWCHI
(Figure 4-4, lane 2 & Figure 4-6, lane 3). These findings indicate that the
amino acid residues within the N-terminal region of FLYWCHI may affect the
expression efficiency of this protein.
The primary structure of ~-catenin contains 781 amino acids distributed over
three regions; the central armadillo (arm) repeats (-550 aa), a distinct amino-
terminal (-130 aa) and carboxy-terminal (-100 aa) domains (Huber et aI.,
1997, Huber and Weis, 2001, Xing et al., 2008). The armadillo repeat region
provides the binding surface for the majority of ~-catenin partners (more than
20) including members of the TCF/LEF family of proteins (Behrens et aI.,
1996, Graham et al., 2000, van de Wetering et al., 1997). The N-terminus
domain plays an important role in regulation and stability of ~-catenin. It
provides phosphorylation sites for GSK3~ (Barth et aI., 1997, Yost et aI., 1996)
and CKla (Liu et aI., 2002) which subsequently phosphorylate ~-catenin to be
recognized and degraded by the proteasomal degradation system. The
transactivation function has been assigned to the C-terminus region of ~-
catenin (van de Wetering et aI., 1997) which is crucial for gene activation.
Previous studies have shown that ~-catenin can interact with many proteins in
the cell. Some of them are membranous, some are located in the cytoplasm and
others localized into the nucleus. As part of the classical cadherin junction, ~-
catenin directly interacts to E-cadherin and u-catenin to form the cadherin-
catenin complex (Aberle et al., 1994). The entire armadillo repeats of p-catenin
has shown to be required for its interaction with E-cadherin however the amino
acid positions 118 to 149 were determined as the binding site for u-catenin
(Aberle et al., 1996). In the cytoplasm, the free unbound p-catenin is usually
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found in a complex which mainly composed of APC, Axin, GSK3p and CKla.
Deletion mutagenesis studies have shown that the ann repeat region mediates
the binding of p-catenin to APC (Rubinfeld et al., 1993, Hulsken et al., 1994),
Axin (Behrens et aI., 1998, Ikeda et al., 1998), and EGF receptor tyrosine
kinase domain (Hoschuetzky et al., 1994).
The p-catenin nuclear interactors are crucial factors that play pivotal roles in
gene regulation controlled by the Wntlp-catenin signalling pathway. The
binding sites of the majority of nuclear partners have been mapped to the
central ann repeat and the C-tenninus domain of p-catenin. It has been reported
that members of TCF family interact with the armadillo repeats 3-10 and
recruit p-catenin to specific promoters of target genes (Graham et aI., 2001,
Graham et al., 2000). In addition, the armadillo repeat no.1 (RI) and armadillo
repeat no.11 (RH) were also found to be essential for transactivation of Wnt-
target genes through interaction with transcriptional co-activators such as
BCL9, Pygopus, parafibromin, Brgl, CBP/p300, and MED12 (Barker et aI.,
2001, Hecht et aI., 2000, Kim et al., 2006, Kramps et al., 2002, Mosimann et
al., 2006). The p-catenin Rll region has also been shown to interact with
many transcriptional inhibitors such as ICAT, HDPRl, and Chibby (Tago et
al., 2000, Takemaru et al., 2003 {Yau, 2005 #1186)}. Other factors such as Sox
proteins were found to bind regions on p-catenin which overlaps with the
established TCF binding site (Zorn et al., 1999).
To investigate which part of p-catenin is interacting with FLYWCHl, a series
of overlapping deletions across the p-catenin coding region were generated.
Each deletion lacks a distinct domain or a specific sequence of the p-catenin
coding region, while the rest of the protein remains intact (Figure 4-9). Similar
approaches have been previously undertaken to map the interaction site of p-
catenin with other nuclear partners (Aberle et al., 1994, Olson et al., 2006).
Surprisingly, the mutational analysis data revealed that the armadillo repeats
domain of p-catenin is not essential for its interaction with FLYWCH 1, but the
amino-tenninal domain is required (Figure 4-13).
It should be mentioned that in the current work the entire armadillo repeats
domain of p-catenin was not used in the Co-IP experiments, but instead
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deletions that contain two third of this domain were used (Figure 4-9).
Moreover, due to instability and/or low expression efficiency, clear evidence
about the interaction of the armadillo repeats 10-12 and the C-terminal domain
of ~-catenin (covered by deletions MD3 and ~C, respectively) with
FLYWCHI was not obtained in this study (see section 4.2.4.3 & Figure 4-13).
Therefore, interaction of FLYWCHI with the entire armadillo repeats and/or
the C-terminal domain of ~-catenin cannot be excluded. However, as the N-
terminal deletion of ~-catenin was sufficient to abolish the interaction between
~-catenin and FLYWCH 1 even in the presence of intact armadillo and C-
terminal domains (Figure 4-13). Therefore, it is unlikely that the C-terminal
region of ~-catenin play role in its interaction with FLYWCH 1. Based on this
notion, we assumed that the deletion mutants MD3 and ~C of ~-catenin might
also interact with FLYWCHI. This view is further supported by our luciferase
analyses data discussed in the next chapter.
To sum up, in this study, the human FLYWCHI was defined as a novel nuclear
partner of ~-catenin. The N-terminal domain of ~-catenin was found to be
responsible for its interaction with FLYWCHI, whereas the C-terminal domain
of FLYWCHI was found to be required for this interaction as summarized
below in (Figure 4-14).
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Figure 4-14: Schematic presentation of the interaction sites between FLYWCH1
and p-catenin. The interaction ability of FLYWCH1 constructs to bind ~-catenin and
vice versa is indicated by (+1-) in the right panel of both A & B. (+) stands for
experimentally approved interaction, while (-) for no interaction. (+/7) means
interactionis likelyoccurredbut experimentallynot approved.
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CHAPTERS
Human FLYWCHI Inhibits Cell Migration
and Alters Cell Morphology of
Colorectal Cancer (CRC) Cells
through Negative Regulation of
Wnt/p-catenin Signalling Pathway
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5.1 Introduction
Cell migration involves a precise regulation of a process which becomes
altered and/or lost during invasion and metastasis. The process of cell
migration demonstrates the phenotypic and genetic modifications required for
tumour metastasis including increased cell migration/invasion and pseudopod
formation. ~-catenin, a key downstream effector of Wnt signalling pathway,
plays a crucial role in this process. It can directly modulate gene expression
through its interaction with TCF/LEF-transcription factors and also mediate
tight intercellular adhesions by linking E-cadherin to the cytoskeleton. The ~-
catenin/TCF activity is tightly modulated by the nuclear ~-catenin partners
(either co-activators or co-repressors). Indeed, these cofactors act as potential
gatekeepers for the ~-cateninITCF complex, ensuring the proper threshold of~-
catenin is achieved before it complexes with TCF family members. Such
conventional regulation usually involves a highly specialized set of molecular
interactions, which may specifically tum on a particular cell phenotype and
may have a crucial effect on the cell signalling network.
In the previous chapter, the physical interaction between FLYWCHI and ~-
catenin was reported. Herein, the functional interaction between these two
proteins and its consequences are further investigated. The TCF transcriptional
(TOP-FALSHIFOP-FLASH) dual luciferase reporter assay was employed to
evaluate the effect of FLYWCH1 on the transcriptional activity of ~-catenin in
human cell culture. The Luciferase data demonstrate a consistent functional
interaction between FLYWCHI and ~-catenin resulting in inhibition of Wntl~-
catenin signalling in various cell lines. Subsequently, our further mutational
analysis using site directed mutagenesis has identified the FLYWCHI and ~-
catenin protein domains that are involved in the repressive activity.
Our results demonstrate a significant inhibition of cell migration by ectopic
expression of FLYWCHI. Strikingly, we observed no influence on cell
proliferation, whereas the wound closure capacity of FLYWCHI expressing
cells was reduced. In addition, forced expression of FLYWCHI changed the
morphology of CRC cells. Finally, our data shows that the expression of
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several downstream Wnt-target genes associated with cell migration was
significantly repressed by FLYWCHI. Taken together, our data suggest that
FLYWCHI may regulate cell migration and morphology by repressing Wntlp-
catenin target genes.
5.2 Results
5.2.1 FLYWCHI represses p-cateninITCF4 transcriptional
activity
To elucidate the consequences of FLYWCH1/~-catenin interaction on the
transcriptional activity of p-cateninlTCF4, a TCF transcriptional dual-
luciferase reporter assay was performed. The Renilla-Iuciferase reporter was
used as an internal control to normalize variations in the transfection
efficiency. The TCF-firefly reporters; TOP-FLASH (containing three copies of
the TCF binding site, ATCAAAG) and FOP-FLASH (containing three
mutated copies of the TCF binding site, GCCAAAG) were used to measure the
transactivation activity of ~-cateninlTCF complex with the dual-luciferase
assay kit (see section 2.2.6.1). In addition to HEK293T cells, two CRC cell
lines (HCTI16 & SW620) were also used to evaluate the effect ofFLYWCHI
on the transcriptional activity of ~-catenin. The endogenous level of
FLYWCHI protein is not detectable in HEK293T cells by FLYWCHI
antibody (Figure 3-14C). Moreover, the mRNA expression of FLYWCHI is
very low (almost undetectable) in CRC cells including HCT116 and SW620
(Figure 5-14). Therefore, FLYWCHI was overexpressed in all these cell lines.
HEK293T cells also contain low endogenous active Wnt signals (Porfiri et al.,
1997). In contrast, HCT1l6 and SW620 cells contain high Wnt signals due to
different mutations in APe gene (Korinek et al., 1997, Morin et aI., 1997). In
this assay, the effect of the overexpressed FLYWCHI on the transcriptional
activity of both endogenous and overexpressed ~-catenin is investigated as
detailed below.
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HEK293T cells were transiently transfected with plasmids encoding FLAG-~-
catS33\ and FLYWCHI-WT (encoding the untagged-FLYWCHI protein;
section 3.2.3.1), along with the luciferase reporter constructs; firefly
(TOPIFOP-FLASH) and Renilla. Cells transfected with the luciferase reporter
constructs were used as an experimental control and their luciferase activity
were normalization to Renilla internal control and then arbitrarily set to 1. The
luciferase activities of other experimental plots were also normalized to Renilla
and compared to the control. The data are presented as folds of induction or
reduction as detailed in (section 2.2.6.1). This format of calculation was
applied to all TCF-Iuciferase reporter assays performed in this study.
The luciferase data show that the ectopic expression of FLYWCHI
significantly reduced the TOP-FLASH reporter activity in HEK293T cells
without affecting the FOP-FLASH reporter (Figure 5-1A, lane 2 vs. lane 1),
indicating that FLYWCHI could negatively regulate the endogenous
transcriptional activity of ~-catenin. To further confirm the negative effect of
FLYWCHI on ~-catenin, both the stabilized construct of ~-catenin (FLAG-~-
catS33A)and FLYWCHI were co-expressed in these cells. As shown in the
figure, in the absence of FLYWCHI the FLAG_~_catS33Ahighly induced the
TOP-Flash reporter activity by -100 folds (Figure 5-1B, lane 2 vs. lane I).
However, this induction was dramatically (77%) inhibited by FLYWCHI
(Figure 5-IB, lane 3), suggesting that FLYWCHI strongly suppresses the ~-
catenin-mediated transcriptional activation. Notably, no changes for the FOP-
FLASH reporter (the negative control) were detected in the entire experiment,
indicating that the TOP-FLASH reporter specifically responded to ~-
cateninlTCF signalling.
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Figure 5-1: FLYWCH1 represses the transcriptional activity of p-cateninITCF4.
HEK293T cells were transfected to express FLYWCH1-WT (A) and FLYWCH1-WT plus
FLAG-~-catS33A(8) in the presence of Renilla and TOP-FLASH or FOP-FLASH
reporters as indicated. Activity of the firefly luciferase reporters (TOP-FLASH & FOP-
FLASH) relative to Renilla luciferase transfection control is shown as folds of
expression (induction/repression). Data are mean ± SO (n = 3; **, P < 0.01; ***, P <
0.001). Experiment run in triplicate and repeated at least on three independent
occasions.
Next, to investigate whether elevated levels of TCF4 could rescue the repressed
activity of ~-catenin by FLWYCH1, in a separate experiment, both FLAG-~-
catS33A and TCF4 were coexpressed with or without FLYWCHI-WT construct.
The results show that the combination of ~-catenin and TCF4 induced the
TOP-FLASH reporter activity to a very high level (413 folds) in comparison to
the control (Figure 5-2, lane 2 vs. lane 1). However, this induction was
dramatically (77%) reduced in the presence of FLYWCHI (Figure 5-2, lane 3).
Notably, the suppression level of FLYWCHI on ~-cateninlTCF4 (77%)
(Figure 5-2, lane 3) is comparable to the suppression level ofFL YWCHI on ~-
catenin alone (77%) (Figure 5-1, lane 3). This finding indicates that TCF4 does
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not affect/rescue the transcriptional repression of FLYWCHI on ~-catenin.
Taken together these results suggest that FLYWCHI and ~-catenin are
functionally interacting, leading to transcriptional repression of ~-
cateninlTCF4. These data also suggest that FLYWCHI may compete and/or
have a greater affinity to bind ~-catenin than TCF4.
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Figure 5-2: TCF4 does not rescue the transcriptional repression of FLYWCH1 on
p-catenin. HEK293T cells were transfected with the indicated expression plasmids in
the presence of Renilla and TOP-FLASH or FOP-FLASH reporters. Folds of
induction/repression of TOP/FOP-FLASH luciferase activity relative to Renilla luciferase
are shown as indicated. Data are mean ± SO (n = 3; ***, P < 0.001). Experiment run in
triplicate and repeated on two independent occasions.
To examine the suppression effect of FLYWCHI on the transcriptional activity
of endogenous ~-catenin in CRC cells, the in vivo transactivational activity of
~-cateninlTCF4 in SW620 and HCT1l6 CRC cell lines was examined. These
cell lines contain high level of nuclear ~-catenin due to mutations in APC and
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~-catenin respectively. Therefore, in this experiment we relied on the
endogenous level of ~-catenin to induce the TOP-FLASH activity.
Accordingly, cells were transfected with FLYWCHl alone in addition to the
luciferase reporters.
The results show that the TOP-FLASH reporter activity significantly (50%)
reduced by FLYWCHI in both SW620 and HCT1l6 cell lines (Figure 5-3,
lanes 2 & 4 vs. lanes 1 & 3), indicating that FLYWCHI might normally
interact and repress the transactivational activity of ~-cateninJTCF4 complex in
vivo. Collectively, these data suggest that FLYWCHI might function as an
endogenous negative modulator of WntJ~-catenin signalling pathway.
SW620 HCT116
.TOP-FLASH
o FOP-FLASH1.2
***Z;-
.s;
i5 c 1.0
ro 0
Q) .-
en en
~ ~ 0.8
Q) ~_ 0.
'(3 X
:::I Q) 06
-"C .
Q) -
> 0
.- LL.
ro -0.4
Q)
a:::
0.2
0.0
1 2 3 4
FLyweH1-WT + +
Figure 5-3: Suppression of endogenous p-cateninfTCF4 by FLYWCH1. eRe cell
lines (SW620 and HeT116) were transiently transfected to express FLYWCH1-WT in
the presence of Renilla and TOP-FLASH or FOP-FLASH reporters as indicated. The
TOP/FOP-FLASH luciferase activity relative to Renilla luciferase is presented. Data are
mean ± SO (n = 3; ***, P < 0.001). Experiment run in triplicate and repeated on two
independent occasions.
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5.2.2 FLYWCHI may compete with TCF4 for binding to p-
catenin
To explore the possibility that FLYWCHI competes with TCF4 for binding to
~-catenin, an in vivo co-immunoprecipitation (Co-IP) assay in human cell
culture was performed. HEK293T cells were co-transfected with expression
plasmids encoding; FLAG-~-catS33\ eGFP-FLYWCHl-WT, and
hemagglutinin tagged TCF4 (HA-TCF4). The protein lysate was co-
immunoprecipitated with anti-fLAG-conjugated agarose beads and analysed
by Western blotting analysis using anti-HA and anti-GFP antibodies.
The Co-IP blot shows that both HA-TCF4 and eGFP-FLYWCHl were co-
precipitated with FLAG_~_catS33A(Figure 5-4). Moreover, the blot also shows
that the amount of HA-TCF4 co-precipitated with ~-catenin was decreased in
the presence ofFLYWCHl (Figure 5-4, lane 1 vs. lane 3), while the amount of
FLYWCHI is not reduced (Figure 5-4, lane 2 vs. lane 3). In agreement with
our previous luciferase data (Figure 5-2), these results further support the
notion that FLYWCH I may compete with TCF4 for binding to ~-catenin and
the interaction affinity of FLYWCHl/~-catenin might be stronger that
TCF4/~-catenin.
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Figure 5-4: FLYWCH1 competes with TCF4 for interaction with p-catenin.
HEK293T cells were co-transfected to express the FLAG-~-catS33A,eGFP-FLYWCH1-
WT, and HA-TCF4. The protein lysate was co-immunopricipitated with anti-FLAG -
conjugated agarose beads. Both the Input (bottom panels) and Co-IP (top panels)
samples were immunoblotted with anti-HA and anti-GFP antibodies as indicated.
Asteriks (*) indicate unspecific bands.
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5.2.3 The C-terminus domain of FLYWCHI is essential for its
functional interaction with p-catenin.
In the previous chapter, the C-tenninal domain of FLYWCHI (containing
FLYWCH motifs 3-5) was shown to be responsible for its interaction with p-
catenin (see section 4.2.3). To explore the importance of this domain in the
transcriptional repression of p-catenin, a TCF luciferase assay was performed,
HEK293T cells were transfected with expression plasmids encoding; the wild-
type and the deletion mutants of MYC-FLYWCHI (M2, M3, and M4) (see
section 4.2.2) in the presence of FLAG_p_catS33A and the transcriptional
activity of p-cateninITCF4 was evaluated as described above.
The analysis showed that the nuclear p-catenin (FLAG_p_catS33A) substantially
(-95 folds) induced the TOP-FLASH reporter activity (Figure 5-5, lane 2 vs.
lane 1). This induction was dramatically suppressed by each of the wild-type
and deletion mutants M2 and M3 ofFLYWCHI (Figure 5-5, lane 2 vs. lanes 3-
5). However, deletion mutant M4 in which FLYWCH motifs number 3, 4, and
5 are removed from FLYWCHl, lost its suppression activity against p-catenin
signalling (Figure 5-5, lane 6).
Notably, the suppression level of deletion mutant M2 (lacking FLYWCH
motifs 1 & 2) and M3 (lacking FLYWCH motif 5) is comparable to the
suppression level of FLYWCHI-WT (Figure 5-5, lanes 4 & 5 vs. lane 3).
These data suggest that motifs 1, 2, and 5 are not mediating the repression
activity of FLYWCHI against p-catenin. Therefore, FLYWCH motifs 3 and 4
within the C-tenninal domain of FLYWCHI might be essential for the
functional interaction and suppression activity of FLYWCHI against p-
cateninlTCF4. These observations are in agreement with the previous Co-IP
results (see section 4.2.3) and collectively support the concept that FLYWCHI
directly binds to p-catenin through its C-tenninal domain and functions as a
negative modulator of p-cateninlTCF4-mediated transcriptional activation
likely through the FLYWCH motifs number 3 and 4.
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Figure 5-5: A C-terminal deletion of FLYWCHl (FLYWCH1-M4) lost its
suppression activity against p-cateninfTCF4. HEK293T cells were transfected to
express FLAG-~-catS33Aand MYC-tagged constructs of FLYWCH 1 (the wild-type and
deletion mutants M2, M3, and M4) in the presence of Renilla and TOP-FLASH or FOP-
FLASH reporters as indicated. The TOP/FOP-FLASH luciferase activity relative to
Renilla luciferase is presented. Data are mean ± SD (n = 3; ***, P < 0.001). Experiment
run in triplicate and repeated at least on two independent occasions.
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5.2.4 The N-terminal domain of p-catenin is required for its
functional interaction with FLYWCHI
The N-terminal domain of p-catenin was shown to be essential for its physical
interaction with FLYWCHI (see section 4.2.5). To investigate whether this
domain is also required for the functional interaction and repression of p-
catenin by FLYWCH1, a TCF-dual luciferase assay was carried out.
Expression plasmids encoding; full-length (FLAG_p_catS33A) and the deletion
mutants (~N, MD1, MD2, MD3, and ~C) of p-catenin (see section 4.2.4) were
individually transfected into HEK293T cells in the presence or absence of
MYC-FLYWCHI-WT plasmid.
In the absence of FLYWCH1, FLAG_p_catS33A highly (> 200 folds) induced
the TOP-FLASH luciferase activity in comparison to the control (Figure 5-6).
This induction was significantly (> 50%) reduced by overexpressed
FLYWCHI (Figure 5-6, lane 2, blue box vs. red box). Notably, all mutant
clones of p-catenin showed less luciferase activity than the wild-type clone
(Figure 5-6, lanes 3-7, blue boxes), especially deletions MD1 (lane 4) and
MD2 (lane 5) in which armadillo repeats (RI-4 and R5-9) comprising the
TCF4 binding site are deleted. Although the induction activity of p-catenin is
influenced by different p-catenin mutations but there is still some activity that
could explore the significant role of FLYWCH 1 on the transcriptional activity
of different domains of p-catenin. As shown in (Figure 5-6), regardless of the
level of induction, the luciferase activity of all deletion mutants except ~N was
significantly inhibited by FLYWCHI (Figure 5-6, lanes 4-7, red boxes vs. blue
boxes).
Consistent with the previous Co-IP data (section 4.2.5), these results indicate
that the N-terminal domain of p-catenin (~N) may be required for its functional
interaction with FLYWCHI. Taken together, these data gives the notion that
the N-terminal domain of p-catenin may have essential attribution to both
physical and functional interaction of p-catenin with FLYWCH 1.
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Figure 5-6: The N-terminal domain of p-catenin is required for its functional
interaction with FLYWCH1. The full-length (FLAG-~-catS33A)and the deletion mutants
of ~-catenin (~N, MD1, MD2, MD3, and ~C) were separately transfected in HEK293T
cells with (red boxes) and without (blue boxes) FLYWCH1. The activity of the firefly
luciferase reporter (TOP-FLASH) relative to Renilla is shown. Due to differences in the
induction levels, the figure is shown in two different scales; low scale (0 to 30) and high
scale (50 to 200) as indicated. Data are mean ± SD (n = 3; *, P < 0.05; ", P < 0.01; ***,
P < 0.001). Experiment run in triplicate and repeated on two independent occasions.
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5.2.5 Ectopic expression of FLYWeHl reduces cnc cell
motility
5.2.5.1 FLYWCH1 suppresses wound closure capacity o/CRC cells
To examine the effect of FLYWCHI on the motility of cancer cells, initially,
the in vitro scratch assay was performed. CRC cell lines (HCTI16 and SW480)
were transiently transfected with either pEGFP-C2 (an empty vector used as a
negative control) or eGFP-FLYWCHI-WT clone (encoding the wild-type
eGFP-tagged FLYWCHI protein). The transfected cells were incubated for 24
hours in a serum free RPMI medium to synchronize the cells at the GOthen the
scratch assay was performed as outlined in (section 2.2.6.2).
As shown in (Figure 5-7), the percentage of wound closure of the control cells
(green boxes) in both HCT116 (55%) and SW480 (17%) cell lines was
significantly reduced to 38% and 13% respectively by forced expression of
FLYWCHI (red boxes) after 24 hours of incubation. Moreover, the effect of
FLYWCHI on the wound closure rate of SW480 cells was more pronounced
after 48 hours of incubation (Figure 5-7B). This inhibitory effect of
FLYWCHI on wound closure rate of CRC cells could be due to defects in
either cell migration or cell proliferation. To further elucidate this, both cell
cycle analysis and migration assays were performed as outlined below.
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Figure 5-7: FLYWGH1 reduces wound-closure capacity of GRG cells. HCT116 and
SW480 cells were transiently transfected to express eGFP (control) or eGFP-
FLYWCH1-WT protein. The transfected cells were subjected to scrach wound assay.
Top panels) Charts show the percentage of wound closure for both eGFP (green
boxes) and eGFP-FLYWCH1 (red boxes) transfected cells after 24 hours in HCT116
cells (A) or 24 & 48 hours in SW480 cells (B). Bottom panles) Show representative
images of the wounds at time zero (TO)and 24 hours (T24) for HCT116 cells or TO,
T24, & T48 for SW480 cells. Data are mean ± SO (n = 6; **, P < 0.01). Experiment run
in triplicate and repeated at least on two independent occasions.
175
Chap 5: Biological Activities o(FLYWCHl
5.2.5.2 FLYWCHI has no effect on cell cycle progression ofCRC cells
To evaluate whether the reduced wound-closure of FYWCHI expressing cells
related to defects in cell proliferation, cell cycle analysis of CRC cell lines
(HCT116, SW480, and DLD-l) was performed. Cells were transiently
transfected with eGFP-FLYWCHI-WT clone or empty vector (control) and the
transfection efficiency was evaluated through the GFP fluorescence of the
EGFP reporter gene. 36 hours after transfection, cells were fixed and subjected
to cell cycle analysis using propidium iodide (PI) staining as previously
established in our lab (Babaei-J adidi et al., 2011, Ibrahim et al., 2012) and
described in (section 2.2.6.4).
As shown in (Figure 5-8), FLYWCHI (blue boxes) did not significantly
changed the percentage of cells at any phases of cell cycle in comparison to the
control (red boxes) in all cell lines tested. Thus, FLYWCHI may not be
associated to cell cycle progression and subsequently, the slow wound-closure
rate of FLYWCHI expressing cells (Figure 5-7) may due to defects in cell
migration.
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Figure 5-8: FLYWCH1 has no significant effects on cell proliferation. HCT116,
SW480, and DLD-1 CRC cell lines were transiently transfected with pEGFP-C2 vector
(control, red boxes) or eGFP-FLYWCH1-WT plasmid (blue boxes) and subjected to cell
cycle analysis. Upper panels) Charts show the percentage of cells in different phases
of cell cycle (Sub-G1, GO/G1, S, and G2/M) in A) HCT116, 8) SW480, and C) DLD-1
cell lines as indicated. Lower panels) Show representative cell cycle histograms for
each cell line. Data are mean ± SO (n = 3; no significant changes detected).
Experiment run in triplicate and repeated at least on three independent occasions.
To further validate the above cell-cycle results, the effect of FLYWCH 1 on the
total cell growth was also examined. HCT116 cells were transiently transfected
with eGFP-FLYWCHl-WT plasmid and the cells were counted over a course
of 4 days to generate a growth curve as outlined in (section 2.2.6.5). As
expected, the total cell count of transfected cells was not significantly affected
by FLYWCHI in comparison to the control (cells transfected with pEGFP-C2
vector) (Figure 5-9), suggesting that FLYWCHI might not affect the total
growth of cancer cells.
It should be mentioned that the transient transfection allow the gene of interest
to be expressed for a short period of time (few days). It has been reported that
the GFP fluorescence can be used as a reliable reporter to monitor changes in
gene expression (Soboleski et al., 2005). Therefore, in this experiment the
expression level of the eGFP-fusion FLYWCHI protein was examined through
a fluorescent microscope during the course of the experiment and detectable
GFP fluorescence was seen throughout the indicated times. As this method is
not quantitative, reduction in FLYWCHI gene expression by time cannot be
excluded. However, as no significant effect of FLYWCHI on the total number
of cells was observed at early stages of transfection (24 & 48 hours) this
possibility is unlikely to affect the results.
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Figure 5-9: FLVWCH1 does not affect the total cell growth. Transiently transfected
HCT116 cells with either eGFP-FLYWCH1-WT or pEGFP-C2 (control) plasmids were
seeded at an initial density of 5 x 104 cells/ml. The logarithmic growth curve was
generated by counting the total number of cells on daily basis for 4-days (96 hours) as
indicated. V-axis indicates the total number of cells/ml at specific time points given on
X-axis. Experiment run in triplicate and data are means ± SD (n = 3; no significant
changes were detected).
5.2.5.3 FLYWCHI reduces migration o/CRC cells
To examine the effect of FLYWCHI on cell motility of CRC cells, a migration
assay was performed. HCT116 cells were transiently transfected with eGFP-
FLYWCHI-WT clone or pEGFP-C2 vector (control) and the migration ability
of the transfected cells was examined using trans-well migration assay as
described in (section 2.2.6.3).
The results of the assay showed that overexpressed FLYWCHI significantly
reduced the total number of migrated cells in comparison to the control (Figure
5-10). These data support our previous findings (sections, 5.2.5.1 and 5.2.5.2)
and together suggest that FLYWCHI causes real defects in cell migration
which leads to reduced cell motility without affecting cell proliferation.
179
Chap 5: Biological Activities o(FLYWCHl
HCT116
120
.!E.
~ 100
"'C
Q)
**T§ 80
C')
·E
-
600
~
Q)
..c 40E
:=l
c::
co 20
.......
~
0
Control FLYWCH1
Figure 5-10: FLYWeH1 reduces the migration of eRe cells. Chart shows the total
number of migrated HCT116 cells transiently transfected with eGFP-FLYWCH1-WT
clone (red box) vs. control (green box) using trans-well migration assay. Data are mean
± SO (n = 3; **, P < 0.01). Experiment run in triplicate and repeated at least on three
independent occasions.
5.2.6 FLYWCHI modulates the gene expression of migration
effectors
To underline the mechanisms by which FLYWCHI suppresses cell migration,
the gene expression of several migration effectors was analyzed. The mRNA
level of several WntlJ3-catenin target genes including CDHl (E-cadherin
encoding gene), c-Jun, cyclin D 1 and Eph/Ephrin molecules was evaluated by
qRT-PCR using specific primers (Table 2-5). The cDNA derived from two
transiently transfected CRC cell lines (HCTI16 and SW480) with either
pEGFP-C2 (control) or eGFP-FLYWCHl-WT plasmids was used for the
analysis. This method allowed us to compare the mRNA level of the indicated
genes (Table 2-5) in FLYWCHI expressing cells relatively to the control cells
(transfected with empty vector). The qRT-PCR analysis revealed that the
mRNA level of CDHl significantly increased in FLYWCHI expressing cells
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of SW480 but not HCT116 cell line in comparison to the control (Figure 5-11,
A & B). This observation indicates that FLYWCHI may regulate the
expression of CDHl in a cellular context-dependent manner. Moreover, the
analysis also show that the mRNA expression of c-Jun, cyclin Dl and Ephrin
molecules (EPHA4 and EFNB2) which are best known for their contribution to
cell movement, polarity, and invasion (see the discussion) were significantly
reduced in the presence of FLYWCHI in both HCT1l6 and SW480 cell lines
(Figure 5-11, A & B). However, the mRNA level of c-Myc, EPHB2, and
EFNBl were not significantly affected (Figure 5-11, A & B). These data
suggest that FLYWCHI might differentially modulate the expression of Wnt-
target genes. Wnt signalling could also modulate gene expression indirectly,
for instance, EPHA4 has not been identified as Wnt-target gene, but it is
expression was significantly reduced by FLYWCHI. Collectively, these data
suggest that FLYWCHI may affect cell motility through modulation of Wnt-
target genes.
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SW480 OControl
.FLYWCH1
EPHB2 EPHA4 EFNB1 EFNB2 c-Jun e-Mye cyelin01 COH1
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Figure 5-11: Fl YWCH1 modulates the expression of Wnt-target genes. GRG cell
lines A) SW480 and B) HCT116 were transiently transfected to express eGFP (control)
or eGFP-Fl YWCH1-WT (Fl YWCH1). The expression of several Wnt-target genes in
FLYWCH1 expressing cells (blue boxes) relatively to the control cells (red boxes) is
shown as indicated. Data are mean ± SO (n = 3; *, P < 0.05; **, P < 0.01; ***, P <
0.001). Experiment run in triplicate and repeated at least on three independent
occasions.
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5.2.7 Ectopic expression of FLYWeHl changes the
morphology of eRe cells
Changes in cell morphology through actin reorganization and filopodia
formation have been involved in cell migration and invasion (Li et al., 201Oa,
Vignjevic et al., 2006). To investigate whether the reduced cell motility caused
by FLYWCHI correlates to alteration of cell morphology, a fluorescent
microscopic observation of eGFP-FLYWCHI expressing cells was carried out.
SW480 CRC cells express undetectable level of FLYWCHI (see Figure 5-14)
and display elongated shape that allows better observation of cell morphology.
Therefore, these cells were grown on cover-slips and transiently transfected
with either pEGFP-C2 (control) or eGFP-FLYWCHI-WT plasmids. The
transfected cells were stained with Phalloidin [a high-affinity filamentous actin
(F-actin) probe] (see section 2.2.6.7) and observed under a fluorescent
microscope.
The microscopic analysis revealed that most of the eGFP expressing (control)
cells display normal, similar to non-transfected cells, morphology in the same
field (Figure 5-12, top panel). These cells are characterized by flat, elongated,
and branched cells with prominent actin fibres. Conversely, most of the
FLYWCHI expressing cells show different phenotype, characterized by less
elongated, circular epithelial-like morphology with actin fibres concentrated at
the edge of the cells, whereas non-transfected cells within the same
culture/field show normal elongated morphological properties (Figure 5-12,
bottom panel). Taken together, these results indicate that FLYWCHI may
regulate cell migration possibly through alterations in cell morphology.
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Changes in cell morphology often associated with a cellular process called
epithelial to mesenchymal transition (EMT) (Nelson et al., 2008). This process
is commonly accompanied by enhanced cell migration and metastasis through
acquisition of mesenchymal characteristics (such as up-regulation of Vimentin
& ZEB2) and loss of epithelial traits (such as E-cadherin) (Mani et al., 2008,
Mendez et al., 2010, Nelson et al., 2008).
To examine whether or not FLYWCHI associated to the EMT process, the
protein expression of a key epithelial marker (E-cadherin) and a mesenchymal
marker (Vimentin) in addition to a potential EMT regulator (ZEB2) were
evaluated by Western blotting analysis. The protein lysates derived from
transiently transfected SW480 cells with either pEGFP-C2 or eGFP-
FLYWCHI-WT plasmids were immunoblotted with anti-E-cadherin, anti-GFP,
anti-Vimentin and anti-ZEB2 antibodies (see Table 2-7).
The data show that the protein level of E-cadherin was increased in the
presence of overexpressed FLYWCHI in comparison to the control cells
(Figure 5-13, lane 1 vs. lane 2). The protein level of ZEB2 was not affected per
se, whereas Vimentin was slightly decreased. These data gives the notion that
the changes on cell morphology caused by FLYWCHI might not be associated
to EMT through ZEB2 protein.
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Figure 5-13: FLYWCH1 enhaces the expression of E-Cadherin. SW480 cells were
transiently transfected to express eGFP (lane 1, control) or eGFP-FLYWCH1-WT (lane
2). The protein lysate was immunoblotted with anti-ZEB2, anti-GFP, anti-E-cadherin,
anti-Vimentin and anti-~-actin antibodies. The expression of each protein is shown as
indicated. "M", denotes the ColorPlus Protein marker (in kDa) from NEW ENGLAND
BioLabs.
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5.2.8 Endogenous expression of FLYWCHl in human cell lines
Following the above interesting results regarding the crucial role of
FLYWCHI on migration and morphology of CRC cells, we sought to evaluate
the endogenous expression of FLYWCHI in normal vs. cancer cell lines. To do
this, specific primers (forward: 5'-GCAAAGGTCGAAGACCAGGA-3'and
reverse: 5'-TTCCTGGTGTACGAGTCCTT-3')were designed to quantify the
mRNA level of FLYWCHI by qRT-PCR using cDNA derived from normal
human fibroblast, embryonic stem cells (ESC) and different CRC cell lines
including HCT1l6, SW480, SW620, and DLD-l. SW480 cells that transiently
transfected with EGFP-FLYWCHI were used as a positive control. Human
ESCs pellet was kindly provided by C. Denning, university of Nottingham. The
RNA extraction and the cDNA preparation of the ESCs along with the qRT-
PCR experiment for all samples were kindly performed by Dr Roya Babaei-
Jadidi (Dr Nateri's lab).
The results show that FLYWCHI expression level was not detectable in each of
SW480 and SW620 cell lines, whereas its expression is slightly detected in
HCTl16, DLD-l, and ESC cells (Figure 5-14). However, the highest
expression of FLYWCHI was detected in the normal human fibroblast cells
(Figure 5-14). Cells transfected with pEGFP-C2 empty vector (SW480-EGFP)
did not show any expression of FLYWCHl, whereas cells transfected with
EGFP-FLYWCHI plasmid (SW480-FLYWCHl) show high induction of this
gene, indicating the specificity of the PCR reaction. Taken together, these data
suggest that FLYWCHI is differentially expressed in human cell lines and its
expression may be tightly regulated in CRe cells.
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Figure 5-14: Endogenous expression of FLYWCH1 in different human cell lines.
The mRNA level of the indicated normal and eRe cell lines was quantified by qRT-
peR. Transiently transfected SW480 cells with FLYWCH1 (SW480-FLYWeH1) were
used as a positive control. Experiment run in triplicate and data are mean ± SO (n = 3).
This experiment was kindly performed by Dr Roya Babaei-Jadidi (Dr Nateri's lab) as
explained in the text.
5.2.9 Endogenous expression of FLYWCHI in normal and
tumour tissues
Following the above observation of differential FLYWCHI expression in eRC
cell lines, exploring the endogenous expression of FLYWCHI in normal vs.
tumour tissues was thought to be important. As there is no commercially
available FLYWCHI-antibody that endogenously forworks
immunocytochemistry, Western blot, or ChIP-assays, the In Situ Hybridization
(ISH) assay on ApcMinl+ mouse and human colorectal tumour tissues was
performed.
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ApcMinl+ (Min, multiple intestinal neoplasia) is assigned to mice heterozygous
for a nonsense point mutation at codon 850 of the APC gene. Like humans with
germline mutations in APC, Min/+ mice also develop multiple intestinal
adenomas (Moser et aI., 1995, Moser et aI., 1990, Su et aI., 1992). This mouse
model is widely used to study the tumourigenesis of intestine (Babaei-Jadidi et
aI., 2011, Moser et aI., 1995, Nateri et aI., 2005). In the current work, intestinal
tissues from ApcMinl+ mice and colorectal tumour tissues from human were
analyzed by ISH assay using a cDNA-probe against a shared sequence of both
human and mouse FLYWCHI. The cDNA-probe was designed and cloned into
the pcDNA3 vector (Appendix 8) as outlined in (section 2.2.6.8.1), then the
probe and tissue sections were sent to Dr B Spencer-Dene, CRUK-LRI,
Histopathology Lab to perform the ISH assay as described in (section
2.2.6.8.2).
In normal gut from ApcMinl+ mice, Flywch 1 expression was not detected in
differentiated epithelial cells in the villi, whereas Flywch 1 was highly
expressed in a population of crypt based cells (2-6 cells) where the Lgr5+ve
cells are located (Barker et al., 2007) (Figure 5-15A, right panel, magnified box
E). In contrast, Flywch 1 expression was down-regulated at the crypt based cells
of tumour tissues from ApcMinl+ mice (Figure 5-15A, left panel, magnified box
B). This finding indicates that Flywch 1 expression becomes gradually silenced
as cells differentiate and also when transformed.
The ISH assay also show that Flywch 1 expression was restricted to the late
stages of ApcMinl+ intestinal adenocarcinomas (Figure 5-l5A, left panel,
magnified box C), and metastatic CRCs in a tissue microarray (TMA) study
(Figure 5-15, F & G), indicating that the expression level of FLYWCHI may be
correlated to pathological staging of CRes.
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Figure 5-15: Endogenous expression of FLYWCH1 in normal vs. tumour tissues
of intestine. ISH for FL YWCH1 on representative intestinal tissue sections of A)
Apcfliin/+ mice and E) human colorectal tumours tissues. Red arrowheads indicate
FLYWCH1 +ve cells in A) normal crypts of Apcfldn/+ murine intestine and F) section of
human colorectal tumour tissue. Boxes (8, C, D, E & G) represent magnified views of
the indicated area. This experiment was performed in collaboration with Dr B Spencer-
Dene, CRUK-LRI, Histopathology Lab.
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Consistent with the in vitro qRT-PCR data (Figure 5-14), our in vivo ISH
analysis revealed that Flywch 1mRNA is highly expressed in the myofibroblast
compartment of the ApcMinl+ mouse intestine (Figure 5-15A, magnified box D).
However, further quantification of FLYWCHI expression in different human
tissues including normal, primary and secondary tumours is required to explore
the significant differential expression of FLYWCHI in human tissues. On the
other hand, the expression of Flywch 1 is also evident in the adenocarcinomas
of the ApcMinl+ mouse intestine (Figure 5-15A). However, as no quantification
data is available, it remains uncertain whether the expression of Flywch 1 is
quantitatively higher in the stroma or in the tumour compartment of the
ApcMinl+ mouse intestine. Therefore, further validation of these results is
required through quantification of the ISH data and/or performing qRT-PCR
analysis. Taken together, these data suggest that FLYWCHI may play crucial
roles in maintaining the homeostasis of normal intestine.
5.3 Discussion
Several nuclear proteins have been shown to functionally interact and
negatively regulate the transcriptional activity of Wnt/~-catenin signalling
pathway. FLYWCHI was identified as a novel partner for nuclear ~-catenin in
the previous chapter. Herein, the functional interaction between FLYWCHI
and ~-catenin was further investigated. The data demonstrated that FLYWCHI
negatively modulates ~-catenin signalling as judged by a dramatic repression
of ~-catenin transactivational activity by this protein both exogenously in
HEK293T cells (Figure 5-1) and endogenously in SW620 and HCT116 cells
(Figure 5-3). Furthermore, the luciferase data revealed that the C-terminal
truncated form ofFLYWCHI (deletion mutant M4) lacking motifs number 3, 4
and 5 lost its suppression against ~-catenin (Figure 5-5). However, the
transcriptional activity of ~-catenin was highly repressed by each of the
deletion mutants M2 (lacking motifs 1 & 2) and M3 (lacking motif 5) of
FLYWCHI to a comparable level to the wild-type (WT) clone, indicating the
critical involvement of motifs number 3 & 4 in the negative regulation of ~-
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catenin signalling. These data highlight the importance of FLYWCHI and its
motifs 3 & 4 in the functional interaction ofFL YWCHI with ~-catenin.
Negative regulators tightly modulate Wnt pathway through different
mechanisms such as enhanced degradation of ~-catenin by activated p53 and
Nur77 (Sadot et al., 200 I, Sun et al., 2011) or competition with members of
TCFs for binding to ~-catenin in case of Chibby and Sox 9 (Takemaru et al.,
2003, Akiyama et al., 2004). Similar to the later reports, our data also suggest
that FLYWCHI might compete with TCF4 for binding to ~-catenin and also
indicate that the interaction affinity of ~-catenin to FLYWCHI might be
stronger than its interaction affinity to TCF4 as shown by the Co-IP (Figure
5-4) and luciferase (Figure 5-2) data. Alternatively, it is also possible that
FLYWCHI may form a complex with both ~-catenin and TCF4 and disrupt the
transcriptional activity of this complex leading to attenuated ~-cateninITCF4
signalling as it is the case for RUNX3 (Ito et al., 2008). Furthermore, it cannot
be excluded that FLYWCHI may bind to specific elements of DNA through its
zinc finger domains and recruit nuclear ~-catenin to the promoter of target
genes independently to TCFs.
The armadillo repeats (the central domain) and the C-terminal domain of ~-
catenin are providing interaction sites to many critical partners, especially the
N-terminal region of the C-terminal domain which has been described as a key
component of the C-terminal transactivation domain (Xing et al., 2008),
whereas the N-terminal domain is providing phosphorylation sites (Liu et al.,
2002). However, our Iuciferase results, consistent with our previous Co-IP data
(see Figure 4-13), suggested that the N-terminal domain of ~-catenin may be
required for its functional interaction with FLYWCHI (Figure 5-6), indicating
that, in addition to its role in phosphorylation, The N-terminal domain of ~-
catenin may also interact with transcription factors and thereby play roles in the
transcriptional activity of ~-catenin as it has also been suggested by (Tolwinski
and Wieschaus, 2004).
Cell migration is one of the critical biological processes regulated by Wnt/~-
catenin signalling pathway (Arnan and Piotrowski, 2008, Humtsoe et al., 20 I0,
Matsuda et al., 2009). ~-catenin, the major player of this pathway, together
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with TCFs modulates the expression program of many genes thereby
promoting cell migration and/or invasion. Thus, factors that suppress ~-catenin
transcriptional activity, in principle, should decrease cell motility and
migration. Interestingly, the results of in vitro scratch assay and trans-well
migration assays obtained in this study show that FLYWCHI decreases cell
motility (Figure 5-7 and Figure 5-10) without affecting cell cycle and growth
(Figure 5-8 and Figure 5-9). Although plausible data was produced by the
approaches applied in this study, some experimental limitations such as using
of alternative approaches cannot be excluded. For instance, in the trans-well
migration assay, the migrated cells can be counted in different ways, each with
distinct advantages or disadvantages. The migration ability of cells can be
evaluated through staining and counting the cells that have migrated through
and remained attached to the bottom side of the trans-well chambers (Pino et
al., 2010). However, this method is very delicate and technically difficult to set
up. In addition, this method of cell counting could be very subjective especially
when the distribution and/or staining of the cells on the bottom side of the filter
are uneven (Staton et al., 2009). On the other hand, this method may be helpful
if the protein of interest known to affect the adhesion properties of the cells.
An alternative way to evaluate the results of the trans-well migration assay is to
count the cells that migrate down to the lower chamber and attached to the
bottom of the well (Entschladen et al., 2005, Elsaba et al., 2010, Al-Ghamdi et
al., 2012). This method allows the user to count the viable cells individually
excluding any dead cells or debris that might have passed through the chamber.
It also helps to study the morphology of the migrated cells through direct visual
assessment under microscope without staining. Moreover, one can even re-
cultivate these cells and use them for further investigations.
In the current work, we used the later approach to evaluate the effect of
FLYWCHlon the migration properties of HCT116 cells based on the reasons
mentioned above. However, using the former method (i.e. staining and
counting the cells on the bottom side of the chamber) could give more strength
to the results of this assay. Despite of this limitation, the results of the trans-
well migration assay (Figure 5-10) was in line with the results of in vitro
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scratch assay (Figure 5-7) and together suggested that FLYWCHI may reduce
the migration ability of cancer cells.
It has been reported that the results of in vitro scratch assay could be associated
to effects on cell migration and/or cell proliferation (Coomber and Gotlieb,
1990, Zahm et al., 1997). Therefore, mitosis inhibitors such as mitomycin-C
could be used to block cell proliferation and evaluate cell migration alone
(Leung et al., 2005). However, this approach is commonly used to evaluate the
migration effect of growth factors such as epidermal growth factor (EGF) and
transforming growth factor ~1 (TGF~I) that known to affect cell proliferation
(Kanazawa et al., 2010, Singer et al., 2009, Rose, 2012). In the present study,
we have shown that FLYWCHI reduces the percentage of wound closure of
CRC cells without affecting cell proliferation through cell cycle analysis and
growth curve (Figure 5-8 and Figure 5-9) (more information about these assays
is given below). Therefore, cell proliferation inhibitors were not used.
Additionally, we further confirmed the results of the in vitro scratch assay by
the trans-well migration assay as mentioned above.
Different cell lines could show different migration capacity (Kubens and
Zanker, 1998). In our hand, SW480 cells showed more adhesiveness and
slower migration capacity in comparison to HCTI16 cells. Therefore, we
analyzed the scratch assay for HCT116 cells at time 0 and after 24 hours
(Figure 5-7A), as this time was sufficient to detect a significant change
between the controls (transfected with empty vector) and experimental samples
(transfected with FLYWCH1). Moreover, the edge of the wound was not
perceptible at later times. However, for SW480 cells scratches were imaged at
time 0, 24, and 48 hours. We noticed that the rate of wound closure was
significantly reduced by FLYWCHI at both 24 and 48 hours time course.
However, the reduction was more pronounced at 48 hours as shown in (Figure
5-7B).
Although we have used different established techniques to evaluate the effect
of FLYWCHI on cell migration and proliferation (see above), potential
improvement of these technical approaches should be considered. For example,
certain factors/drugs that known to either promote or inhibit cell migration
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and/or cell proliferation (i.e. positive and negative controls) can be used to
further evaluate the effect ofFLYWCHI on these cellular traits. This approach
not just helps to show the biological impact of FLYWCHI more efficiently,
but it also ensures that the experimental condition is optimal and the assay
worked as expected. Moreover, it is also valuable to compare the migration rate
of the control cell lines used in this study with published data. However,
researchers often do not show the absolute values of migrated cells of the
control samples; instead they arbitrarily normalize control values to number
one then show folds of induction or reduction of migrated cells of the
experimental samples in comparison to the controls (Pino et al., 2010,
Vignjevic et al., 2007). In addition, migration rate of cells in the trans-well
assay could be affected by many experimental parameters such as type and the
pore size of the chamber, number of seeded cells, incubation period, and serum
concentration in the culture medium. These parameters were found to be
significantly variable between different laboratories which led to difficulties to
perform such a comparison. However, the percentage of wound closure of
untreated HCT116 (55%) and SW480 (32%) cells (i.e. controls) obtained in
this work is comparable to the wound closure rate of these cells (43% for
HCT116 & 29% for SW480) in a recent work published by Fan et al. (2011),
though variation in the control wound closure rate in the same paper is also
evident (Fan et al., 2011).
Our data also revealed that FLYWCHI expressing cells are morphologically
transformed into less branched, more rounded epithelial-like shape (Figure
5-12). In addition, our western blotting analysis showed up-regulation of E-
cadherin without changes in ZEB2 EMT regulator (Figure 5-13). These data
suggest that FLYWCHI may regulate cell migration possibly through
alterations in cell morphology that may not be related to ZEB2-mediated EMT.
These findings uncovered a novel migratory role of FLYWCHI in CRC cells
and encouraged us to explore the molecular mechanisms underlying this effect
in more detail.
Considering the importance of FLYWCHI as a potential repressor of ~-
catenin-mediated transcriptional activity (see above), it is plausible that
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FLYWCHI may regulate the expression of Wnt-target genes, especially those
which are related to cell migration and morphology. Therefore, in this study the
expression of several Wnt-target genes were evaluated by qRT-PCR.
Interestingly, our data showed that FLYWCHI significantly modulates the
expression of several key migration effector genes such as CDH J, c-Jun, and
Eph/Ephrin molecules (Figure 5-11, A & B). Each of these genes has critical
involvement in cell motility and/or morphology (Haldimann et al., 2009,
Hermiston et al., 1996, Katiyar et al., 2007). For example, E-cadherin (encoded
by CDHJ) mediates cytoskeletal rearrangement through actin reorganization
which may lead to formation of a distinct phenotype in favour or against cell
migration (Alt-Holland et al., 2008, Chen et al., 2012). Accordingly, high level
of E-cadherin protein has been widely associated to reduced cell motility
(Hermiston et al., 1996, Mao et al., 2008), while its low level often linked to
increased cell migration and/or invasion (Alt-Holland et al., 2008, Chen et al.,
2012).
In the current work, both the mRNA and the protein levels of E-cadherin were
found to be significantly increased by FLYWCHI in SW480 cells (Figure
5-11A & Figure 5-13). Consistent with the previous reports, the up-regulated
E-cadherin led to the acquisition of phenotypic properties that suppressed cell
motility in this cell line (Figure 5-7B). Interestingly, our data indicated that the
effect of FLYWCHI on cell morphology and migration may not be related to
ZEB2-mediated EMT (see above & section 5.2.7). These findings appreciate
the role of FLYWCHI transcription factor in controlling the key metastasis-
suppressing protein, E-cadherin.
Among other Wnt-target genes, Cyclin DJ was significantly down-regulated by
FLYWCHI (Figure 5-11, A & B). Although cyclin DJ is widely involved in
cell-cycle regulation, cell-cycle independent roles of this gene were also
reported (Fernandez et al., 2011, Li et al., 2006a). It has been shown that cyclin
DI affects cell migration and morphology through repression of the metastasis
suppressor Thrombospondin 1 (TSP-l) and inhibition of ROCK signalling (Li
et al., 2006a). Furthermore, cyclin Dl was also involved in enhanced cell
detachment and motility in collaboration with Ral GTPases (Fernandez et al.,
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2011). In addition, down-regulation of cyclin Dl through ~-catenin siRNA did
not affect cell proliferation in U20S/GR cells (Takayama et al., 2006).
Consistence with these findings, our observations suggest that FLYWCHI
might influence the cell-cycle independent roles of cyclin Dl to reduce cell
migration without affecting the cell cycle or growth.
c-Jun was another strongly down-regulated gene by FLYWCHI (Figure 5-11,
A & B). This gene is frequently overexpressed in diverse tumour types and has
been implicated in promoting cellular migration and invasion in addition to
proliferation, and angiogenesis (Katiyar et al., 2007, Jiao et al., 2008, Jiao et
al., 2010). Moreover, c-Jun is a critical component of the activator protein I
(AP-l) complex (Eferl and Wagner, 2003) which induces cellular migration
and invasion by two regulatory mechanisms. First, by inducing the expression
of several critical regulatory genes such as MMP9, CD44, Krpl, stem cell
factor (SCF) and CCL5 (Jiao et al., 2010, Katiyar et al., 2007, Ozanne et al.,
2007). Second, by suppressing the inhibitors of invasion such as TSC-36,
fibronectin, STAT6 and PCDHGC3 (Ozanne et al., 2007). In addition, deletion
of c-Jun reduces cellular migration and invasion through inhibition of c-Src
and hyperactivation of ROCK II Kinase (Jiao et al., 2008). Ultimately, both up-
regulated and down-regulated genes functionally interact to form pseudopods
and support the mesenchymal mode of invasion. These findings fit our
observations that FLYWCHI caused migration defects and morphological
changes through down-regulation of c-Jun.
Our results also showed that the expression of EPHA4 and EFNB-B2 was also
significantly repressed (Figure 5-11, A & B). Ephrin-B2 has been associated to
EMT, stem cell compartment, angiogenesis and metastasis (Haldimann et al.,
2009, Kaenel et al., 2012), whereas EphA4 is mainly implicated in Axon
Guidance (Wegmeyer et al., 2007). Moreover, targeting EphA4 receptor has
been recently considered as a potential task in the therapeutic field for
treatment of spinal cord injuries (Goldshmit and Bourne, 2010, Goldshmit et
al., 2011). Furthermore, EphA4 is the only receptor that binds both classes (A
and B) of ligands (Gale et al., 1996, Pasquale, 2008). Indeed, interaction and
coordination between EphA4 and Ephrin-B2 has been reported and contributed
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to EMT during somite morphogenesis (Barrios et al., 2003). Thus, down-
regulation of both EPHA4 and EFNB-B2 by FLYWCHI might be strongly
associated to the reduced cell migration observed in this study.
Despite the fact that FLYWCHI strongly inhibits p-catenin/TCF4
transcriptional activity, the expression of some but not all Wnt-target genes that
examined in this study were affected by forced expressed FLYWCHl. Some
genes such as c-Myc, EPHB2 and EFNB-BJ were not affected, while others
were either up-regulated such as CDHJ or down-regulated such as c-Jun,
cyclin DJ, EPHA4 and EFNB-B2. These data indicate that Wnt-target genes
differentially responded to FLYWCHI overexpression. This finding is similar
to an earlier report where Wnt-target genes were differentially responded to
inhibited p-cateninITCF signalling (van de Wetering et al., 2002).
Our ISH analysis showed that in normal compartments of ApCMinl+ mouse
intestine Flywch 1 was strikingly expressed in the crypt-based cells and down-
regulated in differentiated intestinal epithelial cells (Figure 5-15, right panel).
Conversely, in tumour tissues Flywchl was less expressed in the crypt (Figure
5-15, left panel), while it is expression increased in late stages of intestinal
adenocarcinomas (Figure 5-15A, left panel, magnified box C). In addition,
FLYWCHI mRNA expression is restricted to a subpopulation of tumour cells
in both humans and ApCMinl+ mouse (Figure 5-15, A & F), suggesting that
FLYWCHI may have crucial roles during tumourigenesis.
On the other hand, some of the FLYWCHlI~-catenin target genes such as c-
Jun and EFNB-B2 (see above) were found to be highly expressed in CBS
(crypt base columnar) cells of mice intestine, while their expression is
decreased at the top of the villi (Batlle et al., 2002, Sancho et al., 2009),
indicating important involvement of these genes in intestinal homeostasis
(Babaei-Jadidi et al., 2011, Sancho et aI., 2009). Moreover, c-Jun and Ephrin
molecules, including EFNB-B2, are widely implicated in intestinal cell
migration/positioning, proliferation, and tumourigenesis (Babaei-Jadidi et al.,
2011, Batlle et al., 2002, Genander et al., 2009, Holmberg et aI., 2006, Nateri et
aI., 2005, Sancho et aI., 2009). It is thus possible that FLYWCHI exerts its
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influence on intestinal homeostasis and/or carcinogenesis through regulating
the above genes as key regulators of cancer pathways.
Given the fact that Flywch 1 is highly expressed at the bottom of the crypts of
mouse intestine (see above) where the Lgr5+ve stern cells are located (Barker et
al., 2007), and that its expression is restricted to small population of cells in
both human and APCMinl+ mouse intestinal tumours (see above), it is therefore,
plausible to speculate that FLYWCHI may regulate intestinal stern cells in
normal conditions and control the activity of cancer stern cells during cancer
development.
Taken together, the data in this chapter introduced FLYWCHI as a novel
antagonist to the Wnt signalling pathway through functional interaction and
inhibition of ~-cateninITCF4 transcriptional activity. The data also highlighted
the anti-migratory role of FLYWCHI transcription factor in colon cancer cell
lines and explored the mechanisms by which FLYWCHI deliver its regulatory
function. Based on these data, it is likely that FLYWCHI inhibits cell motility
by regulating the gene expression of critical migration effectors including
cyclin DJ, c-Jun, CDRJ, EPRA4, and EFNB-B2 as illustrated in (Figure 5-16).
As changes in cell motility is a key step toward invasion and metastasis,
FLYWCHI may functions as a potential metastasis-suppressing factor which
could be of use in the therapeutic field of colon cancer to limit cancer spread.
Finally, linking the endogenous expression of FLYWCHI in mouse intestine
and human tumour tissues to the regulatory effects of FLYWCHI on key
homeostasis factors such as c-Jun and Ephrin molecules further highlights the
importance ofFLYWCHl in normal vs. cancer development.
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I FlYWCH1 I
________________________________ ......1 ------,
1
Wnt/~-catenin signalling pathway
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Figure 5-16: A simplified diagram shows the mechanism by which Fl YWCH1
reduces cell motility. Fl YWCH1 modulates the expression of Wntl~-catenin target
genes through inhibition of the canonical Wnt signalling pathway leading to defects in
cell motility through changes in cell morphology. It is also possible that FLYWCH1 may
affect cell migration and morphology through other factors.
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6.1 Introduction
Stable gene expression IS a powerful approach to achieve long-term,
reproducible, and large scale protein production. This cost effective method not
only helps to overcome the transfection efficiency problems, but it also allows
one to perform several biochemical and biological analyses more efficiently.
Among different methods, the Lentiviral-based vectors offer an attractive
system for efficient gene delivery and integration. The use of this system has
been expanded in the past decade and adapted to be used to transduce almost
all types of cells such as human monocyte-derived dendritic cells (Rouas et al.,
2002), human and mouse ESCs (Gropp and Reubinoff, 2006, Kosaka et al.,
2004). In our laboratory, this system has been successfully established to
deliver genes of interest into different mammalian cells.
In the current study, a Lentiviral-based gene delivery system was applied to
obtain a stable expression of eGFP reporter and eGFP-FLYWCHl genes in
HEK293T and HCTl16 cell lines. This system necessitates cloning the
nucleotide sequence of these genes into a Lentiviral vector called pLVX-Puro.
Herein, the cloning process and the expression pattern of stably expressed
FLYWCHI in these cell lines are evaluated. The preliminary data indicated
abnormal protein products expressed by the genome-integrated FLYWCHI.
Therefore, different approaches such as microscopic observations, Western
blotting, genomic PCR analysis, luciferase and migration assays were
employed to fully characterize the exogenous FLYWCHI (both the integrated
eDNA sequences and their protein products) in these cell lines. Moreover, the
genome-integrated sequence of FLYWCHI was PCR amplified and re-cloned
into mammalian expression vectors for further characterization and study. Our
analyses revealed that the integrated eGFP-FLYWCHI is spontaneously
mutated in both HEK293T and HCTll6 stable cell lines resulting in a modified
unfunctional FLYWCHI protein that cannot interact with ~-catenin.
Subsequently, the mutated protein lost its repression activity on cell migration
and morphology. To this end, we were able to obtain a successful integration
and expression of full-length FLYWCHI eDNA in the HEK293T cell line by
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limiting the cell-passage number of stably the transduced cells with Lenti-
FLYWCHI. Moreover, within this chapter the morphological changes caused
by FLYWCHI were mechanistically further investigated which indicates up
regulation of E-cadherin.
6.2 Results
6.2.1 Cloning of eGFP and eGFP-FL YWCHI-WT cDNAs into
pLVX-Puro
pLVX-Puro is a HIV based Lentivirus expression vector (www.clontech.com).
It contains a constitutively active human cytomegalovirus immediately
promoter (PCMV IE) just upstream to the multiple cloning site (MCS) (Figure
6-1A). The CMV-promoter also drives the expression of eGFP and eGFP-
FLYWCHI cDNA in both pEGFP-C2 and eGFP-FLYWCHI-WT plasmids
(Figure 6-1, B & C). Moreover, the nucleotide sequence of the CMV-promoter
contains a single unique restriction site for SnaBI which is not present
elsewhere in these expression plasmids (neither in the backbone nor in the
coding region of eGFP or eGFP-FLYWCHI-WT). In addition, the EcoRI
restriction site is present in the MCS of both pLVX-Puro and pEGFP-C2
vector. Moreover, the EcoRI restriction site is also present at the 3'-end of the
FLYWCHI cDNA cloned in pEGFP-C2 vector (Figure 6-1C). Thus,
SnaBII EcoRI restriction enzymes were used to excise the full length coding
sequence ofeGFP and eGFP-FLYWCHI-WT coding regions from pEGFP-C2
plasmid and eGFP-FLYWCHI-WT clone respectively. These DNA fragments
were sub-cloned into the pLVX-Puro Lentiviral vector as illustrated in (Figure
6-2). It is noteworthy to mention that SnaBI is a blunt end restriction enzyme
which allows the two halves of the CMV-promoter (the N-terminal half from
pLVX-Puro and the C-terminal half from pEGFP-C2 vector or eGFP-
FLYWCHI-WT clone) to ligate and restore the complete sequence of CMV
without introducing extra nucleotides that might interfere and affect the
functionality of this promoter.
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The successful construction of eGFP and eGFP-FLYWCHl cDNA into the
viral vector was examined by restriction enzyme digestion analysis using the
same enzymes (SnaBIIEcoRI) used for cloning. As shown in (Figure 6-3), this
digestion could release DNA fragments corresponding to eGFP (1.0 Kb, lane
1) and eGFP-FLYWCH1 (3.1 Kb, lane 2) from the backbone vector (7.8 Kb,
lanes 1 & 2). As mentioned above, SnaBI restriction site is located inside the
CMV-promoter (~265 bp upstream to the eGFP coding sequence) in both
pEGFP-C2 vector and eGFP-FLYWCHI clone. Consequently, the digested
DNA fragments (both eGFP and eGFP-FLYWCH1) have slightly higher
moleculare weights than their plain sequences due to this extra-sequence of the
CMV-promotor. These data confirmed the succesful cloning of both eGFP and
eGFP-FLYWCH1 cDNA into the Lentiviral vector (pLVX-Puro).
M 1 2
1,018
pLVX-Puro
(7.8 Kb)7,126
3,054 EGFP-FLYWCH1
(3.1 Kb)
EGFP(1.0 Kb)
Figure 6-3: Restriction enzyme digestion analysis of Lentiviral constructs
containing eGFP and eGFP-FLYWGH1-WT cDNAs. Both LVX-eGFP (lane 1) and
LVX-eGFP-FLYWCH1 (lane 2) constructs were digested with SnaBI and feaR I
restriction enzymes. The digested DNA fragments were run on 1% agarose gel and
visualized as indicated. Letter M, represents 1Kb-ONA marker in bp (Invitrogen).
206
Chap 6: Stable Expression o(FLYWCHl
6.2.2 Transduction and selection of cells with pLVX-eGFP and
pLVX-eGFP-FLYWCHl-WT
The Lentiviral constructed clones (LVX-eGFP and LVX-eGFP-FLYWCHI-
WT) (see section 6.2.1) were used to produce Lentiviral particles using
HEK293T cells as a producer cell line for packaging as outlined in (section
2.2.4.3.1). The viral particles were used to deliver eGFP and eGFP-
FLYWWCHI cDNA into the genome of HEK293T and HCTl16 cell lines in
order to obtain stable gene expression of these genes as described in (section
2.2.4.3.2). Briefly, HEK293T cells were co-transfected with expression
plasmids encoding components of Lentiviral particles to produce a viral soup.
The viral soup was concentrated and used to infect HEK293T and HCT116
cells. The infected cells were maintained and selected with Puromycin to
produce stable cell lines expressing either eGFP or eGFP-FLYWCHI as
detailed in (section 2.2.4.3.2). The resistant cells were kept in culture and
passaged several times during the process of single clone selection,
amplification and maitenance before being used for characterization. In our
first attempt to generate stable clones, the transduction efficiency of
FLYWCHI into the above mentioned cell lines was intitially low. An average
of 2-3 resistant clones for each cell lines were obtained from the 96-well plates
method for single cell selection (section 2.2.4.3.2). In addition, the GFP
expression level of eGFP-FLYWCHI in these clones was not equal. Some
were losing the intensity of the GFP fluorescence even during the selection
procedure. Therefore, the best expressed clone with high GFP fluorescence
judged by the floursecent micrscopy was choosen, expanded, and used for
further validation and characterization as detailed below (section 6.2.3).
However, in the second attempt of stable cell line generation, two clones for
each cell line were selected and evaluated by Western blot analysis as detailed
in (section 6.2.7).
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6.2.3 Characterization of cell lines stably expressing eGFP and
eGFP-FL YWCHI
6.2.3.1 Evaluation of FLYWCH1 gene expression by Western blotting
analysis
To investigate the stable expression of eGFP and eGFP-FLYWCHl-WT
protein in HEK.293T and HCTl16 cell lines, initially, Western blotting analysis
was performed. The protein lysate was extracted from these cell lines, run on
SDS-PAGE gel, and immunoblotted with anti-GFP antibody as outlined in
(section 2.2.5). The eGFP protein (-26 kDa) was clearly detected in both cell
lines (Figure 6-4A, lanes 1 and 3), whereas detection of eGFP-FLYWCHl-WT
was ambiguous. The expected molecular weight of this protein (-106 kDa) was
only barely detected in HCTl16 cells stably expressing eGFP-FLYWCHl-WT
(HCT1l6-FLYWCH1+ve) (Figure 6-4A, red-dashed box, lane 4), while a
strongly expressed protein band migrating at -50 kDa was detected in the same
lane (boxed in red), suggesting that eGFP-FLYWCHl protein may be
aberrantly expressed (i.e. presumably truncated) in these cells.
In addition, in HEK.293T cells stably expressing eGFP-FLYWCHl-WT
(HEK.293T-FLYWCHl+Vj, a band ofeGFP-FLYWCHl (just below 100 kDa)
was detected. This protein band is slightly smaller than the calculated
molecular weight (-106 kDa) of this protein (Figure 6-4A, red box, lane 2).
Therefore, it is assumed that FLYWCHI is either abnormally expressed in this
cell line or, alternatively, FLYWCHI might have been migrated faster on the
SDS-PAGE gel. To further elucidate this, the same Lentiviral particles (LVX-
eGFP-FLYWCHl-WT) that originally used to transduce and generate the
stable cell lines were used to transiently express eGFP-FL YWCHI-WT protein
in HEK.293T cells. The protein lysates extracted from the transiently infected
cells as well as stable cell lines were run on 8% SDS-PAGE gel and
immunoblotted with anti-GFP antibody. The low percentage gel was used to
separate the band of eGFP-FLYWCHl from the closely detected possible
unspecific bands.
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The analysis showed that a band of eGFP-FL YWCHl- WT protein with correct
molecular weight (~106 kDa) was detected in the lysate of transiently infected
HEK293T cells (Figure 6-4B, red-dashed box, lane 3), whereas a smaller band
of eGFP-FL YWCHI « 100 kDa) was detected again in the lysate of
HEK293T-FLYWCHl +vestable cell line (Figure 6-4B, red box, lane 2) but not
in the lysate of the control (HEK293T-eGFp+Vj cell line (Figure 6-4B, lane 1).
Collectively these findings suggest that the stably expressed eGFP-FLYWCHl
protein might be spontaneously modified in these stable cell lines.
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Figure 6-4: FLYWCH1-WT aberrantly expressed in both HEK293T and HCTl16
stable cell lines. Protein Iysates extracted from A) HEK293T and HCT116 cell lines
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stably expressing eGFP or eGFP-FLYWCH1-WT, and B) HEK293T cells stably and
transiently expressing these genes were immunoblotted (IB) with anti-GFP antibody.
Panel (A) shows the expression of eGFP (bottom panel, lanes 1 & 3) and eGFP-
FLYWCH1 (top panel, red boxes in lanes 2 and 4) in both cell lines as indicated. Panel
(B) shows the stable vs. transient expression of the eGFP-FLYWCH1 (red box in lane 2
vs. red-dashed box in lane 3). Two bands of FLYWCH1 with different molecular weights
were detected in lane 4 of panel A, for explanation about this see the text. "M", denotes
the full range Rain Bow marker from GE Healthcare. Asterisks (*) indicate unspecific
bands.
The above Western blotting data was further supported by the fluorescent
microscopic observations of GFP that visulalise the expression patteren of the
eGFP-FLWCHI protein inside the cells as outlined in the following section.
6.2.3.2 Stably expressed FLYWCHI shows different expression
pattern and sub-cellular localization: fluorescent-microscopic
analysis
To furher invistigate the expression pattern of eGFP-FLYWCHI in HEK293T
and HCTl16 cell lines, a fluorescent microscopic analysis was performed. The
analysis revealed that the eGFP protein alone (control cell line) was
ubiquitously expressed in both nucleus and cytoplasmic compartments of
HCTl16 and HEK293T cells in a spotty format (Figure 6-5, A & E). In
contrast, FLYWCHI showed two different expression patterns in these cell
lines. In HEK293T cells, the expression was restricted to the nucleus in a
punctate manner (Figure 6-5G) resembling the the transient expression of the
wild-type eGFP-FLYWCHI as adreesed in (section 3.2.5), whereas in HCTl16
cells FLYWCHI showed both nucleus and cytoplasmic expression but it failed
to form foci (spots) into the nucleus (Figure 6-5C). This pattern of expression
is somehow simillar to the expression of the mutant clone M4 (Figure 4-8) in
210
Chap 6: Stable Expression ofFLYWCHI
which the C-tenninal region of FLYWCHI was deleted (Figure 4-2).
Consistent with the WB data, these observations also suggest that the eGFP-
FLYWCHI is abnonnaly expressed in HCT116 cells.
Collectively, the WB and fluorescent microscope data indicate that FLYWCHI
aberrantly expressed in both HEK293T and HCT116 stable cell lines. This
might be resulted from different modifications, for example a) alterations of
the genome-integrated FLYWCHI cDNA such as point mutations or deletion of
large nucleotide sequences, b) post-transcriptional or post-translational
modifications including ubiquitination and/or degradation of the protein
product. Therefore, further analysis of the genomic-integrated sequences of
FLYWCHI cDNA in these cell lines was initially focused.
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6.2.3.3 DNA sequence analysis of genomic PCR products illustrates
deletional mutation in FLYWCHI exogenous gene in
HEK293T stable eel/line
To explore possible alterations of the genome-integrated FLYWCHI in
HEK293T stable cell line, a genomic-Pf'R and DNA sequencing analysis were
performed. The standard PCR protocol (section 2.2.2.5) was used to amplify
the N-terminal region of the exogenous FLYWCHI cDNA from the genomic
DNA extract ofHEK293T stable cell line using specific primers (Table 2-6).
A forward primer inside the eGFP coding sequence (GFP-Fwd; located 83 bp
upstream to the start codon of FLYWCHl) and a reverse primer (FLYWeHI-
Rev990, located 990 bp downstream to the start codon of FLYWCHl) were
used to amplify a 1.1 Kb fragment of the N-terminal region of FLYWCHI
fused to the 3'-end of the eGFP-epitope tag (Figure 6-6A). Using a forward
primer inside the eGFP-epitope tag (i.e. GFP-Fwd) provides specificity to the
peR reaction in term of preventing endogenous amplification of FLYWCHI.
The peR reaction could specifically amplify the N-terminal region of eGFP-
FLYWeHI (-1.1 Kb) from the genomic DNA derived from FLYWCHI+vebut
not eGFp+vecells (Figure 6-6B, lane 2 vs. lanes I). These data suggest that no
modifications [such as deletion (s)] happened to the first IKb of the N-terminal
region of the genome-integrated FLYWCHI in HEK293T stable cell lines per
see.
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A)
I eGFP I FLYWCH1 eDNA
~
FLYWCH1-Rev990
1,018
<1l
>
+ Q)0.._
LL ..c(9jg
Q) Cl)
B)
1,636
FLYWCH1
(1.1 Kb)
Figure 6-6: peR amplification of the N-terminal region of the genomic-integrated
exogenous FL YWCH1. A) A diagram shows the approximate positions of the forward
(GFP-Fwd) and reverse (FLYWCH1-Rev990) primers used for the peR reaction. B)
Agarose gel shows the amplified N-terminal fragment of FL YWCH1 (1.1 Kb, lane 2)
from the genomic DNA extracted from stably expressing eGFP-FLYWCH1
(FLYWCH1+ve)HEK293T stable cell line. The eGFP expressing stable cell line
(eGFp+ve,lane 1) was used as a negative control. Asterisks (*) indicate unspecific
bands.
The above findings could not explain the aberrant expression pattern of eOFP-
FLYWCHI protein (see section 6.2.3.1) observed in the lysate of HEK293T
stable cell line. Therefore, presence of the full-length coding sequence of
exogenous FLYWCHI in the genomic DNA of the stable cell line was
investigated by standard peR. Specific primers (Table 2-6), including the same
forward primer described above (OFP-Fwd) and a reverse primer (Full-
FLYWCH1-Rev) marking the 3'-end of FLYWCHI cDNA (Figure 6-7A), the
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full-length genome-integrated exogenous FLYWCHI was amplified from the
genomic DNA of HEK293T stable cell line.
The expected size of the amplified DNA fragment by the above described
primers is 2.2 Kb. However, surprisingly, a smaller band of FLYWCHI (~1.6
Kb) was amplified from the genomic DNA of this stable cell line (Figure 6-7B,
lane 2), suggesting that FLYWCHI might have spontaneously mutated in this
cell line. Notably, no PCR product was amplified from the control (eGFp+ve)
stable cell line (Figure 6-7B, lane 1), confirming the specificity of the PCR
reaction.
A) G~Fwd
I eGFP I FLYWCH1 cDNA
~
Full-FLYWCH1-Rev
B)
Q)
or
..-
Q) I
:r u
a..~ s: Q)
u.. ..0 >-..0
C>S ....J ro
Q) en u..Ci)
M 1 2
2,036
1,636
1,018
FLYWCH1
(1.6 Kb)
Figure 6·7: peR amplification of the full-length genome-integrated FL YWCH1. A)
Diagram shows the approximate positions of the forward (GFP-Fwd) and reverse (Full-
FLYWCH1-Rev) primers used for the PCR reaction. B) Agarose gel shows amplified
DNA fragments of the genome-integrated exogenous eGFP-FLYWCH1 (lane 2) from
the genomic DNA extract of HEK293T-FLYWCH1 +vebut not eGFp+vestable cell line as
indicated.
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To further evaluate the above observation, the PCR product derived from the
genomic DNA of HEK293T-FLYWCH1+vestable cell line was gel extracted
and subjected to automated DNA sequencing. The sequencing result was then
aligned to the previously approved nucleotide sequence of FLYWCHI IMAGE
clone [provided by the NCB! gene bank (GeneBank ID: BC028572.l)] using
CiustalW2 Alignment database. As shown in (Figure 6-8), the alignment data
revealed that the sequence of the PCR amplified DNA contains a relatively
large internal deletion (537 bp) mapped to nucleotides 1405-1942 within the C-
terminal region of FLYWCHI (Figure 6-8C). Surprisingly, the mutated
fragment of the exogenous FLYWCHI (downstream to the deleted area) was
re-ligated with the rest of FLYWCHI coding sequence without making any
frameshift mutations (Figure 6-8, A & B). Interestingly, the deleted region
caused a complete removal of FLYWCH motif 4 (FM4) and partial removal of
FLYWCH motifs 3 and 5 (FM3 & FM5) (Figure 6-8C). Moreover, deep
analysis of the sequencing data revealed that the remaining (undeleted) partial
sequences of motifs 3 & 5 comprising the first 145 nucleotide of motif 3 and
the last 32 nucleotide of motif 5 were ligated, in-frame, to restore a complete
recombinant motif containing the same nucleotide number (177 bp) as an
original FLYWCH motif (Figure 6-8D).
Importantly, we previously (in sections 4.2.3 & 5.2.3) discovered that the
putative physical and functional interaction site of FLYWCHI with ~-catenin
is located within the C-terminal region of FLYWCHI especially the area that
contain FLYWCH motifs 3 & 4. Thus, one can speculate that the above
spontaneous genomic alteration of the exogenous FLYWCHI in HEK293T-
FLYWCHI +vestable cell line may affect the interaction and repression activity
ofFLYWCHI against ~-catenin signalling.
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A)
Approved seq. CGCAGCCGCGCCATCACCCAGGGCCGACGGGTGACTGTCATGCGTGGTCACTGCCACC
Proposed seq.
~**~~~*************~*** *
Approved seq. AGCCGCGCCATAACCCAGGGCCACCGCATCATGGTCATGCGCAGCCACTGCCATCAGCC
Proposed seq. ~c:~GCATCATGGTCATGCGCAGCCACTGCCATCA
B)
R S R A I T Q G H R I M V MRS H C H Q
Deleted region
(537 bp)
C) 1,405 1,942 2,151
eGFP-FLYWCH1
eDNA, full-length '----
D) 1,405 1,614
eGFP-FLYWCH1
eDNA, truncated '---- L,--J
Recombin ant motif
Figure 6-8: The C-terminus region of the genome-integrated FL YWCH1 in
HEK293Tstable cell line contains an internal in-frame deletion mutation. The
proposed full-length genome-integrated FL YWCH1 (Proposed seq.) was amplified by
PCR. A) Shows nucleotide sequence alignment of the PCR product to the nucleotide
sequence of approved FL YWCH1 (Approved seq.) using CiustalW2 Alignment tool.
Asterisks (*) indicate identical nucleotides, while dashes (-) indicate missing (deleted)
nucleotides. Nucleotides upstream and downstream to the deleted region of the PCR
amplified FLYWCH1 (Proposed seq.) are highlighted in grey and nucleotides marking
the 3'and 5'-ends of the deleted region are enlarged in font size. B) Shows the in-frame
recombined nucleotide and amino acid sequence of FLYWCH1. Schematics show C)
the position of the deleted fragment (537 bp) within the C-terminal region of FL YWCH1
cDNA highlighting the affected FLYWCH motifs and D) the truncated FL YWCH1 cDNA
highlighting a new recombinant nucleotide sequence of FLYWCH motif. Letters "FM",
denote FLYWCH motif.
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6.2.3.4 DNA sequence analysis of genomic PCR products illustrates
nonsence point mutation in FLYWCHI exogenous gene in
HCTl16 stable eel/line
Following the above undesirable yet interesting findings regarding the genomic
alteration of the exogenous FLYWCHI in HEK293T stable cell line, possible
genomic modifications of the genome-integrated FLYWCHI in HCT1l6-
FLYWCHI +vestable cell line was also examined. Specific primers including
the GFP-Fwd primer inside the eGFP-epitope (described above) and reverse
primers (Full-FLYWCHI-Rev and FLYWCHI-Rev1446) (see Table 2-6) were
used to amplify the full-length and a 1.5 Kb fragment of exogenous FLYWCHI
from the genomic DNA extract of HCT1l6-FLYWCHl+ve stable cell line
(Figure 6-9A) using standard PCR analysis.
As shown in (Figure 6-9B), despite single cell selection/cloning-based strategy
as outlined above, we failed to amplify a clear band of the full-length genome-
integrated FLYWCHI using GFP-Fwd & Full-FLYWCHI-Rev primers.
Instead, a smeary PCR product containing multiple bands (from -2.2 Kb and
smaller) of FLYWCHI was amplified from the genomic DNA of HCTl16-
FLYWCHI +vestable cell line (Figure 6-9B, lane 2). Notably, none of these
bands were amplified from the control (eGFp+Vj stable cell lines (Figure 6-9B,
lane 1), confirming the specificity of the PCR reaction. Thus, based on this
observation, presence of heterogeneous population of cells harbouring the
wild-type and different modified/mutated sequences of eGFP-FLYWCHl m
HCTl16 stable cell line was assumed.
In this notion, the PCR was repeated using the GFP-Fwd & FLYWCHl-
Rev1446 primers to amplify a shorter sequence of the exogenous FLYWCHI.
The results show that a band of FLYWCHI with expected molecular size (-1.5
Kb) was amplified from the genomic DNA of HCT1l6-FLYWCH1+ve cell line
(Figure 6-9C, lane 2) but not from the control (eGFp+Vj cell line (Figure 6-9C,
lane 1). This observation suggests that the amplified fragment of the genome-
integrated FLYWCHI may not contain large deletion mutations (as observed
for HEK293T stable cell line) per see. Thus, involvement of other possible
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modifications such as point mutations of the exogenous FLYWCHI sequence
or degradation of the protein product ofFL YWCHI was concerned.
A) GFP-Fwd
~
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~
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Figure 6-9: PCR amplification of the genome-integrated FLYWCH1 from HCT116
stable cell line. A) Diagram shows the approximate positions of the forward (GFP-
Fwd) and reverse primers (FLYWCH1-Rev1446 and Full-FLYWCH1-Rev) used for the
PCR reaction. 8 & C) Agarose gels show the amplified DNA fragments of FL YWCH1
(lane 2 in B & C) from the genomic DNA extract of HCT116-FLYWCH1+vebut not
eGFp+vestable cell line as indicated. For multiple bands of FLYWCH1 in (8) see the
text above.
In order to confirm the nucleotide sequence identity and integrity and also to
investigate the presence of possible point mutations within the genome-
integrated sequence of FLYWCHl, the above amplified DNA fragment (Figure
6-9C) was gel extracted and analyzed by automated DNA sequencing. In the
first attempt, the N-terminal region of FLYWCHI (~770 bp) was sequenced.
The sequencing data revealed that the nucleotide sequence of the proposed
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genomic-Pf'R product of FLYWCHI completely (100%) matches the
nucleotide sequence of the approved sequence of FLYWCH1 cDNA (Figure
6-10). These results indicated that the N-terminal region of the exogenous
FLYWCH1 (~770 bp, covered by the sequencing primers used) has not been
modified in this cell line.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Proposed seq.
Approved seq.
Start codon of
FLYWCH1 cDNA
.-----------------~-------------------.~
GGGGGTGTCTCGGCATGGACGAGCTGTACAAGTCCGGCCGGACTCAGATCTACATGCCCC 60
_____________________________________________________ ATGCCCC 7
eGFP sequence
TGCCCGAGCCCAGCGAGCAGGAGGGCGAGAGTGTGAAGGCCGGCCAGGAGCCATCCCCCA 120
TGCCCGAGCCCAGCGAGCAGGAGGGCGAGAGTGTGAAGGCCGGCCAGGAGCCATCCCCCA 67
AGCCAGGCACGGACGTCATCCCGGCAGCCCCCAGGAAGCCCAGGGAGTTCTCCAAACTGG 180
AGCCAGGCACGGACGTCATCCCGGCAGCCCCCAGGAAGCCCAGGGAGTTCTCCAAACTGG 127
**********************~*****~****************k************
TGCTGCTCACAGCCTCCGACCAAGATGAGGATGGGGTGGGATCCAAGCCCCAGGAAGTGC 240
TGCTGCTCACAGCCTCCGACCAAGATGAGGATGGGGTGGGATCCAAGCCCCAGGAAGTGC 187
ACTGCGTCCTGTCCCTGGAGATGGCTGGCCCCGCCACCCTCGCCAGCACCTTGCAGATCC 300
ACTGCGTCCTGTCCCTGGAGATGGCTGGCCCCGCCACCCTCGCCAGCACCTTGCAGATCC 247
TGCCAGTTGAGGAGCAGGGAGGGGTGGTCCAGCCAGCCCTAGAGATGCCTGAACAGAAGT 360
TGCCAGTTGAGGAGCAGGGAGGGGTGGTCCAGCCAGCCCTAGAGATGCCTGAACAGAAGT 307
GCAGCAAGCTGGATGCAGCAGCCCCTCAGTCCCTGGAGTTCCTGAGGACACCATTCGGGG 420
GCAGCAAGCTGGATGCAGCAGCCCCTCAGTCCCTGGAGTTCCTGAGGACACCATTCGGGG 367
GCCGCCTCCTGGTGCTGGAGTCCTTCCTGTACAAGCAGGAGAAGGCAGTGGGGGACAAGG 480
GCCGCCTCCTGGTGCTGGAGTCCTTCCTGTACAAGCAGGAGAAGGCAGTGGGGGACAAGG 427
TGTACTGGAAGTGCCGCCAACATGCTGAGCTGGGCTGCCGGGGCCGGGCCATCACCCGAG 540
TGTACTGGAAGTGCCGCCAACATGCTGAGCTGGGCTGCCGGGGCCGGGCCATCACCCGAG 487
GCCTGCGGGCCACAGTGATGCGGGGCCACTGCCACGCGCCCGATGAGCAAGGCCTGGAGG 600
GCCTGCGGGCCACAGTGATGCGGGGCCACTGCCACGCGCCCGATGAGCAAGGCCTGGAGG 547
CCCGGCGCCAGAGGGAGAAACTGCCCAGCCTGGCCCTGCCAGAGGGCTTGGGAGAGCCCC 660
CCCGGCGCCAGAGGGAGAAACTGCCCAGCCTGGCCCTGCCAGAGGGCTTGGGAGAGCCCC 607
AGGGTCCTGAGGGCCCTGGAGGCCGAGTGGAGGAGCCCCTGGAGGGGGTGGGCCCGTGGC 720
AGGGTCCTGAGGGCCCTGGAGGCCGAGTGGAGGAGCCCCTGGAGGGGGTGGGCCCGTGGC 667
AGTGCCCTGAGGAGCCCGAGCCCACTCCTGGGCTGGTGCTGAGCAAGCCGGCCCTGGAGG 780
AGTGCCCTGAGGAGCCCGAGCCCACTCCTGGGCTGGTGCTGAGCAAGCCGGCCCTGGAGG 727
~~******.***~*******j-***********************+*
Proposed seq. AGGAGGAGGCACCCCGAGCCCTGTCACTGCTGAGCCTGCCGCCCAAGAA 829
Approved seq. AGGAGGAGGCACCCCGAGCCCTGTCACTGCTGAGCCTGCCGCCCAAGAA 776
****************************~***~******~.*~****~~
Figure 6-10: The N-terminal region of the genome-integrated exogenous
Fl YWCH1 has not been modified in HCT116 cell line. The N-terminal region (-770
bp) of the proposed genome-integrated FL YWCH1 (Proposed seq.) was amplified by
PCR and aligned to the approved gene bank sequence of FL YWCH1 cDNA (Approved
seq.) using CiustalW2 Alignment tool. Asterisks (*) indicate identical nucleotides. A
short sequence of the 3'-end of the eGFP-epitope and the start codon of FL YWCH1
eDNA are labelled as indicated.
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In the second attempt of sequencing, a longer fragment of the PCR amplified
exogenous FLYWCHI was sequenced and aligned to the gene bank sequence
of this gene. Interestingly, the alignment data showed that a single base
replacement (C to A) at nucleotide position 831 within the N-terminal region of
FLYWCHI was occurred. This point mutation caused a stop codon formation
(Figure 6-11) at amino acid position 277, which in tum led to production of a
truncated protein (-55 kDa, based on the aa sequence) lacks four FLYWCH
motifs. Thus, this finding explains the present of a smaller eGFP-FLYWCHI
protein in the lysate of HCT1l6-FLYWCHI +ve stable cell line (Figure 6-4A,
lane 2). Additionally, the recombinant truncated protein also lacks the putative
NLS sequence (see section 3.2.1) which is required for proper spotty/nuclear
localization of FLYWCHI. This finding, therefore, could explain the non
spotty cytoplasmic expression (Figure 6-5) of FLYWCHI in HCT1l6-
FLYWCHI +ve stable cell line.
To sum up, the Western blotting and genomic PCR analyses performed in this
study revealed that in HEK293T stable cell line, the predominant genome
integrated FLYWCHI developed a spontaneous in-frame deletion of large
nucleotide sequence within the C-terminal region, whereas, in HCT1l6 stable
cell line, a heterogeneous mixture containing a predominant nonsense point
mutation (within the N-terminal region of FLYWCH1) was detected.
Collectively, these data indicate that alterations of the genome-integrated
eGFP-FLYWCHI are likely happened at the genomic level in both HEK293T-
FLYWCHI +ve andHCTlI6-FL YWCHI +ve stable cell lines. To examine if these
modifications affect the function of FLYWCHl, the following functional
analyses were ensued.
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A) ~Approved seq. TCGATCCTGGGGCTGGGACAGGCCCGGCCCCTCGAGTTCCTGAGGACG~ ACGGGGG
Proposed seq. TCGATCCTGGGGCTGGGACAGGCCCGGCCCCTCGAGTTCCTGAGGACG~ ACGGGGG
B)
TCGATCCTGGGGCTGGGACAGGCCCGGCCCCTCGAGTTCCTGAGGACG~~TACGGG
S L L G L G Q ARPLEFLRT YG[nnnnnnnnnnnunu{StopJ
~
eGFP-FLYWCH1
protein, full-length '------'
C)
D)
eGFP-FLYWCH1
protein, truncated '----
Figure 6-11: A nonsense point mutation resulted in a stop-codon formation within
the N-terminal region of the genome-integrated FLYWCH1 in HCT116stable cell
line. A) Shows alignment of the PCR amplified sequence of genome-integrated
FL YWCH1 (Proposed seq.) to the gene bank sequence of FL YWCH1 (Approved seq.).
A nonsense point mutation caused by a single nucleotide replacement (C to A) is
shown as indicated. B) Shows the resulted stop-codon (TGA) highlighted in yellow. C)
Shows the approximate position of the resulted stop-codon within the full-length
FLYWCH1 amino acid sequences. D) Shows the resulted truncated protein that lacks
the FLYWCH motifs 2, 3, 4, and 5.
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6.2.4 Functional analyses of stably expressed FLYWCHI
6.2.4.1 Evaluation of FLYWCH1lp-catenin transcriptional activity in
HCT116 and HEK293Tstahie eel/lines
To evaluate whether the above described spontaneous modifications of
FLYWCHI in the stable cell lines affect the functional interaction of
FLYWCHI with ~-catenin, a TCF dual luciferase assay was performed. The
FLYWCHl+ve and eGFp+ve (control) stable cell lines (both HEK293T and
HCT116) were co-transfected with expression plasmids encoding the firefly
luciferase reporter (TOP-FLASH) and Renilla transfection control. Due to low
level of nuclear ~-catenin, HEK293T cells were also transfected with FLAG-~-
catenins33A.
The analysis revealed that the luciferase activity of the firefly reporter in
HEK293T-FLYWCH1+ve stable cell line not reduced by the stable expression
of FLYWCH I in comparison to the control cell line (Figure 6-12A, lane 2 vs.
lane 1), even though it slightly but not significantly induced. In contrast, the
firefly luciferase activity in HCT1l6 cells stably expressing FLYWCHI is
significantly reduced (Figure 6-128, lane 2 vs. lane 1). These observations
indicate that the spontaneously mutated genome-integrated FLYWCH1 in
HEK293T cell line lost its suppression activity against ~-cateninlTCF4,
suggesting that the functional interaction ofFLYWCH1 with ~-catenin is likely
disrupted. This result is in line with our previous finding that deletion mutant
M4, in which the C-terminal region of FLYWCH 1 is deleted, significantly lost
its suppression activity against ~-catenin (see section 5.2.3). Conversely,
despite the genomic alterations of FLYWCHI in HCT116-FLYWCH1+ve stable
cell line, the endogenous transcriptional activity of p-catenin is still suppressed
(Figure 6-128). This observation further supports our previous view that this
cell line may contain a heterogeneous population of cells harbouring the full-
length and different modified forms of integrated FLYWCHI (see section
6.2.3.4). Subsequently, presence of functional full-length FLYWCHl, even in
small quantities (small population of cells), could significantly repress the ~-
catenin transcriptional activity.
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Figure 6-12: FLYWCH1/p-catenin transcriptional activity in HCT116 and HEK293T
stable cell lines. Cells stably expressing eGFP (eGFp+ve,green boxes) and eGFP-
FLYWCH1 (FLYWCH1+ve,blue boxes) were transiently transfected to express FLAG-~-
catS33A and TOP-FLASH reporter in HEK293T (A) and TOP-FLASH alone in HCT116
(B) stable cell lines in addition to the Renilla transfection control (added to all samples).
Activity of the firefly luciferase reporter (TOP-FLASH) relative to Renilla luciferase is
shown as indicated. Data are mean ± SO (n = 3; **, P < 0.01; NS, non-significant).
Experiment run in triplicate and repeated on three independent occasions.
6.2.4.2 Evaluation of FLYWCHl repression activity on cell migration
in HEK293Tand HCTl16 stable cell lines
Cell migration was significantly reduced by FLYWCHI transient expression in
cancer cells including HCT116 (see Figure 5-10). To examine whether the
stable expression of this gene affects cell motility, a migration assay was
performed. In addition to HEK.293Tand HCTll6 stable cell lines, a transiently
infected HEK.293Tcells with Lentiviral particles expressing full-length EGFP-
FLYWCHI were also used. The migration ability of the transiently and stably
FLYWCHl-expressing cells was evaluated using a trans-well migration assay
as outlined in (section 2.2.6.3).
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As shown in (Figure 6-13A), the total number of migrated cells in HEK293T-
FLYWCHI +vecell line is not significantly decreased in comparison to the
control cell line (eGFp+Vj, nevertheless, it tends to be slightly but not
significantly increased (Figure 6-13A). Conversely, the migration ability of the
transiently infected HEK293T cells expressing EGFP-FLYWCHI-WT
significantly reduced in compression to the control eGFP expressing cells
(Figure 6-13B). Moreover, the total number of migrated cells in HCT116-
FLYWCHI +ve stable cell line is significantly reduced in comparison to the
control (eGFp+ve) cell line (Figure 6-13C). It should be noted that the number
of migrated cells of the control samples between the stably transfected and the
transiently transfected HEK293T cells is different (Figure 6-13, eGFp+veplot in
panel A vs. eGFP plot in panel B). Panel A cells were infected with Lentiviral
particles containing (LVX-eGFP), while panel B cells were transiently
transfected with pEGFP-C2 plasmid vector. Therefore, vehicles for transgene
expression (i.e. eGFP) are different between panels A & B. This difference
may, subsequently, affect the biological behaviours ofHEK293 cells.
Consistent with the results of the luciferase assay (Figure 6-12), these data
further support the notion that the stably expressed exogenous FLYWCHI in
HEK293T -FLYWCHI +ve stable cell line, lost its suppression role on cell
migration, whereas in HCTI16-FL YWCHI +vecell line the suppression effect is
still exist.
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6.2.5 Cloning the automodified FLYWCHl recombinant cDNA
into mammalian expression vectors
Our previous data showed that the spontaneous deletion of the genome-
integrated exogenous FLYWCHI in HEK293T-FLYWCHI+ve cell line
disrupted FLYWCH motifs number 3-5 (section 6.2.3.3) which are responsible
for the physical and functional interaction of FLYWCHI with ~-catenin (see
sections 4.2.3 & 5.2.3). Therefore, further evaluations for this mutant sequence
of FLYWCHI was sought to be important. To this end, specific primers (Table
2-6) were designed to amplify the entire sequence of the exogenous genome-
integrated FLYWCHI by standard PCR and clone it back into mammalian
expression vectors.
The resulted PCR product (-1.7 Kb) contains the entire sequence of the
automodified genome-integrated FLYWCHI (-1.6 Kb) fused to a short
sequence (-150 bp) of the C-terminal end of the eGFP-epitope (Figure 6-148).
A single BglII restriction site is located at the junction between eGFP and
FLYWCH1 (Figure 6-I4A). In addition, the reverse primer (Full-FLYWCH 1-
Rev) used here also contains an EcoRI restriction site at the 3'-end (Table 2-6
& Figure 6-I4A) which together with BglII were used for cloning. The
amplified DNA fragment was gel extracted, digested with BglII!EcoRI and
then inserted into the MCS of pEGFP-C2 vector in-frame to the eGFP-epitope
which is located just upstream to the MCS (see Appendix 6).
The successful cloning of the amplified FLYWCHI cDNA into the vector was
confirmed by restriction enzyme digestion analysis using the same enzymes
(BglIIlEcoRI) used for cloning. As shown in (Figure 6-14C), a single band of
FLYWCH 1 with expected molecular size (-1.6 Kb) was released from the
backbone vector (4.7 Kb), indicating a successful cloning. As four deletion
mutant clones of FYWCHI (eGFP-FLYWCHI- MI to M4) were previously
generated (see section 4.2.2), this clone was named as eGFP-FLYWCHI-M5.
227
Chap 6: Stable Expression o(FLYWCHl
A)
B~AI
GFP-F~d
--71
feaRI
! eGFP I
I
I
I
FLYWCH1 cDNA II
~
Full-FLYWCH1-Rev-C
B) C)
2,036
1,636
Backbone vector
(4.7 Kb)
2,036
1,636
5,090
4,072
FLYWCH1-M5
(1.6 Kb)
Figure 6-14: PCR amplification and restriction enzyme digestion analysis of the
automodified exogenous FL YWCH1 eDNA. A) Diagram shows the approximate
positions of the primers used for amplification of the entire sequence of the genome-
integrated FL YWCH1 by PCR. The restriction sites used for cloning are labelled as
indicated. B) Agarose gel shows the PCR amplified sequence of FL YWCH1 from the
genomic DNA extract of HEK293T-FLYWCH1+ve stable cell line. C) Agarose gel shows
restriction enzyme digestion analysis of eGFP-FLYWCH1-M5 clone with BgAl/EcoRI. A
single band of FLYWCH1-M5 cDNA (1.6 Kb) was released from the backbone vector
(4.7 Kb) as indicated.
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In order to facilitate the biochemical analysis of FLYWCHI-M5 clone, a
MYC-tagged construct of this mutated clone was also generated using a
restriction enzyme digestion strategy. A single XhoI restriction site is located
upstream to the deleted region of FLYWCHI eDNA, while EeoRI is located
downstream to it marking the 3'-end of FLYWCHI in both MYC-FLYWCHl-
WT and eGFP-FLYWCHl-M5 clones (Figure 6-15A). Thus, the C-terminal
domain of MYC-FLYWCHI-WT clone was removed by XhoIlEeoRI
restriction enzymes and replaced by the C-terminal domain of eGFP-
FLYWCHI-M5 clone (i.e. the mutant fragment) using the same restriction
enzymes (Figure 6-15, A & B). The resulted clone (Figure 6-15C) contains the
mutated sequence of FLYWCHI tagged with MYC-epitope. This clone was
named as (MYC-FLYWCHI-M5).
A) MYC·FLYWCH1·WT eGFP·FLYWCH1·M5
Xhal EeaRIMYC.epitope Xhol EeaRI
~~?----+----x----~~
B) 1
~ f---·--
1
C) MYC·FLYWCH1-M5
Figure 6-15: Cloning strategy of MYC-FLYWCH1-M5 plasmid. Schematic shows A)
the approximate restriction sites of Xhol and fcoRl enzymes within the coding
sequence of MYC-FLYWCH1-WT (left panel) and eGFP-FLYWCH1-M5 (right panel)
clones, B) the desired DNA fragments resulted from the enzymatic digestion, and C)
ligation of the desired DNA fragments to produce a MYC-tagged mutant clone of
FLYWCH1 (MYC-FLYWCH1-M5).
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6.2.6 The auto modified clone of FLYWCHI lost its physical
interaction with p-catenin
As mentioned above, the internal mutation of MYC-FLYWCHI-M5 clone
disrupted FLYWCH motifs 3-5 within the C-terminal region. It should be
mentioned that this region contains the putative interaction site of FLYWCHI
with p-catenin (see sections 4.2.3). To examine whether or not this mutation
affect the physical interaction ofFL YWCHI with p-catenin, a Co-IP assay was
performed. HEK293T cells were co-transfected with expression plasmids
encoding; FLAG-p-cateninS33\ MYC-FLYWCHI-M5 and MYC-FLYWCH1-
WT both separately and in combination. The protein lysate was co-
immunoprecipitated with Protein A/G PLUS-Agarose beads which are
manually conjugated to anti-MYC antibody (see section 2.2.5.3.3). Both Input
and Co-IP samples were analyzed by Western blotting using anti-MYC and
anti-FLAG antibodies as shown in (Figure 6-16).
The Co-IP blot shows that the wild-type FLYWCHI was able to pull down
FLAG-p-catenin (Figure 6-16, top panel, lane 2), while the mutated clone did
not show that ability (Figure 6-16, top panel, lane 3. These results are
consistent with our previous observations (section 6.2.4) and collectively
indicate that both physical and functional interaction of FLYWCHI with p-
catenin protein is likely disrupted by the spontaneous mutation (deletion) of the
exogenous genome-integrated FLYWCHI (MS).
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Co-IP: MYC Input
2 3 2 3
MYC-FLYWCH1-WT + +
MYC-FLYWCH1-M5 + +
FLAG-~-cateninS33A + + + + + + 18:
~_catS33A
(87 kOa) FLAG
MYC
FLYWCH1-WT
(80 kOa)
FLYWCH1-M5
(60 kOa)
Figure 6-16: The automutated clone of FLYWCH1 lost its physical interaction with
p-catenin. HEK293T cells were co-transfected to express FLAG-~-cateninS33A,MYC-
FLYWCH1-M5 or MYC-FLYWCH1-WT. The protein lysate was co-immunoprecipitated
with anti-MYC-conjugated agarose beads. Both Input and Co-IP samples were
immunoblotted with anti-FLAG and anti-MYC antibodies as indicated. "M", denotes the
ColorPlus Protein marker (in kDa) from NEW ENGLAND BioLabs.
6.2.7 New strategy to generate FLYWCHI +ve stable cell lines
As demonstrated above, the exogenous genome-integrated FLYWCHI cDNA
underwent critical spontaneous alterations in different cell lines. We speculated
that several cell passages during selection are likely attributed to the genetic
heterogeneity within the parental cells. Therefore, a new strategy to generate
stable cell lines expressing eGFP-FLYWCHl with limited passage number was
applied. To do so, the same procedure described earlier in (section 2.2.4.3.2)
was used to transduce both HEK293T and HCT116 cells with viral particles
containing either eGFP (LVX-eGFP) or eGFP-FLYWCHI (LVX-eGFP-
FLYWCHl). The transduced cells were then selected and maintained in a
slightly different way to the standard protocol that described in (section
2.2.4.3.2). The main differences are outlined below:
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1. Cells were selected in Puromycin for a longer time (20 days instead of 2
weeks) without passaging.
2. The idea of serial dilutions and single clone selections in 96-well plates was
not followed. Instead, the bulks of the transduced cells of each separate
well of 24-well plates were considered as a stable clone. After selection,
cells of each well were subcultured into one well of a 6-well plate and
considered as PO (passage zero). For each cell line two clones (#1 & #2)
were selected for evaluation.
3. The protein expression of FLYWCHI was evaluated within a very limited
passage number, (PO to P2).
6.2.7.1 Evaluation Experiments: Western blotting andfluorescent-
microscopic analysis of new stable cell lines
The expression of eGFP-FLYWCHI in the new stable cell lines was first
evaluated by a fluorescent microscope analysis at PO. As shown in (Figure
6-17), FLYWCHI was expressed in a spotty nuclear format similar to the
expression pattern observed for the transiently expressed wild-type FLYWCH 1
(see Figure 3-15), suggesting that the wild-type eGFP-FLYWCHl may be
successfully expressed in these cell lines.
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Figure 6-17: Expression pattern of eGFP-FLYWCH1 in both HCT116 and HEK293T
stable cell lines. Representative fluorescent images shows the expression pattern of
stably expressed eGFP (A & E) and eGFP-FLYWCH1 (C & G) in both HEK293T and
HCT116 stable cell lines as indicated. B, Or F, and H) are magnified views of the
indicated white boxed area. For both cell lines, Images were taken at PO.Scale bars, 50
IJm
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Next the protein lysate extracted from both HEK293T and HCTl16 stable cell
lines was run on SDS-PAGE and immunoblotted with anti-GFP antibody. In
agreement to the fluorescent-microscope observations, the Western blotting
analysis revealed that both cell lines were expressing the wild-type FLYWCH1
protein with expected molecular weight (~l 06 kDa) (Figure 6-18), indicating a
successful genomic integration and protein expression of the full-length
exogenous FLYWCH1 gene. However, the expression of eGFP-FL YWCHI
protein was hardly detectable in the lysate ofHCT116-FL YWCHI +vestable cell
line (Figure 6-18, lanes 2 & 3).
HCT116 stable HEK293T stable
~ N ~ N
=ti: =ti: =ti: =ti:
Q) Q) Q) Q)
> :r :r t+
~ ~ ~
~
Q) :J: :J: Q) :J: :J:
> U U t U U+
c, 3: 3: o, ~ ~u.. u..
C> ~ ~ C> ~ ~ID u.. u.. ID u.. u..
2 3 4 IB:
eGFP-FLYWCH1 - GFP
(106 kDa) 100
Actin _40 ~-actin
(42 kDa)
Figure 6·18: Evaluation of eGFP-FLYWCH1 protein expression in both HCT116
and HEK293T stable cell lines. Western blotting analysis shows the expression of
eGFP-FLYWCH1-WT in both HCT116 and HEK293T stable cell lines at POas indicated
using anti-GFP antibody. For each cell line, two clones of eGFP-FLYWCH1 (#1 & #2)
were analysed. eGFp+vecells were used as negative controls and ~-actin as a loading
control. "M", denotes the ColorPlus Protein marker (in kDa) from NEW ENGLAND
BioLabs.
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Taken together, the above results indicate that wild-type FLYWCHI
(FLYWCH1-WT+Vj can be expressed in human cell culture such as HEK293T
cells for a limited time (i.e. in a very low passage number). Nevertheless,
maintenance of stably expressed FLYWCHI in eRe cells may not be possible
even for a short period of time. Therefore, the HeTl16 stable cell line was
excluded from further analysis, while the effects of the stably expressed wild-
type FLYWCHI in HEK293T cells was further investigated.
6.2.7.2 Stably expressed eGFP-FLYWCH1-WT up-regulates E-
cadherin in HEK293Tstabie cell line
In the current work, we have reported that the transient expression of
FLYWeHI-WT in SW480 cells caused E-cadherin up-regulation (see Figure
5-11 &Figure 5-13). To delineate the effect of the stably expressed wild-type
FLYWCHI on E-cadherin in HEK293T cells, a Western blotting analysis was
carried out. In parallel to this experiment, the HEK293T-FLYWeHI+ve stable
cell line containing a spontaneously mutated (unfunctional) sequence of
FLYWeHI (eGFP-FLYWeHl-M5) (see sections 6.2.3.3 & 6.2.3.4) was also
analyzed. Protein lysates derived from HEK293T cells stably expressing eGFP-
FLYWCHI-WT or eGFP-FLYWCH1-M5 were analyzed by WB analysis
using anti-GFP and anti-E-cadherin antibodies.
Visual assessments for the Western blot data show that the expression of E-
cadherin clearly up-regulated in FLYWCH1-WT+ve cells, while E-cadherin
level was not affected in FLYWCH1-M5+ve cells in comparison to the control
(eGFp+Vj cells per se (Figure 6-19, top panel, lane 2 vs. lane 1 in A & e). In
addition, the up-regulation of E-cadherin was also evaluated through
quantification of the protein bands. The integrated density value (IDV) of E-
cadherin and Actin bands were measured by the band analysis tool provided by
FluorChem®FC2 Imaging System (Alfa Innotech, UK) following the
manufacturer's instruction. The IDV values of E-cadherin bands were then
normalized (i.e. divided) to their corresponding loading control (Actin bands).
The normalized E-cadherin values of control cells were arbitrarily set to 1 and
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the values of other samples were divided to the values of their controls to
produce folds of change in the level ofE-cadherin (Figure 6-19, B & D).
These findings are in agreement with our previous data regarding up-regulation
ofE-cadherin by transient expression ofFL YWCHI-WT (see Figure 5-13) and
together suggest that the expression of E-cadherin may be positively regulated
by FLYWCHI in the context of Wnt/li-catenin signalling pathway.
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Figure 6-19: Stably expressed Fl VWCH1-WT but not Fl VWCH1-M5 up-regulates
E-cadherin in HEK293T cells. Protein Iysates extracted from HEK293T cells stably
expressing A) FLVWCH1-WT and C) FLYWCH1-M5 in addition to eGFp+ve stable cell
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line in both (A & C) were analyzed by Western blotting using anti-E-cadherin (top
panels) and anti-GFP (middle panels) antibodies as indicated. ~-actin (bottom panels)
was used as a loading control. B & D) Show density quantification of E-cadherin protein
bands as outlined in the text. Data are representative of three independent
experiments.
To further confirm the E-cadherin up-regulation by FLYWCH 1, an
immunofluorescent (IF) assay was performed. The HEK293T cells that stably
expressing eGFP, eGFP-FLYWCHI-WT or eGFP-FLYWCHI-MS were fixed
and stained with E-cadherin antibody as previously outlined in (section
2.2.6.6). The results show that the expression of E-cadherin notably increased
in FLYWCHI-WT+ve cells in comparison to control (eGFP+v~ cells (Figure
6-20, top panels vs. middle panels), whereas the E-cadherin level in
FLYWCHI-MS+vecells is less or not increased (Figure 6-20, bottom panels).
This finding further strengthens the view that full-length FLYWCH 1 is
augmenting the expression of E-cadherin.
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Figure 6-20: E-cadherin up-regulation by the wild-type Fl YWCH1 in HEK293T
stable cell lines. Fixed cells of HEK293T stable cell lines (eGFP+ve,FLYWCH1-WT+ve,
and FLYWCH1-M5+ve) were subjected to IF assay using anti-E-cadherin antibody. The
GFP (green) and E-cadherin (red) expressions were shown as indicated. Large white-
dashed boxes are enlarged views of the indicated small white-boxed area. Scale bars,
50 urn,
6.2.7.3 Stably expressed FLYWCHI-WTchanged the morphology of
HEK293T cells
The effect of FLYWCHI mediated E-cadherin up-regulation on the
morphology of transiently transfected cells was shown in the previous chapter
(see section S.2.7). Herein, the effect of the stably expressed wild-type eGFP-
FLYWCHI (FLYWCHI-WT+Vj and the deletion mutant MS (FLYWCH1-
MS+ve)on the phenotype ofHEK293T stable cell lines was further investigated.
To do so, these cell lines were cultured on coverslips, stained with phalloidin
and analyzed under a fluorescent microscope.
The analysis show that cells expressing wild-type FLYWCHI (FLYWCH1-
WT+Vj are morphologically transformed, characterized by less branched, less
elongated, and more rounded epithelial-like morphology (Figure 6-21, middle
panel). In contrast, cells expressing only eGFP (eGFP+V)or mutant FLYWCHI
(FLYWCHI-MS+ve) displayed distinct characteristics of more elongated and
multi-branched cells (Figure 6-21, top & bottom panels). Moreover, the F-actin
organization (visualized by phalloidin stain) was also changed. The control and
mutant FLYWCHI expressing cells show prominent actin fibres distributed all
over the cells, whereas cells expressing wild-type FLYWCHI display more
actin fibres concentrated at the boundary of the cells.
These observations indicate that FLYWCHI may control cell morphology
through actin cytoskeleton rearrangements and, thereby, modulate cell
migration.
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Figure 6-21: Effects of the stably expressed Fl YWCH1 on the morphology of
HEK293T cells. HEK293T cells stably expressing eGFP (eGFp+ve,top panel), wild-type
Fl YWCH1 (FLYWCH1-WT+ve, middle panel), and deletion mutant M5 (Fl YWCH1-
M5+ve,bottom panel) (green) were stained with phalloidin (red) and OAPI (blue). The
phenotype of these cells is shown as indicated. large white-dashed boxes are enlarged
views of the indicated small white-boxed area. Scale bars, 50 urn.
6.3 Discussion
The inhibitory effect of FLYWCHI on cell migration and changes on cell
morphology (Chapter 5) encouraged us to establish stable cell lines that
constitutively express the FLYWCHI protein.
In the current work, a Lentiviral-based gene delivery system was successfully
applied to achieve an efficient gene delivery and integration (section 6.2.2) in
both HEK293T and HCTl16 cell lines. However, despite the efficient gene
delivery, our attempts to maintain the full-length wild-type sequence of
integrated FLYWCHI in the genome of these cell lines were not successful
(section 6.2.3). Surprisingly, within few passages of these stable cell lines,
which were required for the process of single clone selection, maintenance, and
amplification, the exogenous genome-integrated FLYWCHI underwent various
genomic alterations including deletions and point mutations (sections 6.2.3.3 &
6.2.3.4). Occurrence of a nonsense point mutation which resulted in truncated
protein and a spontaneous internal deletion of large nucleotide sequence of
FLYWCHI including its putative interaction site with ~-catenin (Figure 6-8 &
Figure 6-11), indicate that the forced expressed full-length (wild-type)
FLYWCHI may have outstanding effects on important biological processes
that cannot be tolerated by the cell. This view is further supported by the
finding that the automutated clone of FLYWCHI (FLYWCHI-M5) lost its
physical (Figure 6-16) and functional (Figure 6-12 & Figure 6-13) interaction
with ~-catenin. Moreover, this clone was also failed to up-regulate E-cadherin
in contrast to the wild-type clone (Figure 6-19 & Figure 6-20) and
subsequently, it restored the normal morphological status of HEK293T cells
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(Figure 6-21). Thus, it is much more likely that these cell lines developed
mechanisms to eliminate the effects of overexpressed FLYWCHI through
modifications that disturb the interaction ability of FLYWCHI with ~-catenin,
giving the notion that similar mutations of this gene may normally exist in
nature.
Our preliminary data indicated that maintenance of the stably overexpressed
wild-type FLYWCHI in human cell culture may not be possible (sections 6.2.3
& 6.2.7.1). Therefore, generation of inducible gene expression such as
doxycycline or tetracycline-inducible expression systems (Grill et al., 2003,
Gunther et al., 2002) of FLYWCHI may greatly help to further investigate the
biological roles of this gene in normal versus cancer development.
Following the undesirable yet important consequences of FLYWCHI stable
expression in our first attempt (section 6.2.3), we, therefore, applied a modified
strategy to generate stable expression of FLYWCHI through limiting the
passage number of the transduced cells (section 6.2.7). Interestingly, the
reduced cell passage method prevented the loss of FLYWCH 1 expression
and/or alteration in the stable cell lines (section 6.2.7.1). Subsequently, using
this strategy enabled us to observe the effect of stably expressed FLYWCH 1 on
the phenotype ofHEK293T cells.
Several morphological alterations including less branched, less elongated, and
more rounded epithelial-like morphology was observed for the cells expressing
wild-type FLYWCH I (Figure 6-21, middle panel). Moreover, these cells
showed more actin fibres (stained with phalloidin) concentrated at the
boundary of the cells. In addition, the protein level of the well known epithelial
marker, E-cadherin, was also up-regulated in these cells (Figure 6-19A &
Figure 6-20). In contrast, cells expressing mutant FLYWCHI (FLYWCHl-
MS+v) (Figure 6-21, bottom panel) displayed distinct characteristics of
mesenchymal-like cell morphology of more elongated and multi-branched cells
with prominent actin fibres distributed all over the cells. These cells did not
show up-regulation of E-cadherin (Figure 6-19 & Figure 6-20). Indeed, these
cells very much resembled, in their morphology, the control cell line which
expressed eGFP protein only (same figures mentioned above).
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Consistent to our observations, up-regulation of E-cadherin by different
mechanisms has been widely associated to reduced cell motility and invasion
in addition to morphological changes from mesenchymal-like to epithelial like
shape in various types of cancer (Kajiyama et al., 2003, Wong et al., 201Ob,
Mao et al., 2008, Meng et al., 2000). Moreover, it has also been reported that
E-cadherin mediates cytoskeletal remodelling through actin reorganization
leading to formation of a distinct phenotype in favour or against the process of
cell migration (Alt-Holland et al., 2008, Chen et al., 2012).
Collectively, our data indicate that FLYWCHI may function as a potential
regulator of cell morphology through up-regulation of E-cadherin and actin
cytoskeleton rearrangement which may ultimately affect the process of cell
migration and/or invasion.
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7.1 Introduction
Human FLYWCHI is a conserved member of the mammalian FLYWCH-type
zinc finger containing proteins (F-ZFPs). It was believed that FLYWCHI
localize to the nucleus and bind DNA based on the presence of five FLYWCH-
type zinc finger DNA-binding motifs. However, no published data about the
characterization and/or biological functions of FLYWCHI was previously
available. Thus, in the current study we, for the first time:
I. Bioinformatically and experimentally analyzed the amino acid sequence of
human FLYWCHI and cloned the full-length cDNA sequence of this gene
into different mammalian expression vectors.
2. Identified human FLYWCHI as a novel nuclear ~-catenin interacting
protein that physically interacts with ~-catenin and functionally represses
its transcriptional activity in human cell lines.
3. Evaluated the biological activities of FLYWCHl/~-catenin complex In
CRC cells.
4. Explored the mechanisms by which FLYWCHI exerts its influence on cell
morphology and migration through evaluating the expression of the
downstream target genes that involved in cell motility and cytoskeleton
rearrangement.
7.2 Novelty ofFLYWCHI
As a start point of the present work, a comprehensive online search was
performed to find out whether any evidence has been published in the past that
could have a direct or even indirect link to FLYWCHI in human or other
animals. The analyses revealed that a part of very limited evidences for the
initial identification of FLYWCHI gene through large scale screening assays
(Brandenberger et al., 2004, Stelzl et al., 2005), no data regarding
characterization and/or functional analysis of FLYWCHI protein was
available. Therefore, FLYWCH 1 can be considered as a previously
uncharacterized protein in mammals and the current work provides the first
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report to characterize human FLYWCHI and appreciate its biological roles in
human, particularly, in CRC cells.
7.3 Bioinformatics analysis of FLYWCHI
In this study, sparse information about human FLYWCHI was collected from
various reliable online recourses and databases such as NCB I
(http://www.ncbi.nlm.nih.gov/gene/84256), GeneCards
(http://www.genecards.org!cgi-binicarddisp.pl?gene=FL YWCH I), and UniProt
(http://www.uniprot.org!uniprot/Q4VC44).This information was analyzed by
the available bioinformatics tools such as basic local alignment search tool
(BLAST) (http://blast.ncbi.nlm.nih.gov/Blast.cgi), CiustalW2 alignment
(http://www.ebi.ac.uklTools/msalc1ustalw2D.
(http://www .ncbi .nlm.nih. gov/homologene/), and
HomoloGene
Pfam
(http://pfam.sanger.ac.ukl). Interestingly, the analysis revealed that the coding
sequence of FLYWCHI protein contains a tandem array of five FLYWCH-
type zinc finger motifs (Figure 3-1). Two of these motifs are mapped to the N-
terminal region, while the other three are located in the C-terminal region.
Notably, a part of FLYWCH motifs, none of the other common protein
domains were recognized in FLYWCHI. Moreover, our analyses also revealed
that the aa residues of this protein and its FLYWCH motifs are highly
conserved in all currently identified members of FLYWCHI in mammals
including human, mouse, chimpanzee, dog, cow, and rat (Table 3-1 & Figure
3-2).
Since the initial identification of F-ZFPs in early 2000s, FLYWCH-domains
were found to be involved in protein-protein interactions, DNA-binding, and
targeting microRNA genes in both vertebrates and invertebrates (Beaster-Jones
and Okkema, 2004, Dom and Krauss, 2003, Ow et al., 2008). Given that
FLYWCHI protein is highly conserved in several mammals, and considering
the importance of the so far identified F-ZFPs in both vertebrate and
invertebrates, FLYWCH family of proteins, therefore, may have crucial
biological and physiological functions throughout the animal kingdom.
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7.4 Cloning and characterization of human FLYWCHI
The first evidence about the interaction of human FLYWCHI with ~-catenin is
originated from a recent screening performed in Dr. Nateri's laboratory (Figure
1-8) (Saadeddin A et al. unpublished data). However, the possible in vivo
interaction ofFLYWCHI with ~-catenin in human cell culture was required to
be experimentally validated. Lacking previous work on FLYWCHI protein and
subsequently unavailability of examined mammalian expression plasmids
encoding FLYWCHI protein was the first issue to deal with before starting cell
culture experiments.
In the present study, an IMAGE clone of FLYWCH1, containing a previously
approved (i.e. sequenced) full-length nucleotide sequence of FLYWCHI
eDNA, was obtained from Geneservice (section 3.2.2). The IMAGE clone
facilitated the cloning process of this gene into different mammalian expression
vectors (section 3.2.3). This clone (i.e. the IMAGE clone) was used as a
template for cloning; either directly through restriction enzyme digestion to
clone untagged FLYWCHI (section 3.2.3.1) or indirectly through PCR
amplification which allowed us to tag FLYWCHI cDNA with small epitope
tags such as MYC-epitope (section 3.2.3.2) or EGFP (section 3.2.3.3) as
illustrated in (Figure 7-3). Epitope tagging of FLYWCHI cDNA was an
essential required step to enhance the immunodetection of this protein,
especially as there was no commercially available FLYWCH 1 antibody that
works endogenously for IHC, immunocytochemistry, WB or ChIP assays
during the course of this study.
In the current work, the epitope tagged FLYWCHI clones were successfully
used to express human FLYWCHI protein in different cell lines and detect the
expressed protein by WB analysis using effective commercially available
antibodies such as anti-MYC and anti-GFP (Figure 3-14, A & B). Moreover,
the EGFP-tagged eIone of FLYWCHI was used to evaluate the expression
pattern and the subcellular localization of FLYWCHI in human cells through
dissecting the GFP signal of the EGFP-tag reporter gene fused to the 51-end of
FLYWCHI cDNA (Figure 3-15).
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7.5 Interaction of FLYWCHI with ~-catenin
The Co-IP data presented in this work provided robust evidence of
FLYWCHlI~-catenin interaction in HEK293T cells (Figure 4-1). This
interaction is likely happened in the nucleus judged by the exclusive nuclear
localization of FLYWCHI (Figure 3-15) and also by using a constitutively
active mutant clone of ~-catenin (~_catenins33A)in which the nuclear
localization of ~-catenin is promoted through inhibition of GSK-3~
phosphorylation and proteasomal degradation (Liu et al., 2002).
~-catenin molecule contains three distinct regions; the central armadillo (arm)
repeats, an N-terminal and a C-terminal domain (Huber et al., 1997, Huber and
Weis, 2001, Xing et al., 2008). The armadillo repeats region provides the
binding surface for the majority of ~-catenin partners, the N-terminal domain
plays crucial role in stability of ~-catenin through phosphorylation, and the C-
terminal region functions as a transcriptional activation domain required for
gene activation (Graham et al., 2000, van de Wetering et al., 1997, Yost et al.,
1996). On the other hand, FLYWCHI protein contains five conserved
FLYWCH motifs with a putative function in DNA-binding and protein-protein
interactions by assumption from Drosophila and C. elegans F-ZFPs (Dorn and
Krauss, 2003, Provost and Shearn, 2006, Beaster-Jones and Okkema, 2004).
Therefore, it was highly important to map the interaction site of FLYWCHI
with ~-catenin and vice versa.
In this study, the site directed mutagenesis is employed to identify which
domain(s) involved in FLYWCH1/~-catenin interaction from both sides
(Figure 4-2 & Figure 4-9). Our Co-IP results showed that the C-terminal
deletion of FLYWCHI lacking the last three FLYWCH motifs, lost its
interaction ability with ~-catenin (Figure 4-7). Interestingly, the same deletion
lost the nuclear spotty expression pattern observed for the wild-type clone and
showed a scattered green signal throughout the cells (Figure 4-8). However, the
N-terminal domain of ~-catenin, but not the central armadillo repeats, was
found to be necessary for the interaction of ~-catenin with FLYWCHI (Figure
4-13).
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These results suggest that the last three FLYWCH motifs of human
FLYWCHI are possibly involved in the physical interaction of FLYWCHI
with ~-catenin, supporting the assumption of the previous researchers that
FLYWCH-type zinc finger motifs may involve in protein-protein interactions,
albeit in other organisms such as Drosophila (Dorn and Krauss, 2003, Provost
and Shearn, 2006). Although the N-terminal domain of ~-catenin was mainly
associated to kinases such as GSK3~ and CKlu (Barth et al., 1997, Yost et al.,
1996, Liu et al., 2002), our data indicated that the N-terminal domain of ~-
catenin could also physically interact with transcription factors such as
FLYWCH1, and thereby, control the transcriptional activity of ~-catenin.
The exclusive nuclear localization (Figure 3-15) and the direct interaction of
FLYWCHI with ~-catenin (Figure 4-1) in addition to its putative DNA-
binding domains (FLYWCH motifs), increased the possibility that FLYWCHI
may acts as a nuclear transcription factor and thereby regulate the
transactivation of downstream target genes either through functional interaction
with ~-catenin or by its own. In this work, we investigated the first possibility
and examined the transactivational activity of ~-catenin in response to
FLYWCHI through performing a TCF dual-luciferase reporter assay using
TOPIFOP-FLASH reporter genes. This method is one of the common indirect
transcriptional assays that have been widely used to examine the
transactivational activity of ~-catenin/TCF complex (Molenaar et al., 1996, van
de Wetering et al., 1997, Mahmoudi et al., 2009, Ito et al., 2008).
Intriguingly, our luciferase reporter assays revealed that full-length FLYWCHI
substantially repressed the transactivational activity of ~-catenin in variety of
human cell lines (Figure 5-1 & Figure 5-3), indicating that FLYWCHI may act
as a repressor for the nuclear ~-catenin. Moreover, our deletional analysis
showed that the suppression activity of FLYWCHI against ~-catenin was
abolished by the C-terminal deletion (Figure 5-5) in which the last three
FLYWCH domains of FLYWCHI protein are deleted (Figure 4-2). Our
indirect transcriptional assays, therefore, suggest that in addition to the physical
interaction (see above) these motifs may also be required for the functional
interaction ofFL YWCHI with ~-catenin as summarized in (Figure 7-2).
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Nuclear ~-catenin interacting proteins have been generally divided into two
groups; factors that augment the transcriptional activity of ~-catenin (co-
activators) and those inhibit this activity (co-repressors) (see section 1.2.4). In
agreement to our finding, transcription factors harbouring classical C2H2zinc
finger domains such as KrUppel-like C2H2zinc fingers were found to interact
with the nuclear ~-catenin and repress its transcriptional activity such as KLF4
(Evans et al., 20 I0, Zhang et al., 2006), Glis2 (Kim et al., 2007), Glis3 (Ulloa
et al., 2007), HICI (Valenta et al., 2006), and Osx (Zhang et al., 2008).
Although these domains were found to be necessary for the interaction with ~-
catenin in most of these factors, yet their involvement in the transcriptional
repression of ~-catenin remained poorly understood.
Transcriptional repressors were found to antagonize the activity of nuclear ~-
catenin through various mechanisms such as disruption of ~-catenin/TCF
complex (Ito et aI., 2008, Tago et al., 2000, Wu et al., 2010), competing with
TCFs for binding to ~-catenin (Akiyama et al., 2004, Easwaran et al., 1999,
Kaidi et al., 2007, Takemaru et al., 2003), and disruption of TCF binding to
DNA (Song and Gelmann, 2008, Zhang et al., 2008). Our Co-JP results showed
that FLYWCHI is likely competes with TCF4 for binding to ~-catenin, judged
by reduced amount of TCF4 immunoprecipitated with ~-catenin in the
presence of FLYWCHI (Figure 5-4). Moreover, as adding TCF4 did not
rescued the FLYWCHI-mediated suppression of ~-catenin (Figure 5-2), it
appears that the interaction affinity of FLYWCHI/~-catenin may be stronger
than TCF4/~-catenin. However, as we did not address this issue in detail,
involvement of alternative scenarios cannot be excluded. For example, it is
possible that FLYWCHI may interact with both ~-catenin and TCF4 and
disrupt the transcriptional activity of ~-catenin/TCF4 complex leading to
attenuated ~-catenin signalling as it is the case for RUNX3 (Ito et al., 2008).
Recent studies have found that stabilized ~-catenin interacts with certain
nuclear cofactors such as Prop! (Olson et al., 2006) and Oct-4 (Kelly et al.,
2011) and regulate crucial aspects of development and pluripotency through
TCF-independent mechanisms. In this view, it is possible that FLYWCHI may
bind to specific elements of DNA through its zinc finger domains and recruit
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nuclear ~-catenin to the promoter of downstream target genes independently to
TCFs. This assumption is supported by the finding that FLYWCHI is
efficiently interacts with the nuclear ~-catenin and it has five zinc finger
domains that may enable this protein to specifically bind DNA. Moreover, the
expression of some well known ~-cateninlTCF target genes such as MYC and
EPHB2 were not affected by FLYWCHI overexpression in cancer cells,
whereas expression of other genes such as c-Jun, cyclin DJ, EPHA4 and
EFNB-B2 were significantly affected (Figure 5-11). Collectively, these data
indicate that FLYWCHI may specify the downstream target activation of ~-
cateninlTCF signalling pathway, presumably in TCF-independent manner.
To sum up, the biochemical data presented in this work introduced human
FLYWCHI as a novel nuclear ~-catenin interacting protein that antagonizes
the activity of the canonical Wnt signalling pathway through physical
interaction and transcriptional repression of ~-catenin.
7.6 Biological significance of FLYWCHI
Signalling through ~-cateninlTCF4 controls many crucial aspects of cell
biology such as proliferation, differentiation, migration, and morphology
(Logan and Nusse, 2004, Clevers, 2006). Deregulation of this pathway disturbs
these cellular processes and leads to development of many diseases including
cancer (reviewed by Miller et al., 1999, Polakis, 2000, Clevers, 2006). Given
that FLYWCHI is negatively regulating this pathway (see above), it was of
utmost importance to evaluate the biological effects of FLYWCHI/~-catenin
interaction on fundamental cellular processes controlled by Wntl~-catenin
signalling pathway. In this notion, different approaches such as cell cycle, in
vitro scratch assay, and migration assay were applied in this study to elucidate
the biological impact of FLYWCHI on migration, morphology and
proliferation of CRC cells.
Alterations in cell motility and morphology are initial steps toward invasion
and metastasis, one of the critical hallmarks of cancer (Hanahan and Weinberg,
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2011). WntJ~-catenin signalling pathway, through different mechanisms, often
linked to regulation of these biological traits such as modulation of collective
cell migration and cell branching (Aman and Piotrowski, 2008, Humtsoe et aI.,
2010, Matsuda et aI., 2009).
The data presented in this work, indicated that FLYWCHI inhibits cell
migration (Figure 5-7 & Figure 5-10) without affecting cell proliferation or
growth (Figure 5-8 & Figure 5-9). Moreover, overexpression of FLYWCHI
changed the distribution of actin filaments to be more concentrated at the cell
periphery (Figure 5-12). Furthermore, FLYWCHI altered the morphology of
transiently transfected CRC and stably transfected HEK293T cells from multi-
branched-elongated phenotype to less-branched-rounded shape (Figure 5-12 &
Figure 6-21, respectively).
Defects in cell migration and actin cytoskeleton rearrangement could be related
to the mesenchymal epithelial transition (MET) (Nelson et aI., 2008), a process
which is opposite in meaning to epithelial to mesenchymal transition (EMT)
(Baum et aI., 2008). In contrast to EMT, MET is characterized by up-regulation
of epithelial-specific proteins, including E-cadherin, and down-regulation of
mesenchymal-specific molecules, such as Vimentin (Mani et aI., 2008, Mendez
et aI., 2010, Nelson et aI., 2008).
Our data showed that the expression of E-cadherin, the well known epithelial
marker, was consistently up-regulated by FLYWCHI in both CRC and
HEK293T cells (Figure 5-13 & Figure 6-19, respectively). However,
expression of the EMT regulator, ZEB2, was not affected (Figure 5-13).
Therefore, it is unlikely that FLYWCHI may reduce cell migration through
ZEB2-dependent EMT. Although involvement of the EMTIMET process
through other regulators is not excluded, it is plausible to hypothesize that
FLYWCHI decreases cell migration and mediates the associated cell shape
conversions through modulating the genetic program downstream to ~-
cateninlTCF4 signalling. Especially, as signalling through this pathway
controls the expression of various genes that have crucial roles in cell
morphology and migration/invasion such as CDHI, c-Jun, and ephrin
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molecules (Alt-Holland et al., 2008, Chen et al., 2012, Jiao et al., 2008, Katiyar
et al., 2007, Bochenek et al., 2010, Cortina et al., 2007, Pasquale, 2010).
In favour of this view, our qRT-PCR analysis showed that the expression of c-
Jun, and EFNB2 were significantly reduced by FLYWCHI in eRC cells, while
CDHJ was up-regulated (Figure 5-11). Each of these factors has essential
involvement in cell shape determination and motility (see the discussion part of
chapter 5), in particular E-cadherin, which has been recently reviewed as a
potential molecule associated with the cytoskeletal network during colorectal
cancer development and metastasis (Buda and Pignatelli, 2011). Moreover, the
qRT-PCR analysis also showed that Cyclin DJ (another target gene of Wnt
pathway) was significantly down-regulated by FLYWCHl, whereas no
obvious cell cycle defects was seen. This observation is supported by the
discovery of cell cycle independent roles ofCyclin Dl, especially those related
to cell motility (Fernandez et al., 2011, Li et al., 2006a, Li et al., 2006b). Taken
together, these findings uncover a novel anti-migratory role ofFLYWCHI that
affect the motility of cancer cells in the context of Wntlp-catenin signalling
pathway.
Our in vitro data are further supported by in vivo analyses using ISH assay on
mouse intestine and human CRC tissues. Flywch 1 was found to be strikingly
expressed in the crypt-based cells of the normal compartments of APCMinl+
mouse intestine where the Lgr5+ve stem cells are located, while down-regulated
in differentiated intestinal epithelial cells (Figure 5-15, right panel).
Conversely, in tumour tissues Flywch 1 was less detected in the crypt (Figure
5-15, left panel), while it is expression increased in late stages of intestinal
adenocarcinomas (Figure 5-15A, left panel, magnified box C). Moreover,
FLYWCHI mRNA expression was restricted to a subpopulation of tumour cells
in both humans andAPCMinJ+ mouse (Figure 5-15, A & F).
In addition to FLYWCHl, the expression of some key regulators of cancer
pathways such as c-Jun and EFNB-B2 was found to be up-regulated at the
bottom of crypt, while their expression is down-regulated at the top of the villi
(Batlle et al., 2002, Sancho et al., 2009). Moreover, c-Jun and EFNB-B2 are
widely implicated in intestinal cell migration/positioning, proliferation, and
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tumourigenesis (Babaei-Jadidi et al., 2011, Batlle et al., 2002, Genander et al.,
2009, Holmberg et al., 2006, Nateri et al., 2005, Sancho et al., 2009).
Furthermore, modulation of these genes by FLYWCHI in eRe cells was also
observed in this study (see above). Taken together, these data indicate that
FLYWCHI may play important roles in intestinal homeostasis and/or
carcinogenesis through regulating a number of key signalling molecules that
are involved in intestinal stem cells maintenance and tumourigenesis such as c-
Jun, CDHl, and Ephrin molecules as outlined in (Figure 7-3).
Although the above data provide valuable insight into the mechanisms by
which FLYWCH1 influence cell morphology and migration. Yet, involvement
of other regulatory molecules and/or strategies is also feasible. Indeed, there
are some preliminary data that FLYWCH1 affects the expression of Fascinl
and CDC42, the key regulators of filopodia formation that have role in
collective cell migration and polarity (data not shown, in collaboration with Dr
Roya Babaei-Jadidi, Dr Nateri's lab). Moreover, FLYWeHl was also found to
regulate the expression of miroRNA-302 family (data not shown, in
collaboration with Mr EISayed Ibrahim, Dr Nateri's lab), the major
microRNAs found in human embryonic stem cells with crucial roles in induced
pluripotency and stem cells maintenance (Subramanyam et al., 2011, Rosa and
Brivanlou, 2011, Barroso-del Jesus et al., 2009, Lin et al., 2010, Lipchina et al.,
2012). Therefore, through controlling of these factors FLYWeHl may play
crucial roles in intestinal homeostasis and carcinogenesis. In such a scenario,
FLYWCH1 may work independently to TCF4 and/or p-catenin (Figure 7-3).
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Figure 7-3: FLYWCH1 may modulate intestinal homeostasis and tumourigenesis
through controlling cell migration and morphology. The nuclear events mediated
by the canonical Wnt signalling pathway are mainly controlled by the activity of the
downstream target genes of ~-catenin/TCF4 in both colorectal cancer development and
intestinal homeostasis. Through transcriptional repression of the ~-cateninITCF4
complex, FLYWCH1 controls cell migration and morphology through modulating the
expression of several downstream target genes. Therefore, FLYWCH1 may play crucial
roles in intestinal homeostasis and carcinogenesis, especially as it's highly expressed in
the crypt based cells of intestine and/or a subpopulation of CRC tumour cells. It is also
possible that FLYWCH1 may exert its biological influences through targeting other
factors that involved in stem cell maintenance, cell morphology, and motility in a TCF4-
independent manner (more detail is mentioned in the text above).
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Following the promising data regarding interaction of FLYWCHI with ~-
catenin and its inhibitory effect on cell migration, generation of cell lines stably
expressing FLYWCHI was thought to be important. In the current work,
several attempts were made to stably express FLYWCHI in different cel1lines
such as HCTlI6, and HEK293T using a Lentiviral-based gene delivery system.
However, despite the efficient gene delivery, to our surprise, all these attempts
were failed to maintain the full-length wild-type sequence of the integrated
exogenous FLYWCHI in the genome of these cell lines (section 6.2.3).
A progressive loss of gene expression (silencing) and generation of a mosaic
expression pattern are among the common reported drawbacks for stable cell
lines (Kaufman et aI., 2008). Although these problems are not excluded, our
data revealed unusual spontaneous gene modifications of FLYWCHI in the
genome of these cells including point mutations and internal deletions (section
6.2.3). Our in depth investigation indicated that these cell lines might have
developed mechanisms to eliminate the outstanding effects of overexpressed
FLYWCHI through modifications that disturb the interaction ability of
FLYWCHI with ~-catenin (sections 6.2.4 & 6.2.6), giving the notion that
mutations of this gene might normally exist in nature.
In this study, we considered the possibility that several cell passages during
selection may attributed to the genetic heterogeneity of the parental cells of the
stable cell lines. Therefore, a new batch of stable cell lines within a very
limited passage number was generated (section 6.2.7). We could not evaluate
the effects of stably expressed FLYWCHI in HCT1l6 cells due to their rapid
loose of FLYWCHI expression (section 6.2.7.1). However, the effect of
FLYWCHI on cell migration and morphology in HEK293T stable cell lines
was further observed (sections 6.2.7.2 & 6.2.7.3). Consistent with the results of
the transient transfection (see above), the stably expressed FLYWCHI changed
the morphology of HEK293T cells from elongated to rounded shape (Figure
6-21) and up-regulated E-cadherin (Figure 6-19 & Figure 6-20). These data
further highlight the biological roles of FLYWCHI on cell morphology that
could lead to reduced cell migration.
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In summary, these data indicate that FLYWCHI may functions as a potential
migration suppressor in colon cancer through controlling cell morphology.
FLYWCHI is likely exerts this function through modulating the expression of
the downstream target genes of p-cateninlTCF4 signalling. Yet, clarifying the
full regulatory network and elucidating the precise molecular mechanisms by
which FLYWCHI controls gene expression programs downstream to
FLYWCHlIp-catenin signalling, represents an important agenda for future
research.
7.7 Limitations of this study
1. One limitation of this study is loss-of-function approach (siRNA) which
would be helpful to confirm the negative effect of overexpressed
FLYWCHI on WntJp-catenin signalling pathway. It should be mentioned
that the absence of specific antibody that could recognize the endogenous
expression level of FLYWCH 1 was a major barrier to undertake this
approach during the course of this study. In addition, most of the CRC cell
lines and primary tumour tissues examined in this work expressed almost
undetectable level of FLYWCHI mRNA (Figure 5-14 & data not shown, in
collaboration with Dr Roya Babaei-Jadidi, Dr Nateri's lab). In contrast, the
human fibroblast cells show high level of endogenous FLYWCHI mRNA
measured by qRT-PCR (Figure 5-14). As this observation was obtained at a
very late stage of the current study, we did not have chance to perform
further experiments using this cell line. Thus, performing siRNA of
FLYWCHI in this cell line could provide further insight about the
biological functions of this gene. However, it would be much better if this
approach is performed in cancer cell lines.
2. Another limitation is the absence of xenografts, subcutaneous or metastatic
mouse models. Such approaches are necessary to explore and validate the
possible anti-tumourigenic potentials of FLYWCHI expressing cells. This
could be accomplished through either loss-of-function or gain-of-function
approaches. For which, in both cases stable cell lines were required. We
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could not try the gene silencing approach because of the above mentioned
reasons. On the other hand, our several attempts to stably express and/or
maintain the full-length wild-type sequence of the integrated exogenous
FLYWCHI in the genome of CRC cell lines were failed (sections 6.2.3 &
6.2.7.1). Hence, further progression toward animal model was affected.
3. Limited technical reproducibility and using of alternative approaches for
some assays used in this study cannot be excluded. For example, the trans-
well migration assay is a very subjective assay and the migrated cells can
be counted in different ways. We have used one method (see section
2.2.6.3) to evaluate the result of this assay. However, using of other
methods (discussed in section 5.3) could increase the reproducibility of this
assay.
4. PCR amplification error IS a common drawback of site directed
mutagenesis used in this study to generate deletion mutant clones of
FLYWCHI and l3-catenin. In addition, removing parts of these proteins can
cause changes in the physiochemical properties of the mutant clones and
may lead to unexpected post-translational modifications. Although we
provided plausible data to show the presence of the desired nucleotide
sequence and protein expression of these clones, further investigation in
this regard (discussed in section 4.3) would help to clarify the exact reasons
behind unexpected migration of some of these mutant clones on the SDS-
PAGE.
5. Methods used to show competition between FLYWCHI and TCF4 to bind
l3-catenin cannot exclude other possibilities such as forming of ternary
complex of FLYWCHIITCF4/13-catenin. Additional Co-IP and luciferase
assays using increasing amount of FLYWCHI and/or TCF4 would help to
further delineate the mechanisms of interaction and suppression of
l3-cateninby FLYWCHI.
6. The in vitro use of cell lines for functional analysis does not represent the
real in vivo environment of cancer due to the lack of tumour
microenvironment. Therefore, the in vitro biological functions of
FLYWCHI need to be further validated in vivo. The expression profile of
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FLYWCHI in different stages of cancer may provide valuable information
in this regard.
7.8 Concluding remarks & future directions
Considering our investigations regarding (i) the novelty of FLYWCH 1 protein,
(iI) its interaction and transcriptional repression against ~-catenin, and (iii) its
downstream gene regulation (in CRC cells) and expression pattern (in intestine
and human CRC tissues), in depth understanding of the enigmatic mechanisms
by which FLYWCHI antagonize the canonical Wnt signalling pathway and
control cell migration and morphology may pave new avenues m the
therapeutic field of colon cancer. Yet, implication of FLYWCH 1 in the
therapeutic field is currently far from practice. Nevertheless, the findings of
this study warrant a larger follow-up investigation of this newly identified
protein.
Although plausible data regarding identification, characterization and
functional analysis of FLYWCHI was presented in this work, a number of
complementary investigations and analyses are required to define the
involvement of FLYWCH 1 in the biological processes of cell in more detail.
Points that need further attention are briefly listed below:
1. Production of a specific and effective antibody that detect the endogenous
level of FLYWCH 1.
2. Gene silencing approach usmg FLYWCHI siRNA technology m cells
express high level of FLYWCHI , e.g. human fibroblast cells.
3. Observing the endogenous expression of FLYWCHI in larger number of
cancer cell lines and primary tumours using qRT-PCR. This will provide
valuable information about the expression profile of FLYWCHI in cancer
vs. normal tissues and it also may help to find cancer cell lines that express
high level of FLYWCHI to be used for the siRNA approach.
4. Inducible system for FLYWCHI expression could be helpful to generate
cell lines stably expressing this gene. In particular, as the constitutive
expression ofFLYWCHl was not successful in this study.
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5. In vivo animal studies such as xenograft or knockout mice could be useful
to further study the tissue homeostasis and/or tumourigenic properties of
FLYWCHI.
6. Investigating the comprehensive gene profile downstream to FLYWCHI/~-
catenin signalling could be very helpful to define the precise mechanisms
underlying the cellular effects of FLYWCHI.
7. The qRT-PCR analysis performed in this study showed down-regulation of
several Wnt target genes by FLYWCHI at the mRNA level. Western
blotting analysis should be performed to examine the negative regulatory
effect ofFLYWCHI on the protein expression levels of these genes.
8. The biological effects of FLYWCHI on cell migration and morphology
should be further validated in larger number of cell lines and also by using
different alternative approaches.
9. Studies are required to identify the possible regulatory mechanisms that
control the expression and/or activity of FLYWCHI such as post-
transcriptional and/or post-translational modifications.
10. The molecular mechanisms underlying the possible competition between
FLYWCHI and TCF4 for binding to ~-catenin need to be further
investigated.
11. The ability of FLYWCHI to bind DNA should be experimentally analyzed.
In this case the chromatin immunoprecipitation (ChIP) assay would be
useful.
12. The nuclear localization signal (NLS) motif of FLYWCHI requires further
validation. In this case mutational analysis such as point mutation would be
the assay of choice.
13. As information about the half life of FLYWCHI protein is currently
unavailable, performing a time course expression of FLYWCHI in cell
culture would help to determine the optimal expression time and give
indication about the stability of this protein.
14. The biological effects of FLYWCH1 on cell migration could be further
improved by using positive and negative controls (i.e. chemicals/reagents
that alter the migration rate). This approach should also be applied to the
cell cycle analysis to further validate the results of the PI staining.
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Appendix 1: Multiple sequence alignment of
FLYWCHI aa sequence in different animals
NP 115672.2 --------------------------------------------------
XP 510759.2 --------------------------------------------------
XP 547172.2 1 MVIVRATVPAASDPATSGGSHRPHAGRGGQWPAGGARGSAVPATPGDPAA 50
XP 610323.3 --------------------------------------------------
NP 722486.1 --------------------------------------------------
XP 340761.1 --------------------------------------------------
NP 115672.2 --------------------------------------------------
XP 510759.2 --------------------------------------------------
XP 547172.2 51 CSAPLPEEPEKRSSPEERGPAALLRMLAAIRSGVPRGGLRSGVARSRPAG
100
XP 610323.3 ------------ --------------------------------------
NP 722486.1 --------------------------------------------------
XP 340761.1 --------------------------------------------------
NP 115672.2 --------------------------------------------------
XP 510759.2 --------------------------------------------------
XP 547172.2 101 GQWGRGASARLAAAAGAEVHAVAAAAEARGPAAARSPEREGSAAAAARVG 150
XP 610323.3 --------------------------------------------------
NP 722486.1 --------------------------------------------------
XP 340761.1 --------------------------------------------------
NP 115672.2 --------------------------------------------------
XP 510759.2 --------------------------------------------------
XP 547172.2 151 ALGPANALRAEEAEPDGVSESPQRPPPPGAPRGQSSWTARFPTREEEEEE 200
XP 610323.3 --------------------------------------------------
NP 722486.1 --------------------------------------------------
XP 340761.1 --------------------------------------------------
NP 115672.2 1
___________________ MPLPEPSEQEGESVKAGQEP---SPKPGTDV 28
XP 510759.2 1
___________________ MPLPEPSEQEGESVKAGQEP---SPKPGTDV 28
XP 547l72. 2 201 EKSLCQGLSVACGTGHRPRMPLPESSEQKGESVKAGQEPSPESPEPGTDV
250
XP 610323.3 1
___________________ MPLPEPSEQEGESVKAGQEPSPEPPEPGTDV 31
NP 722486.1 1
___________________ MPLPEPSEQDCESLRAGQEP----------- 20
XP 340761.1 1
___________________ MPLPEPSEQEGESLRAGQEP----------- 20
NP 115672.2 29 IPAAPRKPREFSKLVLLTASDQDEDGVGSKPQEVHCVLSLEMAGPATLA-
77
XP 510759.2 29 IPAAPRKPREFSKLVLLTASNQDEDGVGSKPQEVHCVLSLDMAGPATLA- 77
XP 547l72. 2 251 VPAAPTKPEEFSKLVLLTVSTENVDGVDSQPEGGHCVVSLEMSGPDTLA-
299
XP 610323.3 32 VLEAPTKPMEFSELVLLAASTESGDGMDTQPEEVHCVLTLEMADPDTLA- 80
NP 722486.1 21 _SVGARKPQESSNLV------PARDKERPKPTD---VASQETSSTATLPN 60
XP 340761.1 21 _SRGARKPQESSSLV------PARDKEKPKPTD---VMSQETSSTTTLPN 60
NP 115672.2 78 STLQILPVEEQGGVVQPALEMPEQKCSKLD-AAPQSLEFLRTPFGGRLLV
126
XP 510759.2 78 STLQILPVEEQGGVVQPALEMPEQKCSKLDAAAPQSLEFLRTPFGGRLLV
127
XP 547172.2 300 RMPQILQVEEQVGAVQPTLQAPEQYRSKPD-TAPKPLEFLRTPFGGRLLV
348
XP 610323.3 81 GTPQILPVEEQCGVVQPRPQTQALKPSKPN-IVTQPLEFLRTPFGGRLLV
129
NP 722486.1 61 NTLQVAPVKKQGRIIH-------RKRSRVDAVPPQPLEFLKTPFGGRLLV
103
XP 340761.1 61 NTLQALPAKKQGRIIH-------RKRSRVDAVAPQPLEFLKTPSGSRLLV
103
NP 115672.2 127 LESFLYKQEKAVGDKVYWKCRQHAELGCRGRAITRGLRATVMRGHCHAPD 176
XP 510759.2 128 LESFLYKQEKAVGDKVYWKCRQHAELGCRGRAITRGLRATVMRGHCHTPD 177
XP 547172.2 349 LECFLYKQEKAVGDKVYWKCREHCELGCRGRAITRGPRATVMRGHCHPPD 398
XP 610323.3 130 LESFLYKQEKAVGDKVYWKCREHTELGCRGRAITRGPRATIMRGHCHPPD 179
NP 722486.1 104 HKSFLYKQEKAVGDKVYWKCRQHSELSCRGRAITRGFRVTEMRDHCHPPE 153
XP 340761.1 104 HKSFLYKQEKAVGDKVYWKCRQHSELGCRGRAITRGFRVTEMRDHCHPPE 153
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NP 115672.2 177 EQGLE-ARRQREKLPSLALPEGLGEPQ---GPEGP-GGRVEEPLEGVGPW 221
XP 510759.2 178 EQGLE-ARRQREKLPSLALPEGLGEPQGPEGPEGP-GGRVEEPLEGVGPW 225
XP 547172.2 399 EEGLE-ARRRRQKLPSPSLPEGLG------GPEGPGGGRVEEPLEGVGPW 441
XP 610323.3 180 EEGLA-ARRQRQKRLGPALPEGLA------GSQGP-SSLVEEPLEGAGPW 221
NP 722486.1 154 KEGLDRKKRHRGRPPSSALPE---------GAEVQ--------EDEVSLW 186
XP 340761.1 154 KEGLGKKRRQKEKLPSS-------------GTEGQ--------GDGVSLW 182
NP 115672.2 222 QCPEEPEPTPGLVLSKPALEEEEAPRALSLLSLPPKKRSILGLGQAR-PL 270
XP 510759.2 226 QCPEEPEPTPGLVLSKPALEEEAAPRALSLLSLPPKKRSILGLGEAR-PL 274
XP 547172.2 442 LCPEEPEPAPTLVLSKPAAEEDEGLRALSLLSLPPKKRPTLGIGELRPPL 491
XP 610323.3 222 LCPVEPDPTPGPMLSYLVPEEDEGLRALALLRLPPKKRSTLG-SRGPPPL 270
NP 722486.1 187 LYPVEPEPTPQPSTETP--EEEQGYRSLALQSLPPKKRPTPGVVRYR-PL 233
XP 340761.1 183 LYPVEPEPTPQPSIETP--EEEQGYRSLALQSLPPKKRPTPGVVRYR-PL 229
NP 115672.2 271 EFLRTCYGGSFLVHESFLYKREKAVGDKVYWTCRDHALHGCRSRAITQGQ 320
XP 510759.2 275 EFLRTCYGGSFLVHESFLYKREKAVGDKVYWTCRDQALHGCRSRAITQGQ 324
XP 547172.2 492 EFLRTCYGGSFLVHQSFLYKREKAVGDKVYWTCRDHALHSCRSRAITQGQ 541
XP 610323.3 271 EFLRTCYGGSFLVHQSFLYKREKAVGDKVYWTCRDHTQHGCRSRAITQGR 320
NP 722486.1 234 EFLKTCYGGTFLVHQSFLYKREKTVGSKVYWTCREHAVHGCRSRAITQGQ 283
XP 340761.1 230 EFLKTCYGGTFLVHQSFLYKREKTVGSKVYWTCREHAVHGCRSRAITQGQ 279
NP 115672.2 321 RVTVMRGHCHQPDMEGLEARRQQEKAVETLQAGQDGPGSQ------VDTL 364
XP 510759.2 325 RVTVMRGHCHQPDVEGLEARRQQEKAVETLQAGQDGPGSQ------VDTL 368
XP 547172.2 542 RVTVMRGHCHPPDMEGLEARRQQEKAMETLQARPGGPGGQ------ADQL 585
XP 610323.3 321 RVTVMRGHCHAPDLEGLKARRQQERAMAALRAQPGGPGGP------EDKP 364
NP 722486.1 284 RVTVMRSHCHSPDIEGLQARRQQEKTIKKIQARRIGAGDLEDCDDIEDSL 333
XP 340761.1 280 RVTVMRSHCHSPDMEGLQARRQQEKTIKKIQARRIGAGDLEDCDDIEDTL 329
NLS
NP 115672.2 365 LRGVDSLLYRRGPGPLTL------------------TRPRP EDQ 396
XP 510759.2 369 LRGVDSLLYRRGPGPLTL------------------SRSRP
EDQ 400
XP 547172.2 586 PQGVDSLLCRKGPGTLNL------------------SRTRP LPA 617
XP 610323.3 365 LQGVDSLLYRRGPGPLTL------------------TRPRP NDE 396
NP 722486.1 334 LQGVDSLFYRRGQGTLTLSRSKSKSKSKSRSKSKSKSRSRS QQE 383
XP 340761.1 330 LQGVDSLFYRRGPGTLTL------------------SRSRS QQE 361
NP 115672.2 397 ELPTQPEAPDEHQDMDADPGGPEFLKTPLGGSFLVYESFLYRREKAAGEK 446
XP 510759.2 401 ELPAQPEAPDEHQDMDADPGGPEFLKTPLGGSFLVYESFLYRREKAAGEK 450
XP 547172.2 618 QPPALPGSPAE--DQDKDLGGPEFLRTPLGGSFLVYESFLYRREKAAGEK 665
XP 610323.3 397 ELPAEPQGEE---DKDEDPGGPEFLRTPLGGSFLVYESFLYRREKAAGEK 443
NP 722486.1 384 SSQEPP-EE----DQDVDPRGPEFLKTPLGGNFLVYESFLYRREKVAGEK 428
XP 340761.1 362 PLQESPEEE----DQDVDPKGPEFLKTPLGGNFLVYESFLYRREKVAGEK 407
NP 115672.2 447 VYWTCRDQARMGCRSRAITQGRRVTVMRGHCHPPDLGGLEALRQREKRPN 496
XP 510759.2 451 VYWTCRDQARMGCRSRAITQGRRVTVMRGHCHPPDLGGLEALRQREKRPN 500
XP 547172.2 666 VYWTCRDQARMGCRSRAITQGQRVTVMRGHCHPPDLGGLEALRQQEKHPG 715
XP 610323.3 444 VYWTCRDQARMGCRSRAITQGRRVTVMRGHCHPPDLGGLEALRQREKRPG 493
NP 722486.1 429 VYWTCRDQARMGCRSRAITQGRQVTVMRSHCHPPDLLGLETLRQREKRPG 478
XP 340761.1 408 VYWTCRDQARMGCRSRAITQGRQVTVMRGHCHPPDLLGLETLRQRQKRPG 457
NP 115672.2 497 TAQRGSPGGPEFLKTPLGGSFLVYESFLYRREKAAGEKVYWTCRDQARMG 546
XP 510759.2 501 TAQRGSPGGPEFLKTPLGGSFLVYESFLYRREKAAGEKVYWTCRDQARMG 550
XP 547172.2 716 AAQRGSPGGPEFLRTPLGGSFLVYESFLYRREKAAGEKVYWTCRDQARMG
765
XP 610323.3 494 TAQRGSTGGPEFLRTPLGGSFLVYESFLYRREKAAGEKVYWTCRDQARMG 543
NP 722486.1 479 PSQWDGPEGPEFLKTPLGGSFLVYESFLYRREKATGDKVYWTCRDQARMG
528
XP 340761.1 458 PAQWDGPEGPEFLKTPLGGSFLVYESFLYRREKATGDKVYWTCRDQARMG
507
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NP 115672.2 547 CRSRAITQGRRVMVMRRHCHPPDLGGLEALRQREHFPNLAQWDSPDPLRP 596
XP 510759.2 551 CRSRAITQGRRVMVMRRHCHPPDLGGLEALRQREHFPNLAQWDSPDPLRP 600
XP 547172.2 766 CRSRAITQGQRVMVMRRHCHPPDLGGLEALRQREQIPSPAQREGSGALQP 815
XP 610323.3 544 CRSRAITQGPRVMVMRRHCHPPDLGGLEALRQREQLPSPAQREGSETPQP 593
NP 722486.1 529 CRSRAITQGQRVMVMRRHCHPPDMGGLEALRQRENFPNLTHWEGPEPLQP 578
XP 340761.1 508 CRSRAITQGQRVMVMRRHCHPPDMGGLEALRQRENFPNLTHWEGPEPVQP 557
NP 115672.2 597 LEFLRTSLGGRFLVHESFLYRKEKAAGEKVYWMCRDQARLGCRSRAITQG 646
XP 510759.2 601 LEFLRTSLGGRFLVHESFLYRKEKAAGEKVYWMCRDQARLGCRSRAITEG 650
XP 547172.2 816 LEFLRTSLGGRFLVYESFLYRKEKAAGEKVYWMCRDQARLGCRSRAITQG 865
XP 610323.3 594 LEFLRTSLGGRFLVYESFLYRKEKAAGEKVYWMCRDQARKGCRSRAITQG 643
NP 722486.1 579 LEFLRTSLGGRFLVYESFLYRKEKAAGEKVYWMCRDQARLGCRSRAITQG 628
XP 340761.1 558 LEFLQTSLGGRFLVYESFLYRKEKAAGEKVYWMCRDQARLGCRSRAITQG 607
NP 115672.2 647 HRIMVMRSHCHQPDLAGLEALRQRERLPTTAQQEDPEKI----QVQ-LCF 691
XP 510759.2 651 HRIMVMRSHCHQPDLAGLEALRQRERLPTTAQQEDPEKI----QVQ-LCF 695
XP 547172.2 866 QLVTVMRSHCHLPDLAGLEALRQRERLPSVAPQEDPGRQ----ERQELAA 911
XP 610323.3 644 PRVTVMRGHCHPPDLAGLEALRRREQLPSLAQQEDPEKVKLLPEVQ-LCL 692
NP 722486.1 629 RRVMVMRSHCHPPDLAGLEALRQ--------------RE----------- 653
XP 340761.1 608 RRVMVMRSHCHSPDLAGLEALRQREREKAREREKARERE----------- 646
NP 115672.2 692 KTCSPESQQIYGDIKDVRLDGESQ-------------------------- 715
XP 510759.2 696 KTCSPESQQIYGDIKDVRLDGESQ-------------------------- 719
XP 547172.2 912 AGVHDAGMGPARDGPKKPLDTETPPPGYAALSRKRPPVSRARDFAQDFPV 961
XP 610323.3 693 ETCAPECQQSYGKVESTQLDNESQ-------------------------- 716
NP 722486.1 654 --KAPSAAKKKKKKKKKK-KGIH--------------------------- 673
XP 340761.1 647 --KAPSAAKKKKKKKKKKGKSKS--------------------------- 667
NP 115672.2 ----------
XP 510759.2 ----------
XP 547172.2 962 CQGPASARAH 971
XP 610323.3 ----------
NP 722486.1 ----------
XP 340761.1 ----------
The amino acid sequence of protein accession numbers; NP_115672.2 (Homo
sapiens), XP_510759.2 (Pan troglodytes), XP_547172.2 (Canis lupus familiaris),
XP_610323.3 (80S Taurus), NP_722486.1 (Mus musculus), and XP_340761.1 (Rattus
norvegicus) were analysed as indicated. The consensus sequence of FLYWCH motifs
(F, L, V, W, C, & H) is highlighted in yellow, while a conserved possible NLS motif
(KRAK) is boxed in red as indicatingthe putative consensus sequence of the classical
NLS motif (K-RlK-X-KlR). For more detail see (section 3.2.1).
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Appendix 2: Manual plasmid DNA extraction protocol
Steps of manual Mlniprep Protocol for Recovery of Plasmid DNA:
1. Grow cultures overnight in 2 ml Luria broth supplemented with the
appropriate antibiotics at 37°C with vigorous shaking (200-250 rpm).
2. Pour 1.0 ml of the culture into eppendorf tubes. Store the unused culture in
the fridge.
3. Centrifuge at max speed for 10 minutes (RT or 4°C).
4. Aspirate and discard the supernatant, make the bacteria pellet as dry as
possible.
5. Resuspend pellets in 100 ul ofice-cold resuspension buffer (Solution I).
6. Add 200 ul of freshly prepared alkaline lysis buffer (Solution II). Cap
tubes and mix contents by inverting several times (do not vortex).
7. Incubate tubes on ice for 5 minutes.
8. Add 150 ~l ice-cold neutralization buffer (Solution III). Mix by inverting
and gentle vortexing.
9. Incubate tubes on ice for 3-5 minutes.
10. Centrifuge tubes at 4°C on high speed for 5 minutes.
11. (Optional) Add an equal volume of phenol: chloroform (1:1 v/v). Mix the
organic and aqueous phase by vortexing and then centrifuge the emulsion
at max speed for 2 minutes at 4°C.
12. Transfer the aqueous upper layer from step 11 or the supernatant from step
10 to fresh eppendorf tubes.
13. Precipitate the DNA by adding 2 volumes of absolute ethanol at room
temp. Mix the solution by vortexing and then allow the mixture to stand for
2 minutes at room temperature.
14. Centrifuge tubes at 4°C on high speed for 5 minutes.
15. Remove the supernatant by gentle aspiration. Dry pellets at room
temperature for 10 to 15 minutes.
16. Add 1 ml of 70% ethanol to each pellet and invert the closed tubes several
times. Centrifuge tubes at 4°C on high speed for 2 minutes.
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17. Remove the supernatant by gentle aspiration. Dry pellets at room
temperature for 10 to 15minutes.
18. Gently resuspend pellets in 50 f.ll IX TE buffer (PH=8) or just use Sigma
dH20.
Solution I (Resuspension buffer):
4.50 g glucose (50 mm)
1.97 g Tris-CI (25 mm)
1.86 g EDTA (10 mm)
Dissolve in 500 ml dH20
Solution II (Alkaline lysis buffer):
0.2 N NaOH freshly diluted in 1% SDS from a 10N stock solution ofNaOH
Solution III (Neutralization buffer):
5 M sodium acetate 60 ml
Glacial acetic acid 11.5 ml
28.5 ml
TE buffer (Tris EDTA) PH=8
100mM tris-HCI (PH=8)
10mM EDTA (PH=8)
Sterilize solution by autoclaving for 20 minutes at 15 psi.
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Appendix 3: Cell counting using Neubauer
haemocytometer
This protocol IS taken from the Abeam's website:
http://www.abcam.comlps/pdflprotocolslhaemocytometer cell counts.pdf
A. Preparing haemocytometer
1. Ensure the haemocytometer is clean using 70% ethanol.
2. Moisten the shoulders of the haemocytometer and affix the coverslip using
gentle pressure and small circular motions. The phenomenon of Newton's
rings can be observed when the coverslip is correctly affixed, thus the
depth of the chamber is ensured.
B. Preparing cell suspension
1. Make sure the cell suspension to be counted is well mixed by either gentle
agitation of the flask containing the cells (or other appropriate container). A
serological pipette may be used if required.
2. Before the cells have a chance to settle take out about 1 ml of cell
suspension using a serological pipette and place in an eppendorf tube.
3. Using a 100 III pipette, mix the cells in this sample again (gently to avoid
lysing them).Take out 100 III and place into a new eppendorf, add 100 III
trypan blue and mix gently again.
C. Counting
1. Using the Gilson pipette, draw up some cell suspension containing trypan
blue. Carefully fill the haemocytometer by gently resting the end of the
Gilson tip at the edge of the chambers. Take care not to overfill the
chamber. Allow the sample to be drawn out of the pipette by capillary
action, the fluid should run to the edges of the grooves only. Re-load the
pipette and fill the second chamber if required.
2. Focus on the grid lines of the haemocytometer using the 10X objective of
the microscope. Focus on one set of 16 comer square as indicated by the
circle in (Figure 1)
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1/
Figure 1: Gridlines on haemocytometer.
3. Using a hand tally counter, count the number of cells in this area of 16
squares. When counting, always count only live cells that look healthy
(unstained by Trypan Blue). Count cells that are within the square and any
positioned on the right hand or bottom boundary line.
Dead cells stained blue with trypan blue can be counted separately for a
viability count
4. Move the haemocytometer to another set of 16 corner squares and carry on
counting until all 4 sets of 16 comer squares are counted.
5. The haemocytometer is designed so that the number of cells in one set of
16 comer squares is equivalent to the number of cells x 104/ml.
Therefore, to obtain the count:
The total count from 4 sets of 16 comer = (cells / ml x 104) X 4 squares from
one haemocytometer grid
1. Divide the count by 4
2. Then multiply by 2 to adjust for the 1:2 dilution in trypan blue
These two steps are equivalent to dividing the cell count by 2
As an example:
If the total cell count is 145
The cell density is 1:5 = 72.5 x 104/ml
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D. Viability
1. The trypan blue is used to stain any dead cells. Cells looking faint or dark
blue within the grid being counted are counted as dead cells. To check the
viability of the cells requires:
• Live cell count (not including trypan blue cells)
• Total cell count including those stained with trypan blue.
Live cell count/Total cell count = percentage viability.
Example; 45 x 10
4
4
ml = 0.978 = 97.8% viability
46 x 10 Iml
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Mll,l I
CMV
pI-Egfp2
6.1Kb
Appendices
Py replication ori + enhancer
LacZ
This vector was reconstructed by Dr. Nateri (see section 3.2.3.1).
;
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Appendix 5: plRES2-EGFP vector map
HSVTK
potyA
pIRESZ-EGFP
5.3 kb
IDI 631
. .
GCTAGCGCTACCGGACT~~
AIleI [cot}III
Resltk:tionM pandMul IeClonlng ite{MC )ofplRE 2-EGFPVector.UnlquerestrldJOn es InbOid Notethat
the EC04 7 III SI nas no been contlImed 11\ tile 1\31 construct
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Appendix 6: pEGFP-C2 vector map
Ase'
(8)
Eco01091
I3858l pEGFP·C2
4.7 kb
MCS
30-14211
Stu I
(15811
Restr.etion Map nd Multiple Clonmg ite (MCS) of pEGFP-C2. (UnIQue mtnctton sites are Iflbold) Til Eag I sne 1$
notufIlque ..Tbe Xb31 . cannolbe used Iorfu5lOl'l$SJf1ce It contains an In-frame stop c:odon The Xbal and Sdi sit s .j
are methylated n the DNA pro Ide<1 by BD BJOStlences Clontecl1. If you wISh to d1gest the ector II these enzymes, ~
need ID sform the ector In 0 a darrr host :and m k fresh DNA
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Appendix 7: pLVX-Puro vector map
pUC On
5 LTR
pLVX-Puro
9102 bp cPPT
WPRE Puro'
Appendices
2~71
pIYX-Pwo Vector Map and Multiple Cionill!l Site {MCS).
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Appendix 8: pcDNA3 vector map
Pvul
== - ->
- I- - .«
- 0:::0::: ---
"'Oc::E~oo~=oC\lC\l
.~ c. C\l(/)0 0 (/)o..c.o c.
:x:~cocowwcozxx«
Smal
Tth1111
* There is an ATG upstream
of the Xba I site.
8sml
A-150228
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Appendix 9: Sequencing data of MYC-tagged
FLYWCHI
GPAGCAGAAACTCATCTCTGAAGAAGATC~
GAACAGAAGCTCATCTCTGAGGAAGATCTG TGCCCCTGCCCGAGCCCAGCGAGCAGGAGGG
CGAGAGTGTGAAGGCCGGCCAGGAGCCATCCCCCAAGCCAGGCACGGACGTCATCCC
DNA sequencing shows FL YWCH1 cDNA correct orientation and in-frame construction
with the MYC-epitope tag in pIRES2-EGFP vector. A short sequence of the upstream
CMV-promoter is highlighted in blue, whereas the start codon of the MYC-epitope and
FL YWCH1 cDNA are highlighted in yellow. Two copies of MYC-epitope upstream to the
start codon of FLYWCH1 are boxed. A short sequence of the 5' end of FLYWCH1
cDNA is presented in bold.
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Appendix 10: NCBI primer blast for c-Jun qRT-PCR
primers.
Forward primer
Sequence (5'->3')
ACCCCAAGATCCTGAAACAG
Length
20
18
Tm
57.11
62.22
GC%
50.00
66.67Reverse primer ATCAGGCGCTCCAGCTCG
Products on target templates
>NM 002228.3 Homo sapiens jun proto-oncogene (JUN), mRNA
product length = 151
Forward primer 1
Template 1132
ACCCCAAGATCCTGAAACAG 20
1151
Reverse primer
Template
1
1282
ATCAGGCGCTCCAGCTCG 18
1265
>NM 002229.2 Homo sapiens jun B proto-oncogene (JUNB), mRNA
product length = 181
Forward primer 1 ACCCCAAGATCCTGAAACAG 20
Template 368 ..TA AC C. 387
Reverse primer 1 ATCAGGCGCTCCAGCTCG 18
Template 548 T C 531
>NM 025055.3 Homo sapiens coiled-coil domain containing 33 (CCDC33), transcript variant 1,
mRNA
product length = 2241
Forward primer 1 ACCCCAAGATCCTGAAACAG 20
Template 349 T .........TG.T .....A 368
Reverse primer 1 ATCAGGCGCTCCAGCTCG 18
Template 2589 .G....G..........T 2572
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Appendices
Appendix 15: Mapping the interaction site of
FLYWCHI with p-catenin using Co-IP assay. This figure
represents a long exposure of (Figure 4-7).
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